<SEC-DOCUMENT>0001193125-15-290039.txt : 20150813
<SEC-HEADER>0001193125-15-290039.hdr.sgml : 20150813
<ACCEPTANCE-DATETIME>20150813161912
ACCESSION NUMBER:		0001193125-15-290039
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150630
FILED AS OF DATE:		20150813
DATE AS OF CHANGE:		20150813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PIERIS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001583648
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				300784346
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37471
		FILM NUMBER:		151050943

	BUSINESS ADDRESS:	
		STREET 1:		LISE-MEITNER-STRASSE 30
		CITY:			FREISING-WEIHENSTEPHAN
		STATE:			2M
		ZIP:			85354
		BUSINESS PHONE:		49 81 6114 11400

	MAIL ADDRESS:	
		STREET 1:		LISE-MEITNER-STRASSE 30
		CITY:			FREISING-WEIHENSTEPHAN
		STATE:			2M
		ZIP:			85354

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Marika Inc.
		DATE OF NAME CHANGE:	20130805
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d947317d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended June&nbsp;30, 2015 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 001-37471 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PIERIS
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>30-0784346</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lise-Meitner-Strasse 30</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Freising-Weihenstephan, Germany</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>85354</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+49 81 6114 11400 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;No </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;No </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act
(check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of outstanding shares of the registrant&#146;s common stock, par value $0.001 per share, as of August 13, 2015 was 39,732,258. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PIERIS PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q &#151; QUARTERLY REPORT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_1"><B>PART I &#150; FINANCIAL INFORMATION</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Item 1. Financial Statements</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_3">Condensed Consolidated Balance Sheets at June&nbsp;30, 2015 (unaudited) and December&nbsp;31, 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_4">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three and six months ending
 June&nbsp;30, 2015 and June&nbsp;30, 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_5">Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ending June&nbsp;
30, 2015 and June&nbsp;30, 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_6">Notes to Condensed Consolidated Financial Statements (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_7">Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_8">Item&nbsp;3. Quantitative and Qualitative Disclosures about Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_9">Item&nbsp;4. Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_10"><B>PART II &#150; OTHER INFORMATION</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_11">Item&nbsp;1. Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_12">Item&nbsp;1A. Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_13">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_14">Item&nbsp;3. Defaults Upon Senior Securities </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_15">Item&nbsp;4. Mine Safety Disclosures </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_16">Item&nbsp;5. Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_17">Item&nbsp;6. Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx947317_18"><B>SIGNATURES</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Currency Presentation and Currency Translation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references to &#147;dollars,&#148; &#147;$,&#148; &#147;U.S. $&#148; or &#147;U.S. dollars&#148; are to the lawful currency of
the United States. All references in this Report to &#147;euro&#148; or &#147;&#128;&#148; are to the currency introduced at the start of the third stage of the European Economic and Monetary Union pursuant to the Treaty establishing the European
Community, as amended. We prepare our financial statements in U.S. dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functional currency for our operations is the euro. With respect to our
financial statements, the translation from the euro to U.S. Dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet date and for revenue and expense accounts using a weighted average exchange rate during
the period. The resulting translation adjustments are recorded as a component of other comprehensive income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where in this Report we refer to amounts in
euros, we have for your convenience also in certain cases provided a conversion of those amounts to U.S. Dollars in parentheses. Where the numbers refer to a specific balance sheet account date or financial statement account period, we have used the
exchange rate that was used to perform the conversions in connection with the applicable financial statement. In all other instances, unless otherwise indicated, the conversions have been made using the noon buying rate of &#128;1.00 to U.S. $1.1154
in The City of New York for cable transfers of euro as certified for customs purposes by the Federal Reserve Bank of New York as of June&nbsp;30, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section and other parts
of this Quarterly Report on Form 10-Q contains forward looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934,
as amended (the &#147;Exchange Act&#148;), that involve risks and uncertainties, principally in the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; All statements other than
statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding future events, our future financial performance, expectations for growth and revenues, anticipated timing and amounts of milestone and
other payments under collaboration agreements, business strategy and plans, objectives of management for future operations, timing and outcome of legal and other proceedings, and our ability to finance our operations are forward-looking statements.
We have attempted to identify forward-looking statements by terminology including &#147;anticipates,&#148; &#147;believes,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;ongoing,&#148; &#147;could,&#148; &#147;estimates,&#148;
&#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;appears,&#148; &#147;suggests,&#148; &#147;future,&#148; &#147;likely,&#148; &#147;goal,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;projects,&#148; &#147;predicts,&#148;
&#147;should,&#148; &#147;would,&#148; or &#147;will&#148; or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot
guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#147;Risk Factors&#148; or elsewhere in our most recent Annual Report on Form
10-K, which may cause our or our industry&#146;s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements to differ materially. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time
and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those
contained in any forward-looking statements. Actual results could differ materially from our forward-looking statements due to a number of factors, including, without limitation, risks related to: the results of our research and development
activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical and ongoing or planned clinical testing of our drug candidates; the early stage of our drug candidates presently under development; our
ability to obtain and, if obtained, maintain regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial additional funds in order to continue our operations and the uncertainty of whether
we will be able to obtain the funding we need; our future financial performance; our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual property rights that are valuable to our business,
including patent and other intellectual property rights; our dependence on third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators; our ability to successfully market and sell our drug
candidates in the future as needed; the size and growth of the potential markets for any of our approved drug candidates, and the rate and degree of market acceptance of any of our approved drug candidates; competition in our industry; and
regulatory developments in the U.S. and foreign countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not place undue reliance on any forward-looking statement, each of which applies
only as of the date of this Quarterly Report on Form 10-Q. Before you invest in our securities, you should be aware that the occurrence of the events described in Part I, Item&nbsp;1A (Risk Factors) of our Form 10-K filed on March&nbsp;30, 2015
could negatively affect our business, operating results, financial condition and stock price. All forward-looking statements included in this document are based on information available to us on the date hereof, and except as required by law, we
undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our statements to actual results or changed expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx947317_1"></A>PART I &#151; FINANCIAL INFORMATION </B> </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx947317_3"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </U> </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>(unaudited)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,027,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,474,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,866,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,207,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">732,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,641,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,805,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,811,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,477,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,884,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDENSED CONSOLIDATED BALANCE SHEETS</U> </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>(unaudited)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,058,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,260,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,022,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,543,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,330,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,877,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at
June&nbsp;30, 2015 and December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,503,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,627,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,343,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(843,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,041,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,807,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,147,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,006,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,477,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,884,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx947317_4"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) </U> </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">698,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">377,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,071,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,725,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,118,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,250,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,969,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,349,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,363,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,170,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,694,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,468,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,613,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,512,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,534,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,769,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,235,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,529,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,881,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,234,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,661,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,529,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,881,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,234,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,661,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,429,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,828,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,361,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,828,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) </U> </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended <BR>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,529,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,881,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,234,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,661,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">102,135<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive loss, after tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,427,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,874,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,735,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,658,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx947317_5"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) </U> </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,234,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,661,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash provided by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(628,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(768,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(240,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(422,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,676,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,406,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds of loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in)/provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate change on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(524,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,446,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,204,376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,474,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,689,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,027,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,485,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental cash flow disclosures:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx947317_6"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Corporate Information </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals, Inc. is a holding company incorporated in May 2013 under the name Marika Inc. On December&nbsp;17, 2014 Pieris AG (a
German company which was founded in 2001 by Prof. Dr.&nbsp;Arne Skerra, Professor at the Technical University of Munich, Germany, and Claus Schalper) became a wholly owned subsidiary of Pieris Pharmaceuticals, Inc., pursuant to the Acquisition
(described below). The registered office of Pieris Pharmaceuticals, Inc. and the corporate headquarters and research facility of Pieris AG are located in Freising-Weihenstephan, Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of Pieris
AG, was formed on February&nbsp;14, 2014 to conduct research and development in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2014, Pieris Pharmaceuticals, Inc.,
Pieris AG, and the former stockholders of Pieris AG entered into an acquisition agreement, or the Acquisition Agreement. Pursuant to the Acquisition Agreement, on December&nbsp;17, 2014, the stockholders of Pieris AG contributed all of their equity
interests in Pieris AG to Pieris Pharmaceuticals, Inc. in exchange for shares of Pieris Pharmaceuticals, Inc. common stock, which resulted in Pieris AG becoming a wholly owned subsidiary of Pieris Pharmaceuticals, Inc. (the &#147;Acquisition&#148;).
Upon the closing of the Acquisition, Pieris Pharmaceuticals, Inc. ceased to be a &#147;shell company&#148; under applicable rules of the SEC. For more information on the acquisition, please refer to Note 3 <I>Acquisition</I> of the consolidated
financial statements as of December&nbsp;31, 2014 included in the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2014, Pieris Pharmaceuticals, Inc. entered into a securities purchase agreement, or the Securities Purchase Agreement, with certain
accredited investors (the &#147;Investors&#148;) providing for the issuance and sale to such Investors of an aggregate of 6,779,510 shares of our common stock in a private placement offering conducted through a series of closings occurring on
December&nbsp;17, 18 and 23, 2014, at a purchase price per share of $2.00 and for aggregate gross proceeds of approximately $13.56 million (the &#147;Private Placement&#148;). Northland Securities, Inc. and Katalyst Securities, LLC served as
co-exclusive placement agents (the &#147;Placement Agents&#148;) for the Private Placement. At the closings of the Private Placement we issued to the Placement Agents and their designees, warrants (the &#147;Placement Warrants&#148;), to acquire up
to 542,360 shares of our common stock at an exercise price of $2.00 per share. Each of the Placement Warrants is exercisable at any time at the option of the holder until the five-year anniversary of its date of issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals, Inc. and its consolidated subsidiaries (the &#147;Company&#148;) is a clinical-stage biopharmaceutical company dedicated to the
discovery and development of the Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> class of biotherapeutics for patients with diseases in which the Company believes there is high unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&acute;s core Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology and platform was developed in Germany, and the Company
has partnership arrangements with major multi-national pharmaceutical companies headquartered in the U.S., Europe and Japan and with regional pharmaceutical companies headquartered in India. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of Presentation and Summary of Significant Accounting Policies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the significant accounting policies consistently applied in the preparation of the accompanying condensed
consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Consolidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in
accordance with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain
information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the
information and notes required by U.S. GAAP for complete annual consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of management, the unaudited interim
condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December&nbsp;31, 2014, and all adjustments, including normal recurring adjustments,
considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.&#146;s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June&nbsp;30, 2015 are not
necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2015 or any future period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from
management&#146;s estimates, judgments and assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company&#146;s
chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Milestone Payments and Royalties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of
each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment
of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris
Pharmaceuticals, Inc. evaluates factors such as the scientific, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the
milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris
Pharmaceuticals, Inc. aggregates milestones into three categories (i)&nbsp;research milestones, (ii)&nbsp;development milestones and (iii)&nbsp;commercial milestones. Research milestones are typically achieved upon reaching certain success criteria
as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining
regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global
sales or annual sales of a specified amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For revenues from research and development milestone payments, if the milestones are deemed substantive and
the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line
basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the
milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales
occur, assuming all other revenue recognition criteria are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC Topic 820 <I>Fair Value Measurement</I> defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an
orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization
within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 1 inputs are quoted prices in
active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 2 utilizes quoted
market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the
measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on
a recurring basis. These funds are classified as Level 1 in the fair </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value hierarchy because they are valued using quoted prices for the periods ended June&nbsp;30, 2015 and December&nbsp;31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of
June&nbsp;30, 2015 and December&nbsp;31, 2014, respectively, equal the fair value of the cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s other financial instruments
include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined
using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June&nbsp;30, 2015 and
December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax
assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit
carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The
effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on
the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a
valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB
issued ASU No.&nbsp;2014-09, &#147;Revenue from Contracts with Customers,&#148; (ASU 2014-09) which provides guidance for revenue recognition. The standard&#146;s core principle is that a company will recognize revenue when it transfers promised
goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after
December&nbsp;15, 2016, including interim periods within that reporting period. Early application is not permitted. On April&nbsp;1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to
voluntarily adopt the new standard as of the original effective date. The Company is currently assessing the potential impact the adoption of this standard will have on their financial statements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, the FASB issued ASU No.&nbsp;2015-01, <I>&#147;Income Statement &#150; Extraordinary and Unusual items&#148;</I> (ASU 2015-01). The
amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and
transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. This guidance is effective for fiscal years, and
interim periods within those fiscal years, beginning after December&nbsp;15, 2015. The company is currently evaluating the impact of this new standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2015, the FASB issued ASU No.&nbsp;2015-02, <I>&#147;Consolidation (Topic 810): Amendments to the Consolidation Analysis&#148;</I>(ASU 2015-02).
The amendments in ASU 2015-02 are intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations,
collateralized loan obligations, and mortgage-backed security transactions). This guidance is effective for fiscal years beginning after December&nbsp;15, 2016, and interim periods within fiscal years beginning after December, 15, 2017. The company
is currently evaluating the impact of this new standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2015, the FASB issued ASU No.&nbsp;2015-10, &#147;Technical Corrections and
Improvements&#148; (ASU 2015-10). The amendments in ASU 2015-10 represent changes to clarify the FASB Accounting Standards Codification (the &#147;Codification&#148;), correct unintended application of guidance, or make minor improvements to the
Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. In addition, some of the amendments are intended to make the Codification easier to
understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification. This guidance is effective for fiscal years, and interim periods within those fiscal
years, beginning after December&nbsp;15, 2015. The company is currently evaluating the impact of this new standard. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals, Inc. has considered other recent accounting pronouncements and concluded that they are
either not applicable to the business, or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenues </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals, Inc.
has not generated revenues from product sales. Pieris Pharmaceuticals, Inc. has generated revenues pursuant to (i)&nbsp;license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, payments for
research and development services and milestone payments, and (ii)&nbsp;government grants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaborations and Other Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allergan, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2009, pursuant to an agreement
with Allergan, Inc. (&#147;Allergan&#148;), the Company granted Allergan a worldwide exclusive license to develop and commercialize certain drug candidates for the treatment and prevention of ocular diseases. Allergan is responsible for the
research, development, manufacturing and commercialization of any products resulting from the license. The Company received a non-refundable upfront payment of $10 million upon execution of the contract in 2009 and is entitled to receive up to an
aggregate of $13 million in milestone payments upon the achievement of certain commercial milestones or patents granted to the Company by the United States Patent and Trademark Office that cover a product licensed to Allergan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of the agreement, the Company recognized revenues from the upfront license payment because, based on the stage of development of the licensed
product delivered and the development capabilities of Allergan, the Company determined that the license had standalone value. Through June&nbsp;30, 2015, none of the milestones had been achieved and, as such, the Company has not recognized
milestone-related revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Daiichi Sankyo Co., Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2011, the Company entered into an agreement with Daiichi Sankyo Co., Ltd. (&#147;Daiichi Sankyo&#148;), under which Pieris AG will use its proprietary
Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> scaffold technology to identify drug candidates against certain targets selected by Daiichi Sankyo, with further development and commercialization performed by Daiichi Sankyo. For
any targets selected by Daiichi Sankyo, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. The Company has handed over further development
responsibility for the two collaboration projects to Daiichi Sankyo, which handovers occurred in March 2013 and June 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon execution of the
agreement, Daiichi Sankyo paid the Company a non-refundable upfront payment in the amount of $10.1&nbsp;million in consideration for the licenses, and for each licensed product, the Company is entitled to receive potential milestone payments of
$91.1 million, plus royalties on the commercial sales of any commercial products. The total milestones are categorized as follows: research milestones - $2.6 million; development milestones - $37.4 million; commercial milestones - $50.2 million;
additional diagnostic milestones of $0.9 million. At the inception of the agreement, these milestones were determined to be substantive as there was substantial uncertainty the milestones would be achieved, they would require substantial performance
from the entity, and the consideration was reasonable relative to other deliverables. The agreement includes provisions for the Company to provide research services funded by Daiichi Sankyo at agreed upon full-time employee rates during the initial
identification and research period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the guidance in ASC 605-25, the Company identified the licenses and research funding as
deliverables at the inception of the arrangement. The Company has determined that the licenses and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the
research services provided by the Company to identify drug candidates using the Company&#146;s proprietary Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology against Daiichi Sankyo&#146;s selected targets were necessary
before the licenses would have any standalone value. Therefore, the total arrangement consideration was recognized over the estimated period of substantial involvement, which was determined to be the period Company was required to provide research
services to discover drug candidates against targets identified. The Company estimated this period would be approximately two years. The Company reassesses the estimated term at the end of each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not recognized any milestone payments as revenue for the six months ended June&nbsp;30, 2015. The Company recognized a milestone payment of
$0.4 million as revenue for the six months ended June&nbsp;30, 2014. The milestone payment was based on successful <I>in vitro</I> and <I>in vivo</I> studies. In general, milestones could not be achieved solely upon the passage of time. For revenue
recognition purposes, management determined these milestones to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the
milestones would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. For the three and six months ended
June&nbsp;30, 2015, the Company did not recognize any revenues related to the Daiichi Sankyo Collaboration and for the three and six months ended June&nbsp;30, 2014, the Company recognized $0.4 and $1.1 million in revenues, respectively. $0.4
million of these revenues were related to the achievement of milestones during the three and six months ended June&nbsp;30, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sanofi-Aventis and
Sanofi-Pasteur </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2010, the Company entered into an agreement with Sanofi-Aventis and Sanofi Pasteur (&#147;Sanofi&#148;), under which the
Company agreed to apply its proprietary Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology to identify drug candidates against certain targets selected by Sanofi, with further development and commercialization performed
by Sanofi. The agreement included the initial identification of two targets by Sanofi, with options to select up to four additional targets. For any targets selected by Sanofi, the Company granted an exclusive, worldwide license for the research,
development and commercialization of drug candidates identified by the Company. In addition to the two initial targets selected by Sanofi, Sanofi exercised one of the four options and received a license. The remaining three options expired
unexercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Sanofi paid the Company an upfront payment of $4.9 million in consideration for licenses on the first two
targets and options to select an additional four licenses on other targets (with each option requiring an additional upfront payment upon exercise). Additionally, for each licensed product, the Company is entitled to receive milestone payments up to
$51.6 million, plus royalties on the sales of any commercial products. The total milestones are categorized as follows: research milestones - $1.9 million; development milestones - $29.6 million; commercial milestones - $20.1 million. At the
inception of the agreement, these milestones were determined to be substantive because (i)&nbsp;there was substantial uncertainty the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
milestones would be achieved, (ii)&nbsp;they would require substantial performance from the entity, and (iii)&nbsp;the consideration was reasonable relative to other deliverables. The agreement
included provisions for the Company to provide research services funded by Sanofi at agreed upon full-time employee equivalent rates during the initial identification and research period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the guidance in ASC 605-25, the Company identified the licenses, options to obtain additional licenses and research funding as deliverables
at the inception of the arrangement. The options were considered to be substantive at the inception of the agreement. Factors considered in determining the options were substantive were whether (i)&nbsp;Sanofi could obtain the overall objective of
the agreement without exercising any options, (ii)&nbsp;Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii)&nbsp;the cost to exercise the options was significant relative to the total upfront
payment of $4.9 million for two licenses and four options, and (iv)&nbsp;exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has determined that, for each program selected by Sanofi, the license and research services provided by the Company represent one unit of
accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company&#146;s proprietary Anticalin technology against Sanofi&#146;s selected targets
were necessary before the licenses would have any standalone value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated selling prices for the licenses in the agreement are the Company&#146;s
best estimate of selling price and were determined based on market conditions and entity-specific factors such as considerations of preclinical and clinical testing results and the Company&#146;s pricing practices and pricing objectives. The
estimated selling price of research services are the Company&#146;s best estimate of selling price and are determined based on market conditions and entity-specific factors such as internal cost considerations and the Company&#146;s pricing
practices and pricing objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, the total arrangement consideration of $8.1 million (which comprises the $4.9 million upfront payment and
the expected fees for the research services to be provided under the remainder of the arrangement) was allocated to the deliverables based on the residual method as follows: $3.5 million to the licenses, $1.4&nbsp;million to the four options to
acquire additional licenses and $3.2 million to the estimated research services to be provided. As the license and research services were determined to be one unit of accounting, the consideration allocated to each license is recognized over the
period of substantial involvement, which was determined to be the period the Company was required to provide research services to discover drug candidates against targets identified, approximately two years. The Company reassesses the estimated term
at the end of each reporting period. At the end of 2012, the Company determined that the required research term for one of the initial terms would extend to a period of 40 months, and management updated the estimated required service period to
amortize the remaining deferred upfront payment over the new term. Two of the four options expired un-exercised in 2011, and as a result the Company recognized $0.7 million of revenue upon expiration. The option term for the remaining two options
was extended to February 2013, and Sanofi exercised one option to obtain an additional license. For the exercised option, the allocated consideration of $0.28 million for the option and the $1.1 million payment of the exercise price of the option
were deferred and amortized over the expected required service period of approximately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
two years. The program covered by the exercised option was terminated in December 2013, and accordingly, the Company recognized the remaining deferred revenue upon termination. The remaining
option expired in February 2013 and the allocated consideration of $0.35 million was recognized into revenue at the time of expiration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
not recognized any milestone payments as revenue for the three and six months ended June&nbsp;30, 2015. The Company recognized a milestone payment of $0.3 million as revenue for the six months ended June&nbsp;30, 2014. The Company did not recognize
a milestone payment for the three months ended June&nbsp;30, 2014. The milestone payment was based on successful <I>in vivo</I> studies. The milestone could not be achieved solely upon the passage of time. For revenue recognition purposes,
management determined this milestone to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestone would be achieved
because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. Therefore, the payment was recognized in its entirety as revenue in
the six months ended June&nbsp;30, 2014 when the research milestone was reached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three and six months ended June&nbsp;30, 2015, the Company did
not recognize any revenues related to the Sanofi collaboration and for the three and six months ended June&nbsp;30, 2014, the Company recognized $0.2 million and $0.7 million in revenues respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related-Party Transactions </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and License Agreement with Technische Universit&auml;t M&uuml;nchen (&#147;TUM&#148;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;4, 2003, the Company entered into a research and licensing agreement with TUM, which was subsequently renewed and, on July&nbsp;26, 2007,
superseded and replaced. The agreement established a joint research effort led by Prof. Arne Skerra, Chair of Biological Chemistry of TUM, to optimize Anticalin&reg; technologies for use in therapeutic, prophylactic and diagnostic applications and
as research reagents, and to gain fundamental insights in lipocalin scaffolds. Prof. Dr.&nbsp;Skerra was a member of Pieris AG&#146;s supervisory board when the parties entered into such agreement. The Company provided certain funding for TUM
research efforts performed under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of research efforts to date under the agreement, the Company holds a worldwide exclusive
license under its license agreement with TUM to multiple patents and patent applications, including an exclusive license to an issued U.S. patent, which patent will expire in 2027 (subject to a possible term adjustment period). Pieris AG also holds
an exclusive license to an issued U.S. patent No.&nbsp;8,420,051, which patent is expected to expire in 2029. The Company bears the costs of filing, prosecution and maintenance of patents assigned or licensed to the Company under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the assigned patents and licenses above, the Company is required to pay certain development milestones to TUM. The Company also is
obliged to pay low-single-digit royalties, including annual minimum royalties, on sales of such products incorporating patented </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies. If the Company grants licenses or sublicenses to those patents to third parties, the Company will be obliged to pay a percentage of the resulting revenue to TUM. The Company&#146;s
payment obligations are reduced by the Company&#146;s proportionate contribution to a joint invention. Payment obligations terminate on expiration or annulment of the last patent covered by the agreement. The Company can terminate the licenses to
any or all licensed patents upon specified advance notice to TUM. TUM may terminate the license provisions of the agreement only for cause. Termination of the agreement does not terminate the rights in patents assigned to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred the following expenses related to TUM (excluding value added taxes): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Three&nbsp;months&nbsp;ended</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">June&nbsp;30,</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Six&nbsp;months&nbsp;ended</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">June&nbsp;30,</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of licenses and protective rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total expenses incurred with TUM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has accrued $302,273 and $370,999 as of June&nbsp;30, 2015 and 2014, respectively, related to the amounts due
under the research and license agreement (see Note 9 <I>Commitments and Contingencies</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The part of the agreement requiring the Company to make
payments for research conducted by TUM expired in February 2013 with no further obligations by Pieris AG. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Contract between Prof.
Dr.&nbsp;Arne Skerra and Pieris AG </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2001, the Company entered into a Consulting Agreement with Prof. Dr.&nbsp;Arne Skerra, pursuant to which Prof.
Dr.&nbsp;Arne Skerra provides advice regarding the use of new proteins, in particular Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> proteins and antibodies, for the purpose of research and development. The Consulting Agreement
has an unlimited term but can be terminated by the Company upon three months&#146; notice with effect from the end of a month and by Prof. Dr.&nbsp;Arne Skerra upon one year&#146;s notice with effect from the end of a year. Under the Consulting
Agreement, the Company incurred and paid to Prof. Dr.&nbsp;Skerra consulting fees of $11,157 and $13,711 for the six months ended June&nbsp;30, 2015 and 2014, respectively. For the three months ended June&nbsp;30, 2015 and 2014 the Company incurred
and paid Prof. Dr.&nbsp;Skerra consulting fees of $5,534 and $6,858, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Debt </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TBG Loan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;3, 2014, the
Company and tbg Technologie-Beteiligungs-Gesellschaft mbH (&#147;TBG&#148;), the subsidiary of KfW Bank, Frankfurt (&#147;KfW&#148;), signed a repayment agreement concerning the Company&#146;s repayment of its liabilities to TBG outstanding at
December&nbsp;31, 2013 in a total amount of &#128;1.2&nbsp;million ($1.34 million). The principal amount bore interest at a rate of 10.53%. Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make
semi-annual payments until 2016. On December&nbsp;11, 2014, the Company and TBG entered into an accelerated repayment agreement in respect of the claims of TBG against the Company. Pursuant to terms of the accelerated repayment agreement,
conditioned upon closing of the Acquisition, the Company was obligated to pay &#128;1,050,000 ($1.17 million), the outstanding amount under the repayment agreement, in two tranches as follows: &#128;600,000 ($669,240) plus accrued interest on
January&nbsp;31, 2015 and &#128;450,000 ($501,930) on March&nbsp;31, 2015. The outstanding principal amount for the first and the second tranches, net of capital gain tax withheld, was repaid in full in the first quarter ending March&nbsp;31, 2015
in the amount of &#128;931,312 ($1,038,785). The capital gain tax withheld in the amount of &#128;118,688 ($132,385) was paid on April&nbsp;9, 2015 and with that the TBG loan was repaid in full. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accrued expenses </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has recorded the following accrued expenses as of June&nbsp;30, 2015 and December&nbsp;31, 2014, respectively: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,<BR>2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">333,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued audit and tax expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses non-current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserve for litigation TUM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses restoration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses, non-current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total accrued expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">943,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,077,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock-based compensation </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, the Board of Directors and stockholders of Pieris Pharmaceuticals, Inc. adopted the 2014 Employee, Director and Consultant
Equity Incentive Plan (the &#147;Pieris Plan&#148;), which became effective upon closing of the Acquisition. The Pieris Plan is intended to encourage ownership of common stock by the Company&#146;s employees and directors and certain of their
consultants, including employees of Pieris AG, in order to attract and retain such people, to induce them to work for the benefit of the Company and to provide additional incentive for them to promote the Company&#146;s success. The Pieris Plan
reserves 3,200,000 shares of the Company&acute;s common stock for issuance. In addition, the Pieris Plan provides for an &#147;evergreen&#148; provision whereby the number of shares of the Company&acute;s common stock reserved for issuance under the
Pieris Plan shall be automatically increased on January&nbsp;1 of each of year commencing in fiscal 2016 by the lesser of (i)&nbsp;1,000,000 shares, (ii)&nbsp;4% of the number of shares of the Company&acute;s common stock outstanding on such date,
and (iii)&nbsp;such other amount determined by the Compensation committee of the Board of Directors. As of June&nbsp;30, 2015, options to purchase 1,470,235 shares of the Company&acute;s common stock are outstanding under the Pieris Plan to its
executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014. In addition, options to purchase 1,146,500 shares are outstanding under the Pieris
Plan to other employees and consultants. 25,000 of these shares were granted during the first quarter of 2015, 32,000 of these shares were granted during the second quarter of 2015 and 1,089,500 were granted during the fourth quarter of 2014. As a
result of such grants, 583,265 of the Company&acute;s common stock remain available for future issuances under the Pieris Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted
under the Pieris Plan may be either incentive stock options (&#147;ISOs&#148;), or nonqualified stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally three years) and the exercise prices.
Options have a maximum term of ten years. The exercise price of stock options granted under the Pieris Plan must be at least </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to the fair market value of the common stock on the date of grant. The Pieris Plan become effective in December 2014, therefore there was no stock-based compensation expense in the three
and six months ended June&nbsp;30, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive
officers, directors, employees and consultants recognized for the three and six months ended June&nbsp;30, 2015, was comprised of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Three&nbsp;months&nbsp;ended</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Six&nbsp;months&nbsp;ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,&nbsp;2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stock-option expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">485,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of option grants was estimated using the Black-Scholes model. The following table describes the
weighted-average assumptions used for calculating the value of options granted for the three and six months ended June&nbsp;30, 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Three&nbsp;months&nbsp;ended</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Six&nbsp;months&nbsp;ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.71</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.3&nbsp;-&nbsp;5.8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.3&nbsp;-&nbsp;5.8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the Company&#146;s stock option activity and related information is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<BR>shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted-<BR>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted-<BR>Average<BR>Contractual<br>Life</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,519,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.6&nbsp;-&nbsp;5.8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at March&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,544,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.6&nbsp;-&nbsp;5.8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.3&nbsp;-&nbsp;5.8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,616,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.3&nbsp;-&nbsp;5.8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested at June 30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected to vest after June 30,2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,708,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value for awards granted during the three and six months ended June&nbsp;30,
2015 was $130,456 and $176,898, respectively. There were no options exercised during the three and six months ended June&nbsp;30, 2015 and 2014. 200,673 and 375,319 shares were vested in the three and six months ended June&nbsp;30, 2015,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized share-based compensation expense related to employee stock option awards at June&nbsp;30, 2015, is $2,253,478, which will
be recognized over a weighted-average service period of 2.5 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Consulting Shares </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;6, 2015, the Company entered into an independent consulting agreement (the &#147;Consulting Agreement&#148;) with the Del Mar
Consulting Group, Inc. and Alex Partners, LLC (the &#147;Consultants&#148;), pursuant to which the Company issued 150,000 restricted shares of its common stock (par value $0.01 per share) to the Consultants (the &#147;Consulting Shares&#148;). The
Company agreed to retain the Consultants to provide investor relations consulting to the Company for a period commencing on March&nbsp;6, 2015 (the &#147;Commencement Date&#148;) and ending thirteen months after the Commencement Date (such period,
the &#147;Term&#148;). The shares issued in connection with the Consulting Agreement were deemed to be exempt from registration in reliance upon Section&nbsp;4(a)(2) of the Securities Act as a transaction by an issuer not involving any public
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Consulting Agreement state, that the Company has the right to terminate this agreement at any time during the Term of the
Consulting Agreement, upon providing Consultants ten days&#146; written notice of Company&#146; intention to terminate or immediately upon notice in the event of a breach of this agreement by either consultant. If the Company delivers notice to
terminate this agreement for any reason within one hundred eighty days (180)&nbsp;following the effective date (the &#147;Return Date&#148;), then each Consultant will promptly return and surrender to the Company forty percent (40%)&nbsp;of the
number of Consulting Shares issued to it. Therefore 60,000 of these shares are subject to certain forfeiture provisions within 180 days following the date of entry into the Consulting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, using the Black-Scholes method, estimated the fair value of the 90,000 non-cancellable Consulting Shares to be $284,400 based on the closing
price per share of $3.16 as quoted on the OTCQB tier of the OTC Markets Group Inc., or the OTCQB, on the grant date, March&nbsp;6, 2015. The Company estimated the fair value of the 60,000 cancellable Consulting Shares to be $192,000 based on the
closing price per share of $3.20 as quoted on the OTCQB on the interim financial reporting date, March&nbsp;31, 2015. Therefore, the Company estimated the total fair value of the Consulting Shares to be $476,400 and recognized the 90,000 vested
non-cancellable Consulting Shares, or sixty percent (60%)&nbsp;of the Consulting Shares in an amount of $284,400, as general and administrative expense for the six months ended June&nbsp;30, 2015. The remaining forty percent (40%), or 60,000
Consulting Shares in the amount of $192,000, will be recognized as general and administrative expenses with an offsetting credit to equity on a straight-line basis over 180 days. If the Company exercises the option to terminate the Consulting
Agreement within the 180 days, resulting in the cancellation of forty percent (40%)&nbsp;of the Consulting Shares, expense for cancelled, unvested shares will be reversed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2015 the Company revalued the fair value of the unvested and forfeitable 40% of the shares. As of June&nbsp;30, 2015 the estimated fair value
of the 60,000 unvested and forfeitable shares was $165,000. Therefore the Company recognized expenses in connection with the Consulting Shares of $79,666 in general and administrative expenses for the cancellable Consulting Shares during the three
months ended June&nbsp;30, 2015. For the six months ended June&nbsp;30, 2015 the Company recognized $390,733 in general and administrative expenses, including $284,400 for the non-cancellable Consulting Shares and $106,333 for the cancellable
shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement in December 2014, the Company issued the Placement Warrants to acquire combined up to 542,360
shares of its common stock at an exercise price of two dollars per share ($2.00) to the Placement Agents and their designees during December 2014. The Placement Warrants are exercisable at any time at the option of the holder until the five year
anniversary of its date of issuance. The number of shares of common stock issuable upon the exercise of each Placement Warrant is adjustable in the event of certain stock dividends, stock splits, combinations of shares and similar transactions. Upon
exercise, the aggregate exercise price of the warrants issued are payable by the holders in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of the Placement
Warrants as of the grant date to be $664,064 and recognized the full amount in general and administrative expense for the year ended December&nbsp;31, 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arbitration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2014,
the Company instituted arbitration proceedings, or the TUM Arbitration, against Technische Universit&auml;t M&uuml;nchen, or Munich Technical University and hereafter TUM, to address issues regarding the calculation of payments due from the Company
to TUM under the Company&acute;s Research and Licensing Agreement with TUM, as amended, or the TUM License Agreement. Pursuant to the terms of the TUM License Agreement, the arbitration is proceeding in Munich, Germany and governed by German law, in
accordance with the arbitration rules of the Deutsche Institution f&uuml;r Schiedsgerichtsbarkeit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;4, 2003, or the Effective Date, the
Company and TUM entered into the TUM License Agreement, as superseded and replaced on July&nbsp;26, 2007, under which TUM has exclusively licensed, or in some cases assigned, to the Company certain intellectual property and know-how that has become
part of the Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> proprietary technologies. In return, the Company agreed to pay to TUM certain annual license fees, milestones and royalties for its own proprietary drug development and
sales, as well as an variable fee as a function of out-licensing revenues, or the Out-License Fee, where such Out-License Fees are creditable against annual license payments to TUM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by the TUM License Agreement, the Company provided to TUM its calculation of the Out-License Fee owed by the Company to TUM for the period
beginning on the Effective Date and ending on December&nbsp;31, 2012, the Dispute Period, in the amount of $0.4 million excluding value-added tax. TUM has asserted that, under the TUM License Agreement, the Out-License Fee due to TUM for the Dispute
Period amounts to $3.4 million excluding value-added tax in the aggregate and has threatened to terminate the TUM License Agreement if the Out-License Fee is not paid. We believe that if TUM sought to terminate the license agreement for cause as a
result of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this dispute, it would potentially face wrongful termination claims for substantial damages if the arbitration tribunal in the TUM Arbitration sides with Pieris in its final decision regarding
the proper amount of the Out-License Fee, but we can provide no assurance regarding the timing, nature or consequences of such decision. The Company instituted the TUM Arbitration to request the arbitration tribunal to hold that the Company&#146;s
calculation of the payments owed to TUM is accurate and shall govern all current and future payments due in respect of the Out-License Fee under the TUM License Agreement. The Company has reserved a liability on its balance sheet&acute;s position
other long-term liabilities in respect of such payment in the amount of &#128;271,000 ($302,273). An adverse ruling in the TUM Arbitration could have a material adverse effect on the Company&#146;s results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, TUM argued to the arbitrators that it is not the proper party to be sued under the action for a declaratory arbitration decision brought by the
Company in relation to the Research and Licensing Agreement, and that instead, it is the Free State of Bavaria that is the proper respondent to the action. The Company has responded that TUM has capacity to be sued in relation to any disputes
arising from and regarding contractual provisions of the Research and Licensing Agreement and is thus also the proper respondent in the action. In accordance with the arbitration rules of the Deutsche Institution f&uuml;r Schiedsgerichtsbarkeit,
each party to the arbitration proceeding has appointed one arbitrator and the party-named arbitrators collectively selected the third arbitrator as the chairman of the arbitration panel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2014, TUM filed its statement of defense, maintaining its earlier calculation of the Out-License Fee. On December&nbsp;23, 2014, TUM filed
a counterclaim in the amount of &#128;2,529,400 ($3,060,827) to suspend the statute of limitations on its claims. On January&nbsp;12, 2015, the Company filed a reply brief in response to TUM&#146;s defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The arbitration panel held its first hearing in Munich, Germany on January&nbsp;20, 2015, however the arbitration panel did not come to a conclusion on
whether TUM is the proper respondent in the action or on the merits of the case. The panel had previously indicated that it will first decide the issue of whether TUM is the proper respondent in this action. The panel resolved that the value in
dispute for both parties&#146; claims and counterclaims would be fixed at &#128;3,500,000 ($4,235,350), as the calculation of the outstanding Out-Licensing Fee also impacts future payments. On March&nbsp;3, 2015, the Company submitted a reply brief
responding to TUM&#146;s statement of defense and counterclaim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2015, TUM submitted a rebuttal brief. The panel requested that both the
Company and TUM indicate to the panel by April&nbsp;27, 2015 whether proceedings should be stayed as a result of settlement negotiations. On April&nbsp;27, 2015, the Company submitted a reply brief requesting proceedings to continue without
disruption and moving for leave to comment on TUM&#146;s submission. Following an approved extension by the panel for TUM&#146;s submission, TUM submitted its proposal on May&nbsp;4, 2015, requesting that the panel conduct a mediation hearing and
assist the parties in negotiating a settlement. On May&nbsp;8, 2015, the arbitration tribunal set June&nbsp;1, 2015 as the deadline for final briefs and offered to schedule another oral hearing in mid-June for the purpose of supporting further
settlement negotiations if both parties are in favor of holding a hearing. The Company submitted its brief on June&nbsp;1, 2015. On June&nbsp;8, 2015, the arbitration tribunal issued a procedural order indicating they will proceed with the
arbitration without another oral hearing. TUM did not file its brief by the June&nbsp;1 deadline set by the panel, and instead filed another submission on June&nbsp;23, 2015. In its procedural order issued on the same day, the tribunal panel
reserved the right to reject TUM&#146;s new submission based on the content of its brief. The tribunal&#146;s subsequent procedural order of June&nbsp;25, 2015 provided that the tribunal will close the proceedings on July&nbsp;10, 2015. The order
clarified that any further pleadings or submissions will not be admissible after this date. The Company submitted its final brief on July&nbsp;10, 2015 to address TUM&#146;s arguments raised in its latest submission and to provide the tribunal with
an overview of its costs incurred in this arbitration proceeding. On the same day, TUM submitted its summary of its costs incurred in this arbitration proceeding and subsequently, on July&nbsp;23, 2015, filed an additional brief to correct some of
its earlier submissions on costs and comment on the Company&#146;s cost overview of July&nbsp;10. The Company replied to the TUM brief on August, 7. It is not possible to determine at this time when the arbitration tribunal will make its final
decision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2015
the Company closed a public offering of an aggregate of 9,090,909 shares of the Company&acute;s common stock at a purchase price of $2.75 per share. All shares of common stock were offered by the Company. On July&nbsp;24, 2015 the underwriters
exercised their over-allotment option to purchase 1,211,827 additional shares of the Company&#146;s common stock at the public offering price of $2.75, which sale closed on July&nbsp;28, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross proceeds raised by the Company in the offering, including the exercise of the over-allotment option, were $28.3 million and net proceeds are expected to
be approximately $25.8 million. The Company intends to use the net proceeds from the offering to fund research and development, including preclinical and clinical research and development of its drug candidates, working capital and general corporate
purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Milestone payment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;8, 2015
the Company announced that it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo, and seventh milestone payment overall under the multi program collaboration. The amount
of payment was not disclosed due to the confidential treatment of this agreement. The payment was triggered by the achievement of positive <I>in vivo</I> proof of concept data and progression of the Anticalin drug candidate through a non-GLP
toxicity study in non-human primates. The Company expects to receive this milestone payment in the third quarter of 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cooperation Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July, 14 the Company entered into a Cooperation Agreement (the &#147;Cooperation Agreement&#148;) with the University of Cologne. The University of
Cologne provides research services to the Company for which it will receive up to two milestone payments. For the research services under Milestone 1, the Company shall pay the University a net amount of $48,698 (&#128;43.660)&nbsp;in two
installments. Within thirty days following achievement of Milestone 1, the Company and University shall mutually agree whether to continue with the Cooperation Project. Having agreed on continuing with Milestone 2, the Company shall pay the
University a net amount of $130,301 (&#128;116,820)&nbsp;in two installments. </P>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_7"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
interim financial statements and this Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&nbsp;31, 2014,
and the related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014, filed with the SEC on
March&nbsp;30, 2015. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these
forward-looking statements as a result of certain factors, including but not limited to those set forth under the caption &#147;Risk Factors&#148; in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>As used in this Quarterly Report on Form 10-Q, unless the context indicates or otherwise requires, &#147;our Company&#148;, &#147;the Company&#148;,
&#147;Pieris&#148;, &#147;we&#148;, &#147;us&#148;, and &#147;our&#148; refer to Pieris Pharmaceuticals, Inc., a Nevada corporation, and its consolidated subsidiary, and the term &#147;Pieris Operating&#148; refers to Pieris AG, a company organized
under the laws of Germany that, through the Acquisition completed on December&nbsp;17, 2014, has become our wholly owned subsidiary. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We have
registered trademarks for Pieris<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Pocket Binding<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. All other
trademarks, trade names and service marks included in this Quarterly Report on Form 10-Q are the property of their respective owners. Use or display by us of other parties&#146; trademarks, trade dress or products is not intended to and does not
imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owner. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisition and Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2014, Pieris Pharmaceuticals, Inc., Pieris AG, and the former stockholders of Pieris AG entered into an acquisition agreement, or the
Acquisition Agreement. Pursuant to the Acquisition Agreement, on December&nbsp;17, 2014, the stockholders of Pieris AG contributed all of their equity interests in Pieris AG to Pieris Pharmaceuticals, Inc. in exchange for shares of Pieris
Pharmaceuticals, Inc. common stock, which resulted in Pieris AG becoming a wholly owned subsidiary of Pieris Pharmaceuticals, Inc. (the &#147;Acquisition&#148;). Upon the closing of the Acquisition, Pieris Pharmaceuticals, Inc. ceased to be a
&#147;shell company&#148; under applicable rules of the SEC. For more information on the acquisition, please refer to Note 3 <I>Acquisition</I> of the consolidated financial statements as of December&nbsp;31, 2014 included in the Company&#146;s
Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2014, Pieris Pharmaceuticals, Inc. entered into a
securities purchase agreement, or the Securities Purchase Agreement, with certain accredited investors (the &#147;Investors&#148;) providing for the issuance and sale to such Investors of an aggregate of 6,779,510 shares of our common stock in a
private placement offering conducted through a series of closings occurring on December&nbsp;17, 18 and 23, 2014, at a purchase price per share of $2.00 and for aggregate gross proceeds of approximately $13.56 million (the &#147;Private
Placement&#148;). Northland Securities, Inc. and Katalyst Securities, LLC served as co-exclusive placement agents (the &#147;Placement Agents&#148;) for the Private Placement. At the closings of the Private Placement we issued to the Placement
Agents and their designees, warrants (the &#147;Placement Warrants&#148;), to acquire up to 542,360 shares of our common stock at an exercise price of $2.00 per share. Each of the Placement Warrants is exercisable at any time at the option of the
holder until the five-year anniversary of its date of issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of our Anticalin&reg; class of biotherapeutics for patients with
diseases in which we believe there is high unmet medical need. Our current development plans focus mainly on our Anticalin drug candidates PRS-080, PRS-060, as well as our 300-Series &#147;platform within a product&#148; opportunity in
immuno-oncology, as discussed in more detail below. Anticalin proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood
plasma and other bodily fluids. PRS-080 is an Anticalin protein that binds to hepcidin, a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency, or FID, in anemic
patients with chronic kidney disease, or CKD, particularly in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor, thereby inhibiting IL-4 and IL-13, two cytokines, small proteins
mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. We completed dosing of healthy volunteers in a Phase I clinical trial with PRS-080 in
June 2015, and we expect to report the data from this trial in the second half of 2015. In the trial, no dose-limiting toxicities were observed and a maximum tolerated dose was not reached. PRS-060 is currently in preclinical development, and we
intend to begin a Phase I clinical trial with PRS-060 in 2017. Our 300-Series oncology drug candidates are multispecific Anticalin&reg;-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional
biotherapeutics that genetically link an antibody with one or more Anticalin proteins, thereby constituting a multispecific protein. We are conducting preclinical experiments on a number of 300-Series lead candidates and by the end of 2015 intend to
choose a candidate for pre-clinical studies to support the IND for potential clinical trials in oncology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also developing PRS-110 in oncology. PRS-110 is a monovalent antagonist, a polypeptide molecule with one
target-binding domain,that is designed to block both ligand- dependent and ligand-independent activity of cMet. cMet is a receptor tyrosine kinase, a well-known high- affinity cell surface receptor that transmits signals into the cell when a
corresponding ligand binds to it, which is essential for embryonic development and wound healing and has been associated with several different cancers, including renal, gastric and lung carcinomas, central nervous system tumors and sarcomas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our core Anticalin&reg; technology and platform was developed in Germany, and we have partnership arrangements with major multi-national pharmaceutical
companies headquartered in the U.S., Europe and Japan and with regional pharmaceutical companies headquartered in India. These include existing agreements with Daiichi Sankyo Company Limited, or Daiichi Sankyo, and Sanofi Group (formerly
Sanofi-Aventis and Sanofi-Pasteur SA), or Sanofi, pursuant to which our Anticalin platform has consistently achieved its development milestones. We have discovery and preclinical collaboration and service agreements with both academic institutions
and private firms in Australia. We also intend to establish a greater U.S. presence and take advantage of the U.S. capital markets, additional potential corporate partners, and the broad expertise found in the biotechnology industry in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, we have devoted nearly all of our efforts and resources to our research and development activities. We have incurred significant
net losses since inception. For the six months ended June&nbsp;30, 2015 and 2014 we reported net loss of $7.2 million and $3.7 million, respectively. For the three months ended June&nbsp;30, 2015 and 2014 we reported net loss of $3.5 million and
$2.9 million, respectively. As of June&nbsp;30, 2015, we had an accumulated deficit of $73.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue incurring substantial losses
for the foreseeable future as we continue to develop our clinical and preclinical drug candidates and programs. Our operating expenses are comprised of research and development expenses and general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated any revenues from product sales to date, and we do not expect to generate revenues from product sales for at least the next several
years. Our revenues for the three and six months ended June&nbsp;30, 2015 and 2014 were primarily from license and collaboration agreements with our partners, and, to a lesser extent, from grants from government agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. dollar is the reporting currency for all periods presented. The functional currency for Pieris Operating is euros. All assets and liabilities
denominated in euros are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average rate during the period. Equity transactions are translated using historical exchange rates.
Adjustments resulting from translating foreign currency financial statements into U.S. dollars are included in accumulated other comprehensive loss. Pieris is a holding company without operations and the sole stockholder of Pieris Operating. The
corporate headquarters and research facility of Pieris Operating are located in Freising, Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of Pieris Operating, was formed on February&nbsp;14, 2014 to conduct research and development in
Australia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated any revenues from product
sales to date, and we do not expect to generate revenues from product sales for at least the next several years. Our revenues for the last two years have been primarily from the license and collaboration agreements with Sanofi Group (formerly
Sanofi-Aventis and Sanofi-Pasteur SA), or Sanofi, and Daiichi Sankyo Company Limited, or Daiichi Sankyo and, to a much lesser extent, grants from government agencies. The revenues from Sanofi and Daiichi Sankyo have been comprised primarily of
upfront payments, research and development services and, to a lesser extent, milestone payments. We recognized revenues from upfront payments under these agreements on a straight-line basis over the required service period because we determined that
the licenses to which the payments related did not have standalone value. Research service revenue is recognized when the costs are incurred and the services have been performed. Revenue from milestone payments is recognized when all of the
following conditions are met: (1)&nbsp;the milestone payments are non-refundable, (2)&nbsp;the achievement of the milestone involves substantial risk and was not reasonably assured at the inception of the arrangement, (3)&nbsp;substantive effort on
our part is involved in achieving the milestone, (4)&nbsp;the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (5)&nbsp;a reasonable amount of time passes
between the up-front license payment and the first milestone payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our revenues for the next several years to consist of upfront payments,
research funding and milestone payments from strategic collaborations we currently have or may establish in the future. We also may receive grants from government agencies and foundations funds in connection with our drug development efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of researching and developing drugs for human use is lengthy, unpredictable and subject to many risks. We expect to continue incurring substantial
expenses for the next several years as we continue to develop our clinical and preclinical drug candidates and programs. We are unable with any certainty to estimate either the costs or the timelines in which those costs will be incurred. These
programs consume a large proportion of our current, as well as projected, resources. We anticipate that our expenses will increase significantly compared to recent years as we advance PRS-080 through clinical trials, [including a Phase I clinical
trial in healthy volunteers initiated in November 2014. On June&nbsp;10, we announced the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for our PRS-080 program. engage in first-in-man-enabling
preclinical studies for PRS-060 and, subsequently, clinical development activities for this program, and prepare drug supply for these and other product candidates. We also expect to incur expenses associated with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">further preclinical development activities for 300-Series programs in the area of immune-oncology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and managing relationships with third parties with respect to collaboration and out-licensing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">validating and developing additional novel drug candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any failure or delay in the advancement of
PRS-080, PRS-060 or our 300-Series Programs could require us to re-allocate resources from our other projects to the advancement of those drug candidates, which could have a material adverse impact on the advancement of other projects and on our
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operating expenses are comprised of research and development expenses and general and administrative expenses. Our research and
development costs include costs that are directly attributable to the creation of certain of our Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> drug candidates and are comprised of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">internal recurring costs, such as labor and fringe benefits, materials and supplies, facilities and maintenance costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing, and clinical trial activities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and benefits for employees in executive, finance, business development, legal, accounting,
human resources and other support functions. Other significant general and administrative expenses include the costs associated with obtaining and maintaining our intellectual property portfolio, professional fees for accounting, auditing,
consulting and legal services, travel and allocated expenses and stock based compensation expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the three and six months ended June&nbsp;30, 2015 and June&nbsp;30, 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our revenues and operating expenses for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table provides a comparison of revenues for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $0.2 million decrease in revenues from research and development services in the three months ended June&nbsp;30, 2015
compared to the three months ended June&nbsp;30, 2014 relates to the successful hand over of all collaboration projects in 2014. We have not received research funding from collaboration partners since July 2014. In the three months ended
June&nbsp;30, 2014, we received research funding from a collaboration partner for one collaboration project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris did not recognize any collaboration
milestones in the three months ended June&nbsp;30, 2015. In the three months ended June&nbsp;30, 2014, we achieved one research milestones under a collaboration project. The increase in revenues from grants in the three months ended June&nbsp;30,
2015 compared to the three months ended June&nbsp;30, 2014 relates primarily to our significantly increased activities related to PRS-080&#146;s development in 2015 compared to 2014, resulting in higher reimbursement from the European Commission for
PRS-080&#146;s development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $0.5 million decrease in revenues from upfront payments in the period ended June&nbsp;30, 2015 compared to the period
ended June&nbsp;30, 2014 relates to the successful hand over to collaboration partners of collaboration projects in 2014<I>.</I> Recognition of upfront payments was spread over the expected time period in which we were performing research services
for corresponding partner projects and until hand-over or termination of the projects. Thus, in the six months ended June&nbsp;30, 2014 upfront payments for two projects were recognized. Accordingly, the $0.9 million decrease in revenues from
research and development services in period ended June&nbsp;30, 2015 compared to the period ended June&nbsp;30, 2014 relates to the successful hand over of all collaboration projects in 2014. We have not received research funding from collaboration
partners since July 2014. In the period ended June&nbsp;30, 2014, we received research funding from collaboration partners for two collaboration projects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris did not recognize any collaboration milestones in the six months ended March&nbsp;31, 2015. In the six
months ended June&nbsp;30, 2014, we achieved two research milestones under collaboration projects. The increase in revenues from grants in the six months ended June&nbsp;30, 2015 compared to the six months ended June&nbsp;30, 2014 relates primarily
to our significantly increased activities related to PRS-080&#146;s development in 2015 compared to 2014, resulting in higher reimbursement from the European Commission for PRS-080&#146;s development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total research and
development expenses for advancing our proprietary and co-development projects and improving and maintaining our Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform technology were $1.7 million for the three months ended
June&nbsp;30, 2015 as compared to $1.1 million for the three months ended June&nbsp;30, 2014. The $0.6 million increase in total research and development expenses in the three months ended June&nbsp;30, 2015 compared to the three months ended
June&nbsp;30, 2014 is primarily due to increased external clinical trial expenses associated with PRS-080 and increased salary expenses for our PRS-300 Series immuno-oncology programs, offset by reduced salary expense in lower priority programs as
resources were shifted to PRS-300. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we employed 29 full-time and 5 part-time personnel in our research and development group
compared to 26 full-time and 4 part-time personnel in our research and development group as of June&nbsp;30, 2014. We incurred expenses of $0.6 million and $0.1 million during the three months ended June&nbsp;30, 2015 and 2014, respectively, for
amounts payable to external parties who performed research and development activities for our proprietary and co-development projects and platform technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total research and development expenses were $3.3 million for the six months ended June&nbsp;30, 2015 as compared to $2.3 million for the six months ended
June&nbsp;30, 2014. The $1.0 million increase in total research and development expenses in the six months ended June&nbsp;30, 2015 compared to the six months ended June&nbsp;30, 2014 is primarily due to increased external clinical expenses
associated with PRS-080 and increased internal salary related expenses for the PRS-300 Series immune-oncology programs offset by reduce salary expense in lower priority programs as resources were shifted to PRS-300 and other programs. We incurred
expenses of $1.2 million and $0.3 million during the six months ended June&nbsp;30, 2015 and 2014, respectively, for amounts payable to external parties who performed research and development activities for our proprietary and co-development
projects and platform technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a comparison of the research and development expenses for our drug candidates and projects
for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRS-060</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRS-080</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRS-110</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRS-300 Series</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses related to PRS-080 increased by $0.5 million in three months ended
June&nbsp;30, 2015 as compared to the three months period ended June&nbsp;30, 2014. This increase was a result as Phase I clinical trial started in late 2014 in healthy volunteers. In contrast, no activities related to clinical trials were carried
out during the three months period ended June&nbsp;30, 2014. As PRS-300 project activities were only first initiated during three months ended June&nbsp;30, 2014 the corresponding cost in three months ended June&nbsp;30, 2015 for PRS-300 activities
are significantly higher. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the amounts outlined above, we incurred $0.6 million and $0.8 million in connection with early stage research
projects and platform technology development during the three months ended June&nbsp;30, 2015 and 2014, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incurred zero and $0.1 million
of costs in relation to providing research and development services under the license and collaboration agreements with our collaboration partners for the three months ended June&nbsp;30, 2015 and 2014, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses related to PRS-080 increased by $0.9 million in six months ended June&nbsp;30, 2015 as compared to the six months period
ended June&nbsp;30, 2014. This increase was a result as Phase I clinical trial started in late 2014 in healthy volunteers. In contrast, no activities related to clinical trials were carried out during the six months period ended June&nbsp;30, 2014.
As PRS-300 project activities were only first initiated during six months ended June&nbsp;30, 2014 the corresponding cost in six months ended June&nbsp;30, 2015 for PRS-300 activities are significantly higher. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the amounts outlined above, we incurred $0.9 million and $1.6 million in connection with early stage research projects and platform technology
development during the six months ended June&nbsp;30, 2015 and 2014, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incurred zero and $0.2 million of costs in relation to providing
research and development services under the license and collaboration agreements with our collaboration partners for the six months ended June&nbsp;30, 2015 and 2014, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses decreased from $2.3 million for the three months ended June&nbsp;30, 2014 to $2.0 million in the three months ended June&nbsp;30, 2015. This $0.3 million decrease resulted primarily from lower salary costs and favourable
exchange rate effect offset by increased consulting costs and costs associated with being a public company, including $0.3 million in non-cash stock based compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased from $3.2 million for the six months ended June&nbsp;30, 2014 to $4.4 million in the six months ended
June&nbsp;30, 2015. This $1.2 million increase resulted primarily from increased consulting costs and costs associated with being a public company including legal and investor relations costs and $0.7 million in non-cash stock based compensation
expense, offset by a favourable exchange rate effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expense) decreased to nil in the three months ended June&nbsp;30, 2015 from $0.1 million for the three months ended June&nbsp;30, 2014. This
decrease primarily relates to reduced interest expense on shareholder loans which were converted into shares of common stock in the fourth quarter of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expense) decreased to nil in the six months ended June&nbsp;30, 2015 from $0.2 million for the six months ended June&nbsp;30, 2014. This
decrease primarily relates to reduced interest expense on shareholder loans which were converted into shares of common stock in the fourth quarter of 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through June&nbsp;30,
2015, we have funded our operations with $141.4 million of cash that has been obtained from the following main sources: $76.9 million from sales of equity; $6.5 million from loans; $14.2 million from grants from government agencies; and $43.8
million in total payments received under license and collaboration agreements, including $7.9 million for research and development services costs we received in 2012, 2013, 2014 and the first six months of 2015 from Daiichi Sankyo and Sanofi. We
expect that reimbursements of our development costs by Daiichi Sankyo and Sanofi will decline going forward, and we do not expect such reimbursements to be a significant source of funding in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we had a total of $10.0 million in cash and cash equivalents and $3.3 million of liabilities, including $3.0 million of current
liabilities from operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris has experienced operating losses since its inception and had a total accumulated deficit of $73.0 million
as of June&nbsp;30, 2015. Pieris expects to incur additional costs and require additional capital. We have incurred losses in nearly every year since inception and in the six months ended June&nbsp;30, 2015. These losses have resulted in significant
cash used in operations. During the six months ended June&nbsp;30, 2015 and 2014, our cash used in operations was $6.7 million and $3.4 million, respectively. While we have several research and development programs underway, the PRS-080 and PRS-060
programs have advanced the furthest and will continue to consume, along with our 300-Series programs, increasing amounts of cash for conducting clinical trials and the testing and manufacturing of product material. As we continue to conduct these
activities necessary to pursue FDA approval of PRS-080 and PRS-060 and our other product candidates, including our 300-Series, we expect the cash needed to fund operations to increase significantly over the next several years. We also expect to
incur increased costs in connection with operating and growth as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2014 we entered into a the Securities Purchase
Agreement, with the Investors, providing for the issuance and sale to such Investors of an aggregate of 6,779,510 shares of our common stock in the Private Placement for gross proceeds to us of $13.56 million. After deducting for placement agent and
other fees and expenses, the aggregate net proceeds from the Private Placement were $12.04 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2015 the Company closed a public
offering of an aggregate of 9,090,909 shares of the Company&acute;s common stock at a purchase price of $2.75 per share. On July&nbsp;28, 2015 the underwriters exercised their option to purchase an additional 1,211,827 shares of common stock at the
public offering price of $2.75 per share. Gross proceeds from the offering, including the over-allotment option, were $28.3 million and net proceeds were approximately $25.8 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after giving effect to the public offering, we will need to obtain additional funding in order to continue our operations and pursue our business plans.
If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our existing cash and cash equivalents at June&nbsp;30, 2015 will enable us to fund our operations and capital expenditure requirements for at
least the next twelve months. Our requirements for additional capital will depend on many factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress, results, timing and cost of our clinical studies, preclinical testing and other related activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing clinical supplies, and establishing commercial supplies, of our drug candidates and any products that we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of drug candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing and outcomes of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any collaborative, licensing and other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often
volatile nature of the financial markets, equity and debt financing may be difficult to obtain. In addition, any unfavorable development or delay in the progress for our PRS-080, PRS-060 or 300-Series programs could have a material adverse impact on
our ability to raise additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek to raise any necessary additional capital through a combination of private or public equity
offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our drug candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that
may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect our stockholders&#146; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt,
making capital expenditures or declaring dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot raise adequate capital in the future, we will be required to delay and possibly
eliminate the research and development work not only of our lead drug candidates PRS-080 and PRS-060, but also our other preclinical stage product candidates. In this case, we could be required to relinquish greater or all rights to our product
candidates at an earlier stage of development and on less favorable terms than we would otherwise agree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash is maintained in current cash accounts
at major financial institutions and, to a lesser extent, in money market accounts. Due to the current low interest rates available for these instruments, we are earning limited interest income. Our investment portfolio has not been adversely
impacted by the problems in the credit markets that have existed over the last several years, but there can be no assurance that our investment portfolio will not be adversely affected in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any
off-balance sheet arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Part II, Item&nbsp;7, &#147;Critical Accounting Policies and Estimates&#148; of our Annual Report on Form 10-K for the fiscal year ended on
December&nbsp;31, 2014 for a discussion of our critical accounting policies and estimates. There were no significant changes to our Critical Accounting Policies and Estimates in the six months ended June&nbsp;30, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We review new
accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. For the recently issued accounting standards that we believe may have an impact on our consolidated financial statements, see
&#147;Note 2&#151;Recently Issued Accounting Pronouncements&#148; in our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, establishes a class of company called an &#147;emerging growth company,&#148; which generally
is a company whose initial public offering was completed after December&nbsp;8, 2011 and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. Additionally, Section&nbsp;12b-2 of the Exchange Act
establishes a class of company called a &#147;smaller reporting company,&#148; which generally is a company with a public float of less than $75 million as of the last business day of its most recently completed second fiscal quarter or, if such
public float is $0, had annual revenues of less than $50 million during the most recently completed fiscal year for which audited financial statements are available. We currently qualify as both an emerging growth company and a smaller reporting
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an emerging growth company and a smaller reporting company, we are eligible to take advantage of certain exemptions from various reporting
requirements that are not available to public reporting companies that do not qualify for those classifications, including without limitation the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An emerging growth company is exempt from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report
providing additional information about the audit and financial statements, commonly known as an &#147;auditor discussion and analysis.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An emerging growth company is not required to hold a nonbinding advisory stockholder vote on executive compensation or any golden parachute payments not previously approved by stockholders. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Neither an emerging growth company nor a smaller reporting company is required to comply with the requirement of auditor attestation of management&#146;s assessment of internal control over financial reporting, which is
required for other public reporting companies by Section&nbsp;404 of the Sarbanes-Oxley Act. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A company that is either an emerging growth company or a smaller reporting company is eligible for reduced disclosure obligations regarding executive compensation in its periodic and annual reports, including without
limitation exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A company that is either an emerging growth company or a smaller reporting company is eligible for reduced financial statement disclosure in registration statements, which must include two years of audited financial
statements rather than the three years of audited financial statements that are required for other public reporting companies. Smaller reporting companies are also eligible to provide such reduced financial statement disclosure in annual reports on
Form 10-K. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For as long as we continue to be an emerging growth company and/or a smaller reporting company, we expect that we
will take advantage of the reduced disclosure obligations available to us as a result of those respective classifications. We will remain an emerging growth company until the earlier of (i)&nbsp;December&nbsp;31, 2019, the last day of the fiscal
year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenues
of $1 billion or more; (iii)&nbsp;the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under applicable SEC rules.
We expect that we will remain an emerging growth company for the foreseeable future, but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company on or before December&nbsp;31, 2019. We
will remain a smaller reporting company until we have a public float of $75 million or more as of the last business day of our most recently completed second fiscal quarter, and we could retain our smaller reporting company status indefinitely
depending on the size of our public float. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth companies may elect to take advantage of the extended transition period provided in
Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_8"></A>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quantitative and Qualitative Disclosures about Market Risk </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_9"></A>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Evaluation of Disclosure Controls and Procedures </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were not effective to ensure that
information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#146;s rules and forms, and is accumulated and
communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, due to a material weakness in
internal control over financial reporting disclosed in our most recent Annual Report on Form 10-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Internal Controls </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control required by Rule
13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June&nbsp;30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx947317_10"></A>PART II &#151; OTHER INFORMATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_11"></A>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Legal Proceedings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Arbitration Proceeding with Technische Universit&auml;t M&uuml;nchen </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2014, the Company instituted arbitration proceedings, or the TUM Arbitration, against Technische Universit&auml;t M&uuml;nchen, or Munich
Technical University and hereafter TUM, to address issues regarding the calculation of payments due from the Company to TUM under the Company&#146;s Research and Licensing Agreement with TUM, as amended, or the TUM License Agreement. Pursuant to the
terms of the TUM License Agreement, the arbitration is proceeding in Munich, Germany and governed by German law, in accordance with the arbitration rules of the Deutsche Institution f&uuml;r Schiedsgerichtsbarkeit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;4, 2003, or the Effective Date, the Company and TUM entered into the TUM License Agreement, as
superseded and replaced on July&nbsp;26, 2007, under which TUM has exclusively licensed, or in some cases assigned, to the Company certain intellectual property and know-how that has become part of the Anticalin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> proprietary technologies. In return, the Company agreed to pay to TUM certain annual license fees, milestones and royalties for its own proprietary drug development and sales, as well as a
variable fee as a function of out-licensing revenues, or the Out-License Fee, where such Out-License Fees are creditable against annual license payments to TUM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by the TUM License Agreement, the Company provided to TUM its calculation of the Out-License Fee owed by the Company to TUM for the period
beginning on the Effective Date and ending on December&nbsp;31, 2012, the Dispute Period, in the amount of $0.4 million excluding value-added tax. TUM has asserted that, under the TUM License Agreement, the Out-License Fee due to TUM for the Dispute
Period amounts to $3.4 million excluding value-added tax in the aggregate and has threatened to terminate the TUM License Agreement if the Out-License Fee is not paid. We believe that if TUM sought to terminate the license agreement for cause as a
result of this dispute, it would potentially face wrongful termination claims for substantial damages if the arbitration tribunal in the TUM Arbitration sides with Pieris in its final decision regarding the proper amount of the Out-License Fee, but
we can provide no assurance regarding the timing, nature or consequences of such decision. The Company instituted the TUM Arbitration to request the arbitration tribunal to hold that the Company&#146;s calculation of the payments owed to TUM is
accurate and shall govern all current and future payments due in respect of the Out-License Fee under the TUM License Agreement. The Company has reserved a liability on its balance sheet&acute;s position other long-term liabilities in respect of
such payment in the amount of &#128;271,000 ($327,937). An adverse ruling in the TUM Arbitration could have a material adverse effect on the Company&#146;s results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, TUM argued to the arbitrators that it is not the proper party to be sued under the action for a declaratory arbitration decision brought by the
Company in relation to the Research and Licensing Agreement, and that instead, it is the Free State of Bavaria that is the proper respondent to the action. The Company has responded that TUM has capacity to be sued in relation to any disputes
arising from and regarding contractual provisions of the Research and Licensing Agreement and is thus also the proper respondent in the action. In accordance with the arbitration rules of the Deutsche Institution f&uuml;r Schiedsgerichtsbarkeit,
each party to the arbitration proceeding has appointed one arbitrator and the party-named arbitrators collectively selected the third arbitrator as the chairman of the arbitration panel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2014, TUM filed its statement of defense, maintaining its earlier calculation of the Out-License Fee. On December&nbsp;23, 2014, TUM filed
a counterclaim in the amount of &#128;2,529,400 ($3,060,827) to suspend the statute of limitations on its claims. On January&nbsp;12, 2015, the Company filed a reply brief in response to TUM&#146;s defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The arbitration panel held its first hearing in Munich, Germany on January&nbsp;20, 2015, however the arbitration panel did not come to a conclusion on
whether TUM is the proper respondent in the action or on the merits of the case. The panel had previously indicated that it will first decide the issue of whether TUM is the proper respondent in this action. The panel resolved that the value in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dispute for both parties&#146; claims and counterclaims would be fixed at &#128;3,500,000 ($4,235,350), as the calculation of the outstanding Out-Licensing Fee also impacts future payments. On
March&nbsp;3, 2015, the Company submitted a reply brief responding to TUM&#146;s statement of defense and counterclaim. On March&nbsp;31, 2015, TUM submitted a rebuttal brief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The panel requested that both the Company and TUM indicate to the panel by April&nbsp;27, 2015 whether proceedings should be stayed as a result of settlement
negotiations. On April&nbsp;27, 2015, the Company submitted a reply brief requesting proceedings to continue without disruption and moving for leave to comment on TUM&#146;s latest submission in another brief to rebut TUM&#146;s latest arguments.
Following an approved extension by the panel for TUM&#146;s submission, TUM submitted its proposal on May&nbsp;4, 2015, requesting the panel to conduct a mediation hearing and assist the parties to negotiate a settlement. On May&nbsp;8, 2015, the
arbitration tribunal set June&nbsp;1, 2015 as the deadline for final briefs and offered to schedule another oral hearing in mid-June for the purpose of supporting further settlement negotiations if the parties are in favor of holding a hearing. The
Company submitted its brief on June&nbsp;1, 2015. On June&nbsp;8, 2015, the arbitration tribunal issued a procedural order indicating they will proceed with the arbitration without another oral hearing. TUM did not file its brief by the June&nbsp;1
deadline set by the panel, and instead filed another submission on June&nbsp;23, 2015. In its procedural order issued on the same day, the tribunal panel reserved the right to reject TUM&#146;s new submission based on the content of its brief. The
tribunal&#146;s subsequent procedural order of June&nbsp;25, 2015 provided that the tribunal will close the proceedings on July&nbsp;10, 2015. The order clarified that any further pleadings or submissions will not be admissible after this date. The
Company submitted its final brief on July&nbsp;10, 2015 to address TUM&#146;s arguments raised in its latest submission and to provide the tribunal with an overview its costs incurred in this arbitration proceeding. On the same day, TUM submitted
its summary of its costs incurred in this arbitration proceeding and subsequently, on July&nbsp;23, 2015, filed an additional brief to correct some of its earlier submissions on costs and comment on the Company&#146;s cost overview of July&nbsp;10.
The Company replied to the TUM brief on August, 7. It is not possible to determine at this time when the arbitration tribunal will make its final decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this Quarterly Report on Form 10-Q, other than the arbitration proceeding against TUM, we are not currently involved in any material legal
proceedings. However, from time to time, we could be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, legal proceedings can have an adverse impact on us because
of defense and settlement costs, diversion of management resources and other factors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_12"></A>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Risk Factors </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No material changes from the risk factors previously disclosed in Part I, Item&nbsp;1A
(Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_13"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_14"></A>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Defaults Upon Senior Securities </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_15"></A>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Mine Safety Disclosure </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not Applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_16"></A>Item&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx947317_17"></A>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Executive Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by Principal Executive Officer.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Financial Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by Principal Financial Officer.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, by Principal Financial Officer.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Presentation Linkbase Document</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx947317_18"></A>SIGNATURES </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PIERIS PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;13, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen S. Yoder</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen S. Yoder</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 13, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Darlene Deptula-Hicks</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Darlene Deptula-Hicks</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Acting Chief Financial
Officer, Secretary and Treasurer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d947317dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Stephen S.
Yoder, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this quarterly report on Form 10-Q of Pieris Pharmaceuticals, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;13, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen S. Yoder</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Stephen S. Yoder</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and President (principal executive officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d947317dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Darlene
Deptula-Hicks, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this quarterly report on Form 10-Q of Pieris Pharmaceuticals, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;13, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Darlene Deptula-Hicks</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Darlene Deptula-Hicks</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Acting Chief Financial Officer (principal financial officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d947317dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b)&nbsp;of section 1350, chapter 63 of title 18, United
States Code), the undersigned officer of Pieris Pharmaceuticals, Inc. a Nevada corporation (the &#147;Company&#148;), does hereby certify, to his knowledge, that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June&nbsp;30, 2015 (the &#147;Report&#148;)
fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Dated: August&nbsp;13, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen S. Yoder</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Stephen S. Yoder</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and President (principal executive officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d947317dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b)&nbsp;of section 1350, chapter 63 of title 18, United
States Code), the undersigned officer of Pieris Pharmaceuticals, Inc. a Nevada corporation (the &#147;Company&#148;), does hereby certify, to her knowledge, that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June&nbsp;30, 2015 (the &#147;Report&#148;)
fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Dated: August&nbsp;13, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Darlene Deptula-Hicks</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Darlene Deptula-Hicks</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Acting Chief Financial Officer (principal accounting and financial officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>pirs-20150630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 2 -->
<!-- Creation date: 2015-08-12T12:09:49Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:pirs="http://www.pieris.com/20150630" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="pirs-20150630.xsd" xlink:type="simple" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <us-gaap:DeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_0_20130228_0_1269778x1386521_1272072x1515548_1279908x1273746" decimals="-5" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_6004_9" unitRef="iso4217_USD">1100000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_0_20130228_0_1269778x1424613_1272072x1515548_1279908x1273746" decimals="-4" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_7004_8" unitRef="iso4217_USD">280000</us-gaap:DeferredRevenue>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20141211_0_1272072x1611978" decimals="-4" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_3001_2" unitRef="iso4217_USD">1170000</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20141211_0_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_4001_0" unitRef="iso4217_EUR">1050000</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE913859--1510-Q0003_STD_0_20141223_0" decimals="INF" id="id_8654487_EE28AE2E-0589-402D-B246-E8CAB2E9FD47_3001_4" unitRef="iso4217_USD_per_shares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE913859--1510-Q0003_STD_0_20141223_0_1271382x1277719" decimals="INF" id="id_8654487_EE28AE2E-0589-402D-B246-E8CAB2E9FD47_4001_1" unitRef="iso4217_USD_per_shares">2.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20150131_0_1270482x1270483_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_4005_0" unitRef="iso4217_EUR">600000</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20150131_0_1270482x1270483_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_3005_1" unitRef="iso4217_USD">669240</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE913859--1510-Q0003_STD_0_20150813_0" decimals="INF" id="id_8654487_81E6E1A9-2A99-4AA6-AE02-8F0468365476_2_5" unitRef="shares">39732258</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="eol_PE913859--1510-Q0003_STD_0_20140403_0_1272072x1611978" decimals="4" id="id_8654487_80D889E6-3337-40D7-A2CD-9EEB1D4B2A75_1001_1" unitRef="pure">0.1053</us-gaap:AccountsPayableInterestBearingInterestRate>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20140403_0_1272072x1611978" decimals="-4" id="id_8654487_80D889E6-3337-40D7-A2CD-9EEB1D4B2A75_2_0" unitRef="iso4217_EUR">1200000</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20140403_0_1272072x1611978" decimals="-4" id="id_8654487_80D889E6-3337-40D7-A2CD-9EEB1D4B2A75_1001_0" unitRef="iso4217_USD">1340000</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE913859--1510-Q0003_STD_0_20150306_0_1274544x1434085" decimals="INF" id="id_8654487_247BADA8-9B21-4926-87AF-5FD4E25A0DF3_1001_0" unitRef="shares">150000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE913859--1510-Q0003_STD_0_20150306_0_1274544x1434085" decimals="INF" id="id_8654487_247BADA8-9B21-4926-87AF-5FD4E25A0DF3_1001_1" unitRef="iso4217_USD_per_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1479887_1279908x1273746" decimals="INF" id="id_8654487_878E2C16-9353-444D-BF35-AC11F39B553F_2001_4" unitRef="iso4217_USD">50200000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1561390_1279908x1273746" decimals="INF" id="id_8654487_878E2C16-9353-444D-BF35-AC11F39B553F_3001_3" unitRef="iso4217_USD">37400000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1591420_1279908x1273746" decimals="INF" id="id_8654487_878E2C16-9353-444D-BF35-AC11F39B553F_4001_5" unitRef="iso4217_USD">900000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1592441_1279908x1273746" decimals="INF" id="id_8654487_878E2C16-9353-444D-BF35-AC11F39B553F_5001_2" unitRef="iso4217_USD">2600000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1279908x1273746" decimals="INF" id="id_8654487_878E2C16-9353-444D-BF35-AC11F39B553F_6001_1" unitRef="iso4217_USD">91100000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE913859--1510-Q0003_STD_0_20150706_0_1271378x1273350_1271382x1272538" decimals="2" id="id_8654487_9A5618DC-73D8-448B-AC91-83A4D46282C8_2001_1" unitRef="iso4217_USD_per_shares">2.75</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE913859--1510-Q0003_STD_0_20150724_0_1271378x1273350_1271382x1272538" decimals="2" id="id_8654487_9A5618DC-73D8-448B-AC91-83A4D46282C8_2002_3" unitRef="iso4217_USD_per_shares">2.75</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1272896x1479887_1279908x1273746" decimals="INF" id="id_8654487_87708B91-4B19-44EC-8B57-538B3DE6E5D9_3001_4" unitRef="iso4217_USD">20100000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1272896x1561390_1279908x1273746" decimals="INF" id="id_8654487_87708B91-4B19-44EC-8B57-538B3DE6E5D9_4001_3" unitRef="iso4217_USD">29600000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1272896x1592441_1279908x1273746" decimals="INF" id="id_8654487_87708B91-4B19-44EC-8B57-538B3DE6E5D9_5001_2" unitRef="iso4217_USD">1900000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1279908x1273746" decimals="INF" id="id_8654487_87708B91-4B19-44EC-8B57-538B3DE6E5D9_2001_1" unitRef="iso4217_USD">51600000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:DeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1277733x1320953_1279908x1273746" decimals="-5" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_9001_2" unitRef="iso4217_USD">3500000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1277733x1387995_1279908x1273746" decimals="-5" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_10001_4" unitRef="iso4217_USD">3200000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1277733x1459186_1279908x1273746" decimals="-5" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_11001_3" unitRef="iso4217_USD">1400000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1279908x1273746" decimals="-5" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_8001_0" unitRef="iso4217_USD">8100000</us-gaap:DeferredRevenue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE913859--1510-Q0003_STD_0_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1002_26" unitRef="iso4217_USD">1485006</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="eol_PE913859--1510-Q0003_STD_0_20140630_0_1272896x1557983_1279431x1611680" decimals="0" id="id_8654487_6627DE8A-B79B-4576-BF17-F4A4D3770F70_1002_0" unitRef="iso4217_USD">370999</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_3001_5" unitRef="iso4217_USD_per_shares">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_3001_400005" unitRef="shares">2544500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0_1270482x1275486_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_4006_0" unitRef="iso4217_EUR">450000</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0_1270482x1275486_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_3006_1" unitRef="iso4217_USD">501930</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0_1272072x1611978" decimals="INF" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_4004_6" unitRef="iso4217_EUR">931312</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0_1272072x1611978" decimals="INF" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_3004_7" unitRef="iso4217_USD">1038785</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:SharePrice contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0_1274544x1434085_1276400x1966640" decimals="INF" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_4001_2" unitRef="iso4217_USD_per_shares">3.16</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="eol_PE913859--1510-Q0003_STD_0_20150331_0_1274544x1434085_1276400x1966641" decimals="INF" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_5001_5" unitRef="iso4217_USD_per_shares">3.20</us-gaap:SharePrice>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_24" unitRef="shares">29429522</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_25" unitRef="shares">29429522</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_5001_400010" unitRef="shares">799068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_23" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_5001_9" unitRef="iso4217_USD_per_shares">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_5001_400012" unitRef="shares">799068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_5001_12" unitRef="iso4217_USD_per_shares">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_22" unitRef="iso4217_USD_per_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_5001_400009" unitRef="shares">2616735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_14" unitRef="iso4217_USD">304012</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_10" unitRef="iso4217_USD">943411</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_17" unitRef="iso4217_USD">3022477</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_16" unitRef="iso4217_USD">24446</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:LitigationReserveNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_7" unitRef="iso4217_USD">302273</us-gaap:LitigationReserveNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_21" unitRef="iso4217_USD">29430</us-gaap:CommonStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_27" unitRef="iso4217_USD">-1343694</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_28" unitRef="iso4217_USD">-73041781</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_13" unitRef="iso4217_USD">635561</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_29" unitRef="iso4217_USD">11147196</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_18" unitRef="iso4217_USD">307850</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_4" unitRef="iso4217_USD">153082</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_30" unitRef="iso4217_USD">14477523</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_26" unitRef="iso4217_USD">85503241</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_9" unitRef="iso4217_USD">307850</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_19" unitRef="iso4217_USD">3330327</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_1" unitRef="iso4217_USD">333979</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_12" unitRef="iso4217_USD">2058458</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_8" unitRef="iso4217_USD">5577</us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_2" unitRef="iso4217_USD">10027305</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_A8016A80-D7EB-4E6C-ACB9-3CF3A241E4D5_1001_0" unitRef="iso4217_USD">2253478</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_7" unitRef="iso4217_USD">1811356</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_8" unitRef="iso4217_USD">24446</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Assets contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_9" unitRef="iso4217_USD">14477523</us-gaap:Assets>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_5" unitRef="iso4217_USD">16015</us-gaap:IncomeTaxesReceivable>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_3" unitRef="iso4217_USD">1866180</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_6" unitRef="iso4217_USD">12641721</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_1_4" unitRef="iso4217_USD">732221</us-gaap:PrepaidExpenseCurrent>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_5001_400011" unitRef="shares">1708607</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber>
  <pirs:AccruedTaxAuditAndLegalFees contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1001_2" unitRef="iso4217_USD">148500</pirs:AccruedTaxAuditAndLegalFees>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1269038x1272304" decimals="0" id="id_8654487_EC63E7CD-CD2E-40FD-8C1B-03AFF75687FD_1001_0" unitRef="iso4217_USD">78403</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1269523x1275948_1272072x1570417_1279908x1273746" decimals="INF" id="id_8654487_14B9E489-56A0-4FEB-9284-EEA88D4FD428_2002_1" unitRef="iso4217_USD">13000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1557983_1279431x1611680" decimals="0" id="id_8654487_6627DE8A-B79B-4576-BF17-F4A4D3770F70_1001_0" unitRef="iso4217_USD">302273</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:ContractualObligation contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1626491" decimals="-5" id="id_8654487_32D3D5FE-3E1C-4EAA-AE5F-8BA7F5232637_1002_0" unitRef="iso4217_USD">400000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1626491_1279431x1611680" decimals="-5" id="id_8654487_32D3D5FE-3E1C-4EAA-AE5F-8BA7F5232637_2002_1" unitRef="iso4217_USD">3400000</us-gaap:ContractualObligation>
  <us-gaap:RelatedPartyDepositLiabilities contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1626491_1279431x1611680" decimals="0" id="id_8654487_32D3D5FE-3E1C-4EAA-AE5F-8BA7F5232637_2001_2" unitRef="iso4217_EUR">271000</us-gaap:RelatedPartyDepositLiabilities>
  <us-gaap:RelatedPartyDepositLiabilities contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1626491_1279431x1611680" decimals="0" id="id_8654487_32D3D5FE-3E1C-4EAA-AE5F-8BA7F5232637_2002_2" unitRef="iso4217_USD">302273</us-gaap:RelatedPartyDepositLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1273383x1294863_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_4001_2" unitRef="shares">1470235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1273383x1487857_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_5001_4" unitRef="shares">1146500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE913859--1510-Q0003_STD_0_20150630_0_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_3001_6" unitRef="shares">583265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE913859--1510-Q0003_STD_0_20131231_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2001_25" unitRef="iso4217_USD">3689382</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_24" unitRef="shares">29279522</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_25" unitRef="shares">29279522</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_23" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_1001_1" unitRef="iso4217_USD_per_shares">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_9FC587B7-1974-48E3-A468-0EBACBEDE254_1001_0" unitRef="shares">542360</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_9FC587B7-1974-48E3-A468-0EBACBEDE254_1001_1" unitRef="iso4217_USD_per_shares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_22" unitRef="iso4217_USD_per_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_1001_400001" unitRef="shares">2519500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_14" unitRef="iso4217_USD">242755</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LoansPayableToBankCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_15" unitRef="iso4217_USD">1270605</us-gaap:LoansPayableToBankCurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_10" unitRef="iso4217_USD">1077853</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_17" unitRef="iso4217_USD">3543762</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_16" unitRef="iso4217_USD">26522</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:LitigationReserveNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_7" unitRef="iso4217_USD">327937</us-gaap:LitigationReserveNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_21" unitRef="iso4217_USD">29280</us-gaap:CommonStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_27" unitRef="iso4217_USD">-843097</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_28" unitRef="iso4217_USD">-65807048</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_13" unitRef="iso4217_USD">743865</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_29" unitRef="iso4217_USD">18006418</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_18" unitRef="iso4217_USD">333988</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_4" unitRef="iso4217_USD">7523</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_30" unitRef="iso4217_USD">21884168</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_26" unitRef="iso4217_USD">84627283</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_9" unitRef="iso4217_USD">333988</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_19" unitRef="iso4217_USD">3877750</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_1" unitRef="iso4217_USD">332892</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_12" unitRef="iso4217_USD">1260015</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_8" unitRef="iso4217_USD">6051</us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_2" unitRef="iso4217_USD">18474211</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_7" unitRef="iso4217_USD">2052221</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_8" unitRef="iso4217_USD">26522</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Assets contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_9" unitRef="iso4217_USD">21884168</us-gaap:Assets>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_5" unitRef="iso4217_USD">14810</us-gaap:IncomeTaxesReceivable>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_3" unitRef="iso4217_USD">1207072</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_6" unitRef="iso4217_USD">19805425</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_92EE7702-40D3-4BA8-AD51-B562015D644F_2_4" unitRef="iso4217_USD">109332</us-gaap:PrepaidExpenseCurrent>
  <pirs:AccruedTaxAuditAndLegalFees contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0" decimals="0" id="id_8654487_33011383-DA6E-401F-928C-9AE3F785FC21_1002_2" unitRef="iso4217_USD">403450</pirs:AccruedTaxAuditAndLegalFees>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0_1269038x1272304" decimals="0" id="id_8654487_EC63E7CD-CD2E-40FD-8C1B-03AFF75687FD_1002_0" unitRef="iso4217_USD">4800573</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE913859--1510-Q0003_STD_0_20141231_0_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_3004_0" unitRef="shares">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <pirs:NumberOfTranches contextRef="eol_PE913859--1510-Q0003_STD_1_20141211_0_1272072x1611978" decimals="INF" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_1001_5" unitRef="Tranches">2</pirs:NumberOfTranches>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="eol_PE913859--1510-Q0003_STD_1_20141223_0" decimals="0" id="id_8654487_F8105E64-C8F6-4041-9C05-AF4D1E92D8E4_2_0" unitRef="iso4217_EUR">2529400</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="eol_PE913859--1510-Q0003_STD_1_20141223_0" decimals="0" id="id_8654487_F8105E64-C8F6-4041-9C05-AF4D1E92D8E4_1_0" unitRef="iso4217_USD">3060827</us-gaap:LossContingencyDamagesSoughtValue>
  <pirs:WarrantExercisablePeriod contextRef="eol_PE913859--1510-Q0003_STD_1_20141223_0" id="id_8654487_EE28AE2E-0589-402D-B246-E8CAB2E9FD47_1_5">P5Y</pirs:WarrantExercisablePeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE913859--1510-Q0003_STD_1_20141223_0_1271382x1277719" decimals="INF" id="id_8654487_EE28AE2E-0589-402D-B246-E8CAB2E9FD47_1001_0" unitRef="shares">6779510</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE913859--1510-Q0003_STD_1_20141223_0_1271382x1277719" decimals="-4" id="id_8654487_EE28AE2E-0589-402D-B246-E8CAB2E9FD47_1001_2" unitRef="iso4217_USD">13560000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE913859--1510-Q0003_STD_1_20141223_0_1276401x1270422" decimals="INF" id="id_8654487_EE28AE2E-0589-402D-B246-E8CAB2E9FD47_2001_3" unitRef="shares">542360</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE913859--1510-Q0003_STD_1_20150706_0_1271378x1273350" decimals="-5" id="id_8654487_FE5428DE-69BC-417A-B56F-87BCE74101FA_1001_1" unitRef="iso4217_USD">25800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <pirs:GrossProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE913859--1510-Q0003_STD_1_20150706_0_1271378x1273350" decimals="-5" id="id_8654487_FE5428DE-69BC-417A-B56F-87BCE74101FA_1001_0" unitRef="iso4217_USD">28300000</pirs:GrossProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE913859--1510-Q0003_STD_1_20150706_0_1271378x1273350_1271382x1272538" decimals="INF" id="id_8654487_9A5618DC-73D8-448B-AC91-83A4D46282C8_1001_0" unitRef="shares">9090909</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_1_20150714_0_1271378x1273350_1298684x1560953_1528160x1343859" decimals="0" id="id_8654487_4E9977BB-E6CF-45F2-95E4-20D4824E9E96_1002_1" unitRef="iso4217_EUR">116820</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_1_20150714_0_1271378x1273350_1298684x1560953_1528160x1343859" decimals="0" id="id_8654487_4E9977BB-E6CF-45F2-95E4-20D4824E9E96_1001_1" unitRef="iso4217_USD">130301</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_1_20150714_0_1271378x1273350_1298684x1569519_1528160x1343859" decimals="0" id="id_8654487_4E9977BB-E6CF-45F2-95E4-20D4824E9E96_2002_0" unitRef="iso4217_EUR">43660</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_1_20150714_0_1271378x1273350_1298684x1569519_1528160x1343859" decimals="0" id="id_8654487_4E9977BB-E6CF-45F2-95E4-20D4824E9E96_2001_0" unitRef="iso4217_USD">48698</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE913859--1510-Q0003_STD_1_20150724_0_1271378x1273350_1271382x1272538" decimals="INF" id="id_8654487_9A5618DC-73D8-448B-AC91-83A4D46282C8_1002_2" unitRef="shares">1211827</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_15" unitRef="iso4217_USD">-3406942</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_15" unitRef="shares">11828974</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="2" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_13" unitRef="iso4217_USD_per_shares">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="INF" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_4_1" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_8" unitRef="iso4217_USD">-13091</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_29" unitRef="iso4217_USD">18</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_4_3" unitRef="iso4217_USD">3027</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_21" unitRef="iso4217_USD">136900</us-gaap:RepaymentsOfDebt>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_9" unitRef="iso4217_USD">-3661560</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_5" unitRef="iso4217_USD">-3441142</us-gaap:OperatingIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_4_4" unitRef="iso4217_USD">-3658515</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_8" unitRef="iso4217_USD">2665</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_4_2" unitRef="iso4217_USD">3027</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_0" unitRef="iso4217_USD">2071106</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_17" unitRef="iso4217_USD">4961</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_11" unitRef="iso4217_USD">-3661542</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_28" unitRef="iso4217_USD">41132</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_9" unitRef="iso4217_USD">-68553</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_10" unitRef="iso4217_USD">72570</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_11" unitRef="iso4217_USD">240743</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:InterestExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_7" unitRef="iso4217_USD">223083</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_2" unitRef="iso4217_USD">2341666</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInIncomeTaxes contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="INF" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_14" unitRef="iso4217_USD">49668</us-gaap:IncreaseDecreaseInIncomeTaxes>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_24" unitRef="iso4217_USD">-2204376</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_13" unitRef="iso4217_USD">-422410</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_10" unitRef="iso4217_USD">-18</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_3" unitRef="iso4217_USD">189463</us-gaap:Depreciation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_22" unitRef="iso4217_USD">1224560</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_18" unitRef="iso4217_USD">-4961</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CostsAndExpenses contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_4" unitRef="iso4217_USD">5512248</us-gaap:CostsAndExpenses>
  <us-gaap:PaidInKindInterest contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_4" unitRef="iso4217_USD">181951</us-gaap:PaidInKindInterest>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_23" unitRef="iso4217_USD">-17033</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_4_3" unitRef="iso4217_USD">3170582</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_12" unitRef="iso4217_USD">487595</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_2_20" unitRef="iso4217_USD">1361460</us-gaap:ProceedsFromRepaymentsOfDebt>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1272072x1315471_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_1001_1" unitRef="iso4217_USD">1100000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1272072x1515548_1279908x1273746" decimals="-5" id="id_8654487_35861A84-6B0A-43C4-9790-416415919AD0_1004_0" unitRef="iso4217_USD">300000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1272072x1515548_1279908x1273746" decimals="-5" id="id_8654487_E03918CC-29B3-4EDC-B0A0-B18C63546D39_1004_0" unitRef="iso4217_USD">700000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:ProfessionalAndContractServicesExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1274544x1434085" decimals="0" id="id_8654487_7C52409A-2E69-4B9D-BC44-C3F44E73733C_1004_0" unitRef="iso4217_USD">13711</us-gaap:ProfessionalAndContractServicesExpense>
  <us-gaap:CostsAndExpensesRelatedParty contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1004_1" unitRef="iso4217_USD">34276</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:LicenseCosts contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1004_0" unitRef="iso4217_USD">34276</us-gaap:LicenseCosts>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_181_20140630_0_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_1_0" unitRef="iso4217_USD">400000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_FA15DC4F-763C-43EE-9760-7C839066D877_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Accrued expenses&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company has recorded the following accrued expenses as of
 June&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, respectively:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;333,979&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;332,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued audit and tax expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;403,450&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,523&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total accrued expenses, current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;635,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;743,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued expenses non-current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Reserve for litigation TUM&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;302,273&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;327,937&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued expenses restoration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,577&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,051&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total accrued expenses, non-current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;307,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;333,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total accrued expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;943,411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,077,853&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_558A8412-4FCF-4529-8E43-ACF81F33E3DB_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Revenues&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;General&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. has not generated revenues from
 product sales. Pieris Pharmaceuticals, Inc. has generated revenues
 pursuant to (i)&amp;#xA0;license and collaboration agreements, which
 include upfront payments for licenses or options to obtain
 licenses, payments for research and development services and
 milestone payments, and (ii)&amp;#xA0;government grants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Collaborations and Other Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Allergan, Inc.&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In August 2009, pursuant to an agreement with Allergan, Inc.
 (&amp;#x201C;Allergan&amp;#x201D;), the Company granted Allergan a worldwide
 exclusive license to develop and commercialize certain drug
 candidates for the treatment and prevention of ocular diseases.
 Allergan is responsible for the research, development,
 manufacturing and commercialization of any products resulting from
 the license. The Company received a non-refundable upfront payment
 of $10 million upon execution of the contract in 2009 and is
 entitled to receive up to an aggregate of $13 million in milestone
 payments upon the achievement of certain commercial milestones or
 patents granted to the Company by the United States Patent and
 Trademark Office that cover a product licensed to Allergan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 At the inception of the agreement, the Company recognized revenues
 from the upfront license payment because, based on the stage of
 development of the licensed product delivered and the development
 capabilities of Allergan, the Company determined that the license
 had standalone value. Through June&amp;#xA0;30, 2015, none of the
 milestones had been achieved and, as such, the Company has not
 recognized milestone-related revenues.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Daiichi Sankyo Co., Ltd.&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2011, the Company entered into an agreement with Daiichi
 Sankyo Co., Ltd. (&amp;#x201C;Daiichi Sankyo&amp;#x201D;), under which Pieris
 AG will use its proprietary Anticalin&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;scaffold technology to
 identify drug candidates against certain targets selected by
 Daiichi Sankyo, with further development and commercialization
 performed by Daiichi Sankyo. For any targets selected by Daiichi
 Sankyo, the Company granted an exclusive, worldwide license for the
 research, development and commercialization of drug candidates
 identified by the Company. The Company has handed over further
 development responsibility for the two collaboration projects to
 Daiichi Sankyo, which handovers occurred in March 2013 and June
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Upon execution of the agreement, Daiichi Sankyo paid the Company a
 non-refundable upfront payment in the amount of $10.1&amp;#xA0;million
 in consideration for the licenses, and for each licensed product,
 the Company is entitled to receive potential milestone payments of
 $91.1 million, plus royalties on the commercial sales of any
 commercial products. The total milestones are categorized as
 follows: research milestones - $2.6 million; development milestones
 - $37.4 million; commercial milestones - $50.2 million; additional
 diagnostic milestones of $0.9 million. At the inception of the
 agreement, these milestones were determined to be substantive as
 there was substantial uncertainty the milestones would be achieved,
 they would require substantial performance from the entity, and the
 consideration was reasonable relative to other deliverables. The
 agreement includes provisions for the Company to provide research
 services funded by Daiichi Sankyo at agreed upon full-time employee
 rates during the initial identification and research period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In accordance with the guidance in ASC 605-25, the Company
 identified the licenses and research funding as deliverables at the
 inception of the arrangement. The Company has determined that the
 licenses and research services provided by the Company represent
 one unit of accounting because, based on the stage of development
 of the licensed product, the research services provided by the
 Company to identify drug candidates using the Company&amp;#x2019;s
 proprietary Anticalin&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;technology against Daiichi
 Sankyo&amp;#x2019;s selected targets were necessary before the licenses
 would have any standalone value. Therefore, the total arrangement
 consideration was recognized over the estimated period of
 substantial involvement, which was determined to be the period
 Company was required to provide research services to discover drug
 candidates against targets identified. The Company estimated this
 period would be approximately two years. The Company reassesses the
 estimated term at the end of each reporting period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company has not recognized any milestone payments as revenue
 for the six months ended June&amp;#xA0;30, 2015. The Company recognized
 a milestone payment of $0.4 million as revenue for the six months
 ended June&amp;#xA0;30, 2014. The milestone payment was based on
 successful&amp;#xA0;&lt;i&gt;in
 vitro&lt;/i&gt;&amp;#xA0;and&amp;#xA0;&lt;i&gt;in vivo&lt;/i&gt;&amp;#xA0;studies. In general,
 milestones could not be achieved solely upon the passage of time.
 For revenue recognition purposes, management determined these
 milestones to be substantive in accordance with applicable
 accounting guidance related to milestone revenue. Substantive
 uncertainty existed at the inception of the arrangement as to
 whether the milestones would be achieved because of the numerous
 variables, such as the high rate of failure inherent in research
 and development activities and the uncertainty involved with
 obtaining regulatory approval. For the three and six months ended
 June&amp;#xA0;30, 2015, the Company did not recognize any revenues
 related to the Daiichi Sankyo Collaboration and for the three and
 six months ended June&amp;#xA0;30, 2014, the Company recognized $0.4
 and $1.1 million in revenues, respectively. $0.4 million of these
 revenues were related to the achievement of milestones during the
 three and six months ended June&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Sanofi-Aventis and Sanofi-Pasteur&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In September 2010, the Company entered into an agreement with
 Sanofi-Aventis and Sanofi Pasteur (&amp;#x201C;Sanofi&amp;#x201D;), under
 which the Company agreed to apply its proprietary
 Anticalin&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;technology to identify drug
 candidates against certain targets selected by Sanofi, with further
 development and commercialization performed by Sanofi. The
 agreement included the initial identification of two targets by
 Sanofi, with options to select up to four additional targets. For
 any targets selected by Sanofi, the Company granted an exclusive,
 worldwide license for the research, development and
 commercialization of drug candidates identified by the Company. In
 addition to the two initial targets selected by Sanofi, Sanofi
 exercised one of the four options and received a license. The
 remaining three options expired unexercised.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Upon execution of the agreement, Sanofi paid the Company an upfront
 payment of $4.9 million in consideration for licenses on the first
 two targets and options to select an additional four licenses on
 other targets (with each option requiring an additional upfront
 payment upon exercise). Additionally, for each licensed product,
 the Company is entitled to receive milestone payments up to $51.6
 million, plus royalties on the sales of any commercial products.
 The total milestones are categorized as follows: research
 milestones - $1.9 million; development milestones - $29.6 million;
 commercial milestones - $20.1 million. At the inception of the
 agreement, these milestones were determined to be substantive
 because (i)&amp;#xA0;there was substantial uncertainty the milestones
 would be achieved, (ii)&amp;#xA0;they would require substantial
 performance from the entity, and (iii)&amp;#xA0;the consideration was
 reasonable relative to other deliverables. The agreement included
 provisions for the Company to provide research services funded by
 Sanofi at agreed upon full-time employee equivalent rates during
 the initial identification and research period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In accordance with the guidance in ASC 605-25, the Company
 identified the licenses, options to obtain additional licenses and
 research funding as deliverables at the inception of the
 arrangement. The options were considered to be substantive at the
 inception of the agreement. Factors considered in determining the
 options were substantive were whether (i)&amp;#xA0;Sanofi could obtain
 the overall objective of the agreement without exercising any
 options, (ii)&amp;#xA0;Sanofi was able to obtain value from the initial
 licenses obtained without exercising any options, (iii)&amp;#xA0;the
 cost to exercise the options was significant relative to the total
 upfront payment of $4.9 million for two licenses and four options,
 and (iv)&amp;#xA0;exercising the option created additional financial
 commitments for Sanofi or imposed economic penalties on Sanofi.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company has determined that, for each program selected by
 Sanofi, the license and research services provided by the Company
 represent one unit of accounting because, based on the stage of
 development of the licensed product, the research services provided
 by the Company to identify drug candidates using the
 Company&amp;#x2019;s proprietary Anticalin technology against
 Sanofi&amp;#x2019;s selected targets were necessary before the licenses
 would have any standalone value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The estimated selling prices for the licenses in the agreement are
 the Company&amp;#x2019;s best estimate of selling price and were
 determined based on market conditions and entity-specific factors
 such as considerations of preclinical and clinical testing results
 and the Company&amp;#x2019;s pricing practices and pricing objectives.
 The estimated selling price of research services are the
 Company&amp;#x2019;s best estimate of selling price and are determined
 based on market conditions and entity-specific factors such as
 internal cost considerations and the Company&amp;#x2019;s pricing
 practices and pricing objectives.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 At inception, the total arrangement consideration of $8.1 million
 (which comprises the $4.9 million upfront payment and the expected
 fees for the research services to be provided under the remainder
 of the arrangement) was allocated to the deliverables based on the
 residual method as follows: $3.5 million to the licenses,
 $1.4&amp;#xA0;million to the four options to acquire additional
 licenses and $3.2 million to the estimated research services to be
 provided. As the license and research services were determined to
 be one unit of accounting, the consideration allocated to each
 license is recognized over the period of substantial involvement,
 which was determined to be the period the Company was required to
 provide research services to discover drug candidates against
 targets identified, approximately two years. The Company reassesses
 the estimated term at the end of each reporting period. At the end
 of 2012, the Company determined that the required research term for
 one of the initial terms would extend to a period of 40 months, and
 management updated the estimated required service period to
 amortize the remaining deferred upfront payment over the new term.
 Two of the four options expired un-exercised in 2011, and as a
 result the Company recognized $0.7 million of revenue upon
 expiration. The option term for the remaining two options was
 extended to February 2013, and Sanofi exercised one option to
 obtain an additional license. For the exercised option, the
 allocated consideration of $0.28 million for the option and the
 $1.1 million payment of the exercise price of the option were
 deferred and amortized over the expected required service period of
 approximately two years. The program covered by the exercised
 option was terminated in December 2013, and accordingly, the
 Company recognized the remaining deferred revenue upon termination.
 The remaining option expired in February 2013 and the allocated
 consideration of $0.35 million was recognized into revenue at the
 time of expiration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company has not recognized any milestone payments as revenue
 for the three and six months ended June&amp;#xA0;30, 2015. The Company
 recognized a milestone payment of $0.3 million as revenue for the
 six months ended June&amp;#xA0;30, 2014. The Company did not recognize
 a milestone payment for the three months ended June&amp;#xA0;30, 2014.
 The milestone payment was based on successful&amp;#xA0;&lt;i&gt;in vivo&lt;/i&gt;&amp;#xA0;studies. The milestone could
 not be achieved solely upon the passage of time. For revenue
 recognition purposes, management determined this milestone to be
 substantive in accordance with applicable accounting guidance
 related to milestone revenue. Substantive uncertainty existed at
 the inception of the arrangement as to whether the milestone would
 be achieved because of the numerous variables, such as the high
 rate of failure inherent in research and development activities and
 the uncertainty involved with obtaining regulatory approval.
 Therefore, the payment was recognized in its entirety as revenue in
 the six months ended June&amp;#xA0;30, 2014 when the research milestone
 was reached.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 For the three and six months ended June&amp;#xA0;30, 2015, the Company
 did not recognize any revenues related to the Sanofi collaboration
 and for the three and six months ended June&amp;#xA0;30, 2014, the
 Company recognized $0.2 million and $0.7 million in revenues
 respectively.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_054DAE3B-48A6-42EE-B0D4-A3B69583BB8F_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Arbitration&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On March&amp;#xA0;20, 2014, the Company instituted arbitration
 proceedings, or the TUM Arbitration, against Technische
 Universit&amp;#xE4;t M&amp;#xFC;nchen, or Munich Technical University and
 hereafter TUM, to address issues regarding the calculation of
 payments due from the Company to TUM under the Company&amp;#x2019;s
 Research and Licensing Agreement with TUM, as amended, or the TUM
 License Agreement. Pursuant to the terms of the TUM License
 Agreement, the arbitration is proceeding in Munich, Germany and
 governed by German law, in accordance with the arbitration rules of
 the Deutsche Institution f&amp;#xFC;r Schiedsgerichtsbarkeit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On July&amp;#xA0;4, 2003, or the Effective Date, the Company and TUM
 entered into the TUM License Agreement, as superseded and replaced
 on July&amp;#xA0;26, 2007, under which TUM has exclusively licensed, or
 in some cases assigned, to the Company certain intellectual
 property and know-how that has become part of the
 Anticalin&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt; proprietary
 technologies. In return, the Company agreed to pay to TUM certain
 annual license fees, milestones and royalties for its own
 proprietary drug development and sales, as well as an variable fee
 as a function of out-licensing revenues, or the Out-License Fee,
 where such Out-License Fees are creditable against annual license
 payments to TUM.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As required by the TUM License Agreement, the Company provided to
 TUM its calculation of the Out-License Fee owed by the Company to
 TUM for the period beginning on the Effective Date and ending on
 December&amp;#xA0;31, 2012, the Dispute Period, in the amount of $0.4
 million excluding value-added tax. TUM has asserted that, under the
 TUM License Agreement, the Out-License Fee due to TUM for the
 Dispute Period amounts to $3.4 million excluding value-added tax in
 the aggregate and has threatened to terminate the TUM License
 Agreement if the Out-License Fee is not paid. We believe that if
 TUM sought to terminate the license agreement for cause as a result
 of this dispute, it would potentially face wrongful termination
 claims for substantial damages if the arbitration tribunal in the
 TUM Arbitration sides with Pieris in its final decision regarding
 the proper amount of the Out-License Fee, but we can provide no
 assurance regarding the timing, nature or consequences of such
 decision. The Company instituted the TUM Arbitration to request the
 arbitration tribunal to hold that the Company&amp;#x2019;s calculation
 of the payments owed to TUM is accurate and shall govern all
 current and future payments due in respect of the Out-License Fee
 under the TUM License Agreement. The Company has reserved a
 liability on its balance sheet&amp;#x2019;s position other long-term
 liabilities in respect of such payment in the amount of
 &amp;#x20AC;271,000 ($302,273). An adverse ruling in the TUM Arbitration
 could have a material adverse effect on the Company&amp;#x2019;s results
 of operations and financial condition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2014, TUM argued to the arbitrators that it is not the
 proper party to be sued under the action for a declaratory
 arbitration decision brought by the Company in relation to the
 Research and Licensing Agreement, and that instead, it is the Free
 State of Bavaria that is the proper respondent to the action. The
 Company has responded that TUM has capacity to be sued in relation
 to any disputes arising from and regarding contractual provisions
 of the Research and Licensing Agreement and is thus also the proper
 respondent in the action. In accordance with the arbitration rules
 of the Deutsche Institution f&amp;#xFC;r Schiedsgerichtsbarkeit, each
 party to the arbitration proceeding has appointed one arbitrator
 and the party-named arbitrators collectively selected the third
 arbitrator as the chairman of the arbitration panel.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On December&amp;#xA0;1, 2014, TUM filed its statement of defense,
 maintaining its earlier calculation of the Out-License Fee. On
 December&amp;#xA0;23, 2014, TUM filed a counterclaim in the amount of
 &amp;#x20AC;2,529,400 ($3,060,827) to suspend the statute of limitations
 on its claims. On January&amp;#xA0;12, 2015, the Company filed a reply
 brief in response to TUM&amp;#x2019;s defense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The arbitration panel held its first hearing in Munich, Germany on
 January&amp;#xA0;20, 2015, however the arbitration panel did not come
 to a conclusion on whether TUM is the proper respondent in the
 action or on the merits of the case. The panel had previously
 indicated that it will first decide the issue of whether TUM is the
 proper respondent in this action. The panel resolved that the value
 in dispute for both parties&amp;#x2019; claims and counterclaims would
 be fixed at &amp;#x20AC;3,500,000 ($4,235,350), as the calculation of
 the outstanding Out-Licensing Fee also impacts future payments. On
 March&amp;#xA0;3, 2015, the Company submitted a reply brief responding
 to TUM&amp;#x2019;s statement of defense and counterclaim.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On March&amp;#xA0;31, 2015, TUM submitted a rebuttal brief. The panel
 requested that both the Company and TUM indicate to the panel by
 April&amp;#xA0;27, 2015 whether proceedings should be stayed as a
 result of settlement negotiations. On April&amp;#xA0;27, 2015, the
 Company submitted a reply brief requesting proceedings to continue
 without disruption and moving for leave to comment on TUM&amp;#x2019;s
 submission. Following an approved extension by the panel for
 TUM&amp;#x2019;s submission, TUM submitted its proposal on May&amp;#xA0;4,
 2015, requesting that the panel conduct a mediation hearing and
 assist the parties in negotiating a settlement. On May&amp;#xA0;8,
 2015, the arbitration tribunal set June&amp;#xA0;1, 2015 as the
 deadline for final briefs and offered to schedule another oral
 hearing in mid-June for the purpose of supporting further
 settlement negotiations if both parties are in favor of holding a
 hearing. The Company submitted its brief on June&amp;#xA0;1, 2015. On
 June&amp;#xA0;8, 2015, the arbitration tribunal issued a procedural
 order indicating they will proceed with the arbitration without
 another oral hearing. TUM did not file its brief by the June&amp;#xA0;1
 deadline set by the panel, and instead filed another submission on
 June&amp;#xA0;23, 2015. In its procedural order issued on the same day,
 the tribunal panel reserved the right to reject TUM&amp;#x2019;s new
 submission based on the content of its brief. The tribunal&amp;#x2019;s
 subsequent procedural order of June&amp;#xA0;25, 2015 provided that the
 tribunal will close the proceedings on July&amp;#xA0;10, 2015. The
 order clarified that any further pleadings or submissions will not
 be admissible after this date. The Company submitted its final
 brief on July&amp;#xA0;10, 2015 to address TUM&amp;#x2019;s arguments raised
 in its latest submission to provide the tribunal with an overview
 its costs incurred in this arbitration proceeding. On the same day,
 TUM submitted its summary of its costs incurred in this arbitration
 proceeding and subsequently, on July&amp;#xA0;23, 2015, filed an
 additional brief to correct some of its earlier submissions on
 costs and comment on the Company&amp;#x2019;s cost overview of
 July&amp;#xA0;10, arguing that attorneys&amp;#x2019; fees claimed by the
 Company are disproportionately high. The Company replied to the
 TUM&amp;#x2019;s on [August, 7], pointing out that the higher
 attorneys&amp;#x2019; fees are justified and resulted from the
 Company&amp;#x2019;s submissions on TUM&amp;#x2019;s standing to be sued and
 translation costs are also reimbursable in this case.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_8DA0B000-DE5E-4DD7-BBD3-B374CE410E29_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;TBG Loan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 As of April&amp;#xA0;3, 2014, the Company and tbg
 Technologie-Beteiligungs-Gesellschaft mbH (&amp;#x201C;TBG&amp;#x201D;), the
 subsidiary of KfW Bank, Frankfurt (&amp;#x201C;KfW&amp;#x201D;), signed a
 repayment agreement concerning the Company&amp;#x2019;s repayment of its
 liabilities to TBG outstanding at December&amp;#xA0;31, 2013 in a total
 amount of &amp;#x20AC;1.2&amp;#xA0;million ($1.34 million). The principal
 amount bore interest at a rate of 10.53%. Under the repayment
 agreement, the Company has agreed to a payment schedule pursuant to
 which it will make semi-annual payments until 2016. On
 December&amp;#xA0;11, 2014, the Company and TBG entered into an
 accelerated repayment agreement in respect of the claims of TBG
 against the Company. Pursuant to terms of the accelerated repayment
 agreement, conditioned upon closing of the Acquisition, the Company
 was obligated to pay &amp;#x20AC;1,050,000 ($1.17 million), the
 outstanding amount under the repayment agreement, in two tranches
 as follows: &amp;#x20AC;600,000 ($669,240) plus accrued interest on
 January&amp;#xA0;31, 2015 and &amp;#x20AC;450,000 ($501,930) on
 March&amp;#xA0;31, 2015. The outstanding principal amount for the first
 and the second tranches, net of capital gain tax withheld, was
 repaid in full in the first quarter ending March&amp;#xA0;31, 2015 in
 the amount of &amp;#x20AC;931,312 ($1,038,785). The capital gain tax
 withheld in the amount of &amp;#x20AC;118,688 ($132,385) was paid on
 April&amp;#xA0;9, 2015 and with that the TBG loan was repaid in
 full.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_65193537-5534-4AD6-94B0-7EB0BA6C74F5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of option grants was estimated using the
 Black-Scholes model. The following table describes the
 weighted-average assumptions used for calculating the value of
 options granted for the three and six months ended June&amp;#xA0;30,
 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Three&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted average risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <dei:DocumentType contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_3F7017A0-79F0-42A9-AE36-F3B8DD90A3BD_1_0">10-Q</dei:DocumentType>
  <dei:EntityRegistrantName contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_81E6E1A9-2A99-4AA6-AE02-8F0468365476_1_1">PIERIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
  <dei:TradingSymbol contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_81E6E1A9-2A99-4AA6-AE02-8F0468365476_1_0">PIRS</dei:TradingSymbol>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_F12CDBE9-9313-4D77-B5AE-A1B5D8A865EA_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Basis of Presentation and Summary
 of Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The following is a summary of the significant accounting policies
 consistently applied in the preparation of the accompanying
 condensed consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Basis of Consolidation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The accompanying unaudited condensed consolidated financial
 statements of Pieris Pharmaceuticals Inc. and its wholly owned
 subsidiaries were prepared in accordance with accounting principles
 generally accepted in the United States (&amp;#x201C;U.S. GAAP&amp;#x201D;)
 for interim financial information. All significant intercompany
 balances and transactions have been eliminated in the
 consolidation. Certain information and footnotes normally included
 in financial statement prepared in accordance with U.S. GAAP have
 been omitted pursuant to the Securities and Exchange Commission
 rules and regulations. Accordingly, they do not include all of the
 information and notes required by U.S. GAAP for complete annual
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In the opinion of management, the unaudited interim condensed
 consolidated financial statements have been prepared on the same
 basis as the audited condensed consolidated financial statements
 for the year ending December&amp;#xA0;31, 2014, and all adjustments,
 including normal recurring adjustments, considered necessary for a
 fair presentation of Pieris Pharmaceuticals, Inc.&amp;#x2019;s unaudited
 interim consolidated financial statements have been included. The
 results of operations for the three and six months ended
 June&amp;#xA0;30, 2015 are not necessarily indicative of the results
 that may be expected for the year ending December&amp;#xA0;31, 2015 or
 any future period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The preparation of the condensed consolidated financial statements
 in accordance with U.S. GAAP requires management to make estimates,
 judgments and assumptions that affect the reported amounts of
 assets and liabilities, the reported amounts of revenues and
 expenses in the financial statements and disclosures in the
 accompanying notes. Actual results and outcomes could differ
 materially from management&amp;#x2019;s estimates, judgments and
 assumptions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. operates as a single segment dedicated
 to the discovery and development of biotechnological applications
 and the Company&amp;#x2019;s chief operating decision maker (CODM) makes
 decisions based on the Company as a whole. Accordingly, Pieris
 Pharmaceuticals, Inc. operates and makes decisions as one reporting
 unit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Milestone Payments and Royalties&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 At the inception of each agreement that includes milestone
 payments, Pieris Pharmaceuticals, Inc. evaluates whether each
 milestone is substantive and at risk to both parties on the basis
 of the contingent nature of the milestone. This evaluation includes
 an assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. Pieris
 Pharmaceuticals, Inc. evaluates factors such as the scientific,
 regulatory, commercial and other risks that must be overcome to
 achieve the respective milestone, the level of effort and
 investment required to achieve the respective milestone and whether
 the milestone consideration is reasonable relative to all
 deliverables and payment terms in the arrangement in making this
 assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. aggregates milestones into three
 categories (i)&amp;#xA0;research milestones, (ii)&amp;#xA0;development
 milestones and (iii)&amp;#xA0;commercial milestones. Research
 milestones are typically achieved upon reaching certain success
 criteria as defined in each agreement related to developing an
 Anticalin protein against the specified target. Development
 milestones are typically reached when a compound reaches a defined
 phase of clinical research or passes such phase, or upon gaining
 regulatory approvals. Commercial milestones are typically achieved
 when an approved pharmaceutical product reaches the status for
 commercial sale or certain defined levels of net sales by the
 licensee, such as when a product first achieves global sales or
 annual sales of a specified amount.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 For revenues from research and development milestone payments, if
 the milestones are deemed substantive and the milestone payments
 are nonrefundable, such amounts are recognized entirely upon
 successful accomplishment of the milestones. Milestones that are
 not considered substantive are accounted for as license payments
 and recognized on a straight-line basis over the period of
 performance. To date, Pieris Pharmaceuticals, Inc. has determined
 all milestones are substantive. Revenues from commercial milestone
 payments are accounted for as royalties and are recorded as revenue
 upon achievement of the milestone, assuming all other revenue
 recognition criteria are met. Royalty payments are recognized in
 revenues based on the timing of royalty payments earned in
 accordance with the agreements; which typically is the period when
 the relevant sales occur, assuming all other revenue recognition
 criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 ASC Topic 820&amp;#xA0;&lt;i&gt;Fair Value
 Measurement&lt;/i&gt;&amp;#xA0;defines fair value as the
 price that would be received to sell an asset or be paid to
 transfer a liability in an orderly transaction between market
 participants at the measurement date. Pieris Pharmaceuticals, Inc.
 applies the following fair value hierarchy, which prioritizes the
 inputs used to measure fair value into three levels and bases the
 categorization within the hierarchy upon the lowest level of input
 that is available and significant to the fair value
 measurement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Level 1 inputs are quoted prices in active markets for identical
 assets or liabilities that the reporting entity has the ability to
 access at the measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Level 2 utilizes quoted market prices in markets that are not
 active, broker or dealer quotations, or alternative pricing sources
 with reasonable levels of price transparency.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Level 3 inputs are unobservable inputs for the asset or liability
 in which there is little, if any, market activity for the asset or
 liability at the measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist
 of highly liquid money market funds and are measured at fair value
 on a recurring basis. These funds are classified as Level 1 in the
 fair value hierarchy because they are valued using quoted prices
 for the periods ended June&amp;#xA0;30, 2015 and December&amp;#xA0;31,
 2014. The carrying amounts of $78,403 and $ 4,800,573 as of
 June&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, respectively, equal
 the fair value of the cash equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s other financial instruments include debt
 instruments, prepaid expenses, other current assets, accounts
 payable, accrued expenses and other current liabilities and are
 classified as Level 2 within the fair value hierarchy. The fair
 value of these instruments was determined using the discounted cash
 flow method based on contractual cash flows and the current rate at
 which debt with similar terms could be issued. The fair values for
 these debt instruments approximated carrying values as of
 June&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Income taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Deferred tax assets and liabilities are recognized for the future
 tax consequences attributable to differences between the financial
 statement carrying amounts of existing assets and liabilities and
 their respective tax bases, and operating losses and tax credit
 carry forwards. Deferred tax assets and liabilities are measured
 using enacted statutory tax rates expected to apply to taxable
 income in the jurisdictions and years in which those temporary
 differences are expected to be recovered or settled. The effect on
 deferred tax assets and liabilities of a change in tax rates is
 recognized in income in the period that includes the enactment
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Based on the level of historical operating results and projections
 for the taxable income for the future, the Company has determined
 that it is more likely than not that the deferred tax assets will
 not be realized. Accordingly, the Company has recorded a valuation
 allowance to reduce deferred tax assets to the same amount as
 deferred tax liabilities and determines an effective tax rate of
 zero percent.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &amp;#x201C;Revenue
 from Contracts with Customers,&amp;#x201D; (ASU 2014-09) which provides
 guidance for revenue recognition. The standard&amp;#x2019;s core
 principle is that a company will recognize revenue when it
 transfers promised goods or services to customers in an amount that
 reflects the consideration to which the company expects to be
 entitled in exchange for those goods or services. The new guidance
 is effective for annual reporting periods beginning after
 December&amp;#xA0;15, 2016, including interim periods within that
 reporting period. Early application is not permitted. On
 April&amp;#xA0;1, 2015 the FASB voted in favor of proposing a one year
 delay of the effective date and to permit companies to voluntarily
 adopt the new standard as of the original effective date. The
 Company is currently assessing the potential impact the adoption of
 this standard will have on their financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In January 2015, the FASB issued ASU No.&amp;#xA0;2015-01,&amp;#xA0;&lt;i&gt;&amp;#x201C;Income Statement
 &amp;#x2013; Extraordinary and Unusual items&amp;#x201D;&lt;/i&gt;&amp;#xA0;(ASU 2015-01). The amendments
 in ASU 2015-01 eliminate from U.S. GAAP the concept of
 extraordinary items. Subtopic 225-20, Income Statement -
 Extraordinary and Unusual Items, required that an entity separately
 classify, present, and disclose extraordinary events and
 transactions. Presently, an event or transaction is presumed to be
 an ordinary and usual activity of the reporting entity unless
 evidence clearly supports its classification as an extraordinary
 item. This guidance is effective for fiscal years, and interim
 periods within those fiscal years, beginning after
 December&amp;#xA0;15, 2015. The company is currently evaluating the
 impact of this new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In February 2015, the FASB issued ASU No.&amp;#xA0;2015-02,&amp;#xA0;&lt;i&gt;&amp;#x201C;Consolidation (Topic
 810): Amendments to the Consolidation Analysis&amp;#x201D;&lt;/i&gt;(ASU
 2015-02). The amendments in ASU 2015-02 are intended to improve
 targeted areas of consolidation guidance for legal entities such as
 limited partnerships, limited liability corporations, and
 securitization structures (collateralized debt obligations,
 collateralized loan obligations, and mortgage-backed security
 transactions). This guidance is effective for fiscal years
 beginning after December&amp;#xA0;15, 2016, and interim periods within
 fiscal years beginning after December, 15, 2017. The company is
 currently evaluating the impact of this new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In June 2015, the FASB issued ASU No.&amp;#xA0;2015-10,
 &amp;#x201C;Technical Corrections and Improvements&amp;#x201D; (ASU 2015-10).
 The amendments in ASU 2015-10 represent changes to clarify the FASB
 Accounting Standards Codification (the &amp;#x201C;Codification&amp;#x201D;),
 correct unintended application of guidance, or make minor
 improvements to the Codification that are not expected to have a
 significant effect on current accounting practice or create a
 significant administrative cost to most entities. In addition, some
 of the amendments are intended to make the Codification easier to
 understand and easier to apply by eliminating inconsistencies,
 providing needed clarifications, and improving the presentation of
 guidance in the Codification. This guidance is effective for fiscal
 years, and interim periods within those fiscal years, beginning
 after December&amp;#xA0;15, 2015. The company is currently evaluating
 the impact of this new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. has considered other recent accounting
 pronouncements and concluded that they are either not applicable to
 the business, or that the effect is not expected to be material to
 the unaudited condensed consolidated financial statements as a
 result of future adoption.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_BD5E212C-22C6-4ABC-9EB3-C8182ABF7485_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred tax assets and liabilities are recognized for the future
 tax consequences attributable to differences between the financial
 statement carrying amounts of existing assets and liabilities and
 their respective tax bases, and operating losses and tax credit
 carry forwards. Deferred tax assets and liabilities are measured
 using enacted statutory tax rates expected to apply to taxable
 income in the jurisdictions and years in which those temporary
 differences are expected to be recovered or settled. The effect on
 deferred tax assets and liabilities of a change in tax rates is
 recognized in income in the period that includes the enactment
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Based on the level of historical operating results and projections
 for the taxable income for the future, the Company has determined
 that it is more likely than not that the deferred tax assets will
 not be realized. Accordingly, the Company has recorded a valuation
 allowance to reduce deferred tax assets to the same amount as
 deferred tax liabilities and determines an effective tax rate of
 zero percent.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_9CD3664C-52A2-42F7-A834-0F9BE6FB9C52_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 A summary of the Company&amp;#x2019;s stock option activity and related
 information is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Contractual&lt;br /&gt;
 Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,519,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.6&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.8&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options cancelled or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at March&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,544,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.6&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,235&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options cancelled or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,616,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested at June 30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;799,068&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expected to vest after June 30,2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,708,607&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;799,068&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_2_0" unitRef="iso4217_USD_per_shares">176898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <dei:EntityFilerCategory contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_81E6E1A9-2A99-4AA6-AE02-8F0468365476_1_4">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="INF" id="id_8654487_1B87FDC4-9473-43BB-AA8A-353DCCEFF0ED_1_0" unitRef="pure">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_A8016A80-D7EB-4E6C-ACB9-3CF3A241E4D5_1_1">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_15" unitRef="iso4217_USD">-6676452</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_B6E952B9-073C-4DA9-92E6-9C751B4F2F30_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Related-Party
 Transactions&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Research and License Agreement with Technische Universit&amp;#xE4;t
 M&amp;#xFC;nchen (&amp;#x201C;TUM&amp;#x201D;)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On July&amp;#xA0;4, 2003, the Company entered into a research and
 licensing agreement with TUM, which was subsequently renewed and,
 on July&amp;#xA0;26, 2007, superseded and replaced. The agreement
 established a joint research effort led by Prof. Arne Skerra, Chair
 of Biological Chemistry of TUM, to optimize Anticalin&amp;#xAE;
 technologies for use in therapeutic, prophylactic and diagnostic
 applications and as research reagents, and to gain fundamental
 insights in lipocalin scaffolds. Prof. Dr.&amp;#xA0;Skerra was a member
 of Pieris AG&amp;#x2019;s supervisory board when the parties entered
 into such agreement. The Company provided certain funding for TUM
 research efforts performed under the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a result of research efforts to date under the agreement, the
 Company holds a worldwide exclusive license under its license
 agreement with TUM to multiple patents and patent applications,
 including an exclusive license to an issued U.S. patent, which
 patent will expire in 2027 (subject to a possible term adjustment
 period). Pieris AG also holds an exclusive license to an issued
 U.S. patent No.&amp;#xA0;8,420,051, which patent is expected to expire
 in 2029. The Company bears the costs of filing, prosecution and
 maintenance of patents assigned or licensed to the Company under
 the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As consideration for the assigned patents and licenses above, the
 Company is required to pay certain development milestones to TUM.
 The Company also is obliged to pay low-single-digit royalties,
 including annual minimum royalties, on sales of such products
 incorporating patented technologies. If the Company grants licenses
 or sublicenses to those patents to third parties, the Company will
 be obliged to pay a percentage of the resulting revenue to TUM. The
 Company&amp;#x2019;s payment obligations are reduced by the
 Company&amp;#x2019;s proportionate contribution to a joint invention.
 Payment obligations terminate on expiration or annulment of the
 last patent covered by the agreement. The Company can terminate the
 licenses to any or all licensed patents upon specified advance
 notice to TUM. TUM may terminate the license provisions of the
 agreement only for cause. Termination of the agreement does not
 terminate the rights in patents assigned to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has incurred the following expenses related to TUM
 (excluding value added taxes):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;June&amp;#xA0;30,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Transfer of licenses and protective rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total expenses incurred with TUM&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has accrued $302,273 and $370,999 as of June&amp;#xA0;30,
 2015 and 2014, respectively, related to the amounts due under the
 research and license agreement (see Note 9 &lt;i&gt;Commitments and
 Contingencies&lt;/i&gt;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The part of the agreement requiring the Company to make payments
 for research conducted by TUM expired in February 2013 with no
 further obligations by Pieris AG.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Consulting Contract between Prof. Dr.&amp;#xA0;Arne Skerra and
 Pieris AG&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In 2001, the Company entered into a Consulting Agreement with Prof.
 Dr.&amp;#xA0;Arne Skerra, pursuant to which Prof. Dr.&amp;#xA0;Arne Skerra
 provides advice regarding the use of new proteins, in particular
 Anticalin&amp;#xAE; proteins and antibodies, for the purpose of
 research and development. The Consulting Agreement has an unlimited
 term but can be terminated by the Company upon three months&amp;#x2019;
 notice with effect from the end of a month and by Prof.
 Dr.&amp;#xA0;Arne Skerra upon one year&amp;#x2019;s notice with effect from
 the end of a year. Under the Consulting Agreement, the Company
 incurred and paid to Prof. Dr.&amp;#xA0;Skerra consulting fees of
 $11,157 and $13,711 for the six months ended June&amp;#xA0;30, 2015 and
 2014, respectively. For the three months ended June&amp;#xA0;30, 2015
 and 2014 the Company incurred and paid Prof. Dr.&amp;#xA0;Skerra
 consulting fees of $5,534 and $6,858, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_8A87C40A-33CF-44BA-85E9-FC14C25B6793_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense, related to all share-based
 awards under the Pieris Plan to executive officers, directors,
 employees and consultants recognized for the three and six months
 ended June&amp;#xA0;30, 2015, was comprised of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Three&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&amp;#xA0;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and Development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;129,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;189,488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total stock-option expense&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;268,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;485,375&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:RevenueRecognitionMilestoneMethodMilestone contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_B65DAC0C-93B6-4AEB-86D6-B0E080190093_1_0">Pieris Pharmaceuticals, Inc. aggregates milestones into three categories  (i) research milestones, (ii) development milestones and (iii) commercial  milestones.</us-gaap:RevenueRecognitionMilestoneMethodMilestone>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_181E6C86-DA0F-4F0F-B8CC-81EBFF2A5642_1_1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="3" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_2_1" unitRef="pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_215151F1-9799-408F-B900-7A8DE8FC21A4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company has recorded the following accrued expenses as of
 June&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, respectively:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;333,979&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;332,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued audit and tax expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;403,450&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,523&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total accrued expenses, current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;635,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;743,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued expenses non-current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Reserve for litigation TUM&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;302,273&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;327,937&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued expenses restoration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,577&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,051&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total accrued expenses, non-current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;307,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;333,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total accrued expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;943,411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,077,853&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_72178526-C588-4FA3-87CB-43EBE1967D65_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has incurred the following expenses related to TUM
 (excluding value added taxes):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;June&amp;#xA0;30,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Transfer of licenses and protective rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total expenses incurred with TUM&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="INF" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_2_2" unitRef="shares">375319</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="4" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_2_3" unitRef="pure">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:UseOfEstimates contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_D59759DE-FB0F-448F-A9EB-21432941AB81_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The preparation of the condensed consolidated financial statements
 in accordance with U.S. GAAP requires management to make estimates,
 judgments and assumptions that affect the reported amounts of
 assets and liabilities, the reported amounts of revenues and
 expenses in the financial statements and disclosures in the
 accompanying notes. Actual results and outcomes could differ
 materially from management&amp;#x2019;s estimates, judgments and
 assumptions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_15" unitRef="shares">29361566</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:DocumentPeriodEndDate contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_3F7017A0-79F0-42A9-AE36-F3B8DD90A3BD_1_2">2015-06-30</dei:DocumentPeriodEndDate>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="INF" id="id_8654487_E03F59CF-ADCD-45DF-A2A3-404D4A8E28B1_1_0" unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:RevenueRecognitionForAlternativeRevenueProgramsPolicy contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_FC3D8CFE-A95B-4360-BCB8-D48B9E243263_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Milestone Payments and Royalties&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At the inception of each agreement that includes milestone
 payments, Pieris Pharmaceuticals, Inc. evaluates whether each
 milestone is substantive and at risk to both parties on the basis
 of the contingent nature of the milestone. This evaluation includes
 an assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. Pieris
 Pharmaceuticals, Inc. evaluates factors such as the scientific,
 regulatory, commercial and other risks that must be overcome to
 achieve the respective milestone, the level of effort and
 investment required to achieve the respective milestone and whether
 the milestone consideration is reasonable relative to all
 deliverables and payment terms in the arrangement in making this
 assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pieris Pharmaceuticals, Inc. aggregates milestones into three
 categories (i)&amp;#xA0;research milestones, (ii)&amp;#xA0;development
 milestones and (iii)&amp;#xA0;commercial milestones. Research
 milestones are typically achieved upon reaching certain success
 criteria as defined in each agreement related to developing an
 Anticalin protein against the specified target. Development
 milestones are typically reached when a compound reaches a defined
 phase of clinical research or passes such phase, or upon gaining
 regulatory approvals. Commercial milestones are typically achieved
 when an approved pharmaceutical product reaches the status for
 commercial sale or certain defined levels of net sales by the
 licensee, such as when a product first achieves global sales or
 annual sales of a specified amount.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For revenues from research and development milestone payments, if
 the milestones are deemed substantive and the milestone payments
 are nonrefundable, such amounts are recognized entirely upon
 successful accomplishment of the milestones. Milestones that are
 not considered substantive are accounted for as license payments
 and recognized on a straight-line basis over the period of
 performance. To date, Pieris Pharmaceuticals, Inc. has determined
 all milestones are substantive. Revenues from commercial milestone
 payments are accounted for as royalties and are recorded as revenue
 upon achievement of the milestone, assuming all other revenue
 recognition criteria are met. Royalty payments are recognized in
 revenues based on the timing of royalty payments earned in
 accordance with the agreements; which typically is the period when
 the relevant sales occur, assuming all other revenue recognition
 criteria are met.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionForAlternativeRevenueProgramsPolicy>
  <dei:AmendmentFlag contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_3F7017A0-79F0-42A9-AE36-F3B8DD90A3BD_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_81E6E1A9-2A99-4AA6-AE02-8F0468365476_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_3F7017A0-79F0-42A9-AE36-F3B8DD90A3BD_1_3">2015</dei:DocumentFiscalYearFocus>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_9E5B48E6-DCA9-4D20-A617-44343B24D7E1_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Corporate Information&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. is a holding company incorporated in
 May 2013 under the name Marika Inc. On December&amp;#xA0;17, 2014
 Pieris AG (a German company which was founded in 2001 by Prof.
 Dr.&amp;#xA0;Arne Skerra, Professor at the Technical University of
 Munich, Germany, and Claus Schalper) became a wholly owned
 subsidiary of Pieris Pharmaceuticals, Inc., pursuant to the
 Acquisition (described below). The registered office of Pieris
 Pharmaceuticals, Inc. and the corporate headquarters and research
 facility of Pieris AG are located in Freising-Weihenstephan,
 Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of
 Pieris AG, was formed on February&amp;#xA0;14, 2014 to conduct research
 and development in Australia.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On December&amp;#xA0;17, 2014, Pieris Pharmaceuticals, Inc., Pieris AG,
 and the former stockholders of Pieris AG entered into an
 acquisition agreement, or the Acquisition Agreement. Pursuant to
 the Acquisition Agreement, on December&amp;#xA0;17, 2014, the
 stockholders of Pieris AG contributed all of their equity interests
 in Pieris AG to Pieris Pharmaceuticals, Inc. in exchange for shares
 of Pieris Pharmaceuticals, Inc. common stock, which resulted in
 Pieris AG becoming a wholly owned subsidiary of Pieris
 Pharmaceuticals, Inc. (the &amp;#x201C;Acquisition&amp;#x201D;). Upon the
 closing of the Acquisition, Pieris Pharmaceuticals, Inc. ceased to
 be a &amp;#x201C;shell company&amp;#x201D; under applicable rules of the SEC.
 For more information on the acquisition, please refer to Note
 3&amp;#xA0;&lt;i&gt;Acquisition&lt;/i&gt;&amp;#xA0;of the consolidated financial
 statements as of December&amp;#xA0;31, 2014 included in the
 Company&amp;#x2019;s Annual Report on Form 10-K for the fiscal year
 ended December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On December&amp;#xA0;17, 2014, Pieris Pharmaceuticals, Inc. entered
 into a securities purchase agreement, or the Securities Purchase
 Agreement, with certain accredited investors (the
 &amp;#x201C;Investors&amp;#x201D;) providing for the issuance and sale to
 such Investors of an aggregate of 6,779,510 shares of our common
 stock in a private placement offering conducted through a series of
 closings occurring on December&amp;#xA0;17, 18 and 23, 2014, at a
 purchase price per share of $2.00 and for aggregate gross proceeds
 of approximately $13.56 million (the &amp;#x201C;Private
 Placement&amp;#x201D;). Northland Securities, Inc. and Katalyst
 Securities, LLC served as co-exclusive placement agents (the
 &amp;#x201C;Placement Agents&amp;#x201D;) for the Private Placement. At the
 closings of the Private Placement we issued to the Placement Agents
 and their designees, warrants (the &amp;#x201C;Placement
 Warrants&amp;#x201D;), to acquire up to 542,360 shares of our common
 stock at an exercise price of $2.00 per share. Each of the
 Placement Warrants is exercisable at any time at the option of the
 holder until the five-year anniversary of its date of issuance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. and its consolidated subsidiaries (the
 &amp;#x201C;Company&amp;#x201D;) is a clinical-stage biopharmaceutical
 company dedicated to the discovery and development of the
 Anticalin&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;class of biotherapeutics for
 patients with diseases in which the Company believes there is high
 unmet medical need.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#xB4;s core Anticalin&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;technology and platform was
 developed in Germany, and the Company has partnership arrangements
 with major multi-national pharmaceutical companies headquartered in
 the U.S., Europe and Japan and with regional pharmaceutical
 companies headquartered in India.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_181E6C86-DA0F-4F0F-B8CC-81EBFF2A5642_1_0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_4B8D6D2B-06A5-4B25-BD8F-A02A490DBC66_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Public Offering&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On July&amp;#xA0;6, 2015 the Company closed a public offering of an
 aggregate of 9,090,909 shares of the Company&amp;#xB4;s common stock at
 a purchase price of $2.75 per share. All shares of common stock
 were offered by the Company. On July&amp;#xA0;24, 2015 the underwriters
 exercised their over-allotment option to purchase 1,211,827
 additional shares of the Company&amp;#x2019;s common stock at the public
 offering price of $2.75, which sale closed on July&amp;#xA0;28,
 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Gross proceeds raised by the Company in the offering, including the
 exercise of the over-allotment option, were $28.3 million and net
 proceeds are expected to be approximately $25.8 million. The
 Company intends to use the net proceeds from the offering to fund
 research and development, including preclinical and clinical
 research and development of its drug candidates, working capital
 and general corporate purposes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Milestone payment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On July&amp;#xA0;8, 2015 the Company announced that it will receive its
 third milestone payment for the second program in its discovery and
 development collaboration with Daiichi Sankyo, and seventh
 milestone payment overall under the multi program collaboration.
 The amount of payment was not disclosed due to the confidential
 treatment of this agreement. The payment was triggered by the
 achievement of positive&amp;#xA0;&lt;i&gt;in vivo&lt;/i&gt;&amp;#xA0;proof of concept data and
 progression of the Anticalin drug candidate through a non-GLP
 toxicity study in non-human primates. The Company expects to
 receive this milestone payment in the third quarter of 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Cooperation Agreement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On July, 14 the Company entered into a Cooperation Agreement (the
 &amp;#x201C;Cooperation Agreement&amp;#x201D;) with the University of
 Cologne. The University of Cologne provides research services to
 the Company for which it will receive up to two milestone payments.
 For the research services under Milestone 1, the Company shall pay
 the University a net amount of $48,698 (&amp;#x20AC;43.660)&amp;#xA0;in two
 installments. Within thirty days following achievement of Milestone
 1, the Company and University shall mutually agree whether to
 continue with the Cooperation Project. Having agreed on continuing
 with Milestone 2, the Company shall pay the University a net amount
 of $130,301 (&amp;#x20AC;116,820)&amp;#xA0;in two installments.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_81E6E1A9-2A99-4AA6-AE02-8F0468365476_1_2">0001583648</dei:EntityCentralIndexKey>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_A988A26A-BED3-44B5-AA39-9C1699C880BB_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Stock-based compensation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In December 2014, the Board of Directors and stockholders of Pieris
 Pharmaceuticals, Inc. adopted the 2014 Employee, Director and
 Consultant Equity Incentive Plan (the &amp;#x201C;Pieris Plan&amp;#x201D;),
 which became effective upon closing of the Acquisition. The Pieris
 Plan is intended to encourage ownership of common stock by the
 Company&amp;#x2019;s employees and directors and certain of their
 consultants, including employees of Pieris AG, in order to attract
 and retain such people, to induce them to work for the benefit of
 the Company and to provide additional incentive for them to promote
 the Company&amp;#x2019;s success. The Pieris Plan reserves 3,200,000
 shares of the Company&amp;#xB4;s common stock for issuance. In
 addition, the Pieris Plan provides for an &amp;#x201C;evergreen&amp;#x201D;
 provision whereby the number of shares of the Company&amp;#xB4;s common
 stock reserved for issuance under the Pieris Plan shall be
 automatically increased on January&amp;#xA0;1 of each of year
 commencing in fiscal 2016 by the lesser of (i)&amp;#xA0;1,000,000
 shares, (ii)&amp;#xA0;4% of the number of shares of the Company&amp;#xB4;s
 common stock outstanding on such date, and (iii)&amp;#xA0;such other
 amount determined by the Compensation committee of the Board of
 Directors. As of June&amp;#xA0;30, 2015, options to purchase 1,470,235
 shares of the Company&amp;#xB4;s common stock are outstanding under the
 Pieris Plan to its executive officers and directors. 40,235 of
 these shares were granted during the second quarter of 2015. All
 other shares were granted in the fourth quarter of 2014. In
 addition, options to purchase 1,146,500 shares are outstanding
 under the Pieris Plan to other employees and consultants. 25,000 of
 these shares were granted during the first quarter of 2015, 32,000
 of these shares were granted during the second quarter of 2015 and
 1,089,500 were granted during the fourth quarter of 2014. As a
 result of such grants, 583,265 of the Company&amp;#xB4;s common stock
 remain available for future issuances under the Pieris Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Stock options granted under the Pieris Plan may be either incentive
 stock options (&amp;#x201C;ISOs&amp;#x201D;), or nonqualified stock options.
 The Board of Directors determines who will receive options, the
 vesting periods (which are generally three years) and the exercise
 prices. Options have a maximum term of ten years. The exercise
 price of stock options granted under the Pieris Plan must be at
 least equal to the fair market value of the common stock on the
 date of grant. The Pieris Plan become effective in December 2014,
 therefore there was no stock-based compensation expense in the
 three and six months ended June&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense, related to all share-based
 awards under the Pieris Plan to executive officers, directors,
 employees and consultants recognized for the three and six months
 ended June&amp;#xA0;30, 2015, was comprised of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Three&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&amp;#xA0;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and Development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;129,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;189,488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total stock-option expense&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;268,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;485,375&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of option grants was estimated using the
 Black-Scholes model. The following table describes the
 weighted-average assumptions used for calculating the value of
 options granted for the three and six months ended June&amp;#xA0;30,
 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Three&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted average risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 A summary of the Company&amp;#x2019;s stock option activity and related
 information is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Contractual&lt;br /&gt;
 Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,519,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.6&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.8&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options cancelled or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at March&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,544,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.6&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,235&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options cancelled or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,616,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.3&amp;#xA0;-&amp;#xA0;5.8&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested at June 30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;799,068&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expected to vest after June 30,2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,708,607&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;799,068&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The weighted-average grant date fair value for awards granted
 during the three and six months ended June&amp;#xA0;30, 2015 was
 $130,456 and $176,898, respectively. There were no options
 exercised during the three and six months ended June&amp;#xA0;30, 2015
 and 2014. 200,673 and 375,319 shares were vested in the three and
 six months ended June&amp;#xA0;30, 2015, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The unrecognized share-based compensation expense related to
 employee stock option awards at June&amp;#xA0;30, 2015, is $2,253,478,
 which will be recognized over a weighted-average service period of
 2.5 years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="2" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_13" unitRef="iso4217_USD_per_shares">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_7754CB17-D9DE-4E6E-A6BC-1165B6C2714C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &amp;#x201C;Revenue
 from Contracts with Customers,&amp;#x201D; (ASU 2014-09) which provides
 guidance for revenue recognition. The standard&amp;#x2019;s core
 principle is that a company will recognize revenue when it
 transfers promised goods or services to customers in an amount that
 reflects the consideration to which the company expects to be
 entitled in exchange for those goods or services. The new guidance
 is effective for annual reporting periods beginning after
 December&amp;#xA0;15, 2016, including interim periods within that
 reporting period. Early application is not permitted. On
 April&amp;#xA0;1, 2015 the FASB voted in favor of proposing a one year
 delay of the effective date and to permit companies to voluntarily
 adopt the new standard as of the original effective date. The
 Company is currently assessing the potential impact the adoption of
 this standard will have on their financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In January 2015, the FASB issued ASU No.&amp;#xA0;2015-01,&amp;#xA0;&lt;i&gt;&amp;#x201C;Income Statement
 &amp;#x2013; Extraordinary and Unusual items&amp;#x201D;&lt;/i&gt;&amp;#xA0;(ASU 2015-01). The amendments
 in ASU 2015-01 eliminate from U.S. GAAP the concept of
 extraordinary items. Subtopic 225-20, Income Statement -
 Extraordinary and Unusual Items, required that an entity separately
 classify, present, and disclose extraordinary events and
 transactions. Presently, an event or transaction is presumed to be
 an ordinary and usual activity of the reporting entity unless
 evidence clearly supports its classification as an extraordinary
 item. This guidance is effective for fiscal years, and interim
 periods within those fiscal years, beginning after
 December&amp;#xA0;15, 2015. The company is currently evaluating the
 impact of this new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In February 2015, the FASB issued ASU No.&amp;#xA0;2015-02,&amp;#xA0;&lt;i&gt;&amp;#x201C;Consolidation (Topic
 810): Amendments to the Consolidation Analysis&amp;#x201D;&lt;/i&gt;(ASU
 2015-02). The amendments in ASU 2015-02 are intended to improve
 targeted areas of consolidation guidance for legal entities such as
 limited partnerships, limited liability corporations, and
 securitization structures (collateralized debt obligations,
 collateralized loan obligations, and mortgage-backed security
 transactions). This guidance is effective for fiscal years
 beginning after December&amp;#xA0;15, 2016, and interim periods within
 fiscal years beginning after December, 15, 2017. The company is
 currently evaluating the impact of this new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In June 2015, the FASB issued ASU No.&amp;#xA0;2015-10,
 &amp;#x201C;Technical Corrections and Improvements&amp;#x201D; (ASU 2015-10).
 The amendments in ASU 2015-10 represent changes to clarify the FASB
 Accounting Standards Codification (the &amp;#x201C;Codification&amp;#x201D;),
 correct unintended application of guidance, or make minor
 improvements to the Codification that are not expected to have a
 significant effect on current accounting practice or create a
 significant administrative cost to most entities. In addition, some
 of the amendments are intended to make the Codification easier to
 understand and easier to apply by eliminating inconsistencies,
 providing needed clarifications, and improving the presentation of
 guidance in the Codification. This guidance is effective for fiscal
 years, and interim periods within those fiscal years, beginning
 after December&amp;#xA0;15, 2015. The company is currently evaluating
 the impact of this new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Pieris Pharmaceuticals, Inc. has considered other recent accounting
 pronouncements and concluded that they are either not applicable to
 the business, or that the effect is not expected to be material to
 the unaudited condensed consolidated financial statements as a
 result of future adoption.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_3C0DEDF1-1AB8-407E-9E82-D13D1B2BE42F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Pieris Pharmaceuticals, Inc. operates as a single segment dedicated
 to the discovery and development of biotechnological applications
 and the Company&amp;#x2019;s chief operating decision maker (CODM) makes
 decisions based on the Company as a whole. Accordingly, Pieris
 Pharmaceuticals, Inc. operates and makes decisions as one reporting
 unit.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="3" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_2_2" unitRef="pure">0.741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_3F7017A0-79F0-42A9-AE36-F3B8DD90A3BD_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_4E970D87-A416-4921-944C-67B6494C3B3E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 ASC Topic 820 &lt;i&gt;Fair Value Measurement&lt;/i&gt; defines fair value as
 the price that would be received to sell an asset or be paid to
 transfer a liability in an orderly transaction between market
 participants at the measurement date. Pieris Pharmaceuticals, Inc.
 applies the following fair value hierarchy, which prioritizes the
 inputs used to measure fair value into three levels and bases the
 categorization within the hierarchy upon the lowest level of input
 that is available and significant to the fair value
 measurement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 1 inputs are quoted prices in active markets for identical
 assets or liabilities that the reporting entity has the ability to
 access at the measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 2 utilizes quoted market prices in markets that are not
 active, broker or dealer quotations, or alternative pricing sources
 with reasonable levels of price transparency.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 3 inputs are unobservable inputs for the asset or liability
 in which there is little, if any, market activity for the asset or
 liability at the measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist
 of highly liquid money market funds and are measured at fair value
 on a recurring basis. These funds are classified as Level 1 in the
 fair value hierarchy because they are valued using quoted prices
 for the periods ended June&amp;#xA0;30, 2015 and December&amp;#xA0;31,
 2014. The carrying amounts of $78,403 and $ 4,800,573 as of
 June&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, respectively, equal
 the fair value of the cash equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s other financial instruments include debt
 instruments, prepaid expenses, other current assets, accounts
 payable, accrued expenses and other current liabilities and are
 classified as Level 2 within the fair value hierarchy. The fair
 value of these instruments was determined using the discounted cash
 flow method based on contractual cash flows and the current rate at
 which debt with similar terms could be issued. The fair values for
 these debt instruments approximated carrying values as of
 June&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="INF" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_2_1" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_29" unitRef="iso4217_USD">1206</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="INF" id="id_8654487_F574C5D5-CBB0-4602-931C-FA25ADCA0412_1_0" unitRef="iso4217_USD">0</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_3_3" unitRef="iso4217_USD">-500597</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_21" unitRef="iso4217_USD">1171170</us-gaap:RepaymentsOfDebt>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_9" unitRef="iso4217_USD">-7234733</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_5" unitRef="iso4217_USD">-7235763</us-gaap:OperatingIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_3_4" unitRef="iso4217_USD">-7735330</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_8" unitRef="iso4217_USD">5253</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_3_2" unitRef="iso4217_USD">-500597</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_0" unitRef="iso4217_USD">377864</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_17" unitRef="iso4217_USD">74286</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_11" unitRef="iso4217_USD">-7234733</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_28" unitRef="iso4217_USD">4224</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_10" unitRef="iso4217_USD">628723</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_11" unitRef="iso4217_USD">768905</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_C981CF0D-BC15-45D3-ABF9-30C14302B58A_2_2" unitRef="iso4217_USD">485375</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:InterestExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_7" unitRef="iso4217_USD">4223</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_2" unitRef="iso4217_USD">3250222</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInIncomeTaxes contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="INF" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_14" unitRef="iso4217_USD">-2365</us-gaap:IncreaseDecreaseInIncomeTaxes>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_24" unitRef="iso4217_USD">-8446906</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_13" unitRef="iso4217_USD">30481</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_6" unitRef="iso4217_USD">390734</us-gaap:RestrictedStockExpense>
  <us-gaap:Depreciation contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_3" unitRef="iso4217_USD">154555</us-gaap:Depreciation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_22" unitRef="iso4217_USD">-1171170</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_18" unitRef="iso4217_USD">-72286</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CostsAndExpenses contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_4" unitRef="iso4217_USD">7613627</us-gaap:CostsAndExpenses>
  <us-gaap:LossContingencyDamagesAwardedValue contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A1BF3CD4-56BE-4DCE-B2D7-96A596CEEFA4_1_0" unitRef="iso4217_EUR">3500000</us-gaap:LossContingencyDamagesAwardedValue>
  <us-gaap:LossContingencyDamagesAwardedValue contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A1BF3CD4-56BE-4DCE-B2D7-96A596CEEFA4_2_0" unitRef="iso4217_USD">4235350</us-gaap:LossContingencyDamagesAwardedValue>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_23" unitRef="iso4217_USD">-524998</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_3_3" unitRef="iso4217_USD">4363405</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_5" unitRef="iso4217_USD">485374</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="0" id="id_8654487_4D80C46E-7958-415D-8919-ADD23A18A7B4_1_12" unitRef="iso4217_USD">897130</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_8001_11" unitRef="iso4217_USD_per_shares">2.03</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="3" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_2_0" unitRef="pure">0.060</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
  <pirs:BasisOfConsolidationPolicyTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_2C7613FD-3104-4AC8-93C9-385C786BF7A5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Basis of Consolidation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The accompanying unaudited condensed consolidated financial
 statements of Pieris Pharmaceuticals Inc. and its wholly owned
 subsidiaries were prepared in accordance with accounting principles
 generally accepted in the United States (&amp;#x201C;U.S. GAAP&amp;#x201D;)
 for interim financial information. All significant intercompany
 balances and transactions have been eliminated in the
 consolidation. Certain information and footnotes normally included
 in financial statement prepared in accordance with U.S. GAAP have
 been omitted pursuant to the Securities and Exchange Commission
 rules and regulations. Accordingly, they do not include all of the
 information and notes required by U.S. GAAP for complete annual
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In the opinion of management, the unaudited interim condensed
 consolidated financial statements have been prepared on the same
 basis as the audited condensed consolidated financial statements
 for the year ending December&amp;#xA0;31, 2014, and all adjustments,
 including normal recurring adjustments, considered necessary for a
 fair presentation of Pieris Pharmaceuticals, Inc.&amp;#x2019;s unaudited
 interim consolidated financial statements have been included. The
 results of operations for the three and six months ended
 June&amp;#xA0;30, 2015 are not necessarily indicative of the results
 that may be expected for the year ending December&amp;#xA0;31, 2015 or
 any future period.&lt;/p&gt;
 &lt;/div&gt;</pirs:BasisOfConsolidationPolicyTextBlock>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_8001_10" unitRef="iso4217_USD_per_shares">2.03</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice>
  <pirs:ClassOfWarrantsAndRightsTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_45F48EA1-8C64-4818-843B-4963A8776340_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with the Private Placement in December 2014, the
 Company issued the Placement Warrants to acquire combined up to
 542,360 shares of its common stock at an exercise price of two
 dollars per share ($2.00) to the Placement Agents and their
 designees during December 2014. The Placement Warrants are
 exercisable at any time at the option of the holder until the five
 year anniversary of its date of issuance. The number of shares of
 common stock issuable upon the exercise of each Placement Warrant
 is adjustable in the event of certain stock dividends, stock
 splits, combinations of shares and similar transactions. Upon
 exercise, the aggregate exercise price of the warrants issued are
 payable by the holders in cash.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company estimated the fair value of the Placement Warrants as
 of the grant date to be $664,064 and recognized the full amount in
 general and administrative expense for the year ended
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;/div&gt;</pirs:ClassOfWarrantsAndRightsTextBlock>
  <pirs:ConsultingSharesDisclosureTextBlock contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0" id="id_8654487_6C7FC1FD-8131-4DE4-80FD-EEACBCEE90CC_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Consulting Shares&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;6, 2015, the Company entered into an independent
 consulting agreement (the &amp;#x201C;Consulting Agreement&amp;#x201D;) with
 the Del Mar Consulting Group, Inc. and Alex Partners, LLC (the
 &amp;#x201C;Consultants&amp;#x201D;), pursuant to which the Company issued
 150,000 restricted shares of its common stock (par value $0.01 per
 share) to the Consultants (the &amp;#x201C;Consulting Shares&amp;#x201D;).
 The Company agreed to retain the Consultants to provide investor
 relations consulting to the Company for a period commencing on
 March&amp;#xA0;6, 2015 (the &amp;#x201C;Commencement Date&amp;#x201D;) and ending
 thirteen months after the Commencement Date (such period, the
 &amp;#x201C;Term&amp;#x201D;). The shares issued in connection with the
 Consulting Agreement were deemed to be exempt from registration in
 reliance upon Section&amp;#xA0;4(a)(2) of the Securities Act as a
 transaction by an issuer not involving any public offering.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The terms of the Consulting Agreement state, that the Company has
 the right to terminate this agreement at any time during the Term
 of the Consulting Agreement, upon providing Consultants ten
 days&amp;#x2019; written notice of Company&amp;#x2019; intention to terminate
 or immediately upon notice in the event of a breach of this
 agreement by either consultant. If the Company delivers notice to
 terminate this agreement for any reason within one hundred eighty
 days (180)&amp;#xA0;following the effective date (the &amp;#x201C;Return
 Date&amp;#x201D;), then each Consultant will promptly return and
 surrender to the Company forty percent (40%)&amp;#xA0;of the number of
 Consulting Shares issued to it. Therefore 60,000 of these shares
 are subject to certain forfeiture provisions within 180 days
 following the date of entry into the Consulting Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company, using the Black-Scholes method, estimated the fair
 value of the 90,000 non-cancellable Consulting Shares to be
 $284,400 based on the closing price per share of $3.16 as quoted on
 the OTCQB tier of the OTC Markets Group Inc., or the OTCQB, on the
 grant date, March&amp;#xA0;6, 2015. The Company estimated the fair
 value of the 60,000 cancellable Consulting Shares to be $192,000
 based on the closing price per share of $3.20 as quoted on the
 OTCQB on the interim financial reporting date, March&amp;#xA0;31, 2015.
 Therefore, the Company estimated the total fair value of the
 Consulting Shares to be $476,400 and recognized the 90,000 vested
 non-cancellable Consulting Shares, or sixty percent (60%)&amp;#xA0;of
 the Consulting Shares in an amount of $284,400, as general and
 administrative expense for the six months ended June&amp;#xA0;30, 2015.
 The remaining forty percent (40%), or 60,000 Consulting Shares in
 the amount of $192,000, will be recognized as general and
 administrative expenses with an offsetting credit to equity on a
 straight-line basis over 180 days. If the Company exercises the
 option to terminate the Consulting Agreement within the 180 days,
 resulting in the cancellation of forty percent (40%)&amp;#xA0;of the
 Consulting Shares, expense for cancelled, unvested shares will be
 reversed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On June&amp;#xA0;30, 2015 the Company revalued the fair value of the
 unvested and forfeitable 40% of the shares. As of June&amp;#xA0;30,
 2015 the estimated fair value of the 60,000 unvested and
 forfeitable shares was $165,000. Therefore the Company recognized
 expenses in connection with the Consulting Shares of $79,666 in
 general and administrative expenses for the cancellable Consulting
 Shares during the three months ended June&amp;#xA0;30, 2015. For the
 six months ended June&amp;#xA0;30, 2015 the Company recognized $390,733
 in general and administrative expenses, including $284,400 for the
 non-cancellable Consulting Shares and $106,333 for the cancellable
 shares.&lt;/p&gt;


 &lt;/div&gt;</pirs:ConsultingSharesDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1275948" id="id_8654487_6F0670D7-8B53-4014-BBDD-C5875065102C_4_0">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1275948" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_4002_5">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1275948" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_4002_4">P5Y9M18D</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1277596" id="id_8654487_6F0670D7-8B53-4014-BBDD-C5875065102C_3_0">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1277596" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_4001_5">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1277596" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_4001_4">P5Y3M18D</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1315471_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_1003_1" unitRef="iso4217_USD">0</us-gaap:RecognitionOfDeferredRevenue>
  <pirs:ResearchCollaborationAgreementPeriod contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1315471_1279908x1273746" id="id_8654487_4F92CDB5-734F-4356-A1FA-77035DD457BF_1001_0">P2Y</pirs:ResearchCollaborationAgreementPeriod>
  <us-gaap:RevenueRecognitionMilestoneMethodFactors contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1515548_1279908x1273746" id="id_8654487_27777928-91AC-4C3A-BEF3-324C9A907CF2_1001_0">Factors considered in determining the options were substantive were whether (i)&#xA0;Sanofi could obtain the overall objective of the agreement without exercising any options, (ii)&#xA0;Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii)&#xA0;the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv)&#xA0;exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.</us-gaap:RevenueRecognitionMilestoneMethodFactors>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1515548_1279908x1273746" decimals="INF" id="id_8654487_35861A84-6B0A-43C4-9790-416415919AD0_1002_0" unitRef="iso4217_USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1515548_1279908x1273746" decimals="INF" id="id_8654487_E03918CC-29B3-4EDC-B0A0-B18C63546D39_1002_0" unitRef="iso4217_USD">0</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1570417_1279908x1273746" decimals="INF" id="id_8654487_C5EF6866-BDFE-41DD-A5D7-2BF5A47E6C74_1001_0" unitRef="iso4217_USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:DebtInstrumentPaymentTerms contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1611978" id="id_8654487_80D889E6-3337-40D7-A2CD-9EEB1D4B2A75_3_2">Under the  repayment agreement, the Company has agreed to a payment schedule pursuant to  which it will make semi-annual payments until 2016.</us-gaap:DebtInstrumentPaymentTerms>
  <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_2003_3" unitRef="iso4217_EUR">118688</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
  <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1611978" decimals="0" id="id_8654487_536F28CA-CF5E-4C5B-AC56-3996916614FB_1003_4" unitRef="iso4217_USD">132385</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274159x1269133" decimals="0" id="id_8654487_C981CF0D-BC15-45D3-ABF9-30C14302B58A_1002_1" unitRef="iso4217_USD">355785</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274159x1269570" decimals="0" id="id_8654487_C981CF0D-BC15-45D3-ABF9-30C14302B58A_2002_0" unitRef="iso4217_USD">129590</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ProfessionalAndContractServicesExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="0" id="id_8654487_7C52409A-2E69-4B9D-BC44-C3F44E73733C_1003_0" unitRef="iso4217_USD">11157</us-gaap:ProfessionalAndContractServicesExpense>
  <pirs:AgreementTerminationNoticePeriod contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" id="id_8654487_6B496C22-714B-4F3B-80CA-BD544883F6B9_1001_0">P180D</pirs:AgreementTerminationNoticePeriod>
  <pirs:NumberOfUnvestedShares contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="INF" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_1002_1" unitRef="pure">60000</pirs:NumberOfUnvestedShares>
  <pirs:FairValueOfUnvestedStockOptionsAssumed contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="0" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_1002_2" unitRef="iso4217_USD">165000</pirs:FairValueOfUnvestedStockOptionsAssumed>
  <pirs:TerminationAgreementPercentageOfSharesReturned contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="INF" id="id_8654487_6B496C22-714B-4F3B-80CA-BD544883F6B9_1001_1" unitRef="pure">0.40</pirs:TerminationAgreementPercentageOfSharesReturned>
  <pirs:SharesSubjectToForfeiture contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="INF" id="id_8654487_6B496C22-714B-4F3B-80CA-BD544883F6B9_1001_2" unitRef="shares">60000</pirs:SharesSubjectToForfeiture>
  <pirs:EstimatedFairValueOfConsultingSharesNet contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="0" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1002_6" unitRef="iso4217_USD">476400</pirs:EstimatedFairValueOfConsultingSharesNet>
  <pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="0" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_1002_4" unitRef="iso4217_USD">390733</pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares>
  <pirs:PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="INF" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1002_9" unitRef="pure">0.60</pirs:PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense>
  <pirs:PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="INF" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1002_10" unitRef="pure">0.40</pirs:PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity>
  <pirs:RevaluationOfUnvestedAndForfeitableSharesPercent contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085" decimals="2" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_1002_0" unitRef="pure">0.40</pirs:RevaluationOfUnvestedAndForfeitableSharesPercent>
  <pirs:EstimatedFairValueOfConsultingSharesNet contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085_1276400x1966640" decimals="0" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_2002_7" unitRef="iso4217_USD">284400</pirs:EstimatedFairValueOfConsultingSharesNet>
  <pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085_1276400x1966640" decimals="0" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_2002_5" unitRef="iso4217_USD">284400</pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares>
  <pirs:EstimatedFairValueOfConsultingSharesNet contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085_1276400x1966641" decimals="0" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_3002_8" unitRef="iso4217_USD">192000</pirs:EstimatedFairValueOfConsultingSharesNet>
  <pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085_1276400x1966641" decimals="0" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_3002_6" unitRef="iso4217_USD">106333</pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares>
  <pirs:ExpectedPatentExpirationYear contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1277337x1416981" id="id_8654487_F8E1BFD3-A675-40FB-AEB7-50E64BB87903_1001_1">2029</pirs:ExpectedPatentExpirationYear>
  <us-gaap:CostsAndExpensesRelatedParty contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1003_1" unitRef="iso4217_USD">27893</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:LicenseCosts contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1003_0" unitRef="iso4217_USD">27893</us-gaap:LicenseCosts>
  <pirs:PatentExpirationYear contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1279431x1611680" id="id_8654487_F8E1BFD3-A675-40FB-AEB7-50E64BB87903_2001_0">2027</pirs:PatentExpirationYear>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_3_0" unitRef="iso4217_USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription contextRef="eol_PE913859--1510-Q0003_STD_181_20150630_0_1280964x1626494" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_1_1">(i) 1,000,000 shares, (ii) 4% of the number of shares of  the Company's common stock outstanding on such date, and (iii) such other amount  determined by the Compensation committee of the Board of Directors. As of  June 30, 2015, options to purchase 1,470,235 shares of the Company's common  stock are outstanding under the Pieris Plan to its executive officers and  directors. 40,235 of these shares were granted during the second quarter of  2015. All other shares were granted in the fourth quarter of 2014.</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription>
  <pirs:WarrantExercisablePeriod contextRef="eol_PE913859--1510-Q0003_STD_26_20141231_0" id="id_8654487_9FC587B7-1974-48E3-A468-0EBACBEDE254_1_2">P5Y</pirs:WarrantExercisablePeriod>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE913859--1510-Q0003_STD_30_20100930_0_1272072x1515548_1279908x1273746_1280342x1273416" decimals="-5" id="id_8654487_87708B91-4B19-44EC-8B57-538B3DE6E5D9_1001_0" unitRef="iso4217_USD">4900000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE913859--1510-Q0003_STD_31_20110531_0_1272072x1315471_1279908x1273746_1280342x1273416" decimals="-5" id="id_8654487_878E2C16-9353-444D-BF35-AC11F39B553F_1001_0" unitRef="iso4217_USD">10100000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE913859--1510-Q0003_STD_31_20090831_0_1272072x1570417_1279908x1273746_1280342x1273416" decimals="-6" id="id_8654487_14B9E489-56A0-4FEB-9284-EEA88D4FD428_1001_0" unitRef="iso4217_USD">10000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_365_20111231_0_1269778x1562408_1272072x1515548_1279908x1273746" decimals="-5" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_3002_7" unitRef="iso4217_USD">700000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE913859--1510-Q0003_STD_365_20141231_0" decimals="0" id="id_8654487_0DBD629D-4912-41A0-AEE1-9199F7257929_1_0" unitRef="iso4217_USD">664064</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE913859--1510-Q0003_STD_365_20141231_0_1269523x1275948" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_1002_1">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE913859--1510-Q0003_STD_365_20141231_0_1269523x1277596" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_1001_1">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <pirs:ResearchCollaborationAgreementPeriod contextRef="eol_PE913859--1510-Q0003_STD_366_20121231_0_1269778x1335931_1272072x1515548_1277733x1387995_1279908x1273746" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_1003_6">P40M</pirs:ResearchCollaborationAgreementPeriod>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_366_20121231_0_1269778x1424613_1272072x1515548_1279908x1273746" decimals="-4" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_2003_10" unitRef="iso4217_USD">350000</us-gaap:RecognitionOfDeferredRevenue>
  <pirs:ResearchCollaborationAgreementPeriod contextRef="eol_PE913859--1510-Q0003_STD_366_20121231_0_1272072x1515548_1277733x1387995_1279908x1273746" id="id_8654487_45D7C8D4-8440-4FAC-8D7F-0A108111C7CF_4003_5">P2Y</pirs:ResearchCollaborationAgreementPeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_15" unitRef="shares">11828974</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="2" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_13" unitRef="iso4217_USD_per_shares">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="INF" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_3_1" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_2_3" unitRef="iso4217_USD">6654</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_9" unitRef="iso4217_USD">-2881637</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_5" unitRef="iso4217_USD">-2769925</us-gaap:OperatingIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_2_4" unitRef="iso4217_USD">-2874983</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_8" unitRef="iso4217_USD">2081</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_2_2" unitRef="iso4217_USD">6654</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_0" unitRef="iso4217_USD">698227</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_11" unitRef="iso4217_USD">-2881637</us-gaap:NetIncomeLoss>
  <us-gaap:InterestExpense contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_7" unitRef="iso4217_USD">113793</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_2" unitRef="iso4217_USD">1118920</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_4" unitRef="iso4217_USD">3468152</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_2_3" unitRef="iso4217_USD">2349232</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1272072x1315471_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_1004_1" unitRef="iso4217_USD">400000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1272072x1515548_1279908x1273746" decimals="INF" id="id_8654487_35861A84-6B0A-43C4-9790-416415919AD0_1003_0" unitRef="iso4217_USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1272072x1515548_1279908x1273746" decimals="-5" id="id_8654487_E03918CC-29B3-4EDC-B0A0-B18C63546D39_1003_0" unitRef="iso4217_USD">200000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:ProfessionalAndContractServicesExpense contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1274544x1434085" decimals="0" id="id_8654487_7C52409A-2E69-4B9D-BC44-C3F44E73733C_1002_0" unitRef="iso4217_USD">6858</us-gaap:ProfessionalAndContractServicesExpense>
  <us-gaap:CostsAndExpensesRelatedParty contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1002_1" unitRef="iso4217_USD">17145</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:LicenseCosts contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1002_0" unitRef="iso4217_USD">17145</us-gaap:LicenseCosts>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_88_20140630_0_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_4_2" unitRef="iso4217_USD">400000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" decimals="0" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_4001_3" unitRef="iso4217_USD_per_shares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_4001_400002" unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" decimals="0" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_4001_4" unitRef="iso4217_USD_per_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_4001_4" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_4001_2" unitRef="iso4217_USD_per_shares">2.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_4001_3" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_2003_2">P5Y9M18D</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1269523x1275948" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_2002_3">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1269523x1277596" id="id_8654487_D8D5A0DF-3578-4C43-92C5-9BE863809F69_2001_3">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1273383x1487857_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_2002_5" unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <pirs:NumberOfNonCancellableShares contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1274544x1434085" decimals="INF" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1001_0" unitRef="shares">90000</pirs:NumberOfNonCancellableShares>
  <pirs:NumberOfCancellableShares contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1274544x1434085" decimals="INF" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1001_3" unitRef="shares">60000</pirs:NumberOfCancellableShares>
  <pirs:EstimatedFairValueOfNonCancellableSharesValue contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1274544x1434085" decimals="0" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1001_1" unitRef="iso4217_USD">284400</pirs:EstimatedFairValueOfNonCancellableSharesValue>
  <pirs:EstimatedFairValueOfCancellableSharesValue contextRef="eol_PE913859--1510-Q0003_STD_90_20150331_0_1274544x1434085" decimals="0" id="id_8654487_F313C11F-0033-4222-B793-AD390D371426_1001_4" unitRef="iso4217_USD">192000</pirs:EstimatedFairValueOfCancellableSharesValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_7001_7" unitRef="iso4217_USD_per_shares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_1_0" unitRef="iso4217_USD_per_shares">130456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="3" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_1_1" unitRef="pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_7001_400006" unitRef="shares">72235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="INF" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_1_2" unitRef="shares">200673</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="4" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_1_3" unitRef="pure">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_15" unitRef="shares">29429522</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_7001_8" unitRef="iso4217_USD_per_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="INF" id="id_8654487_039FDDA5-5AC0-4ADB-BF07-30D1FB5BC897_7001_8" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="2" id="id_8654487_64CE8821-0B48-4DEB-9C4C-F2F38738B9CE_7001_6" unitRef="iso4217_USD_per_shares">2.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="2" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_13" unitRef="iso4217_USD_per_shares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="3" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_1_2" unitRef="pure">0.737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="INF" id="id_8654487_D8A5340B-8C99-4BFA-B856-D222F8B645A1_1_1" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_1_3" unitRef="iso4217_USD">102135</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_9" unitRef="iso4217_USD">-3529999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_5" unitRef="iso4217_USD">-3534430</us-gaap:OperatingIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_1_4" unitRef="iso4217_USD">-3427864</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_8" unitRef="iso4217_USD">4484</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_0C2F7D38-A819-4864-856A-9BC200B425C8_1_2" unitRef="iso4217_USD">102135</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_0" unitRef="iso4217_USD">160244</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_11" unitRef="iso4217_USD">-3529999</us-gaap:NetIncomeLoss>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_C981CF0D-BC15-45D3-ABF9-30C14302B58A_1_2" unitRef="iso4217_USD">268039</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:InterestExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_7" unitRef="iso4217_USD">53</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_2" unitRef="iso4217_USD">1725592</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_4" unitRef="iso4217_USD">3694674</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="0" id="id_8654487_A9BD80A0-FA57-42B2-B5E2-4C49C6A17355_1_3" unitRef="iso4217_USD">1969082</us-gaap:GeneralAndAdministrativeExpense>
  <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0" decimals="3" id="id_8654487_AB194D67-396B-4964-832E-6B4A8546CB0C_1_0" unitRef="pure">0.060</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1269523x1275948" id="id_8654487_6F0670D7-8B53-4014-BBDD-C5875065102C_2_0">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1269523x1277596" id="id_8654487_6F0670D7-8B53-4014-BBDD-C5875065102C_1_0">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1272072x1315471_1279908x1273746" decimals="-5" id="id_8654487_7BB81D6F-0AFE-4B47-A900-4AC8C58B09AF_1002_1" unitRef="iso4217_USD">0</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1272072x1515548_1279908x1273746" decimals="INF" id="id_8654487_35861A84-6B0A-43C4-9790-416415919AD0_1001_0" unitRef="iso4217_USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1272072x1515548_1279908x1273746" decimals="INF" id="id_8654487_E03918CC-29B3-4EDC-B0A0-B18C63546D39_1001_0" unitRef="iso4217_USD">0</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1273383x1294863_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_1003_3" unitRef="shares">40235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1273383x1487857_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_2003_5" unitRef="shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274159x1269133" decimals="0" id="id_8654487_C981CF0D-BC15-45D3-ABF9-30C14302B58A_1001_1" unitRef="iso4217_USD">189488</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274159x1269570" decimals="0" id="id_8654487_C981CF0D-BC15-45D3-ABF9-30C14302B58A_2001_0" unitRef="iso4217_USD">78551</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ProfessionalAndContractServicesExpense contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274544x1434085" decimals="0" id="id_8654487_7C52409A-2E69-4B9D-BC44-C3F44E73733C_1001_0" unitRef="iso4217_USD">5534</us-gaap:ProfessionalAndContractServicesExpense>
  <pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274544x1434085_1276400x1966641" decimals="0" id="id_8654487_0C1F15CC-1C83-4279-99F2-A786134FBB51_3001_3" unitRef="iso4217_USD">79666</pirs:GeneralAndAdministrativeExpenseRecognizedInConsultingShares>
  <us-gaap:CostsAndExpensesRelatedParty contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1001_1" unitRef="iso4217_USD">13836</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:LicenseCosts contextRef="eol_PE913859--1510-Q0003_STD_91_20150630_0_1279431x1611680" decimals="0" id="id_8654487_50D3029A-6ADE-4DC8-9066-DF8E0335EC79_1001_0" unitRef="iso4217_USD">13836</us-gaap:LicenseCosts>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE913859--1510-Q0003_STD_92_20141231_0_1273383x1487857_1280964x1626494" decimals="INF" id="id_8654487_1CEAA199-64E1-491B-BC50-7B64356C3F35_2004_5" unitRef="shares">1089500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <context id="eol_PE913859--1510-Q0003_STD_92_20141231_0_1273383x1487857_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pirs:EmployeesAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274544x1434085_1276400x1966641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:CancellableSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274544x1434085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1273383x1487857_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pirs:EmployeesAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1273383x1294863_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1272072x1315471_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_90_20150331_0_1274544x1434085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_90_20150331_0_1273383x1487857_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pirs:EmployeesAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_90_20150331_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_90_20150331_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_88_20140630_0_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_88_20140630_0_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_88_20140630_0_1274544x1434085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_88_20140630_0_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_88_20140630_0_1272072x1315471_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_88_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2014-04-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_366_20121231_0_1272072x1515548_1277733x1387995_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_366_20121231_0_1269778x1424613_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:OptionsExercisedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_366_20121231_0_1269778x1335931_1272072x1515548_1277733x1387995_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:ExtensionTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_365_20141231_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_365_20141231_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_365_20111231_0_1269778x1562408_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:ExpiredOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_31_20090831_0_1272072x1570417_1279908x1273746_1280342x1273416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:AllerganIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-08-01</startDate>
      <endDate>2009-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_31_20110531_0_1272072x1315471_1279908x1273746_1280342x1273416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-05-01</startDate>
      <endDate>2011-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_30_20100930_0_1272072x1515548_1279908x1273746_1280342x1273416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-09-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_26_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2014-12-06</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1277337x1416981">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pirs:PatentOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085_1276400x1966641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:CancellableSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085_1276400x1966640">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:NonCancellableSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274544x1434085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1570417_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:AllerganIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1272072x1315471_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20140630_0_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20140630_0_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20140630_0_1274544x1434085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20140630_0_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20140630_0_1272072x1315471_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_181_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20150724_0_1271378x1273350_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-24</startDate>
      <endDate>2015-07-24</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20150714_0_1271378x1273350_1298684x1569519_1528160x1343859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="pirs:AgreementTypeAxis">pirs:CooperationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="pirs:MilestoneEventsAxis">pirs:MilestoneOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-14</startDate>
      <endDate>2015-07-14</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20150714_0_1271378x1273350_1298684x1560953_1528160x1343859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="pirs:AgreementTypeAxis">pirs:CooperationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="pirs:MilestoneEventsAxis">pirs:MilestoneTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-14</startDate>
      <endDate>2015-07-14</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20150706_0_1271378x1273350_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20150706_0_1271378x1273350">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20141223_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-12-23</startDate>
      <endDate>2014-12-23</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20141223_0_1271382x1277719">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-12-23</startDate>
      <endDate>2014-12-23</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20141223_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <startDate>2014-12-23</startDate>
      <endDate>2014-12-23</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_1_20141211_0_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-12-11</startDate>
      <endDate>2014-12-11</endDate>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20141231_0_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20141231_0_1269038x1272304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1273383x1487857_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pirs:EmployeesAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1273383x1294863_1280964x1626494">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:PierisPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1626491_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:OutLicenseFeeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1626491">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:OutLicenseFeeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1272896x1557983_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1269523x1275948_1272072x1570417_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:AllerganIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0_1269038x1272304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150331_0_1274544x1434085_1276400x1966641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:CancellableSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150331_0_1274544x1434085_1276400x1966640">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:NonCancellableSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150331_0_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150331_0_1270482x1275486_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20140630_0_1272896x1557983_1279431x1611680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pirs:TumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1277733x1459186_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pirs:LicenseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1277733x1387995_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1272072x1515548_1277733x1320953_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pirs:LicensingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1272896x1592441_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1272896x1561390_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20100930_0_1269523x1275948_1272072x1515548_1272896x1479887_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:CommercialMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150724_0_1271378x1273350_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-24</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150706_0_1271378x1273350_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-06</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1592441_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1591420_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:AdditionalMilestonePaymentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1561390_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20110531_0_1269523x1275948_1272072x1315471_1272896x1479887_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:DaiichiSankyoIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:CommercialMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150306_0_1274544x1434085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pirs:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-06</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20140403_0_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-04-03</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150813_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2015-08-13</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20150131_0_1270482x1270483_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20141223_0_1271382x1277719">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-23</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20141223_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
    </entity>
    <period>
      <instant>2014-12-23</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20141211_0_1272072x1611978">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:TbgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-11</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20130228_0_1269778x1424613_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:OptionsExercisedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <context id="eol_PE913859--1510-Q0003_STD_0_20130228_0_1269778x1386521_1272072x1515548_1279908x1273746">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pirs:SanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:OptionsExercisedPriceOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Tranches">
    <measure>pirs:Tranches</measure>
  </unit>
  <unit id="Segment">
    <measure>pirs:Segment</measure>
  </unit>

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>pirs-20150630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 2 -->
<!-- Creation date: 2015-08-12T12:09:49Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
  xmlns:us-types="http://fasb.org/us-types/2014-01-31"
  xmlns:pirs="http://www.pieris.com/20150630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.pieris.com/20150630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome" id="Role_StatementOfOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>108 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>110 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>111 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>112 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>113 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>114 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock" id="Role_NotesToFinancialStatementsConsultingSharesDisclosureTextBlock">
        <link:definition>115 - Disclosure - Consulting Shares</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock" id="Role_NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock">
        <link:definition>116 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>117 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>119 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
        <link:definition>120 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
        <link:definition>121 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>122 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation" id="DisclosureCorporateInformationAdditionalInformation">
        <link:definition>123 - Disclosure - Corporate Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation" id="DisclosureRevenuesAdditionalInformation">
        <link:definition>125 - Disclosure - Revenues - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation" id="DisclosureRelatedPartyTransactionAdditionalInformation">
        <link:definition>126 - Disclosure - Related Party Transaction - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses" id="DisclosureRelatedPartyTransactionsRelatedPartyExpenses">
        <link:definition>127 - Disclosure - Related-Party Transactions - Related Party Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation" id="DisclosureDebtAdditionalInformation">
        <link:definition>128 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses" id="DisclosureAccruedExpensesScheduleOfAccruedExpenses">
        <link:definition>129 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation" id="DisclosureStockbasedCompensationAdditionalInformation">
        <link:definition>130 - Disclosure - Stock-based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan" id="DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan">
        <link:definition>131 - Disclosure - Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted" id="DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted">
        <link:definition>132 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity" id="DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity">
        <link:definition>133 - Disclosure - Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation" id="DisclosureConsultingSharesAdditionalInformation">
        <link:definition>134 - Disclosure - Consulting Shares - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation" id="DisclosureWarrantsAdditionalInformation">
        <link:definition>135 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>136 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>137 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="pirs-20150630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="pirs-20150630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="pirs-20150630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="pirs-20150630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedTaxAuditAndLegalFees" id="pirs_AccruedTaxAuditAndLegalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalMilestonePaymentMember" id="pirs_AdditionalMilestonePaymentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementTerminationNoticePeriod" id="pirs_AgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementTypeAxis" id="pirs_AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="AgreementTypeDomain" id="pirs_AgreementTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllerganIncMember" id="pirs_AllerganIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BasisOfConsolidationPolicyTextBlock" id="pirs_BasisOfConsolidationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CancellableSharesMember" id="pirs_CancellableSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantsAndRightsTextBlock" id="pirs_ClassOfWarrantsAndRightsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercialMilestonesMember" id="pirs_CommercialMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentContingencyAndRelatedPartyTransactionsAbstract" id="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsultingAgreementMember" id="pirs_ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsultingSharesDisclosureTextBlock" id="pirs_ConsultingSharesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CooperationAgreementMember" id="pirs_CooperationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DaiichiSankyoIncMember" id="pirs_DaiichiSankyoIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentMilestonePaymentsMember" id="pirs_DevelopmentMilestonePaymentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract" id="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="pirs_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeesAndConsultantsMember" id="pirs_EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityMethodInvestmentsAndCostMethodInvestmentsAbstract" id="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedFairValueOfCancellableSharesValue" id="pirs_EstimatedFairValueOfCancellableSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedFairValueOfConsultingSharesNet" id="pirs_EstimatedFairValueOfConsultingSharesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedFairValueOfNonCancellableSharesValue" id="pirs_EstimatedFairValueOfNonCancellableSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExecutiveOfficersAndDirectorsMember" id="pirs_ExecutiveOfficersAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExpectedPatentExpirationYear" id="pirs_ExpectedPatentExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExpiredOptionAgreementMember" id="pirs_ExpiredOptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExtensionTermMember" id="pirs_ExtensionTermMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfUnvestedStockOptionsAssumed" id="pirs_FairValueOfUnvestedStockOptionsAssumed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GeneralAndAdministrativeExpenseRecognizedInConsultingShares" id="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrossProceedsFromIssuanceInitialPublicOffering" id="pirs_GrossProceedsFromIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementMember" id="pirs_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseOptionMember" id="pirs_LicenseOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicensingMember" id="pirs_LicensingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneEventsAxis" id="pirs_MilestoneEventsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="MilestoneEventsDomain" id="pirs_MilestoneEventsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneOneMember" id="pirs_MilestoneOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneTwoMember" id="pirs_MilestoneTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCancellableSharesMember" id="pirs_NonCancellableSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfCancellableShares" id="pirs_NumberOfCancellableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfNonCancellableShares" id="pirs_NumberOfNonCancellableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfTranches" id="pirs_NumberOfTranches" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfUnvestedShares" id="pirs_NumberOfUnvestedShares" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionsExercisedMember" id="pirs_OptionsExercisedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionsExercisedPriceOneMember" id="pirs_OptionsExercisedPriceOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndDescriptionOfBusinessLineItems" id="pirs_OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndDescriptionOfBusinessTable" id="pirs_OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OutLicenseFeeMember" id="pirs_OutLicenseFeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentExpirationYear" id="pirs_PatentExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentOneMember" id="pirs_PatentOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" id="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" id="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PierisPlanMember" id="pirs_PierisPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryAssetsAbstract" id="pirs_RegulatoryAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentMilestonesMember" id="pirs_ResearchAndDevelopmentMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentServicesMember" id="pirs_ResearchAndDevelopmentServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchCollaborationAgreementPeriod" id="pirs_ResearchCollaborationAgreementPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevaluationOfUnvestedAndForfeitableSharesPercent" id="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SanofiMember" id="pirs_SanofiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" id="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesSubjectToForfeiture" id="pirs_SharesSubjectToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockBasedCompensationLineItems" id="pirs_StockBasedCompensationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockBasedCompensationTable" id="pirs_StockBasedCompensationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SummaryOfSignificantAccountingPoliciesLineItems" id="pirs_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesTable" id="pirs_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="TbgMember" id="pirs_TbgMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TerminationAgreementPercentageOfSharesReturned" id="pirs_TerminationAgreementPercentageOfSharesReturned" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TumMember" id="pirs_TumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantExercisablePeriod" id="pirs_WarrantExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>pirs-20150630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 2 -->
<!-- Creation date: 2015-08-12T12:09:49Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfIncome" roleURI="http://www.pieris.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureCorporateInformationAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRevenuesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRelatedPartyTransactionAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRelatedPartyTransactionsRelatedPartyExpenses" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureConsultingSharesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsConsultingSharesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxesReceivable" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfDebt" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PaidInKindInterest" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_RestrictedStockExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" order="1.1200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AccruedTaxAuditAndLegalFees" xlink:label="pirs_AccruedTaxAuditAndLegalFees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pirs_AccruedTaxAuditAndLegalFees" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_LitigationReserveNoncurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>pirs-20150630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 2 -->
<!-- Creation date: 2015-08-12T12:09:49Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfIncome" roleURI="http://www.pieris.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureCorporateInformationAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRevenuesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRelatedPartyTransactionAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRelatedPartyTransactionsRelatedPartyExpenses" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureConsultingSharesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsConsultingSharesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="pirs_OrganizationAndDescriptionOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OrganizationAndDescriptionOfBusinessTable" xlink:label="pirs_OrganizationAndDescriptionOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_WarrantExercisablePeriod" xlink:label="pirs_WarrantExercisablePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="pirs_OrganizationAndDescriptionOfBusinessTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="pirs_WarrantExercisablePeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pirs_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pirs_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodMilestone" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodMilestone"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pirs_SummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodMilestone" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AdditionalMilestonePaymentMember" xlink:label="pirs_AdditionalMilestonePaymentMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AllerganIncMember" xlink:label="pirs_AllerganIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CommercialMilestonesMember" xlink:label="pirs_CommercialMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DaiichiSankyoIncMember" xlink:label="pirs_DaiichiSankyoIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DevelopmentMilestonePaymentsMember" xlink:label="pirs_DevelopmentMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExpiredOptionAgreementMember" xlink:label="pirs_ExpiredOptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExtensionTermMember" xlink:label="pirs_ExtensionTermMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicenseOptionMember" xlink:label="pirs_LicenseOptionMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicensingMember" xlink:label="pirs_LicensingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OptionsExercisedMember" xlink:label="pirs_OptionsExercisedMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OptionsExercisedPriceOneMember" xlink:label="pirs_OptionsExercisedPriceOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchAndDevelopmentMilestonesMember" xlink:label="pirs_ResearchAndDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchCollaborationAgreementPeriod" xlink:label="pirs_ResearchCollaborationAgreementPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SanofiMember" xlink:label="pirs_SanofiMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_ProductOrServiceAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TransactionTypeAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="pirs_ResearchCollaborationAgreementPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodFactors" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="pirs_LicensingMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="pirs_LicenseOptionMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="pirs_ResearchAndDevelopmentServicesMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_AllerganIncMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_SanofiMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_DaiichiSankyoIncMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_ResearchAndDevelopmentMilestonesMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_DevelopmentMilestonePaymentsMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_CommercialMilestonesMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_AdditionalMilestonePaymentMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_ExtensionTermMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_ExpiredOptionAgreementMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_OptionsExercisedMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_OptionsExercisedPriceOneMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingAgreementMember" xlink:label="pirs_ConsultingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExpectedPatentExpirationYear" xlink:label="pirs_ExpectedPatentExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicenseAgreementMember" xlink:label="pirs_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PatentExpirationYear" xlink:label="pirs_PatentExpirationYear"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PatentOneMember" xlink:label="pirs_PatentOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="pirs_PatentOneMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pirs_TumMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pirs_ConsultingAgreementMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_PatentExpirationYear" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_ExpectedPatentExpirationYear" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_LicenseAgreementMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pirs_TumMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LicenseCosts" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance" xlink:label="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfTranches" xlink:label="pirs_NumberOfTranches"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TbgMember" xlink:label="pirs_TbgMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pirs_NumberOfTranches" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_TbgMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EmployeesAndConsultantsMember" xlink:label="pirs_EmployeesAndConsultantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExecutiveOfficersAndDirectorsMember" xlink:label="pirs_ExecutiveOfficersAndDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PierisPlanMember" xlink:label="pirs_PierisPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_StockBasedCompensationLineItems" xlink:label="pirs_StockBasedCompensationLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_StockBasedCompensationTable" xlink:label="pirs_StockBasedCompensationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_PierisPlanMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="pirs_StockBasedCompensationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pirs_StockBasedCompensationTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pirs_StockBasedCompensationTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_ExecutiveOfficersAndDirectorsMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_EmployeesAndConsultantsMember" order="1.1500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" order="100.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTerminationNoticePeriod" xlink:label="pirs_AgreementTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CancellableSharesMember" xlink:label="pirs_CancellableSharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingAgreementMember" xlink:label="pirs_ConsultingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfCancellableSharesValue" xlink:label="pirs_EstimatedFairValueOfCancellableSharesValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfConsultingSharesNet" xlink:label="pirs_EstimatedFairValueOfConsultingSharesNet"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfNonCancellableSharesValue" xlink:label="pirs_EstimatedFairValueOfNonCancellableSharesValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_FairValueOfUnvestedStockOptionsAssumed" xlink:label="pirs_FairValueOfUnvestedStockOptionsAssumed"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" xlink:label="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NonCancellableSharesMember" xlink:label="pirs_NonCancellableSharesMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfCancellableShares" xlink:label="pirs_NumberOfCancellableShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfNonCancellableShares" xlink:label="pirs_NumberOfNonCancellableShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfUnvestedShares" xlink:label="pirs_NumberOfUnvestedShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" xlink:label="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharesSubjectToForfeiture" xlink:label="pirs_SharesSubjectToForfeiture"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TerminationAgreementPercentageOfSharesReturned" xlink:label="pirs_TerminationAgreementPercentageOfSharesReturned"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pirs_NonCancellableSharesMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pirs_CancellableSharesMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pirs_ConsultingAgreementMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_AgreementTerminationNoticePeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_TerminationAgreementPercentageOfSharesReturned" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_SharesSubjectToForfeiture" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_NumberOfNonCancellableShares" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_EstimatedFairValueOfNonCancellableSharesValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_NumberOfCancellableShares" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_EstimatedFairValueOfCancellableSharesValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_EstimatedFairValueOfConsultingSharesNet" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_NumberOfUnvestedShares" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_FairValueOfUnvestedStockOptionsAssumed" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OutLicenseFeeMember" xlink:label="pirs_OutLicenseFeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="us-gaap_RelatedPartyDepositLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RelatedPartyDepositLiabilities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pirs_TumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_OutLicenseFeeMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeAxis" xlink:label="pirs_AgreementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeDomain" xlink:label="pirs_AgreementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeDomain" xlink:label="pirs_AgreementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CooperationAgreementMember" xlink:label="pirs_CooperationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pirs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsAxis" xlink:label="pirs_MilestoneEventsAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsDomain" xlink:label="pirs_MilestoneEventsDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsDomain" xlink:label="pirs_MilestoneEventsDomain_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneOneMember" xlink:label="pirs_MilestoneOneMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneTwoMember" xlink:label="pirs_MilestoneTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="pirs_AgreementTypeAxis" xlink:to="pirs_AgreementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="pirs_AgreementTypeAxis" xlink:to="pirs_AgreementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_AgreementTypeDomain" xlink:to="pirs_CooperationAgreementMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="pirs_MilestoneEventsAxis" xlink:to="pirs_MilestoneEventsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="pirs_MilestoneEventsAxis" xlink:to="pirs_MilestoneEventsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_MilestoneEventsDomain" xlink:to="pirs_MilestoneOneMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pirs_MilestoneEventsDomain" xlink:to="pirs_MilestoneTwoMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pirs_GrossProceedsFromIssuanceInitialPublicOffering" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="pirs_AgreementTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="pirs_MilestoneEventsAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>pirs-20150630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 2 -->
<!-- Creation date: 2015-08-12T12:09:49Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1270243_1_1">Accounting Changes and Error Corrections [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1270243_2_1">Accounting Changes and Error Corrections [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_8654487_1276885_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_8654487_1276885_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268663_1_1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268663_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1268664_1_1">Accounts Payable and Accrued Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1268664_2_1">Accrued expenses non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US" id="id_8654487_1273619_1_1">Accounts Payable, Interest-bearing, Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US" id="id_8654487_1273619_2_1">Principal amount, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US" id="id_8654487_1284722_1_1">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US" id="id_8654487_1284722_2_1">Trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1285210_1_1">Accrued Environmental Loss Contingencies, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1285210_2_1">Accrued expenses restoration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1283401_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1283401_2_1">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1283401_6_1">Total accrued expenses, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1278549_1_1">Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1278549_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1282049_1_1">Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1282049_6_1">Total accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AccruedTaxAuditAndLegalFees" xlink:label="pirs_AccruedTaxAuditAndLegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_AccruedTaxAuditAndLegalFees_lbl" xml:lang="en-US" id="id_8654487_1538442_3_1">Accrued Tax Audit And Legal Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_AccruedTaxAuditAndLegalFees_lbl" xml:lang="en-US" id="id_8654487_1538442_1_1">Accrued Tax Audit And Legal Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_AccruedTaxAuditAndLegalFees_lbl" xml:lang="en-US" id="id_8654487_1538442_2_1">Accrued audit and tax expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedTaxAuditAndLegalFees" xlink:to="pirs_AccruedTaxAuditAndLegalFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_8654487_1282967_1_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_8654487_1282967_2_1">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AdditionalMilestonePaymentMember" xlink:label="pirs_AdditionalMilestonePaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_AdditionalMilestonePaymentMember_lbl" xml:lang="en-US" id="id_8654487_1591420_3_1">Additional Milestone Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_AdditionalMilestonePaymentMember_lbl" xml:lang="en-US" id="id_8654487_1591420_1_1">Additional Milestone Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_AdditionalMilestonePaymentMember_lbl" xml:lang="en-US" id="id_8654487_1591420_2_1">Additional Diagnostic Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AdditionalMilestonePaymentMember" xlink:to="pirs_AdditionalMilestonePaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_8654487_1283855_1_1">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_8654487_1283855_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_8654487_1278564_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_8654487_1278564_2_1">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTerminationNoticePeriod" xlink:label="pirs_AgreementTerminationNoticePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_AgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_8654487_1322901_3_1">Agreement termination notice period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_AgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_8654487_1322901_1_1">Agreement Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_AgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_8654487_1322901_2_1">Agreement termination notice period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AgreementTerminationNoticePeriod" xlink:to="pirs_AgreementTerminationNoticePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeAxis" xlink:label="pirs_AgreementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_AgreementTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1528160_3_1">Agreement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_AgreementTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1528160_1_1">Agreement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_AgreementTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1528160_2_1">Agreement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AgreementTypeAxis" xlink:to="pirs_AgreementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeDomain" xlink:label="pirs_AgreementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_AgreementTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1506793_3_1">Agreement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_AgreementTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1506793_1_1">Agreement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_AgreementTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1506793_2_1">Agreement Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AgreementTypeDomain" xlink:to="pirs_AgreementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AllerganIncMember" xlink:label="pirs_AllerganIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_AllerganIncMember_lbl" xml:lang="en-US" id="id_8654487_1570417_3_1">Allergan Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_AllerganIncMember_lbl" xml:lang="en-US" id="id_8654487_1570417_1_1">Allergan Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_AllerganIncMember_lbl" xml:lang="en-US" id="id_8654487_1570417_2_1">Allergan Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AllerganIncMember" xlink:to="pirs_AllerganIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_8654487_1285222_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_8654487_1285222_2_1">Total stock-option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_8654487_1276506_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_8654487_1276506_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_8654487_1275318_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_8654487_1275318_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_8654487_1287793_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_8654487_1287793_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_8654487_1273668_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_8654487_1273668_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_8654487_1288812_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_8654487_1288812_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1276921_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1276921_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_BasisOfConsolidationPolicyTextBlock" xlink:label="pirs_BasisOfConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_BasisOfConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1432521_3_1">Disclosure of accounting policy for basis of consolidation policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_BasisOfConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1432521_1_1">Basis Of Consolidation Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_BasisOfConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1432521_2_1">Basis of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_BasisOfConsolidationPolicyTextBlock" xlink:to="pirs_BasisOfConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_8654487_1270322_1_1">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_8654487_1270322_2_1">Basis of Presentation and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_8654487_1275350_1_1">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_8654487_1275350_2_1">Aggregate shares issued upon acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CancellableSharesMember" xlink:label="pirs_CancellableSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_CancellableSharesMember_lbl" xml:lang="en-US" id="id_8654487_1966641_3_1">Cancellable Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_CancellableSharesMember_lbl" xml:lang="en-US" id="id_8654487_1966641_1_1">Cancellable Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_CancellableSharesMember_lbl" xml:lang="en-US" id="id_8654487_1966641_2_1">Cancellable Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CancellableSharesMember" xlink:to="pirs_CancellableSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8654487_1285262_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8654487_1285262_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8654487_1285262_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8654487_1285262_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_8654487_1287836_1_1">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_8654487_1287836_2_1">Cash and Cash Equivalents, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_8654487_1286290_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_8654487_1286290_6_1">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance" xlink:label="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance_lbl" xml:lang="en-US" id="id_8654487_1288350_1_1">Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Outstanding Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance_lbl" xml:lang="en-US" id="id_8654487_1288350_2_1">Amount of repayment to TBG outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance" xlink:to="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_8654487_1277017_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_8654487_1277017_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_8654487_1275410_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_8654487_1275410_2_1">Exercise price of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ClassOfWarrantsAndRightsTextBlock" xlink:label="pirs_ClassOfWarrantsAndRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ClassOfWarrantsAndRightsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1623992_3_1">Class Of Warrants And Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ClassOfWarrantsAndRightsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1623992_1_1">Class Of Warrants And Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ClassOfWarrantsAndRightsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1623992_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ClassOfWarrantsAndRightsTextBlock" xlink:to="pirs_ClassOfWarrantsAndRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268796_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268796_2_1">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" id="id_8654487_1273746_1_1">Collaborative Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" id="id_8654487_1273746_2_1">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CommercialMilestonesMember" xlink:label="pirs_CommercialMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_8654487_1479887_3_1">Commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_8654487_1479887_1_1">Commercial Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_8654487_1479887_2_1">Commercial Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CommercialMilestonesMember" xlink:to="pirs_CommercialMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:label="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1377083_3_1">Commitment, Contingency And Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1377083_1_1">Commitment, Contingency And Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1377083_2_1">Commitment, Contingency And Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:to="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_8654487_1272029_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_8654487_1272029_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268805_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268805_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_8654487_1278673_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_8654487_1278673_2_1">Common stock reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_8654487_1270422_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_8654487_1270422_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_8654487_1278675_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_8654487_1278675_2_1">Common stock par value of issued shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_8654487_1278675_12_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_8654487_1270423_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_8654487_1270423_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_8654487_1268808_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_8654487_1268808_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8654487_1268809_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8654487_1268809_2_1">Common stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_8654487_1282921_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_8654487_1282921_2_1">Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at June 30, 2015 and December 31, 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_8654487_1283349_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_8654487_1283349_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingAgreementMember" xlink:label="pirs_ConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ConsultingAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1434085_3_1">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ConsultingAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1434085_1_1">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ConsultingAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1434085_2_1">Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConsultingAgreementMember" xlink:to="pirs_ConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingSharesDisclosureTextBlock" xlink:label="pirs_ConsultingSharesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ConsultingSharesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1966630_3_1">Consulting Shares Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ConsultingSharesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1966630_1_1">Consulting Shares Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ConsultingSharesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1966630_2_1">Consulting Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConsultingSharesDisclosureTextBlock" xlink:to="pirs_ConsultingSharesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts_lbl" xml:lang="en-US" id="id_8654487_1286840_1_1">Contracts Receivable, Claims and Uncertain Amounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts_lbl" xml:lang="en-US" id="id_8654487_1286840_2_1">Collaboration agreement, milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_8654487_1283344_1_1">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_8654487_1283344_2_1">Out-License Fee amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CooperationAgreementMember" xlink:label="pirs_CooperationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_CooperationAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1343859_3_1">Cooperation Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_CooperationAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1343859_1_1">Cooperation Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_CooperationAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1343859_2_1">Cooperation Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CooperationAgreementMember" xlink:to="pirs_CooperationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_8654487_1287875_1_1">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_8654487_1287875_19_1">Costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_8654487_1275457_1_1">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_8654487_1275457_2_1">Operating costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US" id="id_8654487_1287876_1_1">Costs and Expenses, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US" id="id_8654487_1287876_2_1">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_8654487_1272072_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_8654487_1272072_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_8654487_1276508_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_8654487_1276508_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DaiichiSankyoIncMember" xlink:label="pirs_DaiichiSankyoIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_DaiichiSankyoIncMember_lbl" xml:lang="en-US" id="id_8654487_1315471_3_1">Daiichi Sankyo Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_DaiichiSankyoIncMember_lbl" xml:lang="en-US" id="id_8654487_1315471_1_1">Daiichi Sankyo Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_DaiichiSankyoIncMember_lbl" xml:lang="en-US" id="id_8654487_1315471_2_1">Daiichi Sankyo Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DaiichiSankyoIncMember" xlink:to="pirs_DaiichiSankyoIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_8654487_1278728_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_8654487_1278728_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268864_1_1">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1268864_2_1">Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_8654487_1270473_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_8654487_1270473_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xml:lang="en-US" id="id_8654487_1270476_1_1">Debt Instrument, Payment Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xml:lang="en-US" id="id_8654487_1270476_2_1">Repayment agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" id="id_8654487_1270482_1_1">Debt Instrument, Redemption, Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" id="id_8654487_1270482_2_1">Debt Instrument, Redemption, Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" id="id_8654487_1273816_1_1">Debt Instrument, Redemption, Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" id="id_8654487_1273816_2_1">Debt Instrument, Redemption, Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" id="id_8654487_1270483_1_1">Debt Instrument, Redemption, Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" id="id_8654487_1270483_2_1">Debt Instrument, Redemption, Period One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" id="id_8654487_1275486_1_1">Debt Instrument, Redemption, Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" id="id_8654487_1275486_2_1">Debt Instrument, Redemption, Period Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_8654487_1273820_1_1">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_8654487_1273820_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_8654487_1284641_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_8654487_1284641_2_1">Collaborative arrangement, consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xml:lang="en-US" id="id_8654487_1280340_1_1">Deferred Revenue Arrangement, by Type [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xml:lang="en-US" id="id_8654487_1280340_2_1">Deferred Revenue Arrangement, by Type [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xml:lang="en-US" id="id_8654487_1280341_1_1">Deferred Revenue Arrangement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xml:lang="en-US" id="id_8654487_1280341_2_1">Deferred Revenue Arrangement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1280342_1_1">Deferred Revenue Arrangement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1280342_2_1">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1275514_1_1">Deferred Revenue [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1275514_2_1">Deferred Revenue [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US" id="id_8654487_1273835_1_1">Deferred Revenue Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US" id="id_8654487_1273835_2_1">Deferred Revenue Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1286339_1_1">Deferred Tax Assets, Net of Valuation Allowance, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1286339_2_1">Deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1282438_1_1">Deferred Tax Liabilities, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1282438_2_1">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_8654487_1286908_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_8654487_1286908_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DevelopmentMilestonePaymentsMember" xlink:label="pirs_DevelopmentMilestonePaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_DevelopmentMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_8654487_1561390_3_1">Development milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_DevelopmentMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_8654487_1561390_1_1">Development Milestone Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_DevelopmentMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_8654487_1561390_2_1">Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DevelopmentMilestonePaymentsMember" xlink:to="pirs_DevelopmentMilestonePaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_8654487_1273909_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_8654487_1273909_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1278832_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1278832_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract" xlink:label="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract_lbl" xml:lang="en-US" id="id_8654487_1405908_3_1">Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract_lbl" xml:lang="en-US" id="id_8654487_1405908_1_1">Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract_lbl" xml:lang="en-US" id="id_8654487_1405908_2_1">Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract" xlink:to="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DocumentAndEntityInformationAbstract" xlink:label="pirs_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_8654487_1430739_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_8654487_1430739_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_8654487_1430739_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="pirs_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_8654487_1279677_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_8654487_1279677_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_8654487_1276510_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_8654487_1276510_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_8654487_1274889_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_8654487_1274889_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_8654487_1269867_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_8654487_1269867_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_8654487_1278860_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_8654487_1278860_2_1">Net loss per share Basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1272229_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1272229_2_1">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1288431_1_1">Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1288431_2_1">Effect of exchange rate change on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1284606_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1284606_2_1">Accrued compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EmployeesAndConsultantsMember" xlink:label="pirs_EmployeesAndConsultantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_EmployeesAndConsultantsMember_lbl" xml:lang="en-US" id="id_8654487_1487857_3_1">Employees and consultants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_EmployeesAndConsultantsMember_lbl" xml:lang="en-US" id="id_8654487_1487857_1_1">Employees And Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_EmployeesAndConsultantsMember_lbl" xml:lang="en-US" id="id_8654487_1487857_2_1">Other Employees and Consultants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EmployeesAndConsultantsMember" xlink:to="pirs_EmployeesAndConsultantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_8654487_1270610_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_8654487_1270610_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_8654487_1272251_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_8654487_1272251_2_1">Recognized weighted average service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_8654487_1285370_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_8654487_1285370_2_1">Unrecognized share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_8654487_1278115_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_8654487_1278115_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8654487_1276513_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8654487_1276513_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_8654487_1271511_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_8654487_1271511_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_8654487_1269875_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_8654487_1269875_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_8654487_1269012_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_8654487_1269012_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_8654487_1272258_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_8654487_1272258_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract" xlink:label="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract_lbl" xml:lang="en-US" id="id_8654487_1386421_3_1">Equity Method Investments And Cost Method Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract_lbl" xml:lang="en-US" id="id_8654487_1386421_1_1">Equity Method Investments And Cost Method Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract_lbl" xml:lang="en-US" id="id_8654487_1386421_2_1">Equity Method Investments And Cost Method Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract" xlink:to="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfCancellableSharesValue" xlink:label="pirs_EstimatedFairValueOfCancellableSharesValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_EstimatedFairValueOfCancellableSharesValue_lbl" xml:lang="en-US" id="id_8654487_1966628_3_1">Estimated fair value of cancellable shares, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_EstimatedFairValueOfCancellableSharesValue_lbl" xml:lang="en-US" id="id_8654487_1966628_1_1">Estimated Fair Value Of Cancellable Shares, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_EstimatedFairValueOfCancellableSharesValue_lbl" xml:lang="en-US" id="id_8654487_1966628_2_1">Estimated fair value of cancellable shares, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EstimatedFairValueOfCancellableSharesValue" xlink:to="pirs_EstimatedFairValueOfCancellableSharesValue_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfConsultingSharesNet" xlink:label="pirs_EstimatedFairValueOfConsultingSharesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_EstimatedFairValueOfConsultingSharesNet_lbl" xml:lang="en-US" id="id_8654487_1966629_3_1">Estimated fair value of consulting shares, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_EstimatedFairValueOfConsultingSharesNet_lbl" xml:lang="en-US" id="id_8654487_1966629_1_1">Estimated Fair Value Of Consulting Shares, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_EstimatedFairValueOfConsultingSharesNet_lbl" xml:lang="en-US" id="id_8654487_1966629_2_1">Estimated fair value of consulting shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EstimatedFairValueOfConsultingSharesNet" xlink:to="pirs_EstimatedFairValueOfConsultingSharesNet_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfNonCancellableSharesValue" xlink:label="pirs_EstimatedFairValueOfNonCancellableSharesValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_EstimatedFairValueOfNonCancellableSharesValue_lbl" xml:lang="en-US" id="id_8654487_1966627_3_1">Estimated fair value of non cancellable shares, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_EstimatedFairValueOfNonCancellableSharesValue_lbl" xml:lang="en-US" id="id_8654487_1966627_1_1">Estimated Fair Value Of Non Cancellable Shares, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_EstimatedFairValueOfNonCancellableSharesValue_lbl" xml:lang="en-US" id="id_8654487_1966627_2_1">Estimated fair value of non-cancellable shares, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EstimatedFairValueOfNonCancellableSharesValue" xlink:to="pirs_EstimatedFairValueOfNonCancellableSharesValue_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExecutiveOfficersAndDirectorsMember" xlink:label="pirs_ExecutiveOfficersAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ExecutiveOfficersAndDirectorsMember_lbl" xml:lang="en-US" id="id_8654487_1294863_3_1">Executive officers and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ExecutiveOfficersAndDirectorsMember_lbl" xml:lang="en-US" id="id_8654487_1294863_1_1">Executive Officers And Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ExecutiveOfficersAndDirectorsMember_lbl" xml:lang="en-US" id="id_8654487_1294863_2_1">Executive Officers And Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ExecutiveOfficersAndDirectorsMember" xlink:to="pirs_ExecutiveOfficersAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExpectedPatentExpirationYear" xlink:label="pirs_ExpectedPatentExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ExpectedPatentExpirationYear_lbl" xml:lang="en-US" id="id_8654487_1966545_3_1">Expected patent expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ExpectedPatentExpirationYear_lbl" xml:lang="en-US" id="id_8654487_1966545_1_1">Expected Patent Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ExpectedPatentExpirationYear_lbl" xml:lang="en-US" id="id_8654487_1966545_2_1">Expected patent expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ExpectedPatentExpirationYear" xlink:to="pirs_ExpectedPatentExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExpiredOptionAgreementMember" xlink:label="pirs_ExpiredOptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ExpiredOptionAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1562408_3_1">Expired option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ExpiredOptionAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1562408_1_1">Expired Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ExpiredOptionAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1562408_2_1">Expired Option Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ExpiredOptionAgreementMember" xlink:to="pirs_ExpiredOptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExtensionTermMember" xlink:label="pirs_ExtensionTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ExtensionTermMember_lbl" xml:lang="en-US" id="id_8654487_1335931_3_1">Extension term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ExtensionTermMember_lbl" xml:lang="en-US" id="id_8654487_1335931_1_1">Extension Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ExtensionTermMember_lbl" xml:lang="en-US" id="id_8654487_1335931_2_1">Extension Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ExtensionTermMember" xlink:to="pirs_ExtensionTermMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_lbl" xml:lang="en-US" id="id_8654487_1286404_1_1">Extinguishment of Debt, Gain (Loss), Income Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_lbl" xml:lang="en-US" id="id_8654487_1286404_2_1">Capital gain tax withheld</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_8654487_1286409_1_1">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_8654487_1286409_2_1">Warrant expense recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_8654487_1269038_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_8654487_1269038_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_8654487_1272304_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_8654487_1272304_2_1">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_8654487_1270691_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_8654487_1270691_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_8654487_1280532_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_8654487_1280532_2_1">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_FairValueOfUnvestedStockOptionsAssumed" xlink:label="pirs_FairValueOfUnvestedStockOptionsAssumed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_FairValueOfUnvestedStockOptionsAssumed_lbl" xml:lang="en-US" id="id_8654487_1563273_3_1">Fair Value Of Unvested Stock Options Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_FairValueOfUnvestedStockOptionsAssumed_lbl" xml:lang="en-US" id="id_8654487_1563273_1_1">Fair Value Of Unvested Stock Options Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_FairValueOfUnvestedStockOptionsAssumed_lbl" xml:lang="en-US" id="id_8654487_1563273_2_1">Estimated fair value of unvested and forfeitable shares, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_FairValueOfUnvestedStockOptionsAssumed" xlink:to="pirs_FairValueOfUnvestedStockOptionsAssumed_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_8654487_1277337_1_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_8654487_1277337_2_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_8654487_1272379_1_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_8654487_1272379_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8654487_1288487_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8654487_1288487_14_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_8654487_1269133_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_8654487_1269133_2_1">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" xlink:label="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares_lbl" xml:lang="en-US" id="id_8654487_1966631_3_1">General and administrative expense recognized in consulting shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares_lbl" xml:lang="en-US" id="id_8654487_1966631_1_1">General And Administrative Expense Recognized In Consulting Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares_lbl" xml:lang="en-US" id="id_8654487_1966631_2_1">General and administrative expense recognized in consulting shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" xlink:to="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pirs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_8654487_1313651_3_1">Gross Proceeds From Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_8654487_1313651_1_1">Gross Proceeds From Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_8654487_1313651_2_1">Gross proceeds from issuance initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="pirs_GrossProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_8654487_1282792_1_1">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_8654487_1282792_6_1">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_8654487_1272476_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_8654487_1272476_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_8654487_1274159_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_8654487_1274159_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_8654487_1270824_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_8654487_1270824_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="id_8654487_1281841_1_1">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="id_8654487_1281841_14_1">Cash received for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US" id="id_8654487_1288512_1_1">Income Taxes Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US" id="id_8654487_1288512_2_1">Income tax receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_8654487_1286481_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_8654487_1286481_14_1">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1270827_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1270827_2_1">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" id="id_8654487_1289043_1_1">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" id="id_8654487_1289043_2_1">Trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_8654487_1284543_1_1">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_8654487_1284543_14_1">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_8654487_1286474_1_1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_8654487_1286474_2_1">Accrued and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xml:lang="en-US" id="id_8654487_1285999_1_1">Increase (Decrease) in Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xml:lang="en-US" id="id_8654487_1285999_2_1">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_8654487_1279090_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_8654487_1279090_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" id="id_8654487_1284984_1_1">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" id="id_8654487_1284984_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_8654487_1284979_1_1">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_8654487_1284979_14_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_8654487_1281825_1_1">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_8654487_1281825_14_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_8654487_1285466_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_8654487_1285466_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_8654487_1284523_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_8654487_1284523_2_1">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_8654487_1272538_1_1">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_8654487_1272538_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_8654487_1284515_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_8654487_1284515_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_8654487_1283630_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_8654487_1283630_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8654487_1275871_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8654487_1275871_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1282281_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1282281_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1272565_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_8654487_1272565_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicenseAgreementMember" xlink:label="pirs_LicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1557983_3_1">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1557983_1_1">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_8654487_1557983_2_1">License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LicenseAgreementMember" xlink:to="pirs_LicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_8654487_1282734_1_1">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_8654487_1282734_2_1">Collaboration agreement, license revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_8654487_1289085_1_1">License Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_8654487_1289085_2_1">Transfer of licenses and protective rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicenseOptionMember" xlink:label="pirs_LicenseOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_LicenseOptionMember_lbl" xml:lang="en-US" id="id_8654487_1459186_3_1">License option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_LicenseOptionMember_lbl" xml:lang="en-US" id="id_8654487_1459186_1_1">License Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_LicenseOptionMember_lbl" xml:lang="en-US" id="id_8654487_1459186_2_1">Options to Acquire Additional Licenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LicenseOptionMember" xlink:to="pirs_LicenseOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicensingMember" xlink:label="pirs_LicensingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_LicensingMember_lbl" xml:lang="en-US" id="id_8654487_1320953_3_1">Licensing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_LicensingMember_lbl" xml:lang="en-US" id="id_8654487_1320953_1_1">Licensing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_LicensingMember_lbl" xml:lang="en-US" id="id_8654487_1320953_2_1">Licenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LicensingMember" xlink:to="pirs_LicensingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1282730_1_1">Estimated Litigation Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1282730_2_1">Reserve for litigation TUM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveNoncurrent" xlink:to="us-gaap_LitigationReserveNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xml:lang="en-US" id="id_8654487_1281781_1_1">Loans Payable to Bank, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xml:lang="en-US" id="id_8654487_1281781_2_1">Bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US" id="id_8654487_1284053_1_1">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US" id="id_8654487_1284053_2_1">Repayment amount of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_8654487_1280798_1_1">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_8654487_1280798_2_1">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_8654487_1279197_1_1">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_8654487_1279197_2_1">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" id="id_8654487_1283601_1_1">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" id="id_8654487_1283601_2_1">Contingent accrual liability for research and licensing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US" id="id_8654487_1288098_1_1">Loss Contingency, Damages Awarded, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US" id="id_8654487_1288098_2_1">Claims and counterclaims amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" id="id_8654487_1285523_1_1">Loss Contingency, Damages Sought, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" id="id_8654487_1285523_2_1">Counterclaim amount filed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_8654487_1275948_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_8654487_1275948_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsAxis" xlink:label="pirs_MilestoneEventsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_MilestoneEventsAxis_lbl" xml:lang="en-US" id="id_8654487_1298684_3_1">Milestone Events [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_MilestoneEventsAxis_lbl" xml:lang="en-US" id="id_8654487_1298684_1_1">Milestone Events [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_MilestoneEventsAxis_lbl" xml:lang="en-US" id="id_8654487_1298684_2_1">Milestone Events [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_MilestoneEventsAxis" xlink:to="pirs_MilestoneEventsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsDomain" xlink:label="pirs_MilestoneEventsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_MilestoneEventsDomain_lbl" xml:lang="en-US" id="id_8654487_1361516_3_1">Milestone Events [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_MilestoneEventsDomain_lbl" xml:lang="en-US" id="id_8654487_1361516_1_1">Milestone Events [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_MilestoneEventsDomain_lbl" xml:lang="en-US" id="id_8654487_1361516_2_1">Milestone Events [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_MilestoneEventsDomain" xlink:to="pirs_MilestoneEventsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneOneMember" xlink:label="pirs_MilestoneOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_MilestoneOneMember_lbl" xml:lang="en-US" id="id_8654487_1569519_3_1">Milestone One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_MilestoneOneMember_lbl" xml:lang="en-US" id="id_8654487_1569519_1_1">Milestone One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_MilestoneOneMember_lbl" xml:lang="en-US" id="id_8654487_1569519_2_1">Milestone One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_MilestoneOneMember" xlink:to="pirs_MilestoneOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneTwoMember" xlink:label="pirs_MilestoneTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_MilestoneTwoMember_lbl" xml:lang="en-US" id="id_8654487_1560953_3_1">Milestone Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_MilestoneTwoMember_lbl" xml:lang="en-US" id="id_8654487_1560953_1_1">Milestone Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_MilestoneTwoMember_lbl" xml:lang="en-US" id="id_8654487_1560953_2_1">Milestone Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_MilestoneTwoMember" xlink:to="pirs_MilestoneTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_8654487_1277596_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_8654487_1277596_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1287111_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1287111_6_1">Net cash (used in)/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8654487_1269355_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8654487_1269355_2_1">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1287595_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1287595_2_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8654487_1277599_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8654487_1277599_2_1">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1272684_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8654487_1272684_6_1">Net cash used in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8654487_1269356_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8654487_1269356_2_1">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_8654487_1284477_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_8654487_1284477_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_8654487_1284477_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1279254_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1279254_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NonCancellableSharesMember" xlink:label="pirs_NonCancellableSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_NonCancellableSharesMember_lbl" xml:lang="en-US" id="id_8654487_1966640_3_1">Non Cancellable Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_NonCancellableSharesMember_lbl" xml:lang="en-US" id="id_8654487_1966640_1_1">Non Cancellable Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_NonCancellableSharesMember_lbl" xml:lang="en-US" id="id_8654487_1966640_2_1">Non Cancellable Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NonCancellableSharesMember" xlink:to="pirs_NonCancellableSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_8654487_1274361_1_1">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_8654487_1274361_2_1">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfCancellableShares" xlink:label="pirs_NumberOfCancellableShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_NumberOfCancellableShares_lbl" xml:lang="en-US" id="id_8654487_1966626_3_1">Number Of Cancellable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_NumberOfCancellableShares_lbl" xml:lang="en-US" id="id_8654487_1966626_1_1">Number Of Cancellable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_NumberOfCancellableShares_lbl" xml:lang="en-US" id="id_8654487_1966626_2_1">Estimated fair value cancellable shares, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfCancellableShares" xlink:to="pirs_NumberOfCancellableShares_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfNonCancellableShares" xlink:label="pirs_NumberOfNonCancellableShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_NumberOfNonCancellableShares_lbl" xml:lang="en-US" id="id_8654487_1966625_3_1">Number Of Non Cancellable Shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_NumberOfNonCancellableShares_lbl" xml:lang="en-US" id="id_8654487_1966625_1_1">Number Of Non Cancellable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_NumberOfNonCancellableShares_lbl" xml:lang="en-US" id="id_8654487_1966625_2_1">Estimated fair value of non-cancellable shares, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfNonCancellableShares" xlink:to="pirs_NumberOfNonCancellableShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_8654487_1276002_1_1">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_8654487_1276002_2_1">Number of Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfTranches" xlink:label="pirs_NumberOfTranches"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_NumberOfTranches_lbl" xml:lang="en-US" id="id_8654487_1437469_3_1">Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_NumberOfTranches_lbl" xml:lang="en-US" id="id_8654487_1437469_1_1">Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_NumberOfTranches_lbl" xml:lang="en-US" id="id_8654487_1437469_2_1">Number of tranches</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfTranches" xlink:to="pirs_NumberOfTranches_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfUnvestedShares" xlink:label="pirs_NumberOfUnvestedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_NumberOfUnvestedShares_lbl" xml:lang="en-US" id="id_8654487_1521488_3_1">Number Of Unvested Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_NumberOfUnvestedShares_lbl" xml:lang="en-US" id="id_8654487_1521488_1_1">Number Of Unvested Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_NumberOfUnvestedShares_lbl" xml:lang="en-US" id="id_8654487_1521488_2_1">Number of unvested and forfeitable shares for revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfUnvestedShares" xlink:to="pirs_NumberOfUnvestedShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_8654487_1283121_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_8654487_1283121_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OptionsExercisedMember" xlink:label="pirs_OptionsExercisedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_OptionsExercisedMember_lbl" xml:lang="en-US" id="id_8654487_1424613_3_1">Options exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_OptionsExercisedMember_lbl" xml:lang="en-US" id="id_8654487_1424613_1_1">Options Exercised [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_OptionsExercisedMember_lbl" xml:lang="en-US" id="id_8654487_1424613_2_1">Options Exercised [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OptionsExercisedMember" xlink:to="pirs_OptionsExercisedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OptionsExercisedPriceOneMember" xlink:label="pirs_OptionsExercisedPriceOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_OptionsExercisedPriceOneMember_lbl" xml:lang="en-US" id="id_8654487_1386521_3_1">Options exercised price one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_OptionsExercisedPriceOneMember_lbl" xml:lang="en-US" id="id_8654487_1386521_1_1">Options Exercised Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_OptionsExercisedPriceOneMember_lbl" xml:lang="en-US" id="id_8654487_1386521_2_1">Options, Exercised Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OptionsExercisedPriceOneMember" xlink:to="pirs_OptionsExercisedPriceOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="pirs_OrganizationAndDescriptionOfBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_OrganizationAndDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_8654487_1556946_3_1">Organization And Description Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_OrganizationAndDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_8654487_1556946_1_1">Organization And Description Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_OrganizationAndDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_8654487_1556946_2_1">Organization And Description Of Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="pirs_OrganizationAndDescriptionOfBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OrganizationAndDescriptionOfBusinessTable" xlink:label="pirs_OrganizationAndDescriptionOfBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_OrganizationAndDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_8654487_1476133_3_1">Organization And Description Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_OrganizationAndDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_8654487_1476133_1_1">Organization And Description Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_OrganizationAndDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_8654487_1476133_2_1">Organization And Description Of Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OrganizationAndDescriptionOfBusinessTable" xlink:to="pirs_OrganizationAndDescriptionOfBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_8654487_1276020_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_8654487_1276020_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1277652_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1277652_2_1">Corporate Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1283556_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1283556_2_1">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1284020_1_1">Other Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1284020_6_1">Total accrued expenses, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_8654487_1288617_1_1">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_8654487_1288617_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_8654487_1284016_1_1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_8654487_1284016_2_1">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" id="id_8654487_1282226_1_1">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" id="id_8654487_1282226_2_1">Total other comprehensive loss, after tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" id="id_8654487_1279287_1_1">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" id="id_8654487_1279287_2_1">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1281714_1_1">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8654487_1281714_2_1">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1283538_1_1">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_8654487_1283538_2_1">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_8654487_1284001_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_8654487_1284001_2_1">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OutLicenseFeeMember" xlink:label="pirs_OutLicenseFeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_OutLicenseFeeMember_lbl" xml:lang="en-US" id="id_8654487_1626491_3_1">Out License Fee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_OutLicenseFeeMember_lbl" xml:lang="en-US" id="id_8654487_1626491_1_1">Out License Fee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_OutLicenseFeeMember_lbl" xml:lang="en-US" id="id_8654487_1626491_2_1">Out License Fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OutLicenseFeeMember" xlink:to="pirs_OutLicenseFeeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_8654487_1288157_1_1">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_8654487_1288157_2_1">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PatentExpirationYear" xlink:label="pirs_PatentExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_PatentExpirationYear_lbl" xml:lang="en-US" id="id_8654487_1623949_3_1">Patent expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_PatentExpirationYear_lbl" xml:lang="en-US" id="id_8654487_1623949_1_1">Patent Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_PatentExpirationYear_lbl" xml:lang="en-US" id="id_8654487_1623949_2_1">Patent expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PatentExpirationYear" xlink:to="pirs_PatentExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PatentOneMember" xlink:label="pirs_PatentOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_PatentOneMember_lbl" xml:lang="en-US" id="id_8654487_1416981_3_1">Patent One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_PatentOneMember_lbl" xml:lang="en-US" id="id_8654487_1416981_1_1">Patent One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_PatentOneMember_lbl" xml:lang="en-US" id="id_8654487_1416981_2_1">Patent No. 8,420,051 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PatentOneMember" xlink:to="pirs_PatentOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_8654487_1269445_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_8654487_1269445_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_8654487_1284434_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_8654487_1284434_14_1">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8654487_1966633_3_1">Percentage of consulting shares recognizable as general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8654487_1966633_1_1">Percentage Of Consulting Shares Recognizable As General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8654487_1966633_2_1">Percentage of consulting shares recognizable as general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" xlink:to="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity_lbl" xml:lang="en-US" id="id_8654487_1966634_3_1">Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity_lbl" xml:lang="en-US" id="id_8654487_1966634_1_1">Percentage Of Consulting Shares Recognizable As General And Administrative Expense Offsetting Credit To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity_lbl" xml:lang="en-US" id="id_8654487_1966634_2_1">Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" xlink:to="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PierisPlanMember" xlink:label="pirs_PierisPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_PierisPlanMember_lbl" xml:lang="en-US" id="id_8654487_1626494_3_1">Pieris Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_PierisPlanMember_lbl" xml:lang="en-US" id="id_8654487_1626494_1_1">Pieris Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_PierisPlanMember_lbl" xml:lang="en-US" id="id_8654487_1626494_2_1">Pieris Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PierisPlanMember" xlink:to="pirs_PierisPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_8654487_1280964_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_8654487_1280964_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_8654487_1279330_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_8654487_1279330_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_8654487_1289180_1_1">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_8654487_1289180_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_8654487_1277719_1_1">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_8654487_1277719_2_1">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_8654487_1288681_1_1">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_8654487_1288681_2_1">Net proceeds from issuance initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_8654487_1287667_1_1">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_8654487_1287667_2_1">Proceeds from sale of stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US" id="id_8654487_1289203_1_1">Proceeds from (Repayments of) Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US" id="id_8654487_1289203_2_1">Proceeds of loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_8654487_1277733_1_1">Products and Services [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_8654487_1277733_2_1">Products and Services [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_8654487_1281004_1_1">Products and Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_8654487_1281004_2_1">Products and Services [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US" id="id_8654487_1288194_1_1">Professional and Contract Services Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US" id="id_8654487_1288194_2_1">Consulting agreement fees paid to Prof. Dr. Skerra</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_8654487_1285626_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_8654487_1285626_2_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_8654487_1269523_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_8654487_1269523_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_8654487_1279402_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_8654487_1279402_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US" id="id_8654487_1283940_1_1">Recognition of Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US" id="id_8654487_1283940_2_1">Collaboration agreement, revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_RegulatoryAssetsAbstract" xlink:label="pirs_RegulatoryAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_RegulatoryAssetsAbstract_lbl" xml:lang="en-US" id="id_8654487_1389970_3_1">Regulatory Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_RegulatoryAssetsAbstract_lbl" xml:lang="en-US" id="id_8654487_1389970_1_1">Regulatory Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_RegulatoryAssetsAbstract_lbl" xml:lang="en-US" id="id_8654487_1389970_2_1">Regulatory Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RegulatoryAssetsAbstract" xlink:to="pirs_RegulatoryAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="us-gaap_RelatedPartyDepositLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDepositLiabilities_lbl" xml:lang="en-US" id="id_8654487_1283467_1_1">Related Party Deposit Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDepositLiabilities_lbl" xml:lang="en-US" id="id_8654487_1283467_2_1">Reserved liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDepositLiabilities" xlink:to="us-gaap_RelatedPartyDepositLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_8654487_1279455_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_8654487_1279455_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_8654487_1274544_1_1">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_8654487_1274544_2_1">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_8654487_1281057_1_1">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_8654487_1281057_2_1">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_8654487_1274545_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_8654487_1274545_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1276208_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8654487_1276208_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_8654487_1279431_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_8654487_1279431_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1272898_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8654487_1272898_2_1">Related-Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" id="id_8654487_1282599_1_1">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" id="id_8654487_1282599_14_1">Repayment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_8654487_1276212_1_1">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_8654487_1276212_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1272896_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1272896_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1281064_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1281064_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_8654487_1285664_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_8654487_1285664_2_1">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_8654487_1285664_14_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_8654487_1269570_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_8654487_1269570_2_1">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchAndDevelopmentMilestonesMember" xlink:label="pirs_ResearchAndDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ResearchAndDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_8654487_1592441_3_1">Research and development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ResearchAndDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_8654487_1592441_1_1">Research And Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ResearchAndDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_8654487_1592441_2_1">Research Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchAndDevelopmentMilestonesMember" xlink:to="pirs_ResearchAndDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" id="id_8654487_1387995_3_1">Research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" id="id_8654487_1387995_1_1">Research And Development Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" id="id_8654487_1387995_2_1">Research Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchAndDevelopmentServicesMember" xlink:to="pirs_ResearchAndDevelopmentServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchCollaborationAgreementPeriod" xlink:label="pirs_ResearchCollaborationAgreementPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ResearchCollaborationAgreementPeriod_lbl" xml:lang="en-US" id="id_8654487_1339775_3_1">Research Collaboration Agreement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ResearchCollaborationAgreementPeriod_lbl" xml:lang="en-US" id="id_8654487_1339775_1_1">Research Collaboration Agreement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ResearchCollaborationAgreementPeriod_lbl" xml:lang="en-US" id="id_8654487_1339775_2_1">Research collaboration agreement, estimated period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchCollaborationAgreementPeriod" xlink:to="pirs_ResearchCollaborationAgreementPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US" id="id_8654487_1286692_1_1">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US" id="id_8654487_1286692_2_1">Non-cash Restricted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_8654487_1283021_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_8654487_1283021_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" xlink:label="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent_lbl" xml:lang="en-US" id="id_8654487_1979818_3_1">Revaluation of Unvested and Forfeitable Shares Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent_lbl" xml:lang="en-US" id="id_8654487_1979818_1_1">Revaluation of Unvested and Forfeitable Shares Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent_lbl" xml:lang="en-US" id="id_8654487_1979818_2_1">Revalued unvested and forfeitable shares, percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" xlink:to="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy" xlink:label="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy_lbl" xml:lang="en-US" id="id_8654487_1276249_1_1">Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy_lbl" xml:lang="en-US" id="id_8654487_1276249_2_1">Milestone Payments and Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy" xlink:to="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors_lbl" xml:lang="en-US" id="id_8654487_1271226_1_1">Revenue Recognition, Milestone Method, Factors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors_lbl" xml:lang="en-US" id="id_8654487_1271226_2_1">Description of factors in determining milestones substantive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodFactors_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodMilestone" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodMilestone_lbl" xml:lang="en-US" id="id_8654487_1272961_1_1">Revenue Recognition, Milestone Method, Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodMilestone_lbl" xml:lang="en-US" id="id_8654487_1272961_2_1">Milestones arrangement, categories description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodMilestone" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodMilestone_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_8654487_1282115_1_1">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_8654487_1282115_2_1">Collaboration agreement, milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_8654487_1284373_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_8654487_1284373_2_1">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_8654487_1279494_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_8654487_1279494_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_8654487_1281096_1_1">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_8654487_1281096_2_1">Sales of common stock, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="id_8654487_1282106_1_1">Sales Revenue, Goods, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="id_8654487_1282106_2_1">Revenues from product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SanofiMember" xlink:label="pirs_SanofiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_SanofiMember_lbl" xml:lang="en-US" id="id_8654487_1515548_3_1">Sanofi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_SanofiMember_lbl" xml:lang="en-US" id="id_8654487_1515548_1_1">Sanofi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_SanofiMember_lbl" xml:lang="en-US" id="id_8654487_1515548_2_1">Sanofi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SanofiMember" xlink:to="pirs_SanofiMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1274583_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1274583_2_1">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_8654487_1277846_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_8654487_1277846_2_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_8654487_1276285_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_8654487_1276285_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1272939_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1272939_2_1">Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_8654487_1272980_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_8654487_1272980_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1274645_1_1">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1274645_2_1">Related Party Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_8654487_1271276_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_8654487_1271276_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1271278_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1271278_2_1">Schedule of Information Regarding Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1269652_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_8654487_1269652_2_1">Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1279551_1_1">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_8654487_1279551_2_1">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_8654487_1288753_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_8654487_1288753_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_8654487_1277943_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_8654487_1277943_2_1">Share-based payment award, award vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_8654487_1273028_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_8654487_1273028_2_1">Maximum term of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_8654487_1273029_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_8654487_1273029_2_1">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_8654487_1273030_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_8654487_1273030_2_1">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_8654487_1279587_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_8654487_1279587_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_8654487_1274709_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_8654487_1274709_2_1">Weighted average risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xml:lang="en-US" id="id_8654487_1431730_3_1">Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xml:lang="en-US" id="id_8654487_1431730_1_1">Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xml:lang="en-US" id="id_8654487_1431730_2_1">Forfeiture rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription_lbl" xml:lang="en-US" id="id_8654487_1610571_3_1">Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Authorized Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription_lbl" xml:lang="en-US" id="id_8654487_1610571_1_1">Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Authorized Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription_lbl" xml:lang="en-US" id="id_8654487_1610571_2_1">Share-based compensation description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_8654487_1269692_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_8654487_1269692_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_8654487_1281179_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_8654487_1281179_2_1">Common stock available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_8654487_1273034_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_8654487_1273034_2_1">Number of shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1273035_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1273035_2_1">Weighted-Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1380762_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1380762_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1380762_2_1">Number of shares, Expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1356273_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Out Standing Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1356273_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1356273_2_1">Weighted-Average Exercise Price, Expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="id_8654487_1277952_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="id_8654487_1277952_2_1">Number of shares, Options cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1276360_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1276360_2_1">Weighted-Average Exercise Price, Options cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_8654487_1274685_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_8654487_1274685_2_1">Number of shares, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8654487_1271328_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8654487_1271328_2_1">Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_8654487_1336623_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_8654487_1336623_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_8654487_1336623_2_1">Weighted-Average Contractual Life, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1281183_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1281183_4_1">Number of shares, Outstanding at ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1281183_5_1">Number of shares, Outstanding at beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1281183_2_1">Number of shares, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1271330_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1271330_4_1">Weighted-Average Exercise Price, Outstanding ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1271330_5_1">Weighted-Average Exercise Price, Outstanding at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_8654487_1613434_3_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_8654487_1613434_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_8654487_1613434_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_8654487_1276363_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_8654487_1276363_2_1">Weighted-Average Contractual Life, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1269697_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_8654487_1269697_2_1">Number of shares, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="id_8654487_1274692_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="id_8654487_1274692_2_1">Options vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1532940_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1532940_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1532940_2_1">Weighted-Average Exercise Price, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1269701_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1269701_2_1">Weighted-Average Exercise Price, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1277960_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8654487_1277960_2_1">Weighted-Average Exercise Price, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_8654487_1273051_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_8654487_1273051_2_1">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharesSubjectToForfeiture" xlink:label="pirs_SharesSubjectToForfeiture"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_SharesSubjectToForfeiture_lbl" xml:lang="en-US" id="id_8654487_1966622_3_1">The number of shares of common stock subject to forfeiture, pursuant to the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_SharesSubjectToForfeiture_lbl" xml:lang="en-US" id="id_8654487_1966622_1_1">Shares Subject To Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_SharesSubjectToForfeiture_lbl" xml:lang="en-US" id="id_8654487_1966622_2_1">Shares subject to forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SharesSubjectToForfeiture" xlink:to="pirs_SharesSubjectToForfeiture_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_8654487_1276400_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_8654487_1276400_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_8654487_1276401_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_8654487_1276401_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_8654487_1281214_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_8654487_1281214_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_8654487_1271363_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_8654487_1271363_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_8654487_1271364_1_1">Statement of Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_8654487_1271364_2_1">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_StockBasedCompensationLineItems" xlink:label="pirs_StockBasedCompensationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_StockBasedCompensationLineItems_lbl" xml:lang="en-US" id="id_8654487_1399627_3_1">Stock Based Compensation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_StockBasedCompensationLineItems_lbl" xml:lang="en-US" id="id_8654487_1399627_1_1">Stock Based Compensation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_StockBasedCompensationLineItems_lbl" xml:lang="en-US" id="id_8654487_1399627_2_1">Stock Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="pirs_StockBasedCompensationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_StockBasedCompensationTable" xlink:label="pirs_StockBasedCompensationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_StockBasedCompensationTable_lbl" xml:lang="en-US" id="id_8654487_1313554_3_1">Stock Based Compensation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_StockBasedCompensationTable_lbl" xml:lang="en-US" id="id_8654487_1313554_1_1">Stock Based Compensation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_StockBasedCompensationTable_lbl" xml:lang="en-US" id="id_8654487_1313554_2_1">Stock Based Compensation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_StockBasedCompensationTable" xlink:to="pirs_StockBasedCompensationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_8654487_1283431_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_8654487_1283431_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8654487_1276413_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8654487_1276413_2_1">Stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_8654487_1274739_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_8654487_1274739_2_1">Stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_8654487_1281224_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_8654487_1281224_2_1">Number of shares, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" id="id_8654487_1274751_1_1">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" id="id_8654487_1274751_2_1">Number of common stock purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_8654487_1269753_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_8654487_1269753_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_8654487_1273350_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_8654487_1273350_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_8654487_1279606_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_8654487_1279606_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1278000_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_8654487_1278000_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_8654487_1273352_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_8654487_1273352_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1271378_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1271378_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1276407_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_8654487_1276407_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_8654487_1271382_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_8654487_1271382_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_8654487_1556063_3_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_8654487_1556063_1_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_8654487_1556063_2_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pirs_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_8654487_1394184_3_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_8654487_1394184_1_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_8654487_1394184_2_1">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pirs_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_8654487_1271385_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_8654487_1271385_2_1">Supplemental cash flow disclosures:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TbgMember" xlink:label="pirs_TbgMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_TbgMember_lbl" xml:lang="en-US" id="id_8654487_1611978_3_1">Tbg [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_TbgMember_lbl" xml:lang="en-US" id="id_8654487_1611978_1_1">Tbg [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_TbgMember_lbl" xml:lang="en-US" id="id_8654487_1611978_2_1">Tbg [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_TbgMember" xlink:to="pirs_TbgMember_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TerminationAgreementPercentageOfSharesReturned" xlink:label="pirs_TerminationAgreementPercentageOfSharesReturned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_TerminationAgreementPercentageOfSharesReturned_lbl" xml:lang="en-US" id="id_8654487_1966621_3_1">The element represents the percentage of shares returned that were previously issued pursuant to agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_TerminationAgreementPercentageOfSharesReturned_lbl" xml:lang="en-US" id="id_8654487_1966621_1_1">Termination Agreement Percentage Of Shares Returned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_TerminationAgreementPercentageOfSharesReturned_lbl" xml:lang="en-US" id="id_8654487_1966621_2_1">Termination agreement percentage of shares returned</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_TerminationAgreementPercentageOfSharesReturned" xlink:to="pirs_TerminationAgreementPercentageOfSharesReturned_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_8654487_1273383_1_1">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_8654487_1273383_2_1">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_8654487_1276433_1_1">Relationship to Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_8654487_1276433_2_1">Relationship to Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_8654487_1269880_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_8654487_1269880_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US" id="id_8654487_1279914_1_1">Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US" id="id_8654487_1279914_2_1">Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1269778_1_1">Transaction Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US" id="id_8654487_1269778_2_1">Transaction Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_TumMember_lbl" xml:lang="en-US" id="id_8654487_1611680_3_1">TUM [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_TumMember_lbl" xml:lang="en-US" id="id_8654487_1611680_1_1">TUM [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_TumMember_lbl" xml:lang="en-US" id="id_8654487_1611680_2_1">TUM [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_TumMember" xlink:to="pirs_TumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_8654487_1279908_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_8654487_1279908_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US" id="id_8654487_1273416_1_1">Up-front Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US" id="id_8654487_1273416_2_1">Upfront Payment Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_8654487_1274809_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_8654487_1274809_2_1">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_WarrantExercisablePeriod" xlink:label="pirs_WarrantExercisablePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pirs_WarrantExercisablePeriod_lbl" xml:lang="en-US" id="id_8654487_1355809_3_1">Warrant Exercisable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pirs_WarrantExercisablePeriod_lbl" xml:lang="en-US" id="id_8654487_1355809_1_1">Warrant Exercisable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pirs_WarrantExercisablePeriod_lbl" xml:lang="en-US" id="id_8654487_1355809_2_1">Warrant exercisable period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_WarrantExercisablePeriod" xlink:to="pirs_WarrantExercisablePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_8654487_1274823_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_8654487_1274823_2_1">Weighted average number of common shares outstanding Basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>pirs-20150630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 2 -->
<!-- Creation date: 2015-08-12T12:09:49Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfIncome" roleURI="http://www.pieris.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureCorporateInformationAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRevenuesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRelatedPartyTransactionAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureRelatedPartyTransactionsRelatedPartyExpenses" roleURI="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity" roleURI="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureConsultingSharesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsConsultingSharesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="pirs-20150630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DocumentAndEntityInformationAbstract" xlink:label="pirs_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxesReceivable" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfIncome" xlink:title="124000 - Statement - Statement of Income (Including Gross Margin)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome" xlink:title="148400 - Statement - Statement of Comprehensive Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RestrictedStockExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="1.1300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="pirs_OrganizationAndDescriptionOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OrganizationAndDescriptionOfBusinessTable" xlink:label="pirs_OrganizationAndDescriptionOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_WarrantExercisablePeriod" xlink:label="pirs_WarrantExercisablePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="pirs_WarrantExercisablePeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_OrganizationAndDescriptionOfBusinessTable" xlink:to="pirs_OrganizationAndDescriptionOfBusinessLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pirs_OrganizationAndDescriptionOfBusinessTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_RegulatoryAssetsAbstract" xlink:label="pirs_RegulatoryAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodMilestone" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodMilestone"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pirs_SummaryOfSignificantAccountingPoliciesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_RegulatoryAssetsAbstract" xlink:to="pirs_SummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodMilestone" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pirs_SummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AdditionalMilestonePaymentMember" xlink:label="pirs_AdditionalMilestonePaymentMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AllerganIncMember" xlink:label="pirs_AllerganIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CommercialMilestonesMember" xlink:label="pirs_CommercialMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DaiichiSankyoIncMember" xlink:label="pirs_DaiichiSankyoIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DevelopmentMilestonePaymentsMember" xlink:label="pirs_DevelopmentMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExpiredOptionAgreementMember" xlink:label="pirs_ExpiredOptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExtensionTermMember" xlink:label="pirs_ExtensionTermMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicenseOptionMember" xlink:label="pirs_LicenseOptionMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicensingMember" xlink:label="pirs_LicensingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OptionsExercisedMember" xlink:label="pirs_OptionsExercisedMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OptionsExercisedPriceOneMember" xlink:label="pirs_OptionsExercisedPriceOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchAndDevelopmentMilestonesMember" xlink:label="pirs_ResearchAndDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ResearchCollaborationAgreementPeriod" xlink:label="pirs_ResearchCollaborationAgreementPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SanofiMember" xlink:label="pirs_SanofiMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_ProductOrServiceAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TransactionTypeAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="pirs_ResearchCollaborationAgreementPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodFactors" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="pirs_LicensingMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="pirs_LicenseOptionMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="pirs_ResearchAndDevelopmentServicesMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_AllerganIncMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_SanofiMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_DaiichiSankyoIncMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_ResearchAndDevelopmentMilestonesMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_DevelopmentMilestonePaymentsMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_CommercialMilestonesMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_AdditionalMilestonePaymentMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_ExtensionTermMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_ExpiredOptionAgreementMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_OptionsExercisedMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_OptionsExercisedPriceOneMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:label="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingAgreementMember" xlink:label="pirs_ConsultingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExpectedPatentExpirationYear" xlink:label="pirs_ExpectedPatentExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_LicenseAgreementMember" xlink:label="pirs_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PatentExpirationYear" xlink:label="pirs_PatentExpirationYear"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PatentOneMember" xlink:label="pirs_PatentOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="pirs_PatentOneMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pirs_TumMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pirs_ConsultingAgreementMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_PatentExpirationYear" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_ExpectedPatentExpirationYear" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_LicenseAgreementMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:label="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pirs_TumMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LicenseCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance" xlink:label="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract" xlink:label="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfTranches" xlink:label="pirs_NumberOfTranches"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TbgMember" xlink:label="pirs_TbgMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pirs_NumberOfTranches" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_TbgMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AccruedTaxAuditAndLegalFees" xlink:label="pirs_AccruedTaxAuditAndLegalFees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LitigationReserveNoncurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pirs_AccruedTaxAuditAndLegalFees" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EmployeesAndConsultantsMember" xlink:label="pirs_EmployeesAndConsultantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ExecutiveOfficersAndDirectorsMember" xlink:label="pirs_ExecutiveOfficersAndDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PierisPlanMember" xlink:label="pirs_PierisPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_StockBasedCompensationLineItems" xlink:label="pirs_StockBasedCompensationLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_StockBasedCompensationTable" xlink:label="pirs_StockBasedCompensationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_PierisPlanMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="pirs_StockBasedCompensationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_StockBasedCompensationTable" xlink:to="pirs_StockBasedCompensationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_ExecutiveOfficersAndDirectorsMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_EmployeesAndConsultantsMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract" xlink:label="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTerminationNoticePeriod" xlink:label="pirs_AgreementTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CancellableSharesMember" xlink:label="pirs_CancellableSharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingAgreementMember" xlink:label="pirs_ConsultingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfCancellableSharesValue" xlink:label="pirs_EstimatedFairValueOfCancellableSharesValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfConsultingSharesNet" xlink:label="pirs_EstimatedFairValueOfConsultingSharesNet"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_EstimatedFairValueOfNonCancellableSharesValue" xlink:label="pirs_EstimatedFairValueOfNonCancellableSharesValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_FairValueOfUnvestedStockOptionsAssumed" xlink:label="pirs_FairValueOfUnvestedStockOptionsAssumed"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" xlink:label="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NonCancellableSharesMember" xlink:label="pirs_NonCancellableSharesMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfCancellableShares" xlink:label="pirs_NumberOfCancellableShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfNonCancellableShares" xlink:label="pirs_NumberOfNonCancellableShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_NumberOfUnvestedShares" xlink:label="pirs_NumberOfUnvestedShares"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" xlink:label="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" xlink:label="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_SharesSubjectToForfeiture" xlink:label="pirs_SharesSubjectToForfeiture"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TerminationAgreementPercentageOfSharesReturned" xlink:label="pirs_TerminationAgreementPercentageOfSharesReturned"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pirs_NonCancellableSharesMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pirs_CancellableSharesMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pirs_ConsultingAgreementMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_AgreementTerminationNoticePeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_TerminationAgreementPercentageOfSharesReturned" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_SharesSubjectToForfeiture" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_NumberOfNonCancellableShares" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_EstimatedFairValueOfNonCancellableSharesValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_NumberOfCancellableShares" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_EstimatedFairValueOfCancellableSharesValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_EstimatedFairValueOfConsultingSharesNet" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_RevaluationOfUnvestedAndForfeitableSharesPercent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_NumberOfUnvestedShares" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_FairValueOfUnvestedStockOptionsAssumed" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_WarrantExercisablePeriod" xlink:label="pirs_WarrantExercisablePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pirs_WarrantExercisablePeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_OutLicenseFeeMember" xlink:label="pirs_OutLicenseFeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="us-gaap_RelatedPartyDepositLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_TumMember" xlink:label="pirs_TumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RelatedPartyDepositLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pirs_TumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_OutLicenseFeeMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeAxis" xlink:label="pirs_AgreementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_AgreementTypeDomain" xlink:label="pirs_AgreementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_CooperationAgreementMember" xlink:label="pirs_CooperationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pirs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsAxis" xlink:label="pirs_MilestoneEventsAxis"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneEventsDomain" xlink:label="pirs_MilestoneEventsDomain"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneOneMember" xlink:label="pirs_MilestoneOneMember"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_MilestoneTwoMember" xlink:label="pirs_MilestoneTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_AgreementTypeAxis" xlink:to="pirs_AgreementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_AgreementTypeDomain" xlink:to="pirs_CooperationAgreementMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_MilestoneEventsAxis" xlink:to="pirs_MilestoneEventsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_MilestoneEventsDomain" xlink:to="pirs_MilestoneOneMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_MilestoneEventsDomain" xlink:to="pirs_MilestoneTwoMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pirs_GrossProceedsFromIssuanceInitialPublicOffering" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="pirs_AgreementTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="pirs_MilestoneEventsAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_BasisOfConsolidationPolicyTextBlock" xlink:label="pirs_BasisOfConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy" xlink:label="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pirs_BasisOfConsolidationPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ConsultingSharesDisclosureTextBlock" xlink:label="pirs_ConsultingSharesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pirs_ConsultingSharesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <loc xlink:type="locator" xlink:href="pirs-20150630.xsd#pirs_ClassOfWarrantsAndRightsTextBlock" xlink:label="pirs_ClassOfWarrantsAndRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="pirs_ClassOfWarrantsAndRightsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`)V.#4?G?S$WN0$``)T7```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V8RT[#,!!%?Z7*%C6N'=ZBW5"V@`0_8))I8S6.+=M]_3UV"@BJ@EJ@
MTMWDT3N>>Y-QSJ(WSVM+OK?23>N'61V"O6;,ES5IZ7-CJ8W*Q#@M0[QU4V9E
M.9-38F(P.&>E:0.UH1]2CVQT\[`@YU1%O=N-D'H/,VEMHTH9E&G9HJVVNO;-
M9*)*JDPYUW%)'J(UG40]ZSU*%^ZECBW8JF&=L#GR/.GL?PR]=20K7Q,%W>0^
MK!ORN_PWRKOSF"9RWH2#C-_>7>ZHZ6I\K>R;U=TJ=O'QMV$65;^7P_;"GY(I
MG89FV^F7%>G^E\^R]1(7NAD[N51;!HNCC2F=<RU5NVM42^-F+\;,_G.;4'JJ
MBJJ^=;'0!;5CE\3BQZAZ%EO_R?M]IY3&T5Z&J?"('T4M'55/P<7Y[OXV/A<<
M+T>::W?]W=`[T;/N=$1(')1#@.0H0'*<@N0X`\EQ#I+C`B3')4B.*Y`<?(`2
M!(6H'`6I'(6I'`6J'(6J'`6K'(6K'`6L'(6L`H6L`H6L`H6L`H6L`H6L`H6L
M`H6L`H6L`H6L`H6L!0I9"Q2R%BAD+5#(6J"0M4`A:_%!5M;]*S]Z!5!+`P04
M````"`"=C@U'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_
M)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B
M]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&10IXV+!XUE])"1#M@2[`LRQ7(K8[9
MK.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)4]`'_K,-
M`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C
M-Z."N[_8_`)02P,$%`````@`G8X-1PQUTFF.`0``J18``!H```!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<\782VK#,!#&\:L$'Z#RS.1-DE4WV;:]@'`4
MVR1^(*FTN7U=+XK[T-!%X-O8V(+1?_5#:->&?/ODKC;671NJN@^S]^;:ANWP
M?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9L^-I
MG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ-?U28
MKPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T)VJ2#
M-I`@RA49<TR2AC5&:U*X)HS7I(!-&+%)(9LP9I."-F'4)H5MPKA-"MR$D9L4
MN@EC-REX$T9O5O1FC-ZLZ,V@L[9VV,;HS8K>C-&;%;T9HS<K>C-&;U;T9HS>
MK.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@MBMZ"
MT5L4O06CMTST#I7U[O0<?=V6X=XUWX:K11.\0[Q=W?U3QJEJPT3K..SDS/B\
MNT#CU,\0\^M6^O`!4$L#!!0````(`)V.#4=M=Y7]G0(``!P*```0````9&]C
M4')O<',O87!P+GAM;+U6WV_:,!#^5ZP\;0]I*$QH0C122Y$V:=-08>VSL2_%
MJF-GMH-@?_W.3J&A))3P,%XXG[_[]=U=DK&RO=',Z`*,$V#))I?*CE!Y$ZV<
M*T9)8MD*<FJO$*+P-M,FIPZ/YCG16288W&M6YJ!<TN_UA@EL'"@./"[V3J-T
M[*/<%H44C#JA5?I3,*.MSAR9;AC(<?(>$"S0\QQ8:83;IKT*4U<%S)Q1"1.,
ME6946JA0;\J`F>B\H&J;5*<?0KW8W\5"WU,'=:O#B\K[BAK@&/3`^UX9,-^V
M6*?TMI,55<_`Z]CCRQT7CV"LK_2Z?]7#WYZ"G;[R#90+]3RCPMATO':C-3"G
MS6N;UN[2+G'-?-/MXP+SLQ%94@M>O(G6U`BJ7$2L^(O'?E2%K;1!EH5U)GW2
MYL6N`)P=)WME$.O8NBR^I(-A0*!TB$SVE:6OM!W4[34+X2387]F,&O>?J`@U
M[8@8#*-:]3L7A"I.ILKA.)+OJ@J%S:M3LI<F&O="6>`$):NEX#AFG-Q1214#
M<H'-H(O-W.$?YMQF<XQTENB,^.6Y(,ZPQ<84VB#@0[;NJ!4A_LR`Q5P",M`]
M+_.<-MH\P!I4";;E4OK\8C]`6[(P5%G*O--F^#TL7>/%+6.FQ#IA4_CJFZWG
M3K.7V(\2)PP)1.3)P;"E=#CO)#Q:FET^48,YN^9+;%(N7-4SSQ&Z]/Y`,=&6
M8;FT\*?T,SQ=0YO?DUVX_MJ1:/)I09=GD1J0N.^?.['[:G7^Y)&8W'(N4.Q>
M?;]Y^W8S^.9:4?D6\Q1CY(BQRDE7EF/RT,R!G^F6O#QY)SLSW74F)G-\P/)2
M@F?FP_Y,ZOVI8G>U\?&ZVPRN+[#IG[>@AR2>7-<N<W!RBTE\WAZWYW;TEGWW
M3DT.OP73?U!+`P04````"`"=C@U'$D6]L3\!``!I`P``$0```&1O8U!R;W!S
M+V-O<F4N>&ULS9--3\,P#(;_"NJ]2[LQ0%77`R!.3$)B",0M)-X6UGPH\=3U
MWY-Y7<N`RV[<ZMKOX]=Q4@I7".OAR5L''A6$BYVN32B$FR5K1%<P%L0:-`^C
M6&%B<FF]YAA#OV*.BPU?`1MGV173@%QRY&P/3%U/3*I2BD)XX&A]AY>BQ[NM
MKPDF!8,:-!@,+!_E+*E>S,;8QI1LT%=E=%SS@',KU5*!O&V'LM^IV!G!ZW"0
M@^S;T]\_/5"&)5WE+JB^JFF:43.ANCAPSM[FC\]T-JDR`;D1$%5!%=@ZF"7'
MSJ^3N_O%0U*-LWR:9C=I/EGDU\5T7$POW_>3G?@;#.MNB'_K^&B0MHL*:SAS
MMZ21M%SZ))"$(+QRJ*PY"T>8;V*"A>W')P@\']0)Z;)MH&VLEZ&B^S5$^Y<3
M5[:ROCVD?D0GKZKZ`E!+`P04````"`"=C@U'F5R<(Q`&``"<)P``$P```'AL
M+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29
MA.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(
ME/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)$Q+#W(*+"$MX
M%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UE
MHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:B.%4PL3`:F<_
M5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BV
MR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/
MTVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3
M(`!8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X`
M-\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.
M:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V
M]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%
MG\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMO
MFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`
M\:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0F
MS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO)(Z:K<(1*T(^
M8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYB
MSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I
M,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX
M@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3
M*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E
M-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU
M)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8
MD;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8
MS\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#
M*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]5
M6_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8
MO./FQW%.4[@2=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V
M^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D
M4.Z2D`83`<V4R43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK`,
M!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:
MOB9@2\-Z;ITM)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6'ODRWSEPVSK>
M`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K
M$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*
M;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0`
M```(`)V.#4>=+).<9@(``&X+```-````>&PO<W1Y;&5S+GAM;,U6W6K;,!1^
M%:&4T<*([71-V]4VC$)@L)5!<[&[(MNR(]"/)\N9T\L]SYYJ3S+].'82EJ;-
MTI+<Z.C3T7<^'1WG**S4@N+[&<8*-(SR*H(SI<J/GE>E,\Q0-10EYGHE%Y(A
MI:>R\*I28I159A.CWLCWQQY#A,,XY#6;,%6!5-1<1?!#!P&W_U9D.((/I^]^
MU$+=G``W#MX/!O[#V<TF?FH7SB!P')^S"`;C"^@]GW3H^]N)S>(&^?B%Y$]Q
M;U!?[J#^\^OWEG3T*_],R)4A]MK,QV$N>'\!(^B`.*P>P1Q1[1\8]U10(8'2
M-ZP56(0CAIW'+:(DD<2`.6*$+AP\,H`MBM:/$2ZDC>TB;,89^GTD6201]-O?
M\\,E/;L=S/$(I>O'TT`<ED@I+/E$3T!K3Q>E/AP7'#N1UF^'=R'1(AA=K&RP
M@XZ;")EAV44.X!**0XISI3=(4LS,J$1II`NE!--&1E`A.**&<KFC-31MBBF]
M-Y_@]WR-N\F!\S%W[$-@5"Q-G8C6[,O`)M5;97/<J[2CO7A!DW<!]&Y4EG3Q
MB9*",^S$.F@BVMDN^F`+?1RB)2N8"4D>M;\IA%0#6$(PQU*1=!7Y*5$YQ8UJ
M*]AK\FT*]SWR:VHZ?-9Z-;H$WSH]>P>WT%W-$BPG]F_QY9+.+W=?F?TZX8;,
MMZV:/20<(#FF8QZMM/'Q2GN=FCJ(M*MCE79^_9_*O+9GK33&M;;8H2"I"56$
M+R4@\Y"Y,[+I6L?J6Z+FS)J^&]I5A1+]^%V+HLDRG*.:JF]D+I1=C&!O?S'R
M@W'G->TH(MC;7W%&:G9M%?0O[/@O4$L#!!0````(`)V.#4>..JZHCP,``&`,
M```/````>&PO=V]R:V)O;VLN>&ULE9;;4MLP$$!_1>.G]B%-+"<!,H09;FV9
MZ84A##PK]H9HD"57DH'R]5W925D3)<"3KSI::8_7>^@FC\;>SXVY9T^ETFYB
MI\G2^VK2[[M\":5P7TP%&I\MC"V%QTM[US>+A<SAS.1U"=KW^6`P[EM0PDNC
MW5)6+EG1W'MHKK(@"K<$\*5J8:60.CDZ=).%5'`#UB&8B:KZ)4J8)D\J84HX
M?UY(#\4T&>*E>83.#5M7)[54X6(T&"7]`%LO]=*RW!30PJZ7TMVN'B2L@(6H
ME;_&8-?S3I.4#SD?MXSPVHV$1T>!X083N9</<"WFTV20,%%[\U4J#_9,>/AF
M35U)?8>LA"VD=7X6EMN\64HM2_D<XL8KMS2/WXV5ST9[H6:Y-4HUH\*#9A#.
MX/[?P1B]S#LO>C&_"IF8)N,!`A^DDW.II/\[39IS!6$E_5=+:;;_Y8SI9G/6
M*69"%^Q<>Z2P"]TF#[<FQ(`O7Q3-Q'8B\<1>%&F[511T:G0!VD'!\,P9)0O<
ME8*=""5T#HR`.`'QCX(R`LH(*'LW:.;Q@$LFH"$!#:.@S>'>,;-`<ED1T(B`
M1A^-:$Q`8P(:QT"V,A9';<G5'AF^MSG\1#C9A']IP>%2FN&-`;.Z+`4![1/0
M_B;H"AY`U^#(B`,RXB`V0H4U]RZ%1=.NK=`N?%:X'52U`75ML$DY@[FG[W?<
MC,AYG.>VQIV&IRKL?V<NJF,:\7'F37[?FXN0MAS3C8"-3X.:F,95=%ATL#ZP
MV5+8;@#4OC2BWZVPN$V^,X:*ED9-*TOI6TU#7C&`,#OH7'8GIZ*E$=-F]=S!
MGSI4B/,'>!4%U2S]J&?I/D51T=*H:=N\89^P7E(4-3"-*/A:A@:@P'VF-8H:
MR",&;K-B!:,H*B>/5L[(Q\QZ[+C`GYTT%-4IG1%7=VXXI[634V5Y1-GUI_T2
MB!;J)4**H@+SB,"KW+&-W+5LBJ)>\XC7.S3HL:O.ME.S><3L4$.V+"ZDD:*H
MYSSB^=JH\[51/3;#;JBH%81D4!3UG$<\IUZ=4J_:2"F*>LXCGN]`A>CHCY3:
MGKUA^P8J2RF*VIY%;-^-XA1%;<_BG4*WJG;325&=5B%B^[K&OFU[1FW/HMW"
MCM++>A1%;<\BMF\4W^T+I+9GXU7_]]+R8=<K-12A(7;---A1YJ%+QD/[%QR.
M0N$,US^Q<YXFH;W%3K96ZA3O_=8_C&B:P):\[HN/_@%02P,$%`````@`G8X-
M1UK^?;I0`@``]`<``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R-E=F.
MFS`4AE\%\0`#MEF2$4&:I*K:BTJCN6BOG<0):`!3VPG3MZ\7PAC7*MS@A?\_
MGX_78J#LG5>$B."C;3J^"RLA^N<HXJ>*M)@_T9YT\L^%LA8+V637B/>,X+,V
MM4T$XSB+6EQW85GHOE=6%O0FFKHCKRS@M[;%[,^>-'38A2!\=+S5UTJHCJ@L
MHLEWKEO2\9IV`2.77?@"G@\@41*M^%F3@5OU0`W^2.F[:GP_[\)8C8$TY"14
M""R+.SF0IE&1)/GW&/23J8QV_1']JTY7#O^(.3G0YE=]%I4<;1P&9W+!MT:\
MT>$;&7-(5<`3;;C^!J<;%[1]6,*@Q1^FK#M=#N9/@D:;WP!'`YP,</M?`QH-
M:#*8J8O,R'1>7[#`9<'H$/`>J]4&SU+.5!`9.9#)<-W4TV5Z[V5<1'<59J;8
M&P74"C`I(AG;"X!SP!Y:=N@#'&P%6@8@)P.D[4C;DV5[XM@3;4^T/?5.@*W(
ME@&I`T@M>^X%V(K-,B!S`)EEWWH!M@+$RX3<(>2V'\P1G4$826J6.0;I,F3C
M0#8VQ+M3]D:2&<F*K;)U$%L;D7@1,\F*+$#L'JC8CI#YC]1,DZ^@_'-L@1UA
MXUV249..N6Q0EJS870"Z*&BC_!MLIH$K=AAP3S%`=@3@I\PT<`7%/>S`/LL0
M^:;M,&K,M*%MCB!,W7F+K$NV)>RJ'Q\>G.BM$^8VG7JG!^X%ZDOZ4UX6/;Z2
M'YA=ZXX'1RKD5:]O^0NE@LBAQ$_R9JCD$SPU&G(1JIK+.C./DFD(VC_>V.FA
M+_\"4$L#!!0````(`)V.#4=>-.N/N@,``!40```8````>&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULC9A+;^,V%$;_BN#]C'@OGPH<`[6*HET4&,RB72LQ'0NC
MARLI\?3?EWK80W*N:VVBA[]+'DKB$97MI>V^]2=KA^1[737]\^8T#.>G-.U?
M3[8N^L_MV3;NEV/;U<7@#KNWM#]WMCA,1765(F,JK8NRV>RVT[DOW6[;O@]5
MV=@O7=*_UW71_;NW57MYWL#F>N)K^78:QA/I;IO>Z@YE;9N^;)NDL\?GS2_P
ME*,:(U/BK])>>F\_&>%?VO;;>/#'X7G#1@9;V==A;*)PFP^;VZH:6W(]_[,T
M^J//L=#?O[;^VS1<A_]2]#9OJ[_+PW!RM&R3'.RQ>*^&K^WE=[N,08X-OK95
M/_U-7M_[H:VO)9ND+K[/V[*9MI?Y%\.6,KH`EP*\%8#XWP*^%/"H()W)IG']
M6@S%;MNUEZ0_%^/=AB<7[\9&7,N)&TP_'4Z7:S[[L4.Q33_&=H+(?H[@'*$2
M>9"0MTCJ^B<A,(+`J9[/]>IQ/8_J^50OYGH=(C;S(.:(GB+`&&K.)!7,@Z`1
M6B#`8R(1$0F?R)!$<T0N'2D%AI%`00Z99AH?\\B(1_H\&<DCO7XT1T0@<?P8
ML(SS%30JHE$>#2='O5=^-XH!?;."E##`'K/HB$7[+.20]SJX`TJ`OG-M@F!F
MF!1K9H.)B(Q/A"21"9X=`"X5">3GD,G@IM[ER2*>S.?A)$_F]R.$H&F"E'(T
MCUF`Q;YB/HT@:9;,];$06DLDN?,@B6",`&564/UD4?`,QE?<<X@5".B/B[Q^
M^R5SNYU&2%(M>1!T3RSSY\]]IEBKX'N5TUY=,G-7BDNIZ*D1Y+3@1JTABK4*
MOE<Y[57PA<F98$#.H3S(H4`MUQ#%8@7?K)PT:PZ!,U$SQ=9T%5L3?&T*6IN@
M5LW$,+9R*L;F!%^=@E8GZ.!F(+K)2!,%02FX5FN88G>"+T]!RQ-,P*2-I%^\
M88[SS*Q10VQ/\/4I:'U"%O;$.+V*R<.@T<YL*UYY&$L4F:<K(5:T$`L/P1\5
M^7+>+YGE(<L$_:;/HQB:-2/Z:07IZY-^Z/?H6]%(Z:XR_=3F85(HU&CX"JI8
MH.@+5-`"15^,GX`+KC+RM9:'2>.N9Z970,4.1=^A@G8H^F[\Y-;*;LUC[ERK
M(*JD<2M4L6*B8&Q2]$TJZ#4J!B8%$!HRVG!ATKAO5P%KJ&+IHB]=6A3[):,?
MKS>"Y)WU1NI]P)V+-_MGT;V539^\M(/[%IP^`X]M.UC7'OOL1GERW^BW@\H>
MAW%7N_UN_FJ=#X;V?/T(O_TG8/<?4$L#!!0````(`)V.#4=,W"!!W`$``&@%
M```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC93-CILP%(5?Q>(!8C`_
MZ40$J<.H:A>51K-HUTYR"6ALS-A.F+Y]_4,H(#)3%K&O.>?XNT%VW@OYJFH`
MC=XY:]4^J+7N=ABK8PV<JHWHH#5O*B$YU::49ZPZ"?3D3)QA$H89YK1I@R)W
M:\^RR,5%LZ:%9XG4A7,J_SP"$_T^B(+;PDMSKK5=P$6.1]^IX="J1K1(0K4/
MOD:[,K,*)_C50*\F<V39#T*\VN+':1^$%@$8'+5-H&:X0@F,V2"S\=N0^6]+
M:YS.;^G?7+>&_D`5E(+];DZZ-K!A@$Y0T0O3+Z+_#D,+J0T\"J;<+SI>E!;\
M9@D0I^]^;%HW]OY-MAULZP8R&,AHB)(/#?%@B!<&[,E<7T]4TR*7HD>JH_9C
M1SLCES;$)"/3C'*E^[O\ZK5(HQQ?;<Y,\N@EQ$G(FJ*<*=)1@LW^JQ!D`4&<
M/_80Y'-_O/#'SI]X?SQ';'T37O+%2<)-&$9KJO*^ZBY+LF!)IBS)*HN7I$X2
MA\.SRO.Q\BY3NF!*ITSI*E,ZV8D\).0A)605:2XDVYGP+E&V(,JF1-DJ4?:_
M1-GG1'AR*#IZAI]4GIM6H8/0YGRYHU4)H<'$A1O386VNO;%@4&D[W9JY]#>!
M+[3H;O?:>+D6?P%02P,$%`````@`G8X-1P6KLC2P`P``1`\``!@```!X;"]W
M;W)K<VAE971S+W-H965T-"YX;6R-E\ERHT@0AE^%T'T,F;51#ED1+:&)Z<-$
M=/1AYHRETA+-H@%D=;_]L`E75:<M?#!0^G+YDX(DE[>R^E&?C&F"GWE6U"^+
M4]-<GL.PWIU,GM9/Y<44[2^'LLK3IKVLCF%]J4RZ[XWR+,0HDF&>GHO%:MFO
M?:M6R_+:9.?"?*N"^IKG:?5K;;+R]K*`Q7WA^_EX:KJ%<+4,)[O].3=%?2Z+
MH#*'E\47>-Z"ZI">^.=L;K5U'G3)OY;EC^[BZ_YE$74YF,SLFLY%VA[>S,9D
M6>>IC?S?Z/0]9F=HG]^]_]G+;=-_36NS*;-_S_OFU&8;+8*].:37K/E>WOXR
MHP;1.=R56=W_#W;7NBGSN\DBR-.?P_%<],?;\(N"T8PVP-$`)X,I#FW`1@/V
M;L`_->"C`9\;08P&PHL0#MK[RB5IDZZ657D+ZDO:[2=X;O&J<])Z#MIRU?UE
M?T.&U;>54,OPK?/C(.L!P0&)*22Q$9B(L(U/)H%N$FNTS)$*L+$)H<D<'CK9
M?N#DPS295RO6V[/>7D:/[;EGSWM[/MB#FV(Q5&)`U%!(&2'G%+:Q,:EC1$5A
MB8TQI6))>MO:&$8*()*/Q0E/G+"+@X_MI6<O[>(PLC@#(GKD#U`HA$:R/"X(
M$&N,R`(Y($,1(9(>MPZ(C(.4,VJD/(W*UDC>B[5R4M=21S&M47D9:60DF#@@
M9Y+Q2)`:'9"!BD0\XS[&GL;8UD@&6L=.(*FY5/0V=T$N8Q"T1@=4$IBDGXBM
M`PH!B#Q^K%%[&K6M49(:M9.Z8)PS<@MN'!"5U!K)JB4.J)`)13\F6S<TYP!\
MQGV$R.\,D?U$JQD>?NLM8-<I)NLT,O<[0BK:N!``4YH$$Q?DB'2%7*REHIC-
MT(>^/K3U:5H?6J$XC^F-[E`8Q61S2!Q*(%VLK>M+6L_@Q\K\3@?,4J;(C;L>
MF6F+HV[_:'4.B7$,DM$-RR7;3<X5^T"E&UU*$'-:,O@]&>RFK,BZ;T=FB`4S
MWA?@-T<0=A3R';8>&36CG@[Y:3T=\M-ZNM&[>LYZ:_AM'.P^KN@^/C)ZB!4]
M`=WA?`S)9R?Y#:.[FX^Q&=^IX#=PL#LXW;368/=1U!RUH#\J-@[9?J5@K&F?
MB>>3=;N=[#O;SWT.2D-K1,A-=>R'LSK8E=>B&5[XT^HT`'[!;L3PUM?PO`%B
M/>D&QGXD>7>_6E[2H_D[K8[GH@Y>RZ8=;/J9YE"6C6E3CY[:HI_:D7:ZR,RA
MZ4Y5=S>&(6^X:,K+?6:=!N?5_U!+`P04````"`"=C@U'1EP'R'L"``!2"```
M&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)5638^;,!#]*XC[+F!C[$0$
M:?-1M8=*JSVT9R=Q`EK`*7:2[;^O/Q)BD'>3YA#LX;V9>>.1A_S,NW=1,B:#
MCZ9NQ2PLI3Q,HTAL2M90\<P/K%5O=KQKJ%3;;A^)0\?HUI":.@)QG$4-K=JP
MR(WMM2MR?I1UU;+7+A#'IJ'=WSFK^7D6)N'5\%;M2ZD-49%'/6];-:P5%6^#
MCNUFX4LR71&-,(!?%3L+9QWHW-><O^O-C^TLC'4*K&8;J3U0]3BQ!:MK[4@%
M_G/Q>0NIB>[ZZOV;4:NR7U/!%KS^76UEJ9*-PV#+=O18RS=^_LXN$I!VN.&U
M,/_!YB@D;ZZ4,&CHAWU6K7F>[9OL2O,3P(4`>D+R-0%>"/!&2+\DI!="^F@$
M="&@483(:C>56U))B[SCYT`<J&ZG9*K@G7:B/`>J7,)LS8%8ZZG`*(].VL\`
M,K<08""(^"!+%Y+TB$C%]R8!ADG,@4,'O@`+%X$FWASN.EE]XN33-.&H5M#P
MH:U5=I^?COBIX:>6/TJQM96P$&P@3Q"!B?KY@(L!$!"29!#[@,L!$`.88@A]
MP-4P=)8E*`7W-:*11N36"-_G9R-^YM:(>&MD(<@V6PP2B+P5<F%9AE)O=5S0
M$XIC-/%6<>7B8`P>$(9'PK`KS'NF<_R8,/R(,/R@,/S?PLA(&'&$D=@KC`Q:
M*P689-ZL%V38U3B=$&^S+@=`C"&"T!MZ-0R=(8(2--(8.3=FP[J]F54BV/!C
M*VTK]]9^'+X`?>..[/-DND@\]J4:GW;:W=P7^8'NV4_:[:M6!&LNU3UOKO@=
MYY*IS.-G5>Y2#?A^4[.=U$NLS\'./+N1_'"=X/UG1/$/4$L#!!0````(`)V.
M#4>"3<ZK#00``,<1```8````>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULG9C)
MCMLX$(9?1?"](U9Q$QMN`Y$'@YE#@""'Y*RV:5N(%H\DMS-O'VJQF^30:&*`
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MCV4S':_S+QE9PL(!N`3@/>">)QQ`EP#Z'L"F2F=G4UU_%$.Q67?M->G/Q3C:
M\&SDW=B(:3DQQ?33Y=1=\]VW30;K]&ULQY'DLP0GR;LB-8T',Z";(4<K'$,)
MMK:"JX\S4*\&.L73N0;\.)YY\6R*9U.\]"PV<Q&S1$Z2)XF424I#PJTCI$(`
M9Q&.N.>(VQ71C^.%%R^LBC(6K&B6\'E4.>.<!^MQ9)EB(L*-]-Q(VTTXC732
M@.(1$RWSTF1V&A$L.K/2L(Q3R3Y.H[PTRDXC@VF4E88J(FE$&B#^RB3V),@B
M6OC/V@;;J@IV_*)9>IX2%='Q@'XBM!(I$DZ$5B*1<1XQD<!?Z4"M1!BL*%\T
M<Z(G@9E9KF%'CE`BER3"D@\/L.FA(&R).9E$IDAX&;A"9$2RF&[R\0'<\D3#
M2V'1\&5R2#/V84O<63.2*Q[AR`<2V$128<:"S1I*F+\=W0S9LB>&R"!FW'PH
M@4TE%9PA.4AG.*AX,&JVC"DA8A:K3R^P\:7"S(;,F=I""L:#?;EUE901H6+V
M(?!A!\J"4,S(HX\Q)'9=X;FX:&[K@V$8WUM79WHZYG'$IR+:5%1A@".X:'AH
M"/Z'(9^>B'8?1\P=]+&(-A95&/1('=`+8")BV:"/.[1Q!R3(C!P=C`%(\Q>F
MBZ>D0I$85S[PD#NNPA1&'NW*5H(A#(_J*Q]Z*!Q78>JA@S..3%E3P#'E"(UU
M&K$UH(\]E(ZG,/?0X5[&F!F6!PO`)2021J6(L.73#S/'5AA_:$,-,F9``>$]
MPE%2L]_2F/<"].F'RG$5I'^.]M.>61$HZ8/=W56:YT]"(OJ*^D2E]H,A1#7A
M,Y""4U@8@M2&V[C/!HMR50`THJ.ICT"*CI_@`L@7T?)N!?A@2GHRGZ>I]7Y<
MZ^XX?3?HDUU[:8;Y)?1^]_YMXO/T:<*[G\/S=O["\-[,9GTNCOI+T1W+ID]>
MV\&\O4\O[H>V';1Q1SX9M)QTL;]?5/HPC*?2G'?S=X;Y8FC/M\\F]V\WF]]0
M2P,$%`````@`G8X-1^(YO)"@`0``L0,``!@```!X;"]W;W)K<VAE971S+W-H
M965T-RYX;6R%4\MNVS`0_!6"'Q!*LMTFABP@=E"TAP)!#LF9EE82$9*KD)25
M_GWYL!7;")*+N+N:F9WEHYS0O-H>P)%W);7=T-ZY8<V8K7M0W-[@`-K_:=$H
M[GQJ.F8'`[R))"59D64_F.)"TZJ,M4=3E3@Z*30\&F)'I;CYMP6)TX;F]%1X
M$EWO0H%5)9MYC5"@K4!-#+0;>I^OM\N`B(!G`9,]BTGPOD=\#<F?9D.S8`$D
MU"XH<+\<8`=2!B'?^.VH^=$R$,_CD_JO.*UWO^<6=BA?1.-Z;S:CI(&6C](]
MX?0;CB.L@F"-TL8OJ4?K4)THE"C^GE:AXSJE/XO\2/N<4!P)Q4RXS:+QU"C:
M?.".5Z7!B=B!A[/+UQYN@HA7)MZ;C6F</E4/59[=E>P0A"XPVX0I$F9&,*_^
M:8OBLL6V.*,7W],75PX7D;Y(W?/L>X'EE<`R"BR_'/$"DU\/R<[V5('IXM6Q
MI,91N[1Y<W6^G?=%/),/>%4.O(._W'1"6[)'YT\V'FJ+Z,";R&Y6E/3^_<R)
MA-:%\*>/3;I2*7$XG![(_$JK_U!+`P04````"`"=C@U'"E`9'Z`!``"Q`P``
M&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(53VT[C,!#]%<L?@!.WL+M5
M&HFR0O"P$N)A]]E-)HF%[0FVT\#?8SMI:"NTO,0SDW/.G/&E&-&^N`[`DS>M
MC-O2SOM^PYBK.M#"76$/)OQIT&KA0VI;YGH+HDXDK1C/LANFA32T+%+MR98%
M#EY)`T^6N$%K8=]WH'#<TIP>"\^R[7PLL+)@"Z^6&HR3:(B%9DMO\\UN'1$)
M\%?"Z$YB$KWO$5]B\EAO:18M@(+*1P41E@/<@5)1*#1^G34_6T;B:7Q4OT_3
M!O=[X>`.U3]9^RZ8S2BIH1&#\L\X/L`\PG44K%"Y]"75X#SJ(X42+=ZF59JT
MCM.?FU\S[6L"GPE\(?S,DO&I4;+Y6WA1%A9'XGH1SR[?!+B-(D&9!&\NI6GZ
MJ7HH\YP7[!"%SC"["<,GS()@0?W+%OR\Q8Z?T/GW]-6%PU6BKV:'V?<"ZPN!
M=1)8_W?$<\SJH@D[V5,-MDU7QY$*!^.GS5NJR^V\Y>E,/N%ET8L6_@C;2N/(
M'GTXV72H#:*'8"*[NJ:D"^]G210T/H8_0FRG*S4E'OOC`UE>:?D!4$L#!!0`
M```(`)V.#4<B@:_:G0$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULA5/+;MLP$/P5@A\02K*<%H8L($Y1M(<"00[MF996$A&2JY*4E?Y]^9`5
MVPB2B[B[FIF=Y:.:T;S8`<"15R6UW=/!N7''F&T&4-S>X0C:_^G0*.Y\:GIF
M1P.\C20E69%E]TQQH6E=Q=J3J2N<G!0:G@RQDU+<_#N`Q'E/<WHN/(M^<*'`
MZHJMO%8HT%:@)@:Z/7W(=X<R("+@MX#97L0D>#\BOH3D9[NG6;``$AH7%+A?
M3O`(4@8AW_COHOG6,A`OX[/Z]SBM=W_D%AY1_A&M&[S9C)(6.CY)]XSS#UA&
MV`;!!J6-7]),UJ$Z4RA1_#6M0L=U3G^^9@OM?4*Q$(H;`DN-HLUOW/&Z,C@3
M._)P=OG.PTT0\<K$>[,QC=.GZJG.\[)BIR!TA3DD3)$P*X)Y]7=;%-<M#L4%
MO?B<OKEQN(GTS>)P^[E`>2-01H'RPQ&O,?<W3=C%GBHP?;PZEC0X:9<V;ZVN
MM_.AB&?R!J^KD??PBYM>:$N.Z/S)QD/M$!UX$]G=EI+!OY\UD="Y$'[QL4E7
M*B4.Q_,#65]I_1]02P,$%`````@`G8X-1_8YW,:@`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3`N>&ULA5/+;MLP$/P5@A\02K+3N(8L($Y0M(<"
M00[MF996$A&2JY"4E?Y]^9`5VPB2B[B[FIF=Y:.<T+S8'L"1-R6UW='>N6'+
MF*U[4-S>X`#:_VG1*.Y\:CIF!P.\B20E69%EWYCB0M.JC+4G4Y4X.BDT/!EB
M1Z6X^;<'B=..YO14>!9=[T*!525;>(U0H*U`30RT.WJ?;_?K@(B`/P(F>Q:3
MX/V`^!*27\V.9L$"2*A=4.!^.<(#2!F$?./76?.]92">QR?U'W%:[_[`+3R@
M_"L:UWNS&24-M'R4[AFGGS"/<!L$:Y0V?DD]6H?J1*%$\;>T"AW7*?U9;6;:
MQX1B)A0+89-%XZE1M/G(':]*@Q.Q`P]GEV\]W`01KTR\-QO3.'VJ'JL\ORO9
M,0A=8/8)4R3,@F!>_<,6Q66+?7%&+[ZFKZX<KB)]-3O<?"VPOA)81X'UIR->
M8KY?-6%G>ZK`=/'J6%+CJ%W:O*6ZW,[[(I[).[PJ!][!;VXZH2TYH/,G&P^U
M173@360WMY3T_OTLB836A?#.QR9=J90X'$X/9'FEU7]02P,$%`````@`G8X-
M1S4=IP&>`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULC5/+
M;MLP$/P5@A\0RK33%(8L($Y0M(<"00[MF996$A&2JY"4E?Y]^9`5VPC27L3=
MU<SL+!_EA/;%]0">O&EEW([VW@];QES=@Q;N!@<PX4^+5@L?4MLQ-U@032)I
MQ7A1?&%:2$.K,M6>;%7BZ)4T\&2)&[46]L\>%$X[NJ*GPK/L>A\+K"K9PFND
M!N,D&F*AW='[U7:_B8@$^"5A<F<QB=X/B"\Q^='L:!$M@(+:1P41EB,\@%)1
M*#1^G37?6T;B>7Q2_Y:F#>X/PL$#JM^R\7TP6U#20"M&Y9]Q^@[S"+=1L$;E
MTI?4H_.H3Q1*M'C+JS1IG?(??C?3/B;PF<`7PM<B&<^-DLU'X4556IR(&T0\
MN]4VP&T4"<HD>',I3=/GZK%:\:)DQRAT@=EG#,^8!<&"^H<M^&6+/3^C\W_3
MUU<.UXF^GAW^1__-E<`F"6P^'?$2<^V2G>VI!MNEJ^-(C:/Q>?.6ZG([[WDZ
MDW=X50ZB@Y_"=M(X<D`?3C8=:HOH(9@H;FXIZ</[61(%K8_A78AMOE(Y\3B<
M'LCR2JN_4$L#!!0````(`)V.#4>?E!V9H0$``*\#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;(53VVZ<,!#]%8L/B,&0IEJQ2-E45?M0*<I#^^R%
M`:S8'FJ;)?W[^K)+R"I*7O#,<,Z9,[[4"YIG.P(X\J*DMOML=&[:46K;$12W
M-SB!]G]Z-(H[GYJ!VLD`[R))2<KR_`M57.BLJ6/MT30USDX*#8^&V%DI;OX=
M0.*RSXKL4G@2P^A"@38U77F=4*"M0$T,]/OLOM@=JH"(@-\"%KN)2?!^1'P.
MR<]NG^7!`DAH75#@?CG!`T@9A'SCOV?-UY:!N(TOZM_CM-[]D5MX0/E'=&[T
M9O.,=-#S6;HG7'[`>83;(-BBM/%+VMDZ5!=*1A1_2:O0<5W2G[(\T]XGL#.!
MK82O>32>&D6;W[CC36UP(7;BX>R*G8>;(.*5B?=F8QJG3]534][5]!1TWD`.
M"<(BI%@1U(N_VX&][7!@&SK[G%Y>&2PCO4S=6?FY0'4E4$6!ZJ,)MY""55<]
MZ&9'%9@A7AQ+6IRU2UNW5M>[><_BB;S"FWKB`_SB9A#:DB,Z?Z[Q2'M$!]Y$
M?G.;D=&_GC61T+L0WOG8I`N5$H?3Y7FL;[3Y#U!+`P04````"`"=C@U'3\FP
MI:`!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R%4\MNVS`0
M_!6"'Q#*LAP7ABP@3A&TAP)!#NV9EE82$9*KD)25_GWYD!7;")J+N+N:F9WE
MHYS0O-H>P)%W);7=T]ZY8<>8K7M0W-[A`-K_:=$H[GQJ.F8'`[R))"59GF7W
M3'&A:57&VK.I2AR=%!J>#;&C4MS\/8#$:4]7]%QX$5WO0H%5)5MXC5"@K4!-
M#+1[^K#:'8J`B(#?`B9[$9/@_8CX&I*?S9YFP0)(J%U0X'XYP2-(&81\X[=9
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M5UK]`U!+`P04````"`"=C@U'@W3H^*`!``"Q`P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6R%4]MNXR`0_17$!Q2'I+O9R+'4M%KM/E2J^M!])O;8
M1@7&"SAN_[Z`'3>)HO;%S(S/.7.&2SZ@?74M@"=O6AFWI:WWW88Q5[:@A;O!
M#DSX4Z/5PH?4-LQU%D252%HQGF4_F!;2T")/M2=;Y-A[)0T\6>)ZK85]WX'"
M84L7]%AXEDWK8X$5.9MYE=1@G$1#+-1;>K?8[%81D0`O$@9W$I/H?8_X&I._
MU99FT0(H*'U4$&$YP#TH%85"X_^3YF?+2#R-C^J_T[3!_5XXN$?U3U:^#68S
M2BJH1:_\,PY_8!KA-@J6J%SZDK)W'O610HD6;^,J35J'Z<]ZHETG\(G`9\(Z
M2\;'1LGF@_"BR"T.Q'4BGMUB$^`VB@1E$KRYE*;IQ^JA6/!US@Y1Z`RS&S%\
MQ,P(%M2OMN#G+7;\A,Z_IR\O'"X3?3DY_/6]P.I"8)4$5E^.>(999A=-V,F>
M:K!-NCJ.E-@;/V[>7)UOYQU/9_()+_).-/`H;".-(WOTX633H=:('H*)[.:6
MDC:\GSE14/L8_@RQ':_4F'CLC@]D?J7%!U!+`P04````"`"=C@U'.NA]7I\!
M``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R-4\MNVS`0_!6"
M'Q#J8;>%(0N(4P3MH4"00WNFI95$A.0J)&6E?U\^9,4V@K87<7<U,SO+1S6C
M>;$#@"-O2FJ[IX-SXXXQVPR@N+W#$;3_TZ%1W/G4],R.!G@;24JR(LL^,<6%
MIG45:T^FKG!R4FAX,L1.2G'S^P`2YSW-Z;GP+/K!A0*K*[;R6J%`6X&:&.CV
M]#[?'38!$0$_!<SV(B;!^Q'Q)23?VSW-@@60T+B@P/UR@@>0,@CYQJ^+YGO+
M0+R,S^J/<5KO_L@M/*#\)5HW>+,9)2UT?)+N&>=OL(RP#8(-2AN_I)FL0W6F
M4*+X6UJ%CNN<_FR+A?8QH5@(Q4KXDD7CJ5&T^94[7E<&9V)''LXNWWFX"2)>
MF7AO-J9Q^E0]U7F95^P4A*XPAX0I$F9%,*_^88OBNL6AN*`7_Z:7-P[+2"\7
MA_\AL+D1V$2!S5]'O,:4-TW8Q9XJ,'V\.I8T.&F7-F^MKK?S/AXB>X?7U<A[
M^,%-+[0E1W3^9..A=H@.O(GL;DO)X-_/FDCH7`@_^]BD*Y42A^/Y@:ROM/X#
M4$L#!!0````(`)V.#4=3`!DFGP$``+$#```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;(53VVZC,!#]%<L?4!-"NE5$D)JNJN[#2E4?=I\=&,"J[6%M
M$[I_7U\(3:*J?<$SPSEGSOA23FA>;0_@R)N2VNYH[]RP9<S6/2AN;W``[?^T
M:!1W/C4=LX,!WD22DBS/LENFN-"T*F/MV50ECDX*#<^&V%$I;O[O0>*THRMZ
M*KR(KG>AP*J2+;Q&*-!6H"8&VAV]7VWW14!$P!\!DSV+2?!^0'P-R:]F1[-@
M`234+BAPOQSA`:0,0K[QOUGSHV4@GL<G]<<XK7=_X!8>4/X5C>N]V8R2!EH^
M2O>"TQ/,(VR"8(W2QB^I1^M0G2B4*/Z65J'C.J4_FWRF?4[(9T*^$.ZR:#PU
MBC9_<L>KTN!$[,##V:VV'FZ"B%<FWIN-:9P^58_5:EV4[!B$+C#[A,D39D$P
MK_YIB_RRQ3X_H^??T]=7#M>1OIX=;KX7**X$BBA0?#GB)>;VJ@D[VU,%IHM7
MQY(:1^W2YBW5Y7;>QT-D'_"J''@'O[GIA+;D@,Z?;#S4%M&!-Y'=;"CI_?M9
M$@FM"^$/'YMTI5+B<#@]D.655N]02P,$%`````@`G8X-1P"..@Z@`0``L0,`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULA5/+;MLP$/P5@A\0RK33
M)(8L($Y1M(<"00[MF996$A&2JY*4E?Y]^9`5VPB:B[B[FIF=Y:.<T+ZZ'L"3
M-ZV,V]'>^V'+F*M[T,+=X``F_&G1:N%#:COF!@NB222M&"^*+TP+:6A5IMJS
MK4H<O9(&GBUQH];"_MV#PFE'5_14>)%=[V.!525;>(W48)Q$0RRT._JXVNXW
M$9$`OR1,[BPFT?L!\34F/YH=+:(%4%#[J"#"<H0G4"H*A<9_9LWWEI%X'I_4
MOZ5I@_N#</"$ZK=L?!_,%I0TT(I1^1><OL,\PFT4K%&Y]"7UZ#SJ$X42+=[R
M*DU:I_R'/\RTCPE\)O"%<%\DX[E1LOE5>%&5%B?B!A'/;K4-<!M%@C()WEQ*
MT_2Y>JQ6Z[N2':/0!6:?,3QC%@0+ZA^VX)<M]OR,SC^GKZ\<KA-]/3N\_UQ@
M<R6P20*;_XYXB7FX:L+.]E2#[=+5<:3&T?B\>4MUN9V//)W).[PJ!]'!3V$[
M:1PYH`\GFPZU1?003!0WMY3TX?TLB8+6Q_`NQ#9?J9QX'$X/9'FEU3]02P,$
M%`````@`G8X-1W"X]XWT`0``$@8``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3@N>&ULC57;;J,P$/T5BP^HS2TW$:2FJZK[L%+5A]UG!R8!U<:L[83NWZ]M
M",4(*7G!GN%<9F0\9)V0GZH"T.B+LT;M@TKK=H>Q*BK@5#V)%AKSYB0DI]J$
M\HQ5*X&6CL09C@A984[K)L@SEWN7>28NFM4-O$ND+IQ3^>\`3'3[(`QNB8_Z
M7&F;P'F&1UY9<VA4+1HDX;0/GL/=(206XA"_:^C49(]L\4<A/FWPL]P'Q-8`
M#`IM):A9KO`"C%DEX_QW$/WVM,3I_J;^ZMHUY1^I@A?!_M2EKDRU)$`EG.B%
MZ0_1O<'00VH%"\&4>Z+BHK3@-TJ`./WJU[IQ:]>_V9"!MDR(!D(T(^#>R)7Y
M@VJ:9U)T2+74'EZX,W!I18PR,K4I%[KN^^PU#Q.2X:L5\C"''A/UF!&!C?JB
M1>1;'*()/;I/CV<5QHX>]^XAN2^0S`02)Y`,+8:++?J8!ZI,9R:I)Q`OFOB8
MY+[):F:R\@3211,?L[IOLIZ9K#V!]:*)C]G<-]G,3#:>P';1Q,.D#QS\=F:R
MG0ALEX]DZWD\\'&'9'Z!B"<1+=\@'Q3/?/#DSG*09S>:%"K$I=']Y1RSX_A[
MCMR=_X;G64O/\(O*<]TH=!3:3`XW-$Y":#!5D"?S`59F0(\!@Y.VV[79RWYD
M]8$6[6T"C[^!_#]02P,$%`````@`G8X-1S6^?2.C`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3DN>&ULA5/;;J,P$/T5RQ]0`R'=*")(3:O5[L-*
M51_:9P>&BVI[6-N$]N_K"Z%)%*DO>&8XY\P97XH)];OI`"SYD$*9'>VL';:,
MF:H#R<T=#J#<GP:UY-:ENF5FT,#K0)*"94ERSR3O%2V+4'O698&C%;V"9TW,
M*"77GWL0..UH2D^%E[[MK"^PLF`+K^XE*-.C(AJ:'7U(M_O<(P+@M8?)G,7$
M>S\@OOOD;[VCB;<``BKK%;A;CO`(0G@AU_C_K/G=TA//XY/Z[S"M<W_@!AY1
MO/6U[9S9A)(:&CX*^X+3'YA'6'O!"H4)7U*-QJ(\42B1_".NO0KK%/^L-C/M
M-B&;"=E"V"3!>&P4;#YQR\M"XT3,P/W9I5L'UU[$*1/GS80T3!^KQS)=YP4[
M>J$+S#YBLHA9$,RIWVR17;;89V?T[&?ZZLKA*M!7L7NZ^5D@OQ+(@T`^C[B^
M.>(EYOZJ"3O;4PFZ#5?'D`I'9>/F+=7E=CYDX4R^X64Q\!;^<=WVRI`#6G>R
MX5`;1`O.1'*WIJ1S[V=)!#36A[]<K..5BHG%X?1`EE=:?@%02P,$%`````@`
MG8X-1^S.23FC`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL
MA5/+;MLP$/P5@A\0RI*=I(8L($X1M(<"00[MF996$A&2JY*4E?Y]^9`5VS"0
MB[B[FIF=Y:.<T+S;'L"1#R6UW='>N6'+F*U[4-S>X0#:_VG1*.Y\:CIF!P.\
MB20E69YE]TQQH6E5QMJKJ4H<G10:7@VQHU+<_-N#Q&E'5_14>!-=[T*!525;
M>(U0H*U`30RT._JTVN[7`1$!OP5,]BPFP?L!\3TD/YL=S8(%D%"[H,#]<H1G
MD#((^<9_9\W/EH%X'I_47^*TWOV!6WA&^4<TKO=F,TH::/DHW1M./V`>81,$
M:Y0V?DD]6H?J1*%$\8^T"AW7*?TIBIEVFY#/A'PA/&;1>&H4;7[GCE>EP8G8
M@8>S6VT]W`01KTR\-QO3.'VJ'JO5YJ%DQR!T@=DG3)XP"X)Y]9LM\LL6^_R,
MGG]-+ZX<%I%>I.YY\;7`^DI@'076\XB/-T>\Q'R[:L+.]E2!Z>+5L:3&4;NT
M>4MUN9U/>3R33WA5#KR#7]QT0EMR0.=/-AYJB^C`F\CN-I3T_OTLB836A?#!
MQR9=J90X'$X/9'FEU7]02P,$%`````@`G8X-1SE!U$RY`0``>P0``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C$N>&ULC53;;J,P$/T5BP^H@23L*B)(3:NJ
M?:A4]6'WV8$!K/I";1.Z?[^^$!H04OJ"/<.YS,#8^2#5AVX!#/KB3.A#U!K3
M[3'690N<Z#O9@;!O:JDX,394#=:=`E)Y$F<XC>,,<T)%5.0^]Z:*7/:&40%O
M"NF><Z+^'8')X1`ET27Q3IO6N`0N<CSQ*LI!:"H%4E`?HOMD?\P<P@/^4!CT
MU1ZYVD]2?KC@I3I$L2L!&)3&*1"[G.$!&'-"UOASU/RV=,3K_47]R7=KJS\1
M#0^2_:65:6VQ<80JJ$G/S+L<GF%L8><$2\FT?Z*RUT;R"R5"G'R%E0J_#N'-
M[WBDK1/2D9`N"#@8^3(?B2%%KN2`=$?<OTOV%JZ<B%5&MC;M0]]]R)Z+)(MS
M?'9",\PQ8-*`F1#8JJ]:I'.+8WI%3V_3-XL*-YZ^">YI=EM@NQ#8>H'MV&*R
MVN(<\X,J=PN3W4Q@LVHRQVQOFV0+DVPFL%LUF6.6GPM?30<'U?A#H%$I>V'"
M&$S9Z9S=IWZZON%%WI$&7HEJJ-#H)(V=43^>M90&;!'QG6VUM3?!%#"HC=O^
MLGL5#D<(C.PN1WVZ;XK_4$L#!!0````(`)V.#4=<I&Q>$0(``-T&```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)55VV[;(!A^%<L/4`P^)G(LK9FJ
M[6)2U8OMFB0DMHJ-"R3NWGX<G,RFI&ENPL'?Z8<`Y<#XJZ@)D<%[2SNQ"FLI
M^R4`8EN3%HL'UI-.?=DSWF*IAOP`1,\)WAE22P&*H@RTN.G"JC1SS[PJV5'2
MIB///!#'ML7\[R.A;%B%,#Q/O#2'6NH)4)7@PMLU+>E$P[J`D_TJ_`:7:X@T
MQ"!^-V00DWZ@PV\8>]6#G[M5&.D,A)*MU!)8-2>R)I1J)>7\-HK^]]3$:?^L
M_F3*5?$W6)`UHW^:G:Q5VB@,=F2/CU2^L.$'&6M(M>"646%^@^U12-:>*6'0
MXG?;-IUI!_NEB$::GX!&`KH08/(I(1X)L4,`-IFIZSN6N"HY&P+18[W;<*G@
M7(LHY4`5(\S0+)>=/54PRTMPTD(SS*/%H!%3^##K*0:E%PA0$;PYD),#&7X\
M>BQN"\2.0&P$$BN01_.0G2W$8G(;TH=8^Q%70R1.B&06`GI7<XY!WM6\AKD:
M)'6"I#.!^+9`Y@AD]^Y'[@CDLP2)=S\L)C68+,\7*8QN&Q6.43$S2KU&Q7W;
MNG`L%C.+S&NQF%C`.,V^4`F,W,,8S8SR+TA\.,_PWHV#[E&$:):B\)8[@NS>
MI0F*/Q0,)A=1CP_D%^:'IA/!ADEUIYGK;,^8)$HM>E#_UUJ]-9<!)7NIN[GJ
M<WO[VH%D_?DQN;QHU3]02P,$%`````@`G8X-1Z"0O/3Y`0``X04``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C,N>&ULE53;;J,P$/T5BP^H"9=`(H+49%5U
M'U:J^K#[[)`AH-J8M9W0_?OUA5!`2$E?\(5SF?%H)NNX^)`5@$*?C#9RYU5*
MM5N,95$!(_*)M]#H/R47C"A]%&<L6P'D9$F,XL#WUYB1NO'RS-Z]B3SC%T7K
M!MX$DA?&B/BW!\J[G;?R;A?O];E2Y@+G&1YXIYI!(VO>(`'ESGM>;0\;@["`
MWS5T<K1')O8CYQ_F\/.T\WP3`E`HE%$@>KG"`2@U0MKX;Z_Y96F(X_U-_<5F
MJZ,_$@D'3O_4)U7I8'T/G:`D%ZK>>?<*?0JQ$2PXE?:+BHM4G-TH'F+DTZUU
M8]?._4G]GK9,"'I"\"@A[`GA0`A<IBXRF]</HDB>"=XAV1)3[-56PX41T<I(
M)R/MT3Z7N[WFJV23X:L1FF#V#A,XS(#`6GW1(IA:[(,Q/?67+`Y3S`,FX2R/
MT`J$O4!P7R":"416(.H%PFF4C<O$8>)''R*>6<03BVCQK:>8^+[)>F:RG@BL
M%TVFF.2^23(S228"Z7V!=":0?K=<FYG`9A+!9K%<#I-83))&_F)1#V-4E/I^
MG(2S</"HI1B(LQTU$A7\TBC7.\/M,,V>`]N27_`\:\D9?A%QKAN)CESIQK8]
M77*N0`?B/^G:5WK>#@<*I3+;1.^%&T'NH'A[&ZC#5,__`U!+`P04````"`"=
MC@U'!)3O$8`%``";(@``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R5
MFMMRHS@0AE^%\@,,Z`PNQU5CYV!/:JNFYF+WFL0D=@T8+Y!X]NW7@.+0;<6T
MYF)LR-\MM=#7DMK,CF7UN]YF61/\*?)]?3/9-LUA&H;U\S8KTOI;><CVI[^\
ME%61-J?+ZC6L#U66;CJC(@]Y%.FP2'?[R7S6W?M9S6?E6Y/O]MG/*JC?BB*M
M_EMD>7F\F;#)QXU?N]=MT]X(Y[/P;+?9%=F^WI7[H,I>;B;?V?0QYJVD4_R]
MRX[UX'O0=OZI+'^W%^O-S21J^Y#EV7/3NDA/'^_9,LOSUM.IY7^MT\\V6\/A
M]P_O]UVXI^X_I76V+/-_=IMF>^IM-`DVV4OZEC>_RN,JLS&HUN%SF=?=_\'S
M6]V4Q8?))"C2/_WG;M]]'ON_Q)$U<QMP:\#/!N=VW`;"&HA/`WG50%H#2350
MUD!1NZ2M@::V8*R!H8Y2;`UB:@N)-4@^#?15@_:9]T\NHK;!S@^;(9.PGR7=
M'+M-FW0^J\IC4!_2ECPV;?55Z^?D/#C-K+J[[.9N?_=]SI)H%KZWGH!FT6NX
MU3"7YFZH4;%+\@#<N!1KV!`_:\)3).YP.`QGP8$'X6IE"372I;F%&N4,>:CA
M+L7]4*$2YZ",.EF-.UG#WFJ7Y@?4&)?F$6IBPO@+-)U$YT%8#PG!@T0>9.=!
M]@,2H0FY[P>MUYA.$Q':4*@-!=I@!`\:>=#><1KDP8`^<%><]V80IXS:?\[A
MZ&4*#<=`L;KBZ.L>QZC',>BQ('A(D(?$>]18A/-5-#YN#U:$1^1*,Q=ID8%F
M),4'QSZX?[B8)R;&P[VSHO[Q,A%]/5.L4KF55_J%*6404T7Q@2EDRG]\,(=,
M@WYH5]2W5F3')Z)'C9EE$%I#\8$I8K%_U)@CEE!F13*6%N[')0_CDA60".K@
M<DPVAV3'SJ"XF^QA4$#"OV;!ZO`J,HP,N#+DR'`RX3"9?+$1`")&:@AG',Z!
M#^8*:FE%?=PQ(T>%4Q,'J8F1=FLXC7#I#0/':82K\7GSPXJ,YY/$Z8:#=,,H
M:R#'280;_YAQ$N'Q>,QK*^IC%HH:,TXV/!F?5(]6U+?%8V);`N<``7(`HRR[
M`M,FF/?X"@R2((#T*(8@,3)(XF+/#$&BK*4"@R3\01(8)*$(V<.*U&!2D8+&
M)`E(DJ;XP"0)?Y($)DG$E*#CX;:)O($6&"4!4:+L'R1&1$;^1RR,B(1KC?.X
MOD8B4D.8(TE9D*S(3BE.'5V).9*`(T[R<7'Z].=(8HZDHHPN$''*&51BAB1@
MB%-68(D9DOX,2<R0A*N1<SNZE$.&%-/DQXPAD@`B3EF#%89(^4.D,$2*$:*V
M(ILY$FK0"H.D`$B<LC`JS(?R+\XHS(>2E*#E<`>>D!^UNJC30$@H*Z/"D"C_
M4HW"D"A"L6:IAF48'I'W`PKCI`!.G+(T*@R)\B^U:`R)A@<RY]EZJ8>G*$F>
MX!K3I`%-G+(T:@R)]B^X:`R)%N/)^P&)2`UADC0DR7W<U>Y*Y_"X"R17BH3C
MKE9`0M_0:HRMAMA2ZLCZHL#JCZW&V&H"M@L]K(TF'E%C;#7$EM1CC*WVQ]9@
M;`VA0KHPH$A"SM`&8VL`MH+D`V-K_+$U&%M#J),NS+#Z*0QY'V\PNP:P*RB;
M-X,A,?[53X,A,9H2M1YNO"+R_MI<_&(!<!*4[:;!D!C_ZJ?!D!A"]7-AAD5)
M\K(48YAB`).@;#9CS$CL7Y"(,2,QV/^YU^)%#`H2[AU(./A]N,BJU^X=ACIX
M+M_V33]<Y[OG]R2^=Z])H/L+-KUECOMW;'KONO_`IBO7_36;_NC?FOCLSGQV
M2%^SO]+J=;>O@Z>R:<JB^PG\I2R;[!1J].U$SS9+-^>+/'MIVJ\M5E7_[D1_
MT92'CU=!SN^CS/\'4$L#!!0````(`)V.#4?E/G%>?`(``/$(```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;)5679.:,!3]*PP_8$D"B#C(S(IVVH?.
M[.Q#^QPU"K-`*(G+]M\W'XB09E=\$7(YY]R/W'B3=+1]8SDAW/FHRIJMW9SS
M9N5Y[)"3"K,GVI!:?#G1ML)<+-NSQYJ6X*,B5:6'`%AX%2YJ-TV4[:5-$WKA
M95&3E]9AEZK"[=\-*6FW=J%[-;P6YYQ+@Y<FWL`[%A6I64%KIR6GM?L,5SL8
M2(A"_"I(QT;OC@Q^3^F;7/PXKET@8R`E.7`I@<7CG62D+*62\/RG%[WYE,3Q
M^U7]FTI7A+_'C&2T_%T<>2ZB!:YS)"=\*?DK[;Z3/H=0"AYHR=2O<[@P3JLK
MQ74J_*&?1:V>G?X2@9YF)Z">@`;"X,=.\'N"?R,$7Q*"GA#,]1#VA-#PX.G<
M5>6VF.,T:6GGL`;+?H(K`6^EB%!V1+F86JH-T=;W%/E!XKU+H0EFHS%(8<*E
M#;(=0^"`\$0`UBC0-(H-&M&1S4$V1H2Q-8:[(KM/1#X-TS>*Y2M^T!<KO"\0
M&`*!$O![@<5]@=`0""<11-,L:UT'C0DU!J`9>2X,+XN)E^5]@<@0B![-<VD(
M+"<1Q+8\-QH3Z=T,S=[5H&P,6BS-[NTK-@9!"$-K77<3E!_!&7T>&VG%X[0"
M<%\``O.\@D=+"_\[\G`2!;26I`<-713-<(1,1VCB",V0,$\<]!].USQS,)A$
MX5M[J0?IS?4!0I$5ETUQ$8AC:V]N9^KMOM+3*7JC__.*M&<U29ESH)>:Z\(,
MUF%:/R,Y#PS[!JXR:+%OY717\^,FGR8-/I.?N#T7-7/VE(LII`;0B5).1.#@
M250[%_>/85&2$Y>OD=P&/9'U@M/F>L$8;CGI/U!+`P04````"`"=C@U'`M#Y
M?10"``!,!@``&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R-5=N.VC`0
M_14K'[!.G'AA48BT7*KVH=)J']IG`P.)UHY3VY#MW]>7$`+*%EZP/3GGS)D)
MGN2M5!^Z!##H4_!:SZ/2F&:&L=Z6()A^D@W4]LE>*L&,/:H#UHT"MO,DP3&)
MXV<L6%5'1>YC;ZK(Y='PJH8WA?11"*;^+H#+=AXET3GP7AU*XP*XR''/VU4"
M:EW)&BG8SZ/79+:F#N$!ORIH]6"/G/>-E!_N\&,WCV)G`3ALC5-@=CG!$CAW
M0C;QGT[SDM(1A_NS^C=?K76_81J6DO^N=J:T9N,([6#/CMR\R_8[="5XAUO)
MM?]%VZ,V4IPI$1+L,ZQ5[=<V/)G&'6V<0#H"Z0E]GG%"VA'2"R'[+R'K"-FC
M&6A'H#<9<*C==V[%#"MR)5ND&^;^3LG,PI43L<K(MDO[HW\A(7HJ2);E^.2$
MKC"+@"$>0Z=CD-40DO0(;`V,NB#7+A9D0"=C"99#!'T9]7!79/V%R)<VTYMF
MI9Z?A@SI\WV![$8@\P)9UVUZ;;(.O0B826AE.AVD&:"65ZA),JZU&J+(9/J2
MCJ'60U2:D<D#A=&;PNA58:.6%_2APNA#A=&'"J-W"L.#NR)`'?R4TF@KC[4)
M[[F/]H/PE;B[=A-?)+-E,A)?V<$9YMQ%OL@;=H"?3!VJ6J.--/:&^\N]E]*`
MM1T_6=^E'>W]@</>N.W$-3],NW`PLCG/[OX#4OP#4$L#!!0````(`)V.#4<@
MI-?GTP(``(\+```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)6677.B
M,!2&_PK##R@)A``==6;5V@]G9SJ]V+U.-2I3("Z)M?OO-U]:PP9+O1`"S_OF
MY)Q#8'1D[1O?42J"C[IJ^#C<";&_C2*^VM&:\!NVIXV\LV%M380<MMN([UM*
MUEI45U$,`(YJ4C;A9*2O/;>3$3N(JFSH<QOP0UV3]N^45NPX#F%XNO!2;G="
M78@FH^BL6Y<U;7C)FJ"EFW'X`]XN(5*()GZ5],@OS@,5_"MC;VKPN!Z'0,5`
M*[H2RH+(PSN=T:I23G+F/];T<TXEO#P_N2_T<F7XKX33&:M^EVNQD]&",%C3
M#3E4XH4='ZA=0ZH,5ZSB^C]8';A@]4D2!C7Y,,>RT<>CN9,B*_,+8BN(SX*X
MN"I(K"`Y"W)P58"L``T5I%:0?H8$KPJP%>"A@LP*LJ&"W`KRH8+""HJA`E5S
M4SDP6'(N-NQ((M,ENL?F1)#)J&7'@.^)>O+@K>);Y2/-`]E97`]U[YJK[Y,8
M9:/H73DYS-0PL65R'S-SF<+'S!TF!3[FSF6@CUFX3.QC[ETF\3$/+H-\S*/+
MI#[FR66PCUFZS&>>(UDD?Z7B3J5B[9!8AWR`0])Q2+0#L@Z=&C6FUH;)-`-A
M!N3/QST:#@(#@K0/?'(,$]3'+5W#&#A@_QI19XWH<HW8VV-/+N/ML64?TQ])
MVHDD=1R\73IS&6^7SON8_DAP)Q+L."!?^F?8*5.<Y*D/FV.G2C#'^9!&S#H!
M94Y`WIFFADD-,V".O#-'[LR!?7/<Y9>+!DF>^5>]R"]7720P@4,B*CH1%4Y$
M0[8`/:.S6X-O;P+POQT??KT-W%O(I`;C(D;>I_;!<C8U>.A3"[N;&XR=Y`Q:
M6'=[@\GWD]/=/B#Z.CEW%C+)20$L$F]R%I:SR4&I)SG1Q>MZ3[;T)VFW9<.#
M5R;DNU^_]C>,"2KMP(W<"7;RZ_@\J.A&J--,GK?F>]$,!-N?/G_/W^"3?U!+
M`P04````"`"=C@U'Z_M?T%L"``#B!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6R-E=F.VC`4AE\ER@-,O,1Q,@I()5757E0:S45[;<!`-$E,8P/3
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M72XW>UZBHJJSLPD4:%9.@YPFIF@"!;E),@T0I4`S"F3]V/HQO>_',S^V_MSE
MIR!D'%P53D-=#HPK6L5D32A#987NX^0SG#S`@5$<IR%6`_.2@"AUX\MR@',"
M[N.0&0X)<%`4A_@X!(,R*FM\&24(WX<I9C!%`(.C,(67I<"$%-$E;'P9S7%9
M/+#SZ`R'>CL/T?Q^@'(6H`SJ(=%Z2@\4`_2/LIM`AFCUR$FH9CA5@%-$<2HO
M#R&41F%\40$(O(\"P?QN`0%,-,]J$ET7AY8D?A!"G3Z_9?D`TH?K#@9(91P)
M>G=`E>,<QO=?H(.`:O;Y@<B\V_C(]OP[&_?M().U4/IBMW?Z3@C%=3CPI`_7
M03^XMT''=\ITJ>Z/[@ER`R6.UQ?U]JPO_P!02P,$%`````@`G8X-1RC6#$E\
M`P``S0\``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULE5==<Z(P%/TK
M##^@D"\^.NI,U=+=AYWI]&'WF6I4ID!<B+7[[S=`I$F:*'T1B.?<>RY)#KFS
M,VO>V@.EW/NHRKJ=^P?.C_=!T&X.M,K;.W:DM?AGQYHJY^*QV0?ML:'YMB=5
M90##,`JJO*C]Q:P?>VX6,W;B95'3Y\9K3U65-_^6M&3GN0_\R\!+L3_P;B!8
MS(*1MRTJ6K<%J[V&[N;^`[A_@J2#](C?!3VWRKW7B7]E[*U[^+F=^V&G@99T
MP[L0N;B\TQ4MRRZ2R/Q7!OW,V1'5^TOTK"]7R'_-6[IBY9]BRP]";>A[6[K+
M3R5_8><?5-;0*]RPLNU_O<VIY:RZ4'RORC^&:U'WU_/P3Y1*FIT`)0&.A#&/
MG8`D`7T2\%4"E@0\E4`D@4PE1)(0C80DO$J()2$V,@3#V^WG9IWS?#%KV-EK
MCWFW8L&]@#==$!'9$Q/2]H_]E`^C[PL8I[/@O0ND898#!O88DM@@F0H!(R(0
M`JPJH*YB"14ZM"58:8@DM&'6&H;8((\JA%BKS6YJ>7($<5:+C'>.>CZ2M4QX
M7=@(@/L`6`8P1-;#*QTP9,!$((H1L>%6&HY@3,+0AEOK.)`Z<-FUO,X"B5$@
MT0I$U@*)DBB&T%$>T62'BFBGF,@0$VEBL'71Z)@)%<=&DE@+$%F3Z)CX=I+$
M2))H`1+K:QTP\;"348A)9)UF#19'29K<EI,:<E)-3FJ5DRKS9UUPJYN(QYN(
M[";BR8YPE@I"TV=#M=C4FF0I07*UBC-#;%WZF89#,4%@@@N!+]8/-$G`+@DH
M$PTA03BVKIOL*M`M"IJBH";*:L"9`4(3\I@>#)`6`D\(8;HPP-_U<6#Z'-",
M+K5:V!JH'H;$LICD8L"T,:!Y5&JW&`,TP6.`Z61`LZG4[C(21.29`L'(6GMV
M#>>69/H>T(POG;)93*\"Z7<G&YH6`#4+<'RVH;JU`8Y#QX<MNPITBS)-`&HF
MX/C42M"0"T_,9.YLJ&Y:-&4)0W/3PF^?G*"Y:>&4LQ-4#S$`X,AUV+D*=(LR
M;0!..>_`+S9@_1Q"]XE'-14-!L(D_:H\4#J)BC;[ODMLO0T[U7R8A'%T[$0?
M8->)&.-+</\(+..9Z%R'/O,S_&)VS/?T5][LB[KU7AD7_4_?^NP8XU0H#^^$
M\H/HK<>'DNYX=QN+^V;H-H<'SHZ7YGGLX!?_`5!+`P04````"`"=C@U'\;6-
M!?`!``#9!0``&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R5E,N.FS`8
MA5_%X@'&@#&7B"!UJ*IV46DTBW;M)":@L3&UG3!]^_I"4H)HD]G@"^=\/OXM
MNQR%?%,MI1J\<]:K;=!J/6P@5/N6<J*>Q$![\Z<1DA-MAO((U2`I.3@39S`.
MPQ1RTO5!5;JY%UF5XJ19U],7"=2)<R)_/U,FQFT0!9>)U^[8:CL!JQ)>?8>.
MTUYUH@>2-MO@4[2I"ZMP@A\='=6L#VSVG1!O=O#ML`U"&X$RNM>60$QSIC5E
MS(+,PK\FYM\EK7'>O]"_N-V:]#NB:"W8S^Z@6Q,V#,"!-N3$]*L8O])I"]@"
M]X(I]P7[D]*"7RP!X.3=MUWOVM'_R</)MFZ()T-\-431?PUH,J"%`?ID;E^?
MB295*<4(U$#L84<;(Y<68LC`;$:YH2N7GSU7*(Q*>+:@&\VSU\23)E[3U/_2
M0)-A-4B\"!([`)H`Z#X`+0#(`9()D-RF[/U.O"9SFCC-0U2LR>JY+,DQRO#]
M.,DB3G(3YP$`7@#P1PN2+@#I`P7Q&NPT68YQM%J/N2J*"UR$]]-DBS3939KT
M/B!?`/*/UJ-8`(H'ZE',3C[*BR3/5PLRER&,3>46<>#L%@[D2+\3>>QZ!79"
MFPOM[G(CA*8&%CZ9DV[-.WL=,-IHV\U,7_JGQP^T&"X/Z?4UK_X`4$L#!!0`
M```(`)V.#4=!>3XF#@(``&P'```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;)65WY*;(!C%7\7Q`98_QL1DC#.-G4Y[T9F=O6BO2231610+)&[?OH`F
M#12[V1L%/.?X^Q`A'[AXE36E*GIK62>W<:U4OP%`'FK:$OG$>]KI)T<N6J)T
M5YR`[`4EE36U#&`(EZ`E31<7N1U[%D7.SXHU'7T6D3RW+1&_=Y3Q81NC^#KP
MTIQJ909`D8.;KVI:VLF&=Y&@QVW\"6U*A(W$*GXT=)!W[<C`[SE_-9UOU3:&
MAH$R>E`F@NC;A9:4,9.DW_QK"OW[3F.\;U_3O]AR-?Z>2%IR]K.I5*UI81Q5
M]$C.3+WPX2N=:DA-X($S::_1X2P5;Z^6.&K)VWAO.GL?QB<9G&QA`YX,^&;`
MZ7\-R61(/`,8R6Q=GXDB12[X$,F>F*^--EHN3(A.CG0QTG;M=(VCER*!JQQ<
M3)"CV8T:/&EP2%/.:8!F"()@#P3;@&0*R-X/2+R`Q`8LIH!UL!)'@V"PDCG-
M+,C"`UDX`2@(<J]!67#:RSG-+$CJ@:0.2/"[[5Q-$@1Q-8OW098>R-()2(,@
MKF89!'$U#\S(R@-9.0$/+++,"\@^NDK77L#:(0BO4D>#PZMT3C,+@J#_YT,G
M`CT0\<_F@3XZ'<C_[1%^8$)<$9[9@>9$(PRXVQ=[<J+?B3@UG8SV7.DMUNZN
M1\X5U5'P2:_X6A]]MPZC1V6:*]T6XV$P=A3OKV?;[8`M_@!02P,$%`````@`
MG8X-1^2*GLG#`P``[1(``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
MG9C;<ILP$(9?A?$#!&DY>QS/U(2XO>A,IQ?M-;%EFRD@%^2X??MRD`E25H;T
MQ@;YV]U_)7D7M+KRZE=]8DQ8?XJ\K!\7)R'.2]NN=R=6I/4#/[.R^>7`JR(5
MS6UUM.MSQ=)]9U3D-A#BVT6:E8OUJAO[5JU7_"+RK&3?*JN^%$5:_=VPG%\?
M%W1Q&_B>'4^B';#7*WNPVV<%*^N,EU;%#H^+3W2YA;!%.N)'QJ[UZ-IJQ;]P
M_JN]^;)_7)!6`\O93K0NTN;KE<4LSUM/3>3?TNE;S-9P?'WS_MREV\A_26L6
M\_QGMA>G1BU96'MV2"^Y^,ZOGYG,P6L=[GA>=Y_6[E(+7MQ,%E:1_NF_L[+[
MOO:_A$2:X08@#6`P&.+@!HXT<`8#N&_@2@/W+8)[U\"3!M[<"+XT\.=&"*1!
MH$6P^]GMUN8I%>EZ5?&K59_3=L?298-7K9/&L]4L2-W==DO>C[ZN'7!6]FOK
M2&$V/0,=XX48DHP1BA%;A8A@8.Q&)*H45*4;&#D`+$2L$"'!F*<QXT5H+I.!
MGJ>=;!4GWG2VCK8N3F?OR'5QIQVXF@.W<^!*!YXJLNRGM&<\*=)U/4(P+E8Y
M&AFXY!YG%.YIPKV1<`@=5+@W"A0`.&AZL:?((7/$^)H87Q$3H6+\41A\_B:)
MITDBF22><<*8:J"E&B@;QD=3#293Q0FCB%`3$2HB`E1$.%Y6G_J!8?G#>;L[
MF>EO&_[/[HZT!",EP1!-,!KO[B@B/HHE=S"C'$KT^D\40?@.EU`?B@8D]`FZ
M-,E=T"SJ75.B8U$.NFP;"4U.TSW.+`ET2:!(HKBD'HKZ+?)`4"J65(`UF)MF
M'#'+U=L'=12Y:)2-A"B5>O'Z%K_#9K0SJK<CJO0C!R_KU)VL+P;$+$1O+]13
MA+BX$&]:"(Z8A>BMA?J*$+Q#2VB8>X).7"RQ^QLOF>=L*['YFT_O)%1I)0[:
M2A()86+,D?1V095^X1B*4O@?D?2Z397"[>"%6T+1W?E-S)3Y65@OVZ"4;0=]
M!HU5".8\<^N5&)1*3&=43M`K)\!''V5!KV;@3&>;J!#,^$N"7J1`*5(N^@81
M:Q#ZMI.H$*">MD9/9L5Z-0.EFL$<%WH=`O_#ZZ/_X2&8LS[!AW>C_G>'<,[Z
MA(8XBI@9T-8(]8KMT9MVP:IC=XI26SM^*44_G\/H<%+S"=HW=6U\0Y=/%!E/
MZ/*Y/X=Y<[]>G=,C^YI6QZRLK1<N!"^ZHX$#YX(UJLE#LR5.+-T/-SD[B/8R
M:*ZK_C2FOQ'\?#M<&DZXUO\`4$L#!!0````(`)V.#4<684D]E0,``!01```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;)U8T7*B,!3]%88/$')#`CCJ
M3-4ZNP\[T^G#[C/5J$R!N("U^_<+2;0DC36V#Q7PW'MN<G-.B),3KU^;/6.M
M]UX653/U]VU[&`=!L]ZS,FM&_,"J[ILMK\NL[6[K7=`<:I9M1%!9!!"&-"BS
MO/)G$_'LJ9Y-^+$M\HH]U5YS+,NL_C=G!3]-?>2?'SSGNWW;/PAFD^`2M\E+
M5C4YK[R:;:?^`QJO,.XA`O$[9Z=F<.WUQ;]P_MK?_-Q,_;"O@15LW?8ILN[C
MC2U84?29.N:_*ND'9Q\XO#YG7XGA=N6_9`U;\.)/OFGW7;6A[VW8-CL6[3,_
M_6!J#*1/N.9%(_Y[ZV/3\O(<XGME]BX_\TI\GN0W2:C"[`&@`N`2@.,O`[`*
MP*X!D0J(7`.("B`?`5^/@:H`:@0$<K+$5"^S-IM-:G[RFD/6+T`T[N!UGZ3+
M['7SVXA;T4'Y]&V&(Y@$;WTB#3.7&!`8DM@@RR$$71!!5X"U"M"KF,,@'$?8
M1K'0,9&U#(<\CSJ&V#`K'4-O#P@;TXI%`BP2`'9($!D)(I$@4A7$>I65G#6)
M(9(DC2`E`#;@TA6XTH$0:\"KM1.C=J+5GEAKEYA$8,)1&")KX4ZHU774U9*I
M43(=E`PXN9T@-A+$]S8\,1(DMQO^F`S:@TC8_=WF20V>]'9S'B4F/4^HPWRB
MT/254.-)[:ZA@8C#:-`G_T):"F3GT4$.2QJ!R0-:"FQ=K@HD&T3=^H-,ZT!8
M8XIL3`L%DDRI(Y/I,4@S&4+L3!(4RY6=1)$3E6D)2/,$0NU4Y!O39RH948W)
M*J2%`LE!H13<J$S-HUBCLFIIJ4"2*HJIV_R9[H`T>R!7Y*2!J`N/Z0Y(LP=Z
M14[IO7("TQY`4SZUOG<L=9`3CVD/H"F?VF6K0'>M.S`-`C2#H%;9+A5(K3M*
MW*A,AP#-(:A5MTL8.@1.PQAC!RK3(D"S".JPKX$I?2#W;HU@:AHT35.[IA5(
M[EIXA%R(3$6#BZ(5B-SEB&`J&A*7)B;?H3)%#;JH'=YNL*E7'-[;1&Q*$2.'
M)BK0N8D.DL>F$#$X]!`/=VK7#0!_>LMW$.)<@:3FXY12Z^:WU&`HI/B37H/!
MR:YD]4X<PAMOS8]5*P\KEZ>7@_X#]"=#X_D<C1?RN/Z19C8Y9#OV*ZMW>=5X
M+[SMSIWBR+GEO&5=@>&HT_&>99O+3<&V;7\9=]>U/+3+FY8?SK]!7'X(F?T'
M4$L#!!0````(`)V.#4<0C\UFY@$``*,%```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;(V4VV[;(!S&7P7Y`8J/9(T<2TNLJKN85/5BNR8QCJV"\8#$
MW=N/@Y/9%FY[$P[^OH_?GP#YP,6;;`A1X)W13NZ"1JE^"Z$\-81A^<![TNDO
M-1<,*ST49RA[07!E38S".`P19+CM@B*W<R^BR/E%T;8C+P+("V-8_-T3RH==
M$`6WB=?VW"@S`8L<WGU5RT@G6]X!0>I=\#W:EL@HK.!72P8YZ0/#?N3\S0Q^
M5+L@-`B$DI,R"5@W5W(@E)H@O?"?,?/_DL8X[=_2GVRUFOZ()3EP^KNM5*-A
MPP!4I,87JE[Y\$S&$C(3>.)4VE]PNDC%V<T2`(;?7=MVMAW<ERP9;7Y#/!KB
MNR%*/S0DHR'YJB$=#>G"`%TI=B-*K'"1"SX`V6-S.J*ME@L3HI.!KE[:H=U?
M-WLM$O28PZL)FFGV3A-;382^^32'J2;.?))R10(UI1<U7J#&UI\XC/CQ\X!D
M$9#8@-35N@GGD)VKPVDRJ\G2.$%>6?F!;!4G7>"D$YS(C[-WFHW;,R_PIXK2
MKUC%S!:8V0PS\IZ0N2;VGI`US2H(6H"@V=\7>6M%DUH12D.4+M:!D^O1XS/Y
MB<6Y[20X<J5OFKUD->>*Z+#P02,W^L6\#RBIE>EN=%^X1\0-%.]O3^+]72[^
M`5!+`P04````"`"=C@U':*Y6C3L"``"Y!P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6R55=V2FR`8?17'!U@$49,=XTPWV4Q[T9F=O6BO24*BLRH6
M2-R^??E+JJQMW%Q$P',.YWP@Y#WC;Z*D5`;O3=V*55A*V3T"(/8E;8AX8!UM
MU9LCXPV1JLM/0'2<DH,A-35`492"AE1M6.1F[(47.3O+NFKI"P_$N6D(__U$
M:]:O0AA>!UZK4RGU`"AR<.,=JH:VHF)MP.EQ%7Z!CUMH(`;QHZ*]&+0#;7['
MV)ON?#NLPDA[H#7=2RU!U.-"U[2NM9*:^9<3_3NG)@[;5_6MB:OL[XB@:U;_
MK`ZR5&ZC,#C0(SG7\I7U7ZG+D&C!/:N%^0_V9R%9<Z6$04/>[;-JS;.W;U+L
M:-,$Y`CH1D#POX38$>*Y!.P(>"XA<81D+B%UA-0C`%LL4^H-D:3(.>L#T1&]
M`>&C@G,MHI0#55]ANF8%[>BEB#.4@XL6&F&>+`8Y3#R%68\Q>`JS&6(07DYA
MGD>8))K";/^%`2KO9&CDA49&('9FD_L"L2<0&P'L!-*QR]96S6(RBXG2:(&R
M*=S:XF#DXJ`ECF9$PIXC/'(T.=,&#QQA%">Q7U^+>\9#1PJD?_<=)9ZC9.1H
M<5\@]032SZY2Y@ED(P?+R9I83&)K,C/IPIMG,9QG,4-@Z0DL/YO4K,WH,XYF
M9'4@&S:>FQ9^.#+@*"^<G@N.MC]"_KG1NF\9CK9_!C]Z`H,3K2,G^IWP4]6*
M8,>D.AS-N7AD3%(E%SVH75>J>_36J>E1ZF:FVMS>++8C67>]*&^W=?$'4$L#
M!!0````(`)V.#4<I3."\^0(``-$,```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;)67VV[B,!"&7R7*`S0^Y.!4@+1`6UIII:H7N]<I&(B:Q&P22O?M
MUR<@]KI@0")Q^/Y_9F*/E8P.K/WHMI3VP5==-=TXW/;][CZ*NN66UD5WQW:T
MX?^L65L7/1^VFZC;M;1825%=10B`-*J+L@DG(WGMM9V,V+ZORH:^MD&WK^NB
M_3NE%3N,0Q@>+[R5FVTO+D234732K<J:-EW)FJ"EZW'X`]Z_P%P@DOA5TD,W
M.`]$\N^,?8C!\VH<`I$#K>BR%Q8%/WS2&:TJX<0C_]&FYYA".#P_NC_*<GGZ
M[T5'9ZSZ7:[Z+<\6A,&*KHM]U;^QPX+J&A)AN&15)W^#Y;[K67V4A$%=?*EC
MV<CC0?U#@):Y!4@+T$F`+PNP%N"3`,&+@E@+8E]!H@7).:7LHB#5@O0<X;(@
MTX+L++A<--$"XALAUX+<5R#F7,T<L"21FG*Y8.9%7TQ&+3L$W:X0;03O!=\*
M'VX>\&72R:%<B.KJYP03-(H^A9/!3!6#-(-=S,QD8A<S-YG$Q3R83.IB'DTF
M<S%/)D-<S,)D<A?S[!'KY3N?B$^`>Q:0-0M(.F#ED`,/!VPY8.D0:P=HYMFH
M^Z:81#+`13Q=)197B>>KQ(N;^+[6V*HU-FI%SEH5DTD&9BA)W-S"X"`D.7)7
M->0P2@!"3K^7(8=P#-,T]:@PL2I,C`JQAT-J.:0WKZC,<LB,'&)7M0_9L%J"
M@?AXA")6*&*$2IRAR#!40GQ#Y5:HW`CE,S<0V%LFN/G>PO^V77A]#<\TI&J.
M29H3%S;7F,R3<SA-O5*R]R"(C)0R'P][%X+X]EMC=S?T:.\9-/H6`PR<6]Y<
M<_K>0)@2Y)64W9#0[$CBXV&W)+R])Z'=E-#LRMS9*AI2&VP.Y-<GF-V6<-B7
M,7!NC%,-Y:HQ[S)W]WY/7<C'[EUH-J]SQJ<:4L5#Q+=T9"_E:/",M"LV]&?1
M;LJF"]Y9SQ^XY+/6FK&><CMPQR=^R]\O3H.*KGMQFO'S5CUQJT'/=L<7B--;
MS.0?4$L#!!0````(`)V.#4?7QGI2M54``*0\`0`4````>&PO<VAA<F5D4W1R
M:6YG<RYX;6SM?<EN)$F6V%GV%8Y&-D0"SJA8N/;T-,!D9M;D3&5E3C*S&\)`
M!V>$D_2JB/!H]P@RV9A#0[\@701(@`XZ#N:DHTXS?U)?HK>:/?,E(EC+"!(:
MF)YBAKO;\NS9VY??UO4ZV2R+/V[RJW*S7/_UKXZ'HU\E7Q;S9?W7O[I?KU>_
M^>JK>GJ?+[)Z4*[R)3RY+:M%MH9_5G=?U:LJSV;U?9ZO%_.OQL/AZ5>+K%C^
MZG>_K8O?_7;]NU?E=+/(E^LD6\Z2U\MUL7Y*WBYYA*)<)D=)?9]5>?W;K]:_
M^^U7^`U_=YJ\*Y?K^QJ^F>6SYM._W2P'R628)N/AZ*3Y\')S-TA&D^Z'?CV7
MW>OYA\N;>EUET_5_[/WRT],J;SX<#8_^OK4.>'M&7[R99W?-I[?9O&X-X^?X
MD%=%B0N<):^R=>L]W;_[=_]NZR;?%/4TFR?_(<^JY`W\V`)S\TV9M_/=OQ\W
M?_E49;-B>9=</RUNRGGSZ8>W'Z^;OPG$/^9W!8(9)OXV6[2V]^'MZX]OKY,/
M?W/Y\=WEU>O/G]Y>77YSG29OO[T:](QX!9NH8`-O`5V^)'^7/S7?N]I451,D
M?>`].AJ-CR:CGJG>%/.\2J[@N[NR:LUSO<CF^/QCOBJK-4+GJERLLF7K15UX
MN5@`WEVOR^GW:7)-ER%YOUG7:[@Q\'EK'R7L<%GG,_AR69?S8@8+F24OLWFV
MG.8P`-S$&J[5Y^M7R<&+P]:!YU/`G!%=CN,^&&5U#8/\IO4XJ^_I'D_QC_R/
MF^(AF\/[+4QYO[X'"$RCT5IG7.6KK)@E^9<5;J?U_.UR6B[R9)U]2:I\FL-4
M-_/607TJUW"6NR8"LE4!I''EN.@5(GR:+/-U&SBW.0PUHUEIM.X)NR=2Z,V+
M[*:8%^LB;X,0;TR>9-,ITMHZ665/7=NZG$ZK3=X/FQB^9K[FBR^SY??)O,R6
M6W>Z98`8P%M>Y"7-R^7=T3JO%KO'W/("W87[<C[+J_K?TY&MV]>9KTW-U^;%
M<#`<C@"<50(HN<D3.'%F+"F0R6$ZY/\)KTFRS?J^K(H_P?X1*<87Z3'\[V0\
MUG^.S_B?15UOY*4R7,DD6R=`@7//@>@%N%GYX@;F[;M=E[-9@3P&-H^8?U0L
MX2*M"@!&Q_EO%ILY7>R2SQIH2)7?`S84#SF`N6X!S7XSRV^+:=&#O/4>T&T=
M$>UPGR_W(T\''S)$J/M\70`Q/@1R]2+YJD<2N%[#",2CREN@O4L8IT!.5=;%
M#HX=XXA'CNVOM5!DK]<94;:_6CZ;J/NMU[CW]X#4)*1L(>^3O<6F%GH*P0W@
M[@?LQ_PA7[8!*0N$"S(MZS7C3!\)^YC7P(&GS$]F,-Z\)+K<?._K?)DC7\?7
MLMFB6)+<L(9;T(;AKCF_@6N3W%;E(BD]*+OI6,&P.)"16F!^NP0BEX/D+"]L
M&Z63T]!2;G*0.W.=#"CQ5BYX`Y"X;5_J;_-U)SW0WP,IA$M8%U,&>#'?K-OX
M\8>\N+M'Q,L>`#YW>;+<$$4#Y)L**C.Z6V*X<]0M*'T5D379[`$"Y[`?QR."
MT#E"/^:^WY.:OH&#*>Z6POFF3PD*J_6<=81L]MVF7B^Z)!\FG'TT.TVR6T`<
M/,X.4K%C27O1"!+1WLS+QRTT@MZYI7?L94"^-H6+U2VX7(8])^L21;(2Z/`\
M1^1F/(-?\6^2#5=5^5```4INGO8;_E4.NP>ZCO!M87*Y/*)1BQVWCN2&HYL,
M883`AW?XP'K>]P,#,5I7Q13!V<V#KNZSY1V2^:7=#DF!A/G;1#XS.$ZV0R+L
MEW49=;M%3Q4825!A2:Q?O'J[A=Y\JR>X02"&[790RB8:%<L'V.F.<_ZP`9H/
M!X2XNNH4S'>NJ&N>76N[9;%AQ]JJ<IKG,[I'*#-W\"R0UY7PS/*;_K4>R&(/
MO[(WH6L5+:WP]C:?T@3YEREA70+PSQ/YNUSR!/MH8;B:63ZM<H1W\8P/>_4\
M%'QO0'5?+G$3>(1D+GC6]SFB:-^7UYO5:D[4#+4./41@+/44:,RFZC@UFHPT
M26"FGD1TOL5W*]<W^V_!55F!\HY@-Z:ACCN'5Q8A\0&H\12EY'[&,QHDG:.Z
M#P5`HDX^`-U99--\0Q(Q<`JXI0,0*Y,L08F;A2JR(]#*923$,?<N>T*!;I)L
M@$$`<[D'HIS!UMYE5?%]Q@.]7P;]9'3&`J!.??EU<I`E7X/6EBW])(_W!0AG
MCQE<H!+'I:LW1B4+$!ENRNW`O:H&R64%:M#U]Z!+9BG]G-<U`!?.&9?Q*9_>
M+W$_R><E`+ZJT>!1WKIW&_CU/I4YGU)"EJMYMJF3:T#T.2#'(2#:%'>1P5+*
M^1R^>USF,U=O;NIB5F05#I1L`QY(_)NJWJ"-"5@3+,==3@$516LXF.7UM"IN
M\&:"[/EX.$@^P8HK,DSEJ!F7MZ!$Y6$6UWU$N'3<JS^3Y#[/9G_<9!4,P]RA
M$EG7W693I,EVZ0!\%,WFY52.,WD#DD<-YWT$TAC*`^M\!7<_=0*L@?]R@Z@&
M=#[Y`"-^LY[!CF-@)1&PPG&G<J[5`K<),^8WU09?&ATS9B#`@+_/-D")_.(;
M@CHNU2]AX+H0+-UQ/F%!3J%(BZHB33,&5K[DTX&+7@)P76;.-+NK\IR-.R7?
M`WOBE_H4(!@0P_6^EB)H.O:$F-2_/@`;</N;#4G1\SD^A`^*2M1E3Z!J!_`+
MG\%FMA."9>`'2+U83'$[KH"7VED!Y3L-WVWF0CK"`N"VE0MB35M0:/M-.$!0
M_O#G_V:@^<.?_SM<K,\K6`."#8FX<(X&V+>C2C+-2:B#X[I!B@"3U/<Y0%>H
M%4PCQ"\#_@$?@OB45)MY7NM4UZ^O!@Z$^F3!&E<P^//2DLRN!7@0\LP*C61X
M--^6Z]Q-['I_!+XKZCI&W:3.0;E@X\I*I:(V!E^'MU1V<@9%'XOU/4"G6F>`
M(2!$PO@%GRT*225@)YZ*`X"]U5_P3$1`Q[.XE8G0@D$F&K+T`+]&:-<;0!C_
M)0(SPVL&\]\AI8-_GZ9G:"L;>=L:_%9N*L$\OBB(O1E,"6(`?+2:`V1$B@+X
M,F<C6H,G?%^5F[M[`D]5T'"*-?#W%-4Q0J`&]$?G;+F;Z$$``\J<!RM,/34V
M05SCB_%@.*2/$`!A2W<5Z<PB"N(%`Y2JRB\%H$L.M^+%:#(X.4T6Q7Q.;$1P
M_@-OSGW0S3'F?UM6Z_LYSA+.T?"-O\M`SGFJU\X^_>:;*]P\RBE`I:?E$5S\
M^8;4P@`Z4,Y1GM+#]=,"^<('=,9ZLK*VQ+\$;'MM[Z._):TWD\=<;:#,0Y/F
M3$JY@<(!1P65.<<]/&85.G?J`!_]S/U!'N$24QR5;AX<RF:%_SHY'J>3TZW8
MA&>+Y#"OIH4_7'^D_I0'R>L,L)>W%@XFT06@<"6#$+V@84'1+Q:YRB_EBDD$
M#\'T/D&9;\[,"L[DZ`D=2=F2Y1LADP6,/I,+HO=JL%W20S#B9U.KVWOBBS=!
MS_K*T[Q#E@^G\X*$K*-ZC3:;FZ)<15,XE>E`BBM8S)##1+FZA'4_-:UPNN7+
M)8T`]_=?_MFA?"23_\O_PI7"H=D7VLZ'NF#NB#($B/3,I/$R;!8+`=4UH$P!
M@A9RXPZ)NCGF>)#L'-;M'I;V<@MLKGS$GPF,=5@4PJ8V(V1AA)6.@`>%HN)R
M#52!V`Z+;_CM"GU;56:0AX8@T,$@^*V8<J+COO7&[=H;=0;.[S>8?9`!?6H,
M"GB9;9CX[QK>U9'-J!LO8[3LEL$1+1^!I\F&&0"XJ&I&K(2XDP4>$.]I`=RU
M=G=LUT783:?Y:AV`!ZJ"MVL!U@/&?QY<#Y*O+R\_(,X[K^85"P,QP]*!O(%H
M8,^/7A=0N1MV1;!H3F8]U,;1JGZ?`8V]R7,@+O,"A*$LK,I-+?!!EQ.6:R4)
M9B;E>EGBPI?X.^X/MCS?S(CO=YWP5MCYG=/:'*T-Q+0U+JRAW5A)@6(M5%Q$
M)P00(<09%HE8);G;L#6S'M`%J5`8F#^1>`N4HH3UKW7I1I!US0WS9JN<:#A9
M.<*:\:00ZO-\C6+%<D.T:"?"OUT*\06RQA<(]!Z@;"SQX*.`ZHH('N5W3V".
MV8->A,`:%$[`#[QOP'KIVNYYI<SX3ODN<8:<C>0MYR#KO`A88TU.'4,<OV#\
M09N%R#SV/5I%,2--:`E#U\1Y2)(!)1-X\<K2QAU:P@]__J]U`*DS(-T;D(KC
MI$0[UC"8>0>?E8(%1+Q<I,SB"\CCY*[*T<3@&DY5("R(A;K!@BX3L3`4AH2P
MRF2@QP'37F1/L""R]Y(XN<]1G("H[9`]WF[6FRH7R]3`?68K)=H:4?9CGM%!
MV9^#&ENON%RBVJ`[WNU%]GT>5I&Z[S:S.X8_81"(%XL50YA`D+$!D4&#(2@H
M1R[8N`S"=+?1.NU['WXC5Q]]X=2QIJ2Z$RO8$^0-=DI`(UY%5`,)SWI#.,[X
M(FYVM,NA>+&9XT"H(SC<>E40.25[;H`0(6^`3A)!QQGH#$#(IB<A,F>[1,:H
MFQ,I`.D`R2-0"!G#BU)N'U$*1+(UFL+*>7E'YC!14VEAWO;A!3O8T?2^R&^-
MKV&6@YB*2(?84"4'5^]?O3ND?]1.G]4)NSZ$F,EPO'SDWWF#TF]5YL/N874T
M3Q+F@2'+I>(+`G(#/'O@WA5S5!3AR0>VD_/7'\NG;(Y8YECM0&J1>\DZ1R'=
MZ[V,PT).:E2S>$0GEO=ZEXZ-'GY:]^-]3HX0'-_Y<5#40_%E#8P3B0A=H74"
M`WZ/=^VF7*,QN2(N*G`D?N#"9<<-XTI!/-A4G@SY&9`$HF;!"\%-ZFX<ZLYP
M_>I:\4+7>)`=ZNA$U>6[FO0>N'$;/`I'Y"(O^(L1?Y%3$!FA#!P8L6:D+*16
M`0H]Y'3W_.+(K'`PUF_O\64C[TOPC+#Z&4A!#VQL@[M]4!\R*O%M)5M`4@.=
M12%+KZT\)+L"W%.W]Q(#_%)W<-,%C2J?T[D"A44]'#Y?9?4Z&A)O_,&T!Y3H
M!BF7;!G"H?#T<0U!M)']XBN,N.KMP8"FFJBUT#W2(._4F+CM&@5\O`4I$VTH
M9%(1Z:(&30*@`P!,G4AD9?64\K%71%B#1P]Q5&C\`@0!Y'-(<-B+43H+3#@%
M9("X17/T^&2.A(FNW2V`C:)R'=N*:*=>CFN<3M>`M#3!8!<=X7.`OPOJ;8CC
M3T"0$,?@0&H7KM0N%5N-/(:NU&Q()IG$33FDDY3MXM!;OLW;*3R`)X:\.S,4
MKAZ>PPOF`,/S0:)!+]%'0$/63RM<*"E#!/19LED1SN._T4`FZ@8@#\I";@J"
M/C)$1"0,]EJR^M"@I7QEZ#!EQ21'+HU:OZJ`,Z%4<@?#UTR>Y5)3<&!UEP.*
MO^K9;[1T6FQ.*('F/N3VZ#F2WY%RR$K=2CW`:KD(H`;RM*(#Y7M";Q+1(GC@
M(I'=A+O"UCFX9/6`%)T6T'O@ZWB52_D>U:D(9Q`PXO[@U1-@0,C9D"#KS`&3
MK10U'3DC/0^Z:B1#85@$OE6C>H24!G@_RE&P,Z4&`C2=];:HZK4NMD[NYN6-
MS%2SM(JZE/[;$&(ON[&QVPMO)#15/2%7YN(&+EO<QG>:`3E#S)JU.&A\^W40
MQP+\LLIO`0_P@NM^1;S$YQA(`HHZAF(B*:R0MN-9.T'UV\U<S!SSHKZWO,I>
MK'=AF2P$5[E#U<&H2=&:*Q]Q(4H"'($<BED^(:]?'BJ\"?J[,$;J"#!71`.B
MPFSVX>!YD+(-5P)YH"1CX`[)Y9ZN,A(]NB/(EQK`-SM`4F*/MHO>>)&I>[N5
M2F4L`\E15#,V.POF.+IV@H>=P$]9`R'",M?()_U:H$=<()`LF&J!5(7EPJ<D
M6J<!>+%T'H$CR79=+,2+5#6'``1G6NB:>A9Q$26-]5^),RQ0AJ*V9XCWT3'G
M@WN,5A:Y;.B"V+;GQ.S9M?;LWJ!R_GN2LMX!3P0!DHCJY?45H`DL)3D?#Y/P
MDK,O?4.\>P2;6VT$6G_<E&0*0A-XS08D9M)9]3VJ>60KF^5,[E7W*Z/H(+XP
M0?W#7;'(1BA)8+MAKS5)&7@IU3Z^"*LC%!_(&L<)X/8<#K'6%?*"S$)UA7I=
M425TO/HTN:E*U')*]"EDF$R!H["V1,P`SCROEBQ&X)"XYKK<5#`V2\E&W@AD
MF!T%9/%#J\]R^J3KG5B8;I;E#?I?Z&OY7>T(!$$+P"=4Z065[M$26B`A6:^1
MUA7H+0-I3O8N,3]/K<&<'ZP?KE?-2!I_63$<8[L+F.S4J,#<`^4"3)\7,,X,
M+2_YDRX.*72@!#(_J49D3B*]P!$%#`8IHGYD\0&J*0/`Q],Y;$QX49T$I"7.
M%T:#U8#4!^SHB2(]-G7.ID<<@EX`&8B<Q1&.>^,:WU,Q'.V(QG=H<./XCBD(
MDF2!,":.%V?GZ?%P0I^]2([3\^$P/3F;D)9[V[1)=07ZIT8^1L4:S@EN&QE(
MPG95@6P<Y,"Z54A)8G)B+=O`=#9,WM0@B\%GSCQ(V3!ETFE2#4*-<F-2'VCH
M)/6$?HF238S*T9'WH3CBNHYY;)6DKJ/F0\`GSD*%XM/"+A\C5BAHX(TLS,40
MCHZ"PX"NW@/%]AR"(C`RMBQ-0QR@C].1/5&H3K9V?'D1H,PG:F`N\ZP2]8.M
M4#?J!0WKYYVQ,,@[H"'L-HSC>!803[[;&[G0'AXBU5P[1:EES&OR4;TR;-]T
M^"$2!4#"G/T@:XY8(8*'N@+9W/C93;Y^1`-O9.T+_J/.^Y1_*>HM`;*D<[+'
MV*B5%.&>$>(2_GG+%\86J[,&5TX1#H[FQ9T]9M6L1@UE/[`H97.,5/DRXZA?
ME.Q)GZ!\,](1O1$9%=75BFT.\!C!Y"1Z4%#]NPW0WUDA;B2<%PW.Q.>4-Y1(
MW_(%AHA53\Z"&)=EY[KAPV/+"X;ZY,A.!/5R"0]=@MZ\>\>D&H@;")?J]P9J
M<R1H)?%^1`B*;7%LRP%XD3#";.FE%<N\;0&T<H`EJ5'A'*V1%^[%=SE#RQ-T
M@:RN)$;:-+)H-D1E7N8:62]%]\R+[\E"!/LF_X$7<+I`]EC,YZ0J$-@S%%IF
M;8]8-'60DQ-OY$-YO7Q4PQ;,L9EVSR?FXII"&^G.P)/X,)O4UF^UIK@'P@"]
M,A5'&;@_Y56)QS8E,\C'?)HW'-]5N82_I^*'>+M,)&J4`]J2-Y?7+S72X_+Z
M<_)M.:"G1\.+%.,W1-UPI&U<"85EFUARM8'C!O6C3C$.ZP`_ET\/!?TE"+IV
M=R!X$)!NRTZ)F9&<4DO@7K,E'([4><<QB^DH,H9(53C!0.[\J*11`Z4@>>\6
MX_1@%8L"\?6N1,F!KE;U0`(IQCOJ+DB,7NKAX&1P5V[G^71==U@6X4LO_ODE
M\76N^38[DJ;G8J&Q07Q,%5JK82`L\\=$P>70H.S/G10XM@`$D5WEH1">3:DF
M+H1)G1`_.4V3X&-45Y]^[+DW[3D>&L-I*@UUF'K+'EZ=%:(G^J0QSMA=PF&!
MQ"<\S2/70RG>]-OLH:PT_I_C`3-R)R#-1'-@YF,PPIXIFH9X0"G3";`+/KV'
M<@ZG13Y"E\W*%5]XA*$B$W-<]BQ7!0`)P!>/S\Y+O>EH?6=1`3=--D850U8E
MAGV0;`;OBK.-9F6?AD.[9)B8$)1\I4PHBZK?\?VWV9(B<1%V6V_FR=%P1#>S
MF;;G?OCS?TY>?P&T)PJ6B4?J\W)3(\:@*1]CKW`R'_>[SVQCFBV*04D.2&=U
MYZ/AX6\27^[`$[GXY<LEQKH5.CF)/GM,/!JF&/440LFO2C@5PVK?+LB"MY"X
M-T^`\--#%J^SL#2,6@[/\0*QIUS8)),"D/^*VR>_+F<(Z;6<:@WKF%%\R=K&
M`=H?*<+-37FY6&,#;AMI*_8*`4KJ+2?5EKR]0.Q!K"S,Q@)(S:16=XY$"$*V
MS-D0&"\X!(W`QN6@<CIE,R9PP77SZSCSDM([R36-_R7R5B#9>HNI<3.)H:T!
M*]5K9N"?4?BM`$*]VZV=@9164.BMH[!>NDJ<)J0/1"0#[5=C=9B@^;`L#-)*
M78AS7>8Y3LEGJ[Y7%C89T/YVQZ$3@6<5R]9"Q=D77FG2Z5NJ-N%(')3)^F@N
M\@)^/9'7/2UWG#;8I.4GHM-V42SU/\+'Y')E0D7G@53;$,8=7I/[K+9F5#5V
M36,40D`;`8.S?TJ)"O$2&&OWXL)$I#7AVA**?X.">5[7$@`MDIM@K_";AK2L
MP0$ZQ/Z!<%'8`OR?"[Y-"091JMXJ.Z+VUU:67G4'3.E/&5^"F`(B4#XT`G-"
M0KM)Y.Q/(YH$RZ^3U.C=QX<PXW@[W'WD%'#J<2#SYF"WB;H]CK.!:.@W4T,Z
MX\!\GMV4(BP%^ZLD(S@U:&Q6L!H,AE-#[BT9V:9LD4!Y06-<RJ2\03^+.E'0
M]F$_ZO5R>&$/]<\NEX>X[PY!(@/E:TD?W5&H\`"D`K,/1F_.Q_2Q^+6[Q+HO
M</H,+>1QEYL[]-2.ARA%6S!E!A8L1#<^QK!'_4DBI8T60JM"1BEO8(!'6<UG
MCW!)70@7UX,(_C\Y$W46H+SLW5;5Y@[4ZN6,+HD)UT)^X"LXK>C4%7G+Z09-
M)3.0JE%U'W@0L,^W7B'=P,NM@^GAI/9D4K<`J0?]XQL.=&NLT=\5W+K@:]T5
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M:=L>@9X3`T\_TI'Z_Q7"`_<J*X#J%LEUMOS^J811!BEE#AJ#P"B>((_S[9ID
M2P9TS0$I;CN>C<D8IVFQRBR1,Y=?LXJ$+@",-4>]L"KR-6HF40+"Y\X;:3"L
ML3TRB-O-9&X["?#1)JS[,T$8C/2Z.KI[5OM7NA9XD68442A&$_U29U>#PF('
MU0C:99M)(9J_N!B%)6&NVL8Z<^52-.(3)'7KR<8M*"5E<KFFPA4-C[,&Q%"A
M)#35H9&K_DU79`R6\!D/?&+47W4'&-0.7IN<#8[#>]W$#%X[&0[&X;7,%T]R
MLR*[6X+F44PC\G>+5:`N]`O-<6I1)!=3I#J*<:!D!GN_2<",0@<PTAC?>LQ,
M)"$L'F5?(L_KIT9X`O!F<2+HA28\>)+?)>8J&LQ&M7FRR%[95"F7BU'Q,>L-
MLV*9W09:L:DCW&5OY"5%J([BM15=T?+"=KR0$^QEJEO.$0<.T[B#J*'B-!+1
M=+N9SX\HQ2I?K.;E4YX[MDC/F/?SB15L7)E)<%R0GCWB:9#VVW9`-0YA=3;T
MK9\.3X[&)Q%E<SI\/HNN<#P/[HM=&4D<J,8)=&UV9R,#/]WWV:P]XW#=TWJX
MVO(1,?\4-=4A><#P6[KA0:7?SBLCKM?#*S4F?,>2G,$/`>D3"9.)$2:#"\]X
M.ETOH6\"#A48P^'PYP[::,)6%'>;&08Q!VX)BC*!R]K#"WWQA,O,EK1G<^W9
MQ`'='A@OKAZ2C7H"%>>A6%<EXO!#\5`BCRUOBZ-+$L`98>2G#UF]SC<5WH9K
MS*4B(P',.7P.+^\?/Y'QB:GS3X:9NV#_]GR6;[RWTC2XNGL>5Y=%M+GY4OFW
MLX=T')A`TLFP@UJI?LVJ7KOU8RGQCN(!#PIGG:/UGR`62OC=8EZJ&<HQE=4A
M#CA:FS)05Q+`C'2>%1P[4',/JG=0=NLA\#'_*CJC?IILT7%K6$EY<3(:G+H=
M0H65))(N2<+M*4DD+4G"Q;Q_%,ZP3Y(@@>/"2!RN5Y(8&QGN%Y(+G,:PH`'D
MN0*":PL(;(C8+B6XG5("!R.WG5:P-/<\62%IR0HS]SQ9(6G+"D)Q=LL()F`F
ML>*"^[\O+J1MRY2]W):]NSVEB@[4;$H5.B?AI;'.=LBK?8)*J(;R1C(3S#@4
MQLS8+HS;15/:&>@'G\D"^":GRJ$S8JPCM]L#9?S"3]^)A;RY%CJ1<K-6\L?$
M\DGGEELAX^/]TI`5`3S'%/FK()@19"Q^#6/4.^=)[#Q\<9RZ.GRY@;4%/UYQ
MXR:Q%VFMI-`UE<PFDZ++`]PG$@6)O>AZ'%_FAT.[X+`0\=G,(O;D@W60+!;K
M8"`5\&%DZ&)5(@?!6G[E`M2I5;X,%)_?&[2$L884:U@27/F[*EL(O[17/+5W
MYGFBK@LNNA\EZNYC%MHEZKJ&]+V7J.N,J-MCT_!)@4^:@.%4O()O/!A5IJ";
M%M)]I7RHI4;"2=C_!PMMF:+H-#5=<H93S"4Q?VILOAX3U1[B+RA&_C7$>%@'
M>@%E3`1Q-"JG"<'*G4$<?U(2?HJ.FB*8UIF''?GL,LF=<IHM$7$SB>W-?3()
MV8_U'VNI%:AIPEW)EAI"K&Y0#5+B7SVYJK="CY-EFQB4\0&Y9\(KB\0-]^/`
MI<DEG-&-1(&(60-X6P#B=@/D<AVX51IH7I2O%<L>2/W.C4WM@-4'*I9:U!)G
M%M'')OW4%:L;T-WF!G?;9\!,T9.74"6ORK%5!:HP;>W]D/G+7`NS:9JO9=>6
MWB!S+V8882'QJ%;*?3$9G/CMR$A>@'`@[1XWGUKR;XOD&#-8Q"Y@AG%SC("H
M/3!Q"A,0BNL]*'1;"L9R7-U4.>T0.R-H4EZNSE?44:9-*Z$F$J2+Y4,Y9Z](
MZD*=PI9X;D:PQ)L-93[/T?4+JA0+RVG=+3*O]%II<Q`/TT;%*&3MY-!OFALX
MJ"BO77Q85#Y?_=Y<+).X:SL@Z]*_A`@,^OYXMZ/"[]QOE^;#,.;@C?`RM62^
M$E/)OV#4!B&C.9CCH9@\4O:KAM(%FQ5[VYNH*/,+E/T)E2Y;X/[^E)N[R:GO
M$AO9DJ,433":`5<*]!E@+5N(;A"0"IITLSQ204X*6J*_@^LH!/=_;&CS:/EB
M.#CS=RR41N!T-9K!QX1XR4R!V]@3XH01(AW#EC'71F5-4FN&"4NGHY(92J=J
M1Y?F`>*]S&Z^#N3:A3O9)M/#P?@\EE+#QM0(_<(X(ZR$:V<,#-(,("*!G"T=
M@9R_(0`^TJ,/;;"BQ;;;IB*IQE.+(.=AX70UF.I$ET6+_OA@FW`,62,JV'4@
M20_N6ESQ$R&RD$@1/I#E*+X6<9#>Q/,^?VRNZ]@F@=L\9A%I)=.?+D9T0U*U
M*6[?H_#/9X'MK_:RQ19KW9G]MMC)%ENLVSK;<4R*@:;'&^PT`,<[VC*VVVWG
M32([+YMWWSP38K%YHK6'A!%38GU,*CA^Y55T$]7BU'7YC$4<]]Z#%\9[QQ**
MI9[%,KC];>Y41Y@5K?OH0X:%PC^9:ET];R;M-[>$4QUC.)69P=GO7-2CXAL1
M52YC!SC'I6*#M%#C^%__Y]J]^]?_O9QB"#K:S#]]?D>ER]YCV"L0*2JS.YQL
ML\Y'<4PB)Y&9HC']YW>IJ=6,8A+E]:PI(1\8HT0/8.X>33T^I;G/,!4;:&A-
M09$L[E%UR5G#W.<`BT':+>I[NHO?E<4RU`36*A)SIJQ4%CHN"7UUC[E><%]?
M%K[XS=5]OL!84@KSI@VLF1LN$&V]=OPO_^Q"T1P1\#>UAF%6V8JBTU)2K>^?
MYJ2I2/$A]0\[6V='V;Q?/$A@=R'R"]:`(AW9YC!>%2TW(.%ALC?IP?-B5;+6
M7D\SV/8<TXYXQU@(FS?,2@.H`,@Y3'7>RZ]9HT>0/Q0U)AK=E!0;?B_)55IT
M)K=%8EF!"Y8Z2[2\/J-106I41#@!5%WCD'SUE4@%"H.[R[BX2^OS-:>Q=WT<
M4P&LDUG;D+2D'9+&@Z!?2"-GVHA-X<$8XX5Y'QK:Q!5".&3)'*ZMG$;%03MB
MX"@LC0+,J>86CZ*!B#(F!:(P]V7Y<'R6',"M^HYJ:I'H6]8<T\9RNB_*YE@B
M.1S8RM[SNE1P[%J4,XNBZ/?S]'@\3(<G([W@\JR(4]-XL8X7>Q'CR`UEH;$B
M5G-RWFTQ)^T,T*=6EQL+[A25359PM*<HN&NJZ3I+@M^L%5;&7L`V-G6'RO@1
M[8D&7?:F?,AC="HB=0W9J2FUT>D9@K<`?6(AAHX"BS4`+;L+(X%^?L2EO8YF
MQ1THL=[I%6,49=N@-7RQ69AWB)6K5XPKEH@OS(4J_:2RT69)NPLD;9"\O8T@
MR=&FP9J'24&;&P\<@GM9A\M`/Q353*E'S%`HM0T5]'C+F>:)22B`&$TDF%+E
M*(&A38EATY"*8#BH$E;*-\64MV90@+=]HF1?+JF1A19(%TN%\A2L0K1DX?-#
MQQQ>.$]4/!:!EW.AYD;O<',J#,6WI2'X]Q!34.S-#&L;ET%W](FK#LR-Y5B.
M@`1Z4WUE]D`)6R"*%5,#1:!F6)LPFB/$-P9'6M,7";N=<\4`LG'#2$%W:+M/
M9F7.X8#Q/)5G8JUK'5_EMMP/6+SAQ,1[6S#7YXH;N1)YS@'1N)G/<T:%E`S8
M7_+Z\#<P>J_H[*Z;Q2`I?8RZ$?B_6#R[Y8Y4D?V+ZABQ4TEV^P);P)Y/3O&/
MLW1T?`)_C,_2\XL)_#$Y3L=GIXZ[-9FJAK)9SX'V&J0!,LVG?S$9CN$%J2LP
M.1NF%Q<7DH7F=^WSOKOJ"#2$=DVQGFT,$W963@SV.X\2!S5`'.O7)Q=<"78=
MJB->:3$[7Q(9Z4@;K4+D0L,)0LD[OEY.%'T?2KK#S4-0]JJT!.QEZ6XW%;D0
M[:T/Q2TNO\8@_*62*4U!]0GJ01(S\B?MT@^`WE_L8+)5[#9S-"3]GJ8G-JQ?
MPEJ[EJ)FQAI)!)(&#`@G8P*M9L,%L="2)26YL`;3D@D[1=D[(QC[=UBFA0<W
MY8SHOR^/L:G0MX?VD;Z$"*6`'?LE-%X"DF%J%16Y1%D':#81RIO<FDH:KC&)
M70_W'%B`4D,.B>%4'A.O,.,\=7J=%MG7888'UU11XBT]([MH9'Q[`.J9RJU=
M>VXX^Y42L+A9T!UL"?O3,`ZY(#`X=S1*1R=G?.>!=IR-1AWA87U52UR;"@3[
MW0Z[PXE3,A*=1WLGS6VX]C:2%R?IR>28=W&:GI^<-Q;5;M_6;H:%OR6O?"'8
M+5KX"=9ON%F[3R^_3KXIL3X=1]]3(O'$&!I,Z!><R,V=^Q2DJ:.7.5P)(!V;
MY5U]]'6.3C50R[-;$`UO_H;5\)=?^UR:1B.AO[O]0X+-<M/D#;"8[Y$6T2?P
M.W\B_!)MQ-X/Y>\+9KKEU;)!(0E!*]LS#/0=%Y5>`JX)>VZTEFV6`)EP_PP.
M)@BAZ3_\IW\:&1O+P8O18.+]2(=J_J2\^?#=32GYE]1'C_+HI81`,AH.3B:_
MMO?$K]WU9'$0G0BQ?EXX1'/(;#//+7$43TTA.A:QCCI?%$<B7(>`-.JO@*GJ
ME$X>DAY'?9B`,,Q;?8&F^=QGJK6/C"Q0A-$^LV>>%0M"/!C/V8*(*AW9OD'B
M&@G5_=NS6:AYCZT&.6UKA6,I$1H4A",&$1Z/'C1#[FF,!S_RIC7![@BE^.@W
M[7.U&CR:53`$$M`?"QXZZ[^$^4Z'.MOIZ44Z/AX><I"@2CL>I\JETR1V7V`;
M#PG&./8K/@$N?#&!,4IL7X;,2=\5[XE9OL=AW8@O#4)QFVH1KS&*9>;73UU7
M*6F*6RRS<0=+9B"ON,_GLU3"X(@H%AQV%@I;8_U%:>*EA</CA282U11=R`MX
M.AF-\4S2X>0\/3L_.=3"4_$RG"ZCG7."ISLZ3T_/SW&<R3B=P"AD6:*EEEIB
MX<)`5T+9M.\:7`CL8"C6?]FAPQVV2/<'K@/%H@3UD<3F#_W$^G20--N3MT1@
M7R$EUAK:E:9^7(6MWX1/HC)?K77I#UW-0%&`GTS2B[,+^FL,0OW8?T`)Q+[F
MD%_OZ/@\/0$$/AY.4D!F)RTYF]L:G4S2X?DX.4M/QA-1,IHOI3X/_W0"S/9T
ME)P=@ZIQ>M+:!:4MRLMDDJXDMQR9"`O*)&"KNC$!!>5B<M8>IZ(N3OP!3'EV
MEIRB>:EW@69>&!RTGI,A@^S\O.<;@.0%[.(8A!Y0F-+A&7XTV;=-:TN`"+)#
MR8U^_1FJL9]Z/J?)-?;[D1%]Z?%^%#X#T:=G#:@C6,^?<)N79*R%5;PJL)A#
M6;4;HH<N"WV-`C&57.X$B6FO);HU]:.J5H;B&+*9U]PS#C[/.=;RPSPS/:<D
M5WLN*<+"8:5O8JA#L(/?,'W2I<\Y>=>6:`#]L-Q0.VAL_U+5]\6*"*OI+==E
M]M'@7>T(8`&G!KQ2NN.I#)IQ[5EO>`MC6%LZ,2LD,%P(8DVG+.5:M4PRQOR6
M*ZQOA\%Z2ZK'!%,M2$TKJ^\]%Y&VVERVI2%AABAFXU@O_&G($`MY<8%=XIKR
MGSCZ+)#Y%"N^R34(N&/FK2[TO#*C<*LE`VJJZ:E-I0`W7*BYL6[,X75.+AF$
M2`/Z7X5,'U$F1'"C'Z+*194+3;]W+$CZ<<E.9M'*C+AA5P0C`I>]R5VV69?8
M1F:J/7*J7'VC*CZ,?.@+_)>*`W$Y_"E7^M!B&2@IJA8ZQX`:6CH&(H\0J@:R
M$C]\_&O=T>Z=N@CT5BPI!<VXM&^(MJ<?*8I>96X;]QB494_+.#YWG7MCK!(;
MYXD-Q6<9LY'X?TU\F&]U-TJ/SX;I>'*R)S91.SRSK6!8LL>&=VA=:Y8.16YC
M@GC5N-L#X(PXMUPF6(XL@B+'-"O=I/J)T*:"%D<QG5`#)\FGZ1I`A;02+4:-
MCX\;5Z(;1J/C4V+D,GH#"*X;=WUV1$S9#.D:).,3DG#WW7\L9\KV4V#AA+6^
M..:/@B(Q$[@"YQ>TU=XE]$#Q,JZ'0FC-_HDT.3D'HG5ZL@.W'(>U)-E#5LPS
M+0,AA5643M3=A&+@KOG&R?'IPKM/1MO^<&$93Z"%/ND8J,^_O7XOG0=+K$"S
MQ$JM;+F/WF5#>`?7-[7X'N]+7WN.DJM\]@#>'NU1KF5^),P5,2VT/F.3#H4K
M'9JP5HY-<AR4#4JPK)^CNF&S7\@+138Y/(%\:2.>XL_IZ)X#2>DLD:T=]D!=
M<RU;'Y6*A4\E!CFN:AM120Z(U0:(-&&;_U'#62NF%$W)BQ.M-<9=,JJ6)<_2
M(;MYR5YJ#>\;PS(0:7;7N)%!'ME8'<1.EU$ATAZH<OY(@W2F@6ZFKI>D=!5R
M[=I81\;I"?=YULCJ68B,%(6LRR'3]L/$ZEEL<HPB9$R7"!#_ST!5.B$]8`P$
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M5K0G@]-HY>\;)R_"`KY]?M+Q7HA2_>'/_\7_3Y].D7W.YQR;(=ZU^,5XP0WS
M%:SV^#BL=K1SM6=C$NUHM1>M4^E<<_)B[U7;5^-UQY@\3D]'I^F9+&0X:2WD
M]X!D^:S]X=G%13H\/9?/:*+7)HSF@>SA5&9/OZ//1NG9\#P]'9[%'T9M@W=.
MA#2E134(KAQ298@7:6K,2P3PS@AK^\:&DFGSQ0C^>7QR*LZHL]/T_*+IR$%R
M5TD.Y]+'I+L0*_XC)O>.**S@.4Q/Q04.E#J=C"XB8?:!#TL$>C_!]NC=D\8>
M"+R;I6&4AC%W2PB!D7O.VR`=?`3-PTV19+R`BW`R`3WKW*>?%*34MG)8LO:I
MM^/7QX,3D=^:=BKCIR0+5ROF5>Q#_9:N\T'2&@2C4)D6G'8$$K>*1&""U`H/
M`>MCA;%,A(&8H[J\JM2DFHI+X$NO\CG.;)?T=55N5J8%]N4\_T(AO$N2D+`7
M>NA[[84BEN#;GO?(\<E1=2/Q.2#O`8%XK=A1BS\N%ET/5IE>Q!=#)(IP3*Q(
M']JBMBJ;=6R=84S=W^/X,^\F$QM5<RQC;.*&;&7E.)^8R&:8H1%]1P1#T<D8
M2+QG14[9+);>X<-[!=>`#HGS"&><5%^`*@A:A=Q`IHHR9_PIQD;Z]'I6?*A6
M;[4@"'`U;P:WA%YR18XE%_#U&?BN.^PB#RVG.*4+Z!((6MK.ZDXD2`HH1V`5
M;'E">^>US'!\D!UBPT.1%4R3Y$LLZ8%*KND!C08:C<BLI`4R)IMI@OB*HO%0
MA,^1+$K!"^L)[-P(E1E-@W_&^$JXR1`2"74J:MQ64=N\6].<WI!DA+3;,G/*
MP`A5<".,RY>@I#UAA$;R6*$):JGQ%&)O9ZF*C<$:K^>7Z"B#',ZFX,P;FDF^
M%_RF6I$<@W%3J26/F_;YG6$%7];;@];3"HR4M$L?[X&57OM`Q;;.)RF&I?5U
M,6KD'K0S)&U$DY]H[\G!Z'QX:`7^^U;9<;TX'W,0F9=.KPRAN_3<,S9[X@5H
M#5YQ##Y^PSR-7"EBM&[<8&QAQ4&9R<'Q\-<>7;V!TK5(C%XH,LT)'R==^70H
M)JC(>.2D@Y@&,ONH\:`+F#!$`1K`)D$HN1@^JMG#<JLG;:#8C8`1$4Q-':B&
M[D4YLZG-@KSOZ!.37/#>R#/%@B3)8&W@<'[KB_'Y<7H,'T25`=05P@:2E1H9
M*>YE,AB=(E60ID,E^WC??[KZ^Y=P^5@YD%^0E5$+*^)AQ,*D:+%\D*HE)$AZ
M:<QYXR#479N7@]UCXR#M7;`)\1D;'P^CC=/*>>/RN5:N#N630TJJW9QWY3N/
ME`T1(]HH)XRW.B5U8+SL[1@D63Q4UNJBS#O!#Q8KW4XTH?,"6=->OU.^?JZ!
MT7KI;&\(A)M@&)7GO`L6#M>P<*C@N6=ALD968`>%H*4+1G0MLQ&;H`B1=LFJ
M>RU=FGUDZ+2[Q9XT.!UWXR'[%HNB*#J[WB:)2D]:]%WU#3:P^,S61KQT;VRF
ML!L=/G4AGET>*1IHW'0_S6WC71J=GE=@L?R9Z"^JTC!HJ6LA9E8-..'+ZF5V
MTU4N?<Z\:37"?S^ZY.4AF28TAL4J2>")F^XAYZ<*-ZW=B4R0QT[C[#2Z*<".
M%Z-3,E58-A/OQ)?.LRWB.P2]#EQ%[#R[2$]/3Q%M[_JMA'YHO43==]O)N"W-
M=5ORZ9M]TD:;QQ>2'2=`>,XF$\S"V6,#UL/M690FKN[F;:S.#T_3R632!0OQ
M_+74R3]0>8MU2XLTW2VNI`D&3O&ZJLHJZK;1KV=>#!(='2,HN@[^0U4\X$7^
M@%F&&H+7#K5PL?[&G_I/=!);$@-TGAON$X>5[-S)\3B=G`ZW:7DD3'=EIS^6
M;H8IL55MN./!"S3F>?TO+.;RSN<OK2F(8993E&C`O6A[X@)I[P5KZN2Q1<G+
M^J(P^-8R]"^..)%`278C/N348P)S84A0%O,H;EVEM1`S\*G;]1W[NNEUKI$L
M_-\#3-WRK;U@GR+.B)-67K$6X+M8TP0SL33#=6!W8;V:%^A=Y`,-M7WJ@/:^
M.9])TQTDG[D``Z^.18U0<;V[",&C`E_0#,]`.B*JDU[C>I"09?5]K,ZW9;68
MN'8=<ZV:FK'\B4AS>GJ<#D^/NT0:"DL41KX7??0D@1""O0'MKH)M6U.4&Y)$
MN2'/>GF_F._1<+`C'^6RNBE$O0\FJ['-.S=![G`<ZPUQ,?,5*#33/$<R6WO)
M'"/ES,BI[WP>$KF=3>1.-)&;1GBW6:*=*30C\J^2D\$A=V1SB>8U9S-0.6O!
ML[J1]>%]1'2W0P.`F:UB9_)M</$;D\802NEVI*IWI+#0HM#FL2"TL$!QK?SV
M1KAST]"!:Y%O7".+PIP!VDO#,>!=8A"FR=<Y5JYDL''##8Z/X=^3>?:8<D/C
MCC;.9OQJP]F78F#<K"D5_ZT@!"6>_NO_KI)K+*PYJ^]`@9G>K^L;5-U`;6YG
MY`M$7GL3P"LQW31"S@%BD:6T`1)K@LGJOES[CJQ\6Q\?Q\-P6I\X3,U[.0$1
M5XKB!K990OJ4AZ2^M&E@4+J+"MP<:\IA>UK,RLPK<8Y]ORP?C^[+1S91X9SB
MGC<)87'5WDN3E2L$LV?[=B4^:1T8-;Y.K#FZ!*P^;]9'.M(;#(QZ;"<:R0AQ
M/V#3_DZ85GR0QLR)NGV3+$K])"!@JPV**F+6;'<%&`Z.M5ANTDAY//(ICP-_
M@%CIJ6)F@0430XS5%I`U83#S2;E>5(S7Z?,#L9SOQ)04ZUV@5Q,]LT3P<-=O
MJBBI&:*1%M9Y\;'9==>JM4-@5LQ`1,1HRSD6N&4\*VX)`#7VQFB9/_..9$:?
M!TM$3+*6G=@4L587@B.E'!,J6>5;*6`.;88DI"J7=UATQ93@<9+X<<O9UK[,
MV"Q;9"@+%[<MHD,)S!P+ZH_1,)6DIJ!+SAKD,!"\?5A_D]H.SO(I1UUZ;D#'
MP#?2H%D'0%/*PGLD>=_["Y8EMG;?5$0E8PZ#134PW1^V2G'45=SZ5P*[G*XH
M-D@9MMK!.MF7`2-QEHSK!-":ZQ^T3-_<VC/<?!6-0J.+1Y]53&[ZZ713*89R
M$"DS#0S$<;ZE'6K*'%\6\=)VLD\#K";BK_-*MFOY^Z#7S+1O+_F4;[(Y'45]
MG^=K3H$O.=9:`@CG@(5'B()1-EB\2G:L]/0E<3_\IW\:GXTDFT8B_[%6.)8`
M(^,#,D9C_VB<G9N:.J&A@9I^&YH%-H],RVA2C$U40S)8!7VN$_?`HEP5EMEP
M%5EUMS$YS;*FLI*^KH7O\H8X)5=B135]M+AQ%+PF?AOV@@$:@W:`HSU%Z.@O
MW$W%M*;!2PCR<X_5./,N@4K;<&3<\SO/9JFL'0=^`V\Y:K"$1_DR>\@`OO(V
MOR$[XR99Z%SU$)GZH'S70#AZ4R95UH(MBZ9%#!VS'2?E"X0VHK+)U8-)O&19
M1.F%;9P>?`%Z,W=*F!DUPH)W,2L,JVV$;3JS345EV69/1>Z6B*?+>*Z(EW*A
M28]!S<&-<$J<>K7":A0YE]@+V.G3S&B@HV6V,+H&%\\FR8J%M%"YEXQ/135S
MX=TDDY(L6!IID9G6(695V3*?DW0:TA]3<XEN"^HGO*Y#!T,<!LO-8:`B5W,1
MXS$%;F?5'+T7NV6M..=R/&G/BGG/&Q1]B6]VDZ;T9'Q!5BT@3J#8#M/S\1E9
M4.I-O<HU8X^:KN=<RP$4028F3H@H<V5<3D@(&'<%+.BJ4*A^<C=5D=\J*2VE
MR`[5W_JOM<)'FL(VX9UP.AZQ:0S+O@>H]2@M)LEQ[$-#0'[.M7!A>W`MT(9B
M-=U*Z8])=(DS,(@W",/KIA$B;PC1P[:(#/T%(/W:JV:H#DC^+^\KX\9]1;FI
MYYC</BND#*M07#)<\Z:15,Y8_B*5%<=L+\WU+(TX=4@JXNGA):S7:H0`DD-1
M>Q&R1.3[!GBC%K)!K[.(91P/&Q!.RI%B89O;X@M'>@'*33"43?CA,0:JI9.3
MX6'J+UNL:9--S829A4N`_T+!E>L%4=?4NBE3T!T17U<71H(4R?VP%2L3QDJ!
M%LE[`2F[;G!KUX-@`E'W&M_)>"X0#M&91M.9(W`BI^D9$*@[5-I$44,I)1_@
MS9-DG([/-+Q,,,)86$#:T2X6L*.G/"ZIB@)-OE[/>:/+_*X$&5O,=^^]D'!F
MH.EV0Y/VQ`[-L`ST;9,="3!,R_P#FE6;4+=TP<U^*8<RS[A</T?.D,PC!^-H
MXIK%XC<AB77)]7T?<BF)6TO<2(`7%M/UI^L':9Z7-L4I:SBQDOOO';/O)K6;
M\[>&!Y?"*E1E;L8P])2*O'<U]C_VO$H$2P]Q?,L<!4$?9S[7F7MU'?B(O2$^
MJYM)P0QD'W+T<;_CI>*?M-'!4!F6]WQ5@&S)8G")W6L-E5T4LR.:H5W%!"TH
MZFN60C&N!Z%08;.T1%I.A[[SJ)`0''3N6+J/3XAQK5Q&6R<"0#^<V_O?K2**
M@9F1=+;!/7/NHEPV4=6>?.0(HG*W)"3X["P`D[`)0"_E,L@4S?H%/7D/X<3P
M2"WF:H=JDF>5L<I<`9&)^U'W]HF"X^U2T5FV*.F9LOE2^P=A]%+VQ*V*/(0\
MEV"%"I_Y@*@JIX`5O4W+_-%<RT981TEA2NKV,#109]);+24RV\M5'^I8^FL;
M>Y7V:_.KIM-".W>NO-J3(+7JC6QM6SETZ3^N0Y(`(X6/5D",9``+;O$K8UDO
M3,R9T<_D)Y*XO()]/-NPF*ZE,[AL5F>MU`IG5-)8?:XR"N86^P5&S0)Q,4=@
MPA:C0_7!`@\8\`K'QEZX>FW*;'F1H5,>)](4HTV;@)I4@/TF,$X!MB68BJFI
MA\W8\W6]!,YD`#,<B6F0<Y2-L+($%;7M`9+"7?NVZ)[3M`PBV)]!(<:E$>2@
M\$`\,\C6H$8L<X[<HY(])"/DK99\U$8"1"Q;@`\&O(?;U2Q&OYH77BOWS`N6
M^`_<PSI-SOYCFI!N1+;3S3KP)1P.LUU;J\+IT1DHI?&XIP!(`QB.(-Z-*&,\
M!ID5D%A*,RHN<CIR`LXUB;9F3RH+;E5>+&XV51W<D$7-8G&K&$$@!Z_13]GR
M=;5>V.;4&@V2UOON`P>-OI>@4>]S..T(*B""0MPBCC2E($I`0MM(^B(=7@S3
MB^'%KCQM[_9V64B"]>[0%^/!V4GP=U/RK1DQRNBDB%QEZ;$1A34UNCS'9F-D
MJ<'HTKRR:05K=)@3JA]A*7-N,![B?DRJ[G@T0NW1WK_.[<H%BMW\+$0@))V'
M9+QQ+:Z*53P5^IX*B%`T<%]79>T=64H4.ZQ(I%?(1#;*`S'=NL_IO:[-IQST
M_&)\;LN;P\U9YFOGYT<\MS5@D2]$5?!?C#$AQK>\L[8DKNQ`<O)&>!=6RO%C
M>[^C!QB\B;6%>PO)V8WV]>'I_=A'*<3]-5(JTD!6*2Z<0P88=7YK954O(=8#
M]ZY9<-W?L_..>Y8MER4VY&OHP)K*BX6ZN+)J?QUXR;K6#@/"(;5A"#LV[4:C
M8NM1]VSIE<O25TWA$J8A8M3O`@W?P?A)U9%-CP,S@=@XO"_!5J%'`7'&3GK*
M\/'J'FSHEAN9`,#7Z`(*955MC+6JEF%(X/MW=X8JN$;K>C:`<Y8O5;N_*KW]
M.-@0]<C2I%'%KE6DL>-CDRC2\=1GHM"XQFU/L=7S\FXI`E3T*)%'H9)&5Y>8
MJ'`(HD=<ZDR1BCMM8I&M=NN$@2__WYZ`SSO@=Z.`)7M#8"#7V%E&%]MX+8_/
MT].+\^0`2W%-!J>GPT.I^H6%SN&.S<6Z\0<-J2S0:$IA\K:(4W2P?EENU/:2
MF\7P*A<;M"[/)1W&FQ$`A*JSVTC!<(P?JA+U@$'R-]F#SSXB0BW?(5^E+P.8
MQCU@:B*`!9.C4-G),)T,1P2GT>@4N(\'5!(!JLG^7W*DZRTLEQK6A4:4UT%,
MO3;]`DWDW8<2F!1JJP?ZUV'O\!@2""_-.JLF=;_%U&`Z96!PH0\J<D49<FC!
MXUPY_20W#AWG+52V#$^CR%%(X4(J^`@Z-IPRU@N:A4J+A:;]K;`FF0CH3>N_
M:>PGE=_0^A]J)F"IO95)&H23Q'^1LX5K/%`A]:\O+S]0SP4J2M.*7#=9P"+P
MF&.AUP543IQY$N=GVTJ0]^P&$Z5RM%_[SC%KZ<WN@3](KGP$1D@^YK#><@W4
MF(I\P>]2"H?;JU*%&UUO,!)N@YW?.:W-T=I*T996C6`>DPE%T9Y?IA3[R4%9
M)(0[CJT1)Y%83VLJ_Q:UP0$244JN%"V=:B-(S$ASP[Q9&SD2UDS>?8#Z/"<_
M+U:%=-T8&<!1DX^1Q)452!KLU@A-J%*10175%1$\RN^>P!RS![VQ9S@.;Q<S
M\[Y7RHSOFN%Z4>!H*(!'`7\8"N@[#D0EZAE_D->`ZDLDTKQG6[N&_I'D,W44
MN[BR!*OWCG.>)@G:'J3.@'1O0"J.LV0J/N4D]BGO+HO0+!Q(*<QKO\&"+A.;
MV$*O675@D]BG=6-4E-[G*$X2\@8^>:<`-V-KDN'/$B<K<:(MM;+YG,MO$X)%
M[KGG8-)6BB!WKC:WPY?P]JM(W7>;V5T([+25+=CTP)$!#$DT*N0A[@A[<=6U
M]D\WD0UIW_NA/Q$*RS9U`#_H1"*N-Z4!IOJNBU@;$1FD4^3*5O0B:_1FC?ZW
M6IH3SPK4<9S&/V"4$&H_`4)<R,Y#)XF@XPQTVG:%G%Y,/FJ*U,X7W+9+)S>#
M:V9F";>L`!&1QX#+P!X]IVTJK1;25+=NBC)TH2!%S312Z6R0BB*?OYR8[:7Q
M%(@]57)P]?[5NT/Z1^U#B>+VF$$LI,XPF/778"1;:R>&W:/[!N=)PCQ8172I
M^,7ENXIUZT""8.@K1.)@'[67QW/?=UU]Y"DL/L2K27@($;LZ2/T^T#?=2F@3
MR@^B;:N@3+$,07LH3(?Y!^D<NZ:B*V05L$X0.0;B5B[0%HZW7OOX,'[@9T`"
MC?UF>"&<:,V[<>@'HP:6BE:^!7C6U7*^J,7P65,<%POKDOA[,.(O<NICRP%3
MIK4]Y7K<2]A@'K9/P;J8V\W?WF>:F2Z[B+*I)(.8S,;YX@#K;<7]CK+$]\\5
M*F&ZHIB:\GLL,<`O=0<W7=#@^A-P>G`/YD]<UAE[EI@AD<`<3'M`R;G-9-VT
M/<>-X!7WE:?:[ZRM2TO/D#47-9??>@L#/C8Z#+,T!$H+M4"=8OX=R8ME]93R
ML5=$QXD$TY$CC@I+T9)C2*\([-@*U``SU/HP<*4G<Z1K=.VX#1F"C&LGF+85
M;"';-2`7468,=M$1/@?XNZ#>ACBY/;/OV4:(>?'^2@VV\P-O":YMYR,)1<?H
M,^0'=R7I7%@+TYL5PMM2#M-P!V>&"A4MS0&&YP,?$!9]A(F!3RNIZBE`EXKG
M5`"`+'J:!L2E4=V4K,-%EE`3WUO*Y2J635IJ:J_)BMF%8\+2I2M&8FNWA]8\
MW*EW8,N4]2^=%IM+?[:,U!(06F;R>TVQAK12MR([-1K*U>[I05UBY"(>J`1S
MXIM$M`@>=QR?9>Z*!!;`(7-N3`OH/?!UO$H3F+"*<$:;4OG5KS7ZBL1L9PZ8
MS."HA_D.6WP>=-5(9$-C";>\$DN?A&GGJ:<&`C2=E0.+9+%U<C<O;V2FFF5I
MJO_OVVAEMIT2B8IL'/.RHE3_Z+$GMVUK*0::1W>ZE@;K5%FDR4'CV^^[V[!Z
ML:QR:A!X,_?[%6F6FV#YU"TDA966Q7"FW2=+JMA0T?(J>['>A66RS%U1/RFK
MQ$5KKG(UFH@*D]6AM91??IQ9ANIXTING36X37Z#(<"60!TK)]=]*G>ZC?MR.
M3'\Q\,T.D)38H^VB-R$WJG.[OB,;RT!R%%2"WO2DI6O7L%_&[)H5'B(LR$J9
M5<G7`CUV-WJ256'P'5`5E@N?DFB=4>-=YQ$X$HPY0I^4H>80@.!,"UUGB*R2
MQOJOM/R1IPP:0,AGB/>1Z\SD<(_1!B27#8/JM^TY,7MVK3TW)>8W:$GX/0E=
M[X!%@CR)J]OO+7=Y?06X!>M/SL?#I.>E;XCACP`BJXV`6.I5<*U4MHDQ9Y?B
M'&3^(Y<&>J%$/Z7B^:8-2VB.KC%&+.=)+@S`6@+\233!FZS.Q458'0=AR!K'
MR08K)/XI]Q4UI&QJ6*BN4.\X17CPZE,,5/^>`GS@&L%9532*M+KD7G1P%DN6
M/7!(7'-=;BH8FT5K(Z0$VLVN3S)BHB%K.7W2]4XL3#?+\@:]#^(]I]]-^T;L
MJQ$`B/&DH?P65?;%S@1K))`%.JU!!)2]^WJ,S<%,"D4O7*^R^IZJ3`!_S+4P
M*MWPT"2LFQ@1W:S)MH^A"I1$!^-@'.`R?]+%(5D/Y$/F)WTJ9/<Z(IO!QD8D
MDXQ8F';+`U342::NA8'524!:8I<F5Q@(484\[(EJ]HLWEJ,VI#($U\N)<-S;
M"[6R<$\OJ;@U1DA`GX+T25828X9Y<7:>'@^E4UURG)X/A^D)ENW[<?TY4JX:
M3"2GG1H];1QDE%C-82=$@ZRQ'CB5Q".IC7F&#:/,@Y2-9X5M8,'C^.0@NONI
M,H]:\[W3CKXD7D_1CRVY$!QQ7<<\MII5UU%+@=EF<1^J6AQV^1CQ3U,VB0P[
MS/H0CNYV7CY*]:3`5FPB!T$;W_*%"OR>.)]J+34,$:#,7'R2/>DL4XWJY5B^
ML'[>&4N0O`,:PF[#!"7,`N+)=WLC5XO1P*TF/1&[2KI7^6W.'2JS+TFW_;')
MBWT#(;+@.OPPRHK#CA+8H93H'^H;9";D9]IO,#)0!@]9Y_7*OQ0<RMNW/`QF
MHH`8HYKBJO!$I3UU,+[-RUIQE%9.)7@<S8L[H\*5J.7L!Q8E=(YQ+%]F7".1
M<C-0)\'OV?9F(T[09,CY--D7JCE2\)D(YG^W`7(\*Z8A/8QK^1I608&3^0+C
M."IL7Q]`W!'=@H?'UAL,C:2X7\%$GZKF9GOLF-0+<71).RC>6U&[2%A+XOV(
M(!7;\]@>!/`BV82YU$LKVGG[!&CV`$M2Q<(Y6KOTBOW;9(#UC@^&K*XD1MIV
M'S8C;IM$N@66ZID7WY.5"?8MF77"9;M`1EV#\2T">X8RS*SM\^MN]Y0EWE"(
M,G_YJ,8Q[@[<.9]8K"G(4V(5LCH^S";Q-47XL8Z+S_#6XT2Z\J>\*K6^4XN`
M?,RI[)-UOU<E!P0MNF(`=[V//D@,H@^5*=Y<7K_4Z.?+Z\_4T!N?'@TO4JXE
MR$H%*3S:S%12AJ\V@"T+K'_ZPY__>W*`G\NGA]H)7*)1W!V(,03CV[)3:)<*
MG!A`"61!0N0JZ@W`GG76%*@/X-2TC0[4TH]*2CT0FK6TX*5PN`7%P=V5*(?0
MS?0Q,<!E9!=QS32<#*[:+2;(:6MR:U^+:KGJDI@::%4_DLWG8B12MS5?#R0J
MK=5(P9O\,5%P89V:@#:WTD,Z*FBGTE4H*$#AUJ8=(<>(G]KH-_6%ZL=>%J`]
MQT,/DM=9-7^RSA>?+8_8C4Y[RC/@W)B1"6(CY'HH)=S`YS5P,@EG>&B35+1(
M9KY2>J.P928]CF@Z`;:TI7PHYW!:Y$1UU+A*`@4?/3)))V-RO5?%'>5]Q.,W
MX@YK%3QPTV3F5*'&I^E+PA7K!C-?],A1])F?F!"4G,E,9XNJ/S(@9.EIDD;/
MS3PYPL;`V"&$R>VUCN-^^/-_3EY_`;0G`IA5&MJTJ1%CT)N`Y7YQ,MO7>.=L
MXU0K!_LXD>2`-&!W/AH>_B:YQ"(M+$>9`IOAY4N`^!/H'S(Y)R[LGG@T3+E&
MKY:PL16^<&=O%V1$I)DM`<)/#S6LT"\-$-`\QPO$H03"99D44,[#DU^7,X3T
M6DZUAG7,*`"'(8'O$GS"C]SD3&/N-TO?H\Q>(6PX(K><%&7R;P.OP&HI9F,!
MI&92JXE'$@CGR3L;(Q12Y+U^80.74-6=LB65*FDTOFY4;J*X?W3&XW^)O!5(
MMC`WVC<RPAP#==P9^&?2SU6;M=%^6SL#(:_@.#L*)J2KQ+50](%(=%B-5X*9
MF*")\LPUF5(7*@DO<RIG(_DL4[5-4`08`=K?[CBV)/`L7P0[+%3\C>&5)IWF
MGE]4ZTPGZZ.YR`ND19B\[FFYX]29)BV7>JS3+HJE+E"IU2&$2B-C+6'<X;BA
MI/U@R55[VS1&(02T$3`D<43"9KP`Q[8"\:(BTLI-8+V%%GJ#<CW06JEL)(*?
M8*_PFX:P[<M!R!#[1PI&@1IQ]J=$RRA5[Q#)R+US]($2]3_9.+N#3^1/:\5#
M:A-(_N2U*._-MSXUA%6?'$3"M`]K-5TRO9\)BSP=-*KG)+YZ#JRHJQ5+J,+9
MZLG"#2RH58C^Y3Z).,59\--@?R!G%B,^9<-A<\W1)#V?G.(?9^GHF%I@G*7G
M%Q/L8'J<CL].I7..B:21S6KYKWT&Z:@/&9M'^@[D6A,\82_ZT;['\I>6L7]I
M&?O\EK%[H2)/S$.P?A[U7Q0,]3UEX>)S/UE^]W)+8Z\64O^EC]C_PWW$MN&0
M;P-U*7U<+DUDY&?M^75E>G[]7JV[VOGH:V[GTY@E^;*8_Z8&82+_ZU^M)`?Z
M5[^+;:P<&4O+_TM'L___.IHEVQ#OK0F@_^A+-7%S3,8LC',EMUJ+;_^E45KQ
MET9I_R\U2FO7&=8\3WL-CI++D`ML'QR\PM9*\T-XX_/UJ^3@Q2&,_95O0+2D
M7"'@ER_P[T_WY:8&X+4D4\#7@2]\U7SXOKK+@(FJ!0:9%1)2OD;O;Y.7HFXE
M__`-QM2\1>M0*TW\=:LD]6-/:78I'IW8\N"LZ#;?E!YBS9_;5=?_X1W=QM:B
MKGW5[Q:/^MVUQF;9_.JTV4>D/;=-*>;(,NE&VU50&L;E-?2M\-(GO\<MI22L
MQS>T_T72\G8B77-6P/6!QW5!1XGY[\0XI8[R:KL,`2_U_>ZE;D.]0+G?>T>4
M9A'\8]*SOG<V=,N'KH(Z$D),9^$:M-#@IX2QVCGVCV--=L6QVGB[UNUL^9.:
M;X#P,/QU?UP3;@UC9E(?^M&'T1330@74\8_7(28B-1%0;;.'A)$]@PZV"E4D
M[UBT>HVB5>OI>.OC=]F31]=1.ZUEY=%^V+K!FSO]<GBQ[1:,MSULS?DFOQE@
ML09\V%(=O2-<X)9<FNCK;5<E#DK48%:*G&N3+Y]Y_]"8H._DHV(`6:@JVHX\
M;0$1A`+D0GB!_/AP>9^_B!\_$KST3MJ0_R*#?UX!T.$G2;WY:2#56%CQ9+:9
MV[*\+7X:)'OG;OAD_]2^35:`0#NI9%90[#6[N9%&&X)F(F?;-&@JQ4B]?;DQ
M#KGK1,*D5&P;24P_^#2>XO!?_H?`AF.`RAO?N%)+49343\ZD5V91PP$L$R2B
M"P?K/^GD3+/]!*C/:K2-3"/M<+4:28$.;:!SWD;*KXEI<\=$.!/[D]G/XDNQ
M1.#`.OV&M=K<#M)FR9BP$<ST13FPKL+@PM=J(=WWL8QMN;?EI@H+8H[T`&LR
M2PXK$8_1+#$5;VQQY=`S`^<2`%(OQA75\\"R).6BF()@MI2@:!2MZ+V.MA\6
MU6/N;OWR/\>E@9=>LQ[C-5>/+;U2Z8^;1Y6HU[[@T"\S06IF^$#2\,\\SS>*
M1K\0@`"W+Z6/DA$F?JE9O9GO6@-%^B;P;T[[*&LP?W4K1.-NA>AG7SEAM98!
MQ7ZLO7LZ'HI!ZV=:TRX._#,-:W=O-(%??E9K!_XWG=CD7OUR\_X8$2>N%_73
M!<"?.MX>2/@+3/%,A/QE5O!,Y/QE%O$\1/UEUF#8QJLBNUN"B`6RQ[_-<G[,
M'8JC!DR@P4_1IS]D5'H6@ZS.T^/Q$)VD/V(%VXV&8H-=\5QD$N;U(:-K"W8=
MO5+[U1?_LFFV@UY$RJ@`(>%#5=X.DE?5(+G^'M3IK.7Y_/RN=_0/>RW8CA`$
MG_T6KU4,R+E,2H*F$W%<K'$NSGV5=[_39X2B'"7=02<61:*-]&+,_G$?W4[F
MO">NXA7F8.R#R9]N[OJO)EI;1K%!$A>,R</[V#FWOO/Z\T<JK=9ZZUU6>1M/
MWTC1.[TC_6VVW#E2]$[O2!$D>M^Z7,&JAI.M!MSHG2WSP?&]]2DT6RG"I:_L
MAYE/3UK1Y]/+KVUO@PZ/`(9^9]I4,HT=F1U]&D\F+6/G1S]AH!=;3,"??32#
M66K6W2*.NK!P>3^J]:BO^^KQMI!9H](B!3_6^:(XDGANGTK+O5(Q7KNM`G.!
M4<K')Y,O&A2P%4B_[7S=<Q<,6/S98%+4CE-.@:K,\H44@)5N;N^7_<KD/M]_
M>BS[;7.-X"P@!]MBM_9@@-O"IOK>[8Z8:GG<.@.FNHEB;\34SI`V$[C4I8IV
MQT_M'-6$3^V[X"T+Z?YD6ZA4%.?T$\2;B.IV.PX[`JOV\T/5TF-=+1);2%?_
M1W>=L36_NPZ!59Z.4(!5RO\A9W9(R6A^/NDV(:@03+$=ZM%4\UZ;?G8/T@HL
M,4V!0^3/_A#PX02M^R,O<)?W-F4V<6$F#FVOB_PQ?/K8W(XDWVPWSB2G/181
M&_36+_>96M^^>P3E^TNGZVWH$.UO"^M"GR/UV:,(%(4Z.1R/?ZU6[XYFVHEE
M:O^^49G<MAXJEUQ'A*MJ!&\E_<C1X<),;$:P*3WN=\&FX77NC?$O2\1Q^,<K
M#1`<))>\N$9\7QG,@:;T^O'9D")9.NNMASUIN?4J[JG4&\)(71):88RT]1#*
M.$B.>7*?'RVK(">%AMI(GW5*(.1RW'_<@&#.9R$A_9>^JD77")JJ76(3#OMU
M;Y?L4%_^`:@F>2T0Z6C`??"8#(:Z^_>Z>XHET<WWJU+=XS&/?!W%?EZ9V,^M
M,1_=O.+?)H#6\IY(2=BB..%BMMWL:&W6(@!WQK[GC0;,$*+/KM!1M(U_]4>6
M]EJRFZ&M?8=BXULOX_C6GWB./U\0:^^Y_0('HU.;:+?4;R71K?B8*G+#I`(]
M8YH*)4/[^W<TPDB;CT^[XC[B\-)>JTV(,&V^@@&G[6$Q_K3]Z[[AJ"TI9'#6
M5N(P5K7UXSO`MVWVW"BRM?E0@M"2B4;NCLZI?'R?!-4WB8YSL6.</?'^&3&T
M%K%#[.#/CM7/E8WC0,^0DRS%R?<7$[NB2I\]OU1&WGORWW>*GNWWFF&F^WSA
MXR+[KLI1'X5X+E!W#[A=&=G[^UY1?N\1]CGE9\%G^XGO'*H;`79^M@L?]AA@
M?_2X,D5SOBEN?\1Y=HS0K\LJB3M3$G?:2>&,9?Z:I=>?)1`UD+9N`M=EBMWK
MFZ$TM=KU<A3RNNOEJRCJ.`[^_<<>$AU)ZJO,9-+(AS+,/VXA\\'WP'H7PWE9
MKOL5V]'YL/,</YD!@LE4ZI,@\@3=L<I!`%FV\>VX,^Q4L*+>4"06]6H*0DP?
M<%[[V(DXR8B,3TP[2*]1,GNML/IYANL,:^T<Y&=<S$];",6^^ZO8/?.'Z#1;
MK_L80,Z&J'TWJXY$MAY=XK03!7[^>5$IQRI+5*V7ZDM1U-P?-QWBZ\=<:]4M
M'R2CA"+>"`DC:`NV]W/U'2-HD1LM,;3OP>U<6"<:;$DS5"C%%:-VXL=6ERS@
M\[>H>!HL%43O5?KPL>1@;*-BNZ9]QI22CO*30L_#<4<F,34[M=FL3X%I`KV+
MY&MHI%A`V#'\XQ(XHCR@GLU$[_0Z];[!YH'Q:K;)_U>F[[?:_J@-:>O%O@[I
M_%'+$KQ9>[<ZMCCO.^70#)W?ZQZMX:_?=_"/:JCU/OH67K<:;OX(D6<^\&TH
M=TD7]/+H>(<#V[S3[W;&MU0"VE-JZI+.]I#)=@]VO'6P)I!_I+,F-/3L8\<?
M^^IT]["X]L+ZS&1Q2TX*%%?#OX\6;W11;6VLU?CRN2/T+I="F+JZ%-IH*I_K
ML<W9^S--L<T?O&V*MQ_>[Y4SV(L!^R4/]K"PK^IZ_;O_`U!+`0(4`Q0````(
M`)V.#4?G?S$WN0$``)T7```3``````````````"``0````!;0V]N=&5N=%]4
M>7!E<UTN>&UL4$L!`A0#%`````@`G8X-1TAU!>[%````*P(```L`````````
M`````(`!Z@$``%]R96QS+RYR96QS4$L!`A0#%`````@`G8X-1PQUTFF.`0``
MJ18``!H``````````````(`!V`(``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L!`A0#%`````@`G8X-1VUWE?V=`@``'`H``!```````````````(`!
MG@0``&1O8U!R;W!S+V%P<"YX;6Q02P$"%`,4````"`"=C@U'$D6]L3\!``!I
M`P``$0``````````````@`%I!P``9&]C4')O<',O8V]R92YX;6Q02P$"%`,4
M````"`"=C@U'F5R<(Q`&``"<)P``$P``````````````@`'7"```>&PO=&AE
M;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`)V.#4>=+).<9@(``&X+```-````
M``````````"``1@/``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`G8X-1XXZ
MKJB/`P``8`P```\``````````````(`!J1$``'AL+W=O<FMB;V]K+GAM;%!+
M`0(4`Q0````(`)V.#4=:_GVZ4`(``/0'```8``````````````"``645``!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"%`,4````"`"=C@U'7C3KC[H#
M```5$```&```````````````@`'K%P``>&PO=V]R:W-H965T<R]S:&5E=#(N
M>&UL4$L!`A0#%`````@`G8X-1TS<($'<`0``:`4``!@``````````````(`!
MVQL``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(4`Q0````(`)V.#4<%
MJ[(TL`,``$0/```8``````````````"``>T=``!X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"%`,4````"`"=C@U'1EP'R'L"``!2"```&```````````
M````@`'3(0``>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`A0#%`````@`
MG8X-1X)-SJL-!```QQ$``!@``````````````(`!A"0``'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+`0(4`Q0````(`)V.#4?B.;R0H`$``+$#```8````
M``````````"``<<H``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"%`,4
M````"`"=C@U'"E`9'Z`!``"Q`P``&```````````````@`&=*@``>&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L!`A0#%`````@`G8X-1R*!K]J=`0``L0,`
M`!@``````````````(`!<RP``'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M`0(4`Q0````(`)V.#4?V.=S&H`$``+$#```9``````````````"``48N``!X
M;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`A0#%`````@`G8X-1S4=IP&>
M`0``L0,``!D``````````````(`!'3```'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"%`,4````"`"=C@U'GY0=F:$!``"O`P``&0``````````````
M@`'R,0``>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(4`Q0````(`)V.
M#4=/R;"EH`$``+$#```9``````````````"``<HS``!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L!`A0#%`````@`G8X-1X-TZ/B@`0``L0,``!D`````
M`````````(`!H34``'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"%`,4
M````"`"=C@U'.NA]7I\!``"Q`P``&0``````````````@`%X-P``>&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+`0(4`Q0````(`)V.#4=3`!DFGP$``+$#
M```9``````````````"``4XY``!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`A0#%`````@`G8X-1P"..@Z@`0``L0,``!D``````````````(`!)#L`
M`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"%`,4````"`"=C@U'<+CW
MC?0!```2!@``&0``````````````@`'[/```>&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+`0(4`Q0````(`)V.#4<UOGTCHP$``+$#```9````````````
M``"``28_``!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`A0#%`````@`
MG8X-1^S.23FC`0``L0,``!D``````````````(`!`$$``'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"%`,4````"`"=C@U'.4'43+D!``![!```&0``
M````````````@`':0@``>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(4
M`Q0````(`)V.#4=<I&Q>$0(``-T&```9``````````````"``<I$``!X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L!`A0#%`````@`G8X-1Z"0O/3Y`0``
MX04``!D``````````````(`!$D<``'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"%`,4````"`"=C@U'!)3O$8`%``";(@``&0``````````````@`%"
M20``>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(4`Q0````(`)V.#4?E
M/G%>?`(``/$(```9``````````````"``?E.``!X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L!`A0#%`````@`G8X-1P+0^7T4`@``3`8``!D`````````
M`````(`!K%$``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"%`,4````
M"`"=C@U'(*37Y],"``"/"P``&0``````````````@`'W4P``>&PO=V]R:W-H
M965T<R]S:&5E=#(W+GAM;%!+`0(4`Q0````(`)V.#4?K^U_06P(``.('```9
M``````````````"``0%7``!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!
M`A0#%`````@`G8X-1RC6#$E\`P``S0\``!D``````````````(`!DUD``'AL
M+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"%`,4````"`"=C@U'\;6-!?`!
M``#9!0``&0``````````````@`%&70``>&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;%!+`0(4`Q0````(`)V.#4=!>3XF#@(``&P'```9``````````````"`
M`6U?``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`A0#%`````@`G8X-
M1^2*GLG#`P``[1(``!D``````````````(`!LF$``'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"%`,4````"`"=C@U'%F%)/94#```4$0``&0``````
M````````@`&L90``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(4`Q0`
M```(`)V.#4<0C\UFY@$``*,%```9``````````````"``7AI``!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L!`A0#%`````@`G8X-1VBN5HT[`@``N0<`
M`!D``````````````(`!E6L``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"%`,4````"`"=C@U'*4S@O/D"``#1#```&0``````````````@`$';@``
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(4`Q0````(`)V.#4?7QGI2
MM54``*0\`0`4``````````````"``3=Q``!X;"]S:&%R9613=')I;F=S+GAM
7;%!+!08`````+0`M`"T,```>QP``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902501286560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consulting Shares - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 06, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="nump">29,429,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,429,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,279,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value of issued shares | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value of issued shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_AgreementTerminationNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_TerminationAgreementPercentageOfSharesReturned', window );">Termination agreement percentage of shares returned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_SharesSubjectToForfeiture', window );">Shares subject to forfeiture | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_NumberOfNonCancellableShares', window );">Estimated fair value of non-cancellable shares, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_EstimatedFairValueOfNonCancellableSharesValue', window );">Estimated fair value of non-cancellable shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_NumberOfCancellableShares', window );">Estimated fair value cancellable shares, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_EstimatedFairValueOfCancellableSharesValue', window );">Estimated fair value of cancellable shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_EstimatedFairValueOfConsultingSharesNet', window );">Estimated fair value of consulting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense', window );">Percentage of consulting shares recognizable as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity', window );">Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_RevaluationOfUnvestedAndForfeitableSharesPercent', window );">Revalued unvested and forfeitable shares, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_NumberOfUnvestedShares', window );">Number of unvested and forfeitable shares for revaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_FairValueOfUnvestedStockOptionsAssumed', window );">Estimated fair value of unvested and forfeitable shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares', window );">General and administrative expense recognized in consulting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Non Cancellable Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_EstimatedFairValueOfConsultingSharesNet', window );">Estimated fair value of consulting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares', window );">General and administrative expense recognized in consulting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Cancellable Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_EstimatedFairValueOfConsultingSharesNet', window );">Estimated fair value of consulting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares', window );">General and administrative expense recognized in consulting shares</a></td>
<td class="nump">$ 79,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_EstimatedFairValueOfCancellableSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of cancellable shares, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_EstimatedFairValueOfCancellableSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_EstimatedFairValueOfConsultingSharesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of consulting shares, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_EstimatedFairValueOfConsultingSharesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_EstimatedFairValueOfNonCancellableSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of non cancellable shares, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_EstimatedFairValueOfNonCancellableSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_FairValueOfUnvestedStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Unvested Stock Options Assumed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_FairValueOfUnvestedStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense recognized in consulting shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfCancellableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Cancellable Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfCancellableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfNonCancellableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Non Cancellable Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfNonCancellableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfUnvestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Unvested Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfUnvestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consulting shares recognizable as general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevaluationOfUnvestedAndForfeitableSharesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of Unvested and Forfeitable Shares Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevaluationOfUnvestedAndForfeitableSharesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock subject to forfeiture, pursuant to the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_TerminationAgreementPercentageOfSharesReturned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The element represents the percentage of shares returned that were previously issued pursuant to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_TerminationAgreementPercentageOfSharesReturned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pirs_NonCancellableSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pirs_NonCancellableSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pirs_CancellableSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pirs_CancellableSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902481127968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pirs_PatentOneMember', window );">Patent No. 8,420,051 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ExpectedPatentExpirationYear', window );">Expected patent expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting agreement fees paid to Prof. Dr. Skerra</a></td>
<td class="nump">$ 5,534<span></span>
</td>
<td class="nump">$ 6,858<span></span>
</td>
<td class="nump">$ 11,157<span></span>
</td>
<td class="nump">$ 13,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember', window );">TUM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_PatentExpirationYear', window );">Patent expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember', window );">TUM [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent accrual liability for research and licensing agreement</a></td>
<td class="nump">$ 302,273<span></span>
</td>
<td class="nump">$ 370,999<span></span>
</td>
<td class="nump">$ 302,273<span></span>
</td>
<td class="nump">$ 370,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ExpectedPatentExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected patent expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ExpectedPatentExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_PatentExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_PatentExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pirs_PatentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pirs_PatentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-15-290039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-15-290039-xbrl.zip
M4$L#!!0````(`&^"#4?F").G#ZT```^F!0`1`!P`<&ER<RTR,#$U,#8S,"YX
M;6Q55`D``]+[S%72^\Q5=7@+``$$)0X```0Y`0``Y%U;;^.XDGY?8/^#-P^+
M76"9\"ZR,3,+R9(.`O3I9).><]F70&VS$^$X5HXD9Y+]]5N4[42V1?D2^=(S
M/<!T)R1MUL=BW5A%_O3?+X^CWK/)BS0;_WQ&SO%9SXP'V3`=W_]\]NLM\F_[
MEY=GO:),QL-DE(W-SV>OICCK_?<O__HO/_T;0KV;FUZ8C<=F-#*OO;\-S,CD
M26EZEV,[9&"@<3!Y-./ROWK?DL(,>]FX][?@YG./GI->[Z$LGSY=7/SVVV_G
M>3Z<?\SY('N\Z"$T_XJ_3*?WJ=>3YY2>\UK33389#S_U:.U7_=PD)73O#6$>
MT(2)0%@A0K\2^@GK3US_;[UW]O2:I_</9>\_!O\)G;%`,(+U;LYOSFN$_7OO
M-AL7T/OQ*1F_]OS1J'=C1Q6]&U.8_-D,SV<?^O(M'_4`U''Q\UF-//OK\RR_
MOX"O8!?I#)VS:<]/`R"CS%_?1E2]"S,XO\^>+V:-%W9>"!/$R-NP29[#:KG&
MS5KM0+XX<&C2YC'0T-#=O`P>FOO;EH8!Z?C9%&7SD&E;`S5ID7%*O#;8ICWF
M`\9).BB:OZ1JLM]!%K]C;.Z!*X;.[]`7>38R%[-N;Z.`#R:/S8.&97Y1OC[!
MF&R,H)?)T\';N/6#%@<\I?DBVSRET%Q4&\(R,I8,S_L6Z:"9=FAHH+PHGW)'
M?VAI&#`IT'V2/+V-^9X4WZK)SQH:EAU:+%5%XYBJI6E0F;<L![3..]J&X1+?
MSOK)BVGC0M>RL:N8=BWK74<M/#=*Q_^PDNNMO_W%0O_?6-6;:*TOJM:WKD7:
MU!$^EES\[<^?;P</YC%!;[(`I$>O5\F/T:>B:KLQWWO5)WY*\H%ES,WF68UX
MR,WWG\\L0Z$YYYR_%,-YLUV-G\^*]/%I9/8)Q<64JAG/?`K-=P-2:7ACGLUX
M8GJ#;%R:E_+&SM5DH[OK2!.FA$:("(+1_V#XWKO;K^$=OK,"`U.JX)^$2NUY
MZ@6Z2D$)_.Q1[-$7&",$5_9GK3&T4X]Y7)[UAF:0/B8C8$PDSGHI[/]T>`=C
M.5?>'1>AUU<A1XISC'CL]Y$*O1AAGV!%".E[_?A.8LSO]%EO,DZGLYW)HKM?
M;\.S7PC!]L]/%PXZ]PH"IUP2MA4(?#<0/`N"<H%`U188]$U>)NGX<Y:,"W_P
MSTD*'2_'7W/X$49]R4I_4.D],XRSW"]"\ZV\-:#1TC(UQ=6DK`P2,%*"9%29
M&=MAR`DEI,)PAIDD1'MJ#4:"R9BJOH_ZL8@0[XL`^7TA$=-::B(EX7%PQV!W
MWU$WHWB+('6,PP\&,MX-8VXQQ@T81[_>`,98'!+C45(45]__FN3P>>557IF%
MT8O)!VEAKD&WF[?&8M9:D.V1I,P2_([<Y9=X!;LHHLJ/:(2P4!IQ3$,4@&Q`
M$>`9T$C'(?>F_,F;^?/NR>1WQ4.2@X7_"SU?P'`7,A>1NDU&T.FVS`;_J`9<
MF_S6?M=N8%BV@E[4RC?/([H3<"K&(EN#XZ+LE':C`,TQVXV83V&#O]E^=J=P
M[TZ)_S`"\'"0,PNY@V\!<JDIWS?DX#E^BL9E6KZ"D_R8C:O=4.V"^I"M$51D
M`\&G2"0CXFM$?0U[V_<E\B-,D8HQEXI!+T_>T3M1`VB^D9GV&*5"_72Q&0&+
M_#4#JKA.7I-O(W,)M$'W,C!)#GWG/][8@,B60@YSS-IUYZI]HG"HE(Z`-QCS
M0,2%'O)I/T0ZB@(2\H#Z'G#)LHA[FN3@>^!S4)OLG4<VI^R4=MP&L#78=1OA
M1EL,#OK'D6E[1)BXK+JIY<SX(4%>%@&713$QPZW%%\-R"A8'(,!5`R*46"?.
M*/<"/_05T@$EB&LJD?+\&`FP42(J?!S&;!6MN40CR]9O,RE.>J^3_"J_+6W\
MZR_):+*KF;9WVC<QT_`Y)HU(N(A<1F5<YLF@+&[,P*3/5A""'9P^%OYX^"OP
M3,6`_F,E*+>$QTI;,O/B!676-A!ZZK5/]Q4CH+6FH0VE)<#G:07XM'CUC9K1
M4Q'M$XDT$PQQSL'JC9D`$X*0F.E`"!;?T1:7X.P7@5?$VQ:PG"Z@0A*F\5X`
MK7PLY@(4ON;W":@FG.X'T,HO$RY`]>\43LHYV0N<HC5&15=<M!\<S\[QDRWZ
M!]AQ)1J\.X`=Q4P$]N;*F#!O"@83"S$4*MB"%4=7H-$^B$P5]I''0@70*.N)
M:H(4\WG()56TKZ:Z9+,(BB>VC:!TAP;EAT*#NA3!A]'8X^;"6#/<MKG>SQ@^
M9IUX6`4`&@\(^.T\ZB,5"`\!^`$+P:<7H6X-6`)PN+O-=DJ`[FJ=;``H;[5.
MJ/XAQ/_V@.ZH3C<`M%V=DA_"/-D"S\[Q:],9X'^0[ACR8R>O[QBM8.*!!@&3
M@V(MV#Z.GW4KBS%QN./G]2`HH%[L`P0KZ5M4`5OV4X^)`@=O2,F]H$!:Y3=9
M=BZ/@T+75*O6X*#:*O^BGQ0/("KL7]$_)R!`1@8DA5_VDSQ_3<?W541HZ[BH
MM%"TG^7P4.$^EQ'RM`";D8@0*0URT0]#RGRB?"_@ELOI'97N]56PVV5-&FY"
MS2(`G[.BL$(46FV"H#\8Y)-DU`D`-84KP":<"D/.2!4HEFH-0%)2+XR4CP)/
M!X@+3X+W13P4<S"J&>B2V,-3@)RLP#RLM7Z'9R-:E]P,:VL'-EO5YGN:<5'E
MD_KV</O>V%S6X/6]RW7R:G_E_Y;DPZLGV[$>7/ZKL2?A9N@_FSRY-PL'YML'
M5!E9Y+!5KT3R?J04)0@''#@LC`*D^[R/8AJ#7`:EJ_O1U*)V1%.63[EKX=,#
MP;*WM?@R>?QF\H^CWF3G8*;C,/0%$GX?9)@?!L"XV$,,AR0.1-!7>IYZ8055
MTTDDA4\2"UD%79-^2N=(,USK9^.@.>1^TA&D^^R.'S17Z`\".;.0NPUZ3,!L
M.!#DG[/Q_5>3/]I1?T[*V:@;\S3=+\75=Q`ZXT'ZE(QNS"-,8VCRJ^]Q6@R2
MT=]-LJ.X:,.T27QLRLC\KLDNJ!A9,\((K>N]CQ'^NX6161@]IWF%04\JL2\<
M*X']`>V_?)QJ?Y;`&"]$2PG_6(=0#%QB(]D(/IPA3BFUIA8#"Y1I#!86X51.
M`T0.9W/!/F#G1"[I*Y<*WQ_-I!.:Q:8V$3NGRSJZ@>:N\@=6G(HF`C6-(K"-
MJ4VL``(#7P%M@J!`2/LAH>0<W,8[RINL#LVI%I3NGB_P\1RO3HEL-*W6$^E,
M\?JH%?874UA#=SR,7I[,`/[Y-;._^KA=NA%J&]FE8FZ7DJ9\$NO*2]6=6;HI
M(&L8SI^4#UF>_M^Q-Q5K@(SAV9\6AGN?_X_A?*Z`MJ/S63&;HY!FV?ED/[CS
M.?MH&Z`^H4U.#[#)5RC?&["GR^1D$Q.J6R[?$)?]Y_YU*F(WP1&?XP^E^AT_
MSK2'K8YUDS$DB?28.%B<Z:I\,/GG-/F6CBK7J5^5I9<?QV<U.+$A0Q'W$1+F
MN.Y$.^:^4@20@X&\V@ULG"_9>+`_>AG#!#Z#H="7X.]B\'$T^+](^Q&+P8N-
M^[8XMI)%SGBY!J>*U';.9M0L10=.:G6=OKVMG.6>5_/MUZSL_!3I:_)R6B0Z
M3X<HYURN'H,U$K"\AF5Z7^W\V8T6I\*ZK<OIL?IJ.BEP*KQ=3KJZ7$GJC)*"
MS\J:_8>&$RO8M)/'R<CJN$ID64&>FP>0Y>FSN1P/LD=CS\&^F/+J._#",0EV
M+B<BC#.I^8(HVH:J14ANC`TJFV&4Y&/03$7MPV!7I(/TF!N8.HOHD0<ZB'BJ
M)I'74[*A/CJFQ'+F*T@FA-Q$_RS9:W8G/&2CH<D+>^Q=OAYS.5LNAB#<([H>
M)5V9>+NYM%\QO.GR.?F581#6V&TQN61PU>^@G+JYQG&:AT0PK);-PPT9MM8.
MEM1)L2]S%]UQL)<$98TF4R,92Z)H.$RM0DY&UTDZO!SWDZ>T3$;'W*I.TTD)
M@1GE=5'4//N-&/E4K">G9&K<N&UT.-GYF'+)31Y`Q&BSK;](2?3X-,I>C;DQ
ME4H]-6'D-!"!0NW5$IW6TM%:NOXU3X;F!.P$=U42%HH+M6`HN`AHM(>B\7.:
M9V,;O4A&BUEA)[1?G8I6B+KGNB5-^\]_[%1&NP_G,7A\N!:[VB'Y<;Y/;L%%
M3`>F.?H%T#U/SZELH*OXF@&^]?9^5I1?LO+O!F8YR.[']ARG4H:SF-@^T/,5
M)A+^AT(O"A"/9!_Y_4`CUH^9#XHKXN&Z(GI*!>.>6A4:>P5C$?_K/'LR>?EZ
M/4JJH))=MR?+P>#''9'IW!DA"K:NJ%GP;00XXT=^49C2NJHG8<^[[W!SQH\:
M"%@2LU6'(Q+E=L)6K-CI7!?G/PTH`*6F5E=R1'*<Y<Y$0J]W6AKGW62C5C0?
M7\6[*Q>4E$2MF*3U:3=QW/$I<N?J4\F)1\DRXS52<YV;)W`S;%;$N#@!4\SI
M!=L+D^HT-4Y\2IN]?K2#0\W33YPA#0=MQ,-*8C#:#H%"#>^9;6AE]@0<6-!0
MG\U],HK-?ERUS6U;MUU7U;3,@&J9_B9F;)RD>67UA6DQ&&7%9-?3ZZH4$K.J
MBHDRS-M1B/J215X_1/V06A3B$*D^"1!F?AQ[0BHO#M<89Y[B]5R`C<D[6(UH
M'9CF&E'/QJZWK1$E/-`15QH)Z=OZ+YM1015'4>0K%?(XY'162>_TA0E;S;?:
MM49T'\51[\@=H#BJA<56CLRV+XZ:`PO]KKZ-9@=N'X5#@J+4"XF\#76"C(8L
M%'&$6$3ZX/_X/O(C$2,5^%X,_$@E\]84A[DNWED@YF#TMBW_KO2W[Q.V`P"S
M>-)U`BY/:)ZR(BT_'/S;!HD&C;,A$,T:IZJ6H!Y9P*&=R-\+(+2EA'Q),FP#
MR(GD3MU5][@HJY=`*TDK7176DL\PY6OU4!^`(UHCR2-[]1QH[Z`O,/("R9F0
M?18SL5H;\6;M<3"I#YA6=7*@<ULWX^T%=+%\*O<&.N'RD#63.W_\],.NOL]R
MOY^3=&1-DCC+_V2OS-X9^^ZQKHI490/60H$<Z8*_UV"Q_U@U(W2YIG?'6OVI
MDG%&:IA4FM4/C'<(5W=32<172=XY(Y>Z*HE`91VUDJAC(ILKB=82Z:PDZJZ$
MI6-"_Q@E+`V@[9C=O_'ULTNO!!REA,4NUXUYFN2#A\3VR.[SY'%)!+^MX]<L
M,.^=]\66<5\H+_`0T1Y'7$4,^5PJA*/`[P=1&%'!W=<;"TZ9K*/Z$0*/\I1'
MMQAMSX<=/.71?<E(QR+MCU`RLB%D&T6RR5O)2%,DFPJB#VEF=U,RTH#/CH<A
MM*5DA'+J";%T:+4V&=#>=3%/7,F"9/R/$R#1?>!(/2SQPIT(CND?H#!F(Y(W
M/9.@+84Q!'O0DZWDW!RV,J;3%7:74@C./%F_/>2`E3&=DNBNC)$+9OM1*F,Z
MYEWW<H*3PA9R'P]3&=/E2K95QE!U(I4QG1+LKHQ1G&&]F/UW0H4QG8+@+HR1
M0F%[<=7Q"V,Z%5C.=!B/V]=-#U\8T^ERNG.R%,:2$[7DR!VB,*;3Y7,7QC"F
ME7+;A0<IC.E8X;A3@A:RZXY8%M/EVKK+8BA1BI/Z?1G'*(OI=*.ZRV*XM$>3
M=3OX&&4Q'7-R6]W(ZK8]1%E,IU+)39[R/*]>]G.PLIBN_3;W`E*E:X;^T<IB
M.EU0=^J<?:V'+)H)IU`6T_%R.]6LQ&*U>/ATRF(ZE=%N6XI[\!/YT#ECAV49
M71+M=(HH%LMIR$<IR^B26'=9AC-XL9^RC"Z)<NJB52MJ7V4979+CCI)R16J*
M]1!E&9U:NVX-`VZWMU+UOI^RC"XI<I=E:(4%IV*9\?96EM$E5>[+";`&VV?S
MLHSNR@0ZUO5./<<QX^)DR@1F5.^G3*`MAUEA++PN"@7>XJ8S#VYZ6#X+$=O+
MUN-)"<-LULXN+T6_X;.7)#7>F!VP\@;0UE36=L@\B<!>13]XV&9;D!D`9%^7
MF)/EZZKG<P2U.ML@R[-OK7((D\?DWA2WV>3^H=S2T)T32]DZ&1"#AA21Y*BO
M8@G<SPG2?2R0'_.01)J&*N)M#ZU3036OK^Y:*GX4HEMK-B16"S=9;$9TQ02S
M/([:O:#7)D^S+3)[%@E=%F<157X$D@P+I8$V&J*`<HDBX-^`1CH.N5>5LOYR
M+?X^XTO7E!K"V--\P7"2`ZG33M/-^\7\5C7ML"/I[/'Z^4.?GF>#)>T[<C,J
M70E+TO.T(,L92VM)6_'.!L8,BSC/'N>2ZBJ?OA.Z;:!T4R@0_P`2;F<5A/BB
MB%Y/VR(6P:1(QZ:8OA525*'(:;=+```@+&=YIE=Y]6EO5Q#/L\&V3:!=QDN"
M\?)2/:)BTXPZ8!VZ_*";*]>M&\K7<]8E3"1-1M>3;Z-T</4=G,VMDG%)RY/#
M:VJ<X@AH5F&$I`[ZB!//M_9OC)07]"./$S`;_37WXE"A\'H&:R2Q)CC_E(.4
M_5&Q<1]<*#;#9@<B#R"@=WBGNC%+<).WF9T"6^/JOX\);&M?)OG`&N:A>3:C
MK`I%S9RQ[5$AS>]5:R45MX\%3]\=%501B5_L19KP86OJ&R*M/2\(4"3[,>(B
MIDB+B".*0ZXHM$9:ND/ME3EF*]/H0A%="\V_4WA:!!%AF&'R(\`#]HG>`SS4
MY<=.7UYC4OX0S+,_=%HD-5=2JYW0:956]6N9YBG?VYI"`!EMAFPO0IHVEUN"
M;[W@%6U/]B)L7TQI(RB@#9_3H1D&K[\6]AFZJR>3)];5\@=E^CP]-ZQ\KPG\
M;M:XU7U?1)%NWXMMR]Q%#+Y'\UI4\&-D+D*V5(6R8&LNO,M7I`/+N.EH4F[%
M;5M`Y>L`P/(QBGWA(4X#"L911!'O<]V7/O&8$'=\$:KW*E)%E?9J-T_O1MG2
M`?HL*VU>/+`'&%;KES:%P1'M7ZB/0/B<U=37&GH.*(2<>#2)F5#Y`G9!@%1?
M@P<6Q&`U*R%12"F-52"Y\(E%I($O-O79-Y`NE^-!;I+"A&;Z]Z7-Q"WSU-[H
M8_?C4>6'.^<23!A-%LZT6JEPGMS91*&MSI'W0&5;+F+CL=ULT@UG=FOR;:^S
MO"J'*0&:;Y-R6B5QG6QW<+0-`KA/8R]D"OD*Z`;3@2-@<1^!GPA61L"I`%7*
MW4=\#-<UZ0=)7+;5WA_*M$]H'I<%6FQUJ1?O`UF<=A-G6SRLT]RD*`/S/<M-
MC9FBES)/LART1I*_7I;FL4I#L;>O9*,1#)U'<(ZJ'9T[!(&M;MVHY7VR%PB6
M-MS<,GG_QJ-BU&9K<4+JME;#U%>.X)8WV?:%"'L0%,XS9N`#H40]W:R%A`;!
M"0N>+8*RO=?6_9*VI-W(Y<H^)P6;J8D8MD1Z/YZ>Q@]>JT>NDT$E2L?#ZJ=1
MM7O^5#V(711^GA;P376;XR0XI.T>H0U428<P+*N;9S/>+N[8/3^YPZ_8(P3+
MNIJ93G<I)#]3/5^SV7/HSM2VX[J=SMP\KNLONFQ.SHI'?B(RGSCMAJEB7'*P
M7>)^KN"L87E<.\@I\4"#U7.(ZC->Y]#,$X]WR=+;`XUN6T8J42_KW822=;0O
MYEH==U<ZI8]'A8?;Z%ZD8AW-4]D^JX#>,LET'W2[#P0Y]GCK@J^2TKQQ3\%8
M<2=$_W][?]K<-I(EC,+?*T+_`>&IGL>.(%38EZKNBN!:XQDO>BR[^_9]XPT'
M1((2NDB`#8"R-;_^GG,R$TB``$5*I$3*[*FI$DD@EY,GS[X8IN:9JW=WKR;T
MW>^OO0&(:>F.XSS()KYZY))>LB_+TZ:(VRIM`QMUO'5X*VUBDYA')CC5AWE>
M3M2N:AB&AD4)[HMS;-[4!LRJEM$%(Q,9*)2V!Z5R[8.PM9IMX!(9EKZ6I&^W
MSQ;[';]2O3`.I]MDA^]#$FOE;FJC%:^Z]'H:"*@EXVC+@KY[..$U'1%\RY%(
MNKSBC;Q7HR@.XO%A>Z_::C6AC\^P*D:GQ^UR(XB]I58WAPVQ]J1SM:IY/6Z/
M=5M5EB/QX#?J>16R5JYAVX@TGFR?JBZ[KFEC`O/_1/%DO_;7#0^V/;?#TWV[
MHE+7UUWS/4ZGX3C_.!U^']]@2:Y/01Y^C)L9Z,&AM]'.\'17,R5Z^-AM5H'V
M!S")-)C!J]W)/(JC+,?';@_"1-GNN@&0V'*)V7MVL:D6+Z<//R^Q:T\'\ES;
MMS=1Y.7-M$>_'I:KJE70T4U'MYR6\-;U?BO>G@UQ'W]F2:3<!OG0W9;I+:9N
M6ZZ^KOM'0U"KV^MY^L`9J5IW-%2MGN6J75_#.H5]KV][/<WOCNZ+L]-K\;[K
MMMEH+I9>>!_-@)HF<?@^S&^22?6!K2KUMH')UFV;-4W9`DRF[3EZU[-4IZ=U
M5<OL6ZKO^@`FW0$4`OSI#JCWQQKCL[D"I6WW_I3(]"`H#373U[U^7S7\GJE:
MPT%?[2%M[<&7CFE;SL#T[X&2^V!<@FLX#;.,"J,@^^&=-7AGQ>R17`0A8<$N
MO^N6:6F>O9[(N'W;L.#JJ,;0P:`7?Z#V^I:E]LV190T!E*;9OP<0NNGJU>SZ
M#7:W7F24>TH\!@Z;-\:PM8&I&0`'ISL`ZC+H>ZJO.8XZ&'F`*Z8][+L<(=:T
M3#$J1H@U>ZJ7@AE3XBV^<&B[;2<2U=W*>WA.RKESAK)YBZ#'DLF:#()RV8I-
MIDS1_0P`ZLV2\9];0ZOHU5;/&NF"B-&W1JKKF'W@',,A<`Y'4]V^9R)V##S7
M)7C\_I^S_+=)=/N?U_EOL`/\1'$]2I;?S<*_O1I]_/!9O7S[_PY_571MD?^F
MT!>C[ONW[_[YJ_)_/D=S4`H_A-^43\D\B/_/;TKOXZ?!\)/:__CN7??B$EX;
M)[-9L,C"WY3/P__GL_KY4_?#Y>CCI_>_*C%`\S?E'_"">GG1[;_]\,>OBK;X
M#E^]'7S\QR7,^)OR;OCY,PQ7_!XG*2`!'^OMA\'PPV?^DOHMO/HSRE6$GPKR
M;_)GJ'Z+)OD-_?Y*&8>S6;8(T&)`UP@_+X+)1'RF9__V"F[*7UXI5TDZ"5/\
M7@9,*G^8**!C1-?QWU[ER:)XW8*7^=>S<)K3Z_CX%?[AG..?OUR)+W_))VM&
M;!V&HY(2<FJT;M!?*HO^A<Y6^F(ASOE]]],?;S^HO8^?/W]\CQ"#H_['?[W]
M/"30#VN`W^00`0,^?OI52:^O7FL=^+\W#'<8'C5ACG3J?#6?/U[\JCBXE)VA
M`=_[YYM0P0B%(+Y3;H),2>$>PXE/E!Q^F`+&)M\PP2NH05J!1Y,IO/_?RSC\
MSV"^^.T_OG>UWTRMH^!E5()XHH`B$F+@L/2S3C];'9@FPWZ.H)C-[GZE`UD\
M]V$86QV&MH_#*"&U`I(?FQ:Y3DE-@"7G8;HA99+>OY?67"5YGLQE`M;VRJZ^
M?[:IJ\0P3QL0R[L?KUZMW0S-7$7H>[9?>V/]NWS%'+,%A2COM:+#?<Z2631Y
MM0)FP'Y`NI@R"*I8A7.LD#3B-ZGR"U\`$K@';.=X`-!(N%>!8.T""!M@XB8D
M#LC!-6PJ`7KP'_W^<#@:M2`G"A1-G&9KDLJ9P;OA")E'.*]1/Q6^$A,UBBF+
M"A!VB!=-[S[7<P>]YEVAWE,BFKD1HHVEKB0"ZYX<Z7[>B./QCRDFG-%KIFEV
M?-??Z.4X^98&B[^]8O]]/,H]QVZ-CN<;^]WMRZ"QFZ%^@-702/W(@^_/2'&W
M>F,5+W3+Z]B:=FRWX+';MC2S8]E[WO;+H_L4T;2BHQ\?TMMF1_/V3`P/;]MN
MQS;,9T=YP,D-]+DG`&?]XG`%AZPN%>WF.]=N&LY@6ZS?]YQ[5@5/4/QAY)S/
M"7;*J)/ZCL*+7Q\=S7=,NV,[^@]'\RVSXSD;F9%.5/^ETJL3%`^)ZC\EC=_.
M7H@^&?79"/QS/7?0:_X11`U>(UR9)JDR*UIH*I^_O#\Z*</4C([A[EG).L!M
M&V['-]UGES(.COYN9DLLZ"]F&"0L:/[H4!_$:W?/&'!XFW8ZFKUGG>)'X`!M
MRN:SRB./9@5NQ]NWB?D`MXUN-<][]CMQ4CA/"N>10_'E"3PXT17^W4SP:=-7
MQ<4\@B`"WS([EGYT5L4'[E;O:"XRM5WH-S\"33>!,DR2Y=4L?$)R]/!)#Y:J
MOS`X'F*&@'<*2C_8H/0])<BTWI767)BMT/@7GN/4VC)[TQ2M>K(CG-U5PI+M
MN]CB[#K$1.Q]YG;9MM?U+-U0K1'UF3!\U1M:IMKMCSQ]9)I#<]`[Y78]=6Z7
MN9O<+E$;=-U@ATBQ#R"GJX`A+X:Q1G[_44%T$85IE"D7-P&,,PZ7>30.9EE'
M>1N/SRD/+DYRY9K`A\TJ4E%7=YHF<WA]D2:3Y3A7LF`69N?WC[8Z$@ZR3+'=
M6*[DB?(Z>E/RV1E+.Z8HUG%)5Y-8":[3D,@J#/[M)AK?P#!1/)XM)Z&R7,#B
M8#11`8/[;<;,A`U_)ZQ%`TZ77.5!%,/+XO=.];64UQ:D)4S*ZH)*QA/>\0=X
M?2YR@8O7._3*ZTC>SW5R&Z8QO7^-O2^S\V/$0]W;ZUWMRP=-\.5AG=WBS$_W
MN!U\W=DL3*^#F%VZ$Z16(/4V5KK+ZV66*X:F^9T*]0DDR@(\/K]1JN"$UU_S
MZPSB6+\`=OG=X+<W'4H9%KG$=-&!WHE'E4#YEJ2S"2PLA.'"[T"TL""ZH$"X
M#$YH.-V;S[&5#,@'_QN"&),BP5(FZ?(:WAYC_Z$)T%-&K7#>/`V#G-:/;R^(
MS!+)3*9*,E[.@E291!G61<IP.\6R(O+N+>#*12@0BN$$`>S(U*^#%"^(E]-@
MG%,I]I65!F)*!`%G$C3!<H8%YP3[P!GXOL\K&=@IE5S&-`;RL:3A=!E/2%*M
M47<8!&;Y6=>0!,]PTN6"<GW"\5*L`6<9\T(EP"7HW&G%$7(?!$\^PT3O1$P+
M8Q38`.AP#0!FLYC%+#!,0?.1A0FF0;/CA,'X)@*(T4G`N^+@2B"5[R-3HC%R
M&D)@#*Q`1J2K._KX)8[PQ\N<3OV"WN%,B.I:S8/T3^7C=`I0A><#K%YUBS'Q
M!:OF\*;QQ>D?)Q\R]D$>NCF!&82)<"$C4$$7JM<[+>N:2!(-HC<])K!57&Z.
M)\I5.`Z66=A1K@(\"HXS61Y<AZR<@"QK\!44!R=.<A+.`%E3O"4QJU,@O474
M85&6KH5!2EHF[V`2YF$ZCV(J=1#D\E0PQDV`";8P?C!#Z>86^XKC54VQS7A+
MT0/RBX9\V;)PE-%P5V$8B^M!2^]@$85LB40FKU5A`.D3!I"`7(P%-&%6$22/
M$X?W*TL-@@ADXTBY#.(_[Q*`['E'>9=/3F)!HUCP/KA#_-6K:$CIX(!G4=PH
M('`0PPAU(%=%A>I1U`0&8&Y`HTF1X3H44J(_8(;93`$ZH43`%^#:+](HS(/T
M3NG&I%I%%(:3+1N=8SIN_N_#3Y_?]KOOU.Z[MW]\^%417C5Q:X<,`V"(JE4X
M&P?3:3(#FA".;^)DEEP#^TE0RYH@PYS>D0@B"R#!-?`W+)S*.1VL\QJ;`63A
M+,3&<,#`X/4J&#H,AM-E2A*^3/0:)0KDDF$*LLF<QJN-=JZ,0&K!,VN8>^6@
MFL6T("Y%LDXIJ14$G,M%1)0:)*-V0:@&KA*2$5N>M)CSE6(T-_`>L@GDY!Q8
M-1Y1R&Y([^]*:?!;4M.<`8O^%:(P1J>Y<AR$@C@=S@5<8TSA+8C]<#U0$0:4
M-6F72/O/6/V#XR2]>Q$?OC1*GY+P4"/)V&BC@H@!#+)>Y,6SH$'G:*WFXN^Y
M7MY=+J.2200%WPPPC9^^P(O2W(%'B=^&P)%71(P.E]'%XD!):!*7%PE*H169
MMI2(29SYV=?/=2$\@\X%%TQ)D[M@QF23F,OHA6Q,]B2N/Z`D4_XBE`EV27+R
MTTL"1I#".'#!KI.4Y(6`Q#$JWY3]6IISI#=4Y6?CW!%K^ZURJ\K'8!1XT'3/
MK?+)9ED>'K.U<Z-\#*W..15,Q#L;!==QD@'UKLC_<(;:N2_>.6^30F&`JAP*
M%$D:YALPJHH\EX"P!9+5%4IPZ(]@X$#R$2K?2.CB/\$6EC&GW#DC1O*XR7*&
M<ELAM7&\N.._I"'U<ZH,Q^ET`*.6XC`ASUU'R*MTLC)Z?J/"6T$&P$+$)Q$/
MEXV6.LXA2.3%7QD&R!`1%D!BE;=11O8C@?$"A6&H!:N#7F`#C%&8\_#2-?$6
M!21CFFC"5+SI<C93<Z`U2CA?S)*[D%@",<()4XG9^44$#$'JQ]QZ&4]*5%Q0
MXXIM2.CW_9'0Q??M*.CW)W6S'@%7V8OG^2WJ2UB.CFX3B4R(7=?+B'T#9+Y[
MV5<<S58-NR+75,4,F?)7D1#1GNPX6>6**4P?9,;UFCY<NC97Y94&G5*RL5>G
M+JX>OY9U:0B>7.##S-8#G`7K=1)K8.Y:7/9Z=;JF%K>HTYV*O:MU63"`1$I:
MI>%E)F@`?[J4^/W?,N8Y>3II7A+BA9A>%X<KZRL%9R%)$VN)@=]G&:[XBIJZ
M5A`*1F+<X"9`1@/P:;(;P##X)@,VX]X2)K4PA$+[)P&8&`EPT#FI_XQ\,BE#
MYC]1?)O,;CFG9&+MMQIF$G?$T=@8TLFR:8FI39HX1HD=:*V-,F9C6S7*"F`+
M*)9WL7IGRNWD-Z3[\5V5C'<!2_A.S\SN2*J_@X5D=:-ID,%!X`UCB"H-"YOF
MEQF8,(*+"7QPM["#,Z#J]FSH8&CN?B3Y.DU#1ZB$BOAU@[1+B$,&*9([&;9F
MT7=E#A+\#8K/2$J:[68K)G`^%\HXJW-QH;&01Z6I&R8F0W?KU!:;>G4.O`B"
MIM(%&R,%`.&GRJ4CA!GY46\C@"<A450E07`I&M^!-VX;7\CRY21"*0^X'W,;
MSSI58^*8;@>>BR2:8J@SWI'"$+^`2\'Y`,IKZ/08D6>7@2HM"SJC*VB1D%8$
M^!8PDE3E96%6,VBNBMC1*K.&VPM4$CDJ'F7)M@H&+FR9,%IY!GR%Y\IE.3J\
M+\OIX?<H(ZM%F]&Z)*V('J3R?[L)292^3\873%6,%2]!V4F6B$FW01J1?-`A
MLRT-#4_<1-<W)`/C*],@FBU37!/2?*:U2@)WW9\>%"V("F.VO%%.S2<$3^3A
MY+='&*;A]1*`EP!3(B()G(;9@8C!W(#$3@/6K^!96\7>FG$\FE0OOL*N9F'I
METX.WULQN%:"%KBJ75D9WJJ-R(/5ZGA`*L!!^K.D9C.(LY56"PV?5PD'.^",
M&;5X?`?Q^]KF:BXM"7E*E8<4PS:@MQ&?HV0Z^[7<`P(ETTCMDO>6W0G^U44`
M5WZ9GDSX36K2)=`_*MF*B*5M8\AG@G`SS!4.\ZI%G_W69,DG*HL29\6PQZP'
M.#>P@[NZ21\-_D^H!M1UEV:Y=8TMGX.F:L&O&:6;C>$5"SX;I=64,UEG1D&Z
M!9*P6!SY%RJKD@*]V,JY8W^:P%F69CDQ`O$-(J3-'@0Q]KU^`U*%6CP'[7Z#
MBIVSW7.PSF_P%D4PL3%!MA%&`H+KML7^2S$IN`8F]!7LGV`F`,H4^")$0P[A
M("8RY\R9L0+Q5OA]00H5,`$QPW&2_N?Q''!:M.HQB(6'H`Q$(>7`*BW*S9Z`
M,BB2B<K3*,UP$/E6X5&OWB,DG^7](=R0!D,!C<F8?)#7=!U)XV1C<>V:A0[)
M0ZWN1,3S$,*\.5>ZQ<.SN\ZC71<-*ARC$3_;^KG#9/UU/@O94='HIN":Y`:.
MBE4W15754%&Z\^]S5)`_PY<<&E7W2>U!K107]^9T@/>%*E&)[MW6#5$8F&1'
M1"W"=KU3HG0?M[LE8+S:@*LF*:)QVW@I&A@;,P%NX:5H\%$4_.Y^[X02%BTP
M*VX*?DOVXZAXX11['V;YSFITNDP>91.Z%(-PC_V^\4K7[?=B7KK/`N6;G8CM
M3@&!YB!*@4:?I)D\$L:M<CI1:HN5:>59Z`MAK*@0#H[SS/Q31/#C_&B&!;X`
M7_Z+Z;HK"Z-C2I:YX"B,`]V5"ZE3%#X9DBFZ[>6QD$V[)"+\"LE^#O8@MUJL
M3EJ9LD9TB&IG%)0L>!_;H0`7DLWH.J:[2O$?)1$J3.MH+:K%#M3E`B(\P.XK
MOAE9UNMPR\+KZ%9:H;21<E4*]ELE85@2#5A/;EH+LJ$H+Y,K.&CAKVB.=K>)
M$@*V)/-H#+0F+ODLUQ%.A*?--%USMTE2$3`1T%#FM2`L69&1<VPV]LD1Z>%>
MN8?YY,XV"G&]SR>'HL5=G7'>[Y,K/3U5KU>C3TY9=9X5('P*I]D)[66T+UU:
M`.T9.:Y2)A35(IN***F"\H/$7=4)JJ=WA5W?Q?"(D)4)Z'[@>1+B%M>MP&T,
MNP^I530C?8R0,L%21<LK$FIERI@B\Z20W;PB6Y(B`==J#/,B\C$#BOB0X^+(
MXHU9%!FGRZW[P66SY:-MG:>J%=\6'++04%H@BTM:O8`!P^.VB[0!+(.*UH`7
M^4&@%(`D:01&0YY#C+,&V$U`12+Y/<`ZW48I4:*0_UK<^37-"64/KU0X88S7
MS$R*;7K2B/NMJ_))77X1YX@E>9#6HI<UE*Y_HX<>Y->"D;%0:_8HFJF8N7;5
M7_:&B7R@D8]E'TA%NI8Y&Y/&H\D2E6QJ"%M1Z7\VS^UB4WRL0N:'=T&UMU8B
M.,6#%=L;&I#'3+6M1!96)#B8SJA/5U[P%B`)E72"X0G=;`/Q8%7W)V6_123H
M**O:=`7`*+*4.V$I::NQ'T7$1VN\1V%_OR?BHR(YU&(^2F!L$/718#M'5K,2
M]='9-I"#,ZP'!'((:TY(BB(\!K3.N#_SIX!`L6F:<4J&<<D<7!B4X5?A/`9R
M@4M"!)4.R=*X#[`C<J5+W_IR,>%1+U7TY&O@\"Y."P\EF.,^_S>4KC#N>L);
MLJ\J/`)M8B"4N%KB=P#W)KMV::%62R,X90QB5@BQK8PBM!D/7N.0=67OJH@U
M0-L,V==A%D)_6?,N`%W;&>*(I/71^SESIP*D1^%5ND3A$N/R.[+/JF;%YW,D
MA?.\9G@M;/C"=RZ]7])X/(#BQJY2=^W<\*JJ9;F],N:WXJ26%%-YUE+XD(8H
MY"]^UG0@'!_DX##.&UH1B=2/M3=1Z$UTQ4OUIX!)82\@LL&N$<$$X"JZ1DI'
MPLQ$<)IHLJ[(33+:M&"TC#W%5(@\7'`K7^%+$E@,:ZF@1\$\BR,\J\?;L4,T
M2U95"\`CWZE84&$'(DLC4J(2L4]RTA[BR+:-K*A&E)U5$BG;(\K*).?5B++-
MHU6J'&TECJ8EIJVZTTVFX1!>'[IV7^#:_4%HU3G(]'CVT]:Q9W+D67D<&\:>
M@3A4KD`(;!M'GC7%G57CE]9'GK7$G17^@_LBSYKCSICDP(3&^P+/UH6=G?VT
M4>#9/6%G?#.M@6?WA)TQ5)0#G&5<K%!1BOY`J3`-81+IGA6F[`VO&8(UKFH^
M<ET"GE`SOCFYVB62?']XX";!@2B)K`T/K,?/%7X+*2B06W$>2N&M->+$SU(6
M&E,*9;%4"@YD\FP9'5A!%/9/<\&\+6K=U8OD%9Z`;CSI)T26PGC<7&!O9W7R
M--L:=(=F3[6\KJ-:QG"H]K2!I7;-GN/;GMGK>:,=U,FK8?>:*GD'4:=.UW93
MJ$XZ5$Y,*P>[K_IU6YY%+0IQM7Y2>A7E4HN+!X18[F9%'WG&=7GGC<9`8#0V
M1/F2V'&Y=F:^&(<A8A)ZE1E]^?SEO2+ML%-$^GU&)P=</2(F7V*T<651SN<>
M6K_ERGO^8=3_+8;'8AKS_3)&.PM[&XW4Q:MW'`>0(093$&-P[@X9!R83(#>9
M$F49(Y+7`>E&S#H4S+!($1<ESJ3*.A/9V2JY>W!+I5&O)=OJDRP`O"-5%V?L
M5FLYT`I1PY\3R96A!F.\XV:I;NGDOI!J1Q'Y)FL(EUMP8>^*0BK=:OT8Z:C0
MSE6>%67:$U0[RA\A1JH(2++J<4P99;\HL^!;ITGLJ\^0+EF4$I<M!N$RQZ-6
MWG+<(76]/-]4N419;))=@[X\OLFS*S3)1_F6(L0C[@'R?>DB_/=R=E?>`PNO
M@686QS.<3KFW?P#LMGH[\+S9\57"?VOG(Y\.Q2,M`(?#"3<QI.%B%HR9TE]?
MB^'08MQJ#0\<&G6](B04E`+AV^RP:D]P:EDR1X0GFVV&SGS\L5;U243@HG-C
MAN[%)0MC2A-8(KMDRI]Q\DV]2;XQ*Q[."Q(TCKT(4F%8.=LHO-BS_[)M='$M
MAKEPEHK4'1!PEVFMY%`9"@VW6]QAOE,2B.)E:9$B^WZG$CJ'9U($XJ'HA-)T
M\HT3O<*%2Y;9>CPR!>S1*7\#@-)MCPO-`N?"!<"7&%(S+@JG+7-U5E"-,JF"
M(^!'^%E@TBAD\;\W+)X%D*'V*P_]`U2,F$PA2'!UVS+I8Q!ZGMO7E:SBW`K6
M<G'D$R[<+61PQ!?PB*K$O0ET<(JK"<#%&$)*YF:\J_`ZBIGA*VX@!-QM.&$/
MP!#","=)T7I'LHN#Z+D`/JI<T/"=ACH;+-%&B-!TNVEX\M2KP-C(^?_]O"``
M:,=/\R(NH^!3?$,M4*P#!5D?OR6E'::Z6KY*PI6?32FYIW61I:I9%KE#B-V0
M6DV1/-QG4I@WU[$U)6H^T(A9O#!J^5SY1PB'-D,MG]&J:,H!D6$YL7QULL+]
M5$R#`&#F`;JES!`O/'@PV82!!4XOYVZ)HCH)$.%I@"PR3>+KZ7(F&U/1$CH+
MHCFC)[)C:1+,@VN,)YBNL-4\C:Z6,3F?I$.5Y"L%3:L9X\F\-B[7_3$N"L8.
MQQ0`6@I!_$@8?9=0KXG,*%=+V".RD+CP5<7D(P')*N6)A;)PE4=S<L/!EM%"
M@I!,8+!_+T%"9U',2+#(PL[6537B29)F@RS)HJIAK$R8A1M!!4_=4%TIX7%J
M],A+E*+TSI8E9;XQQ"2ZDJ'TLTP%^F8W&`#(9"4T=./!L@Y=3-%>TM8K4B4S
M$*'^VP+ILY\D";/QWJZ60$A9T\@)N8MFO(#\'5(J//ZK8$;GD]V$85X+1D@R
M9A%DL<0SP%45$54:)F+A+=*BB=&TU0<Z*XIJ&%JW_YOAZAW0F)77/_-ND!A4
MC[X@%-Q#E!6Y&-IPR.0P*..5%/2>I'A+Q-LAD6!!D!O/MHQ?0<ZZJ(1H%.&"
M9?C'\[`]K!(+@L2,*UP(AB"]7DK)D!PH&(/":%DN:!W#?GZ%40:[*X)H*P$(
MP;C(Q`CPRLT"&N^N=G4*(G&5,BI98X^$";/B#K+9[U-X1`T>7#A<ZS"8=/@.
M<.A12DA/14;QE'H!24C\^4PF4:SP&'JXRS31PK4I&:;XG:!G^<2"26*=RG%4
MA9*T*22)B<*\"$3;48)BL:>D#S(17=`Y4>AUR9(P>(!]243NU01985AX=HGA
M'UDB;98;ROAVQ37CVVV)!E]1P\JE/%0-ZXA`B0*WZA-)ZB1)(8M%$E&:&IK<
M2\P]*T/(:"@U#N:2&8&%;Y/6P528,L"13)51.I%0%;&88<;X)HA(/4U662;@
M0CA[-CUR50+4.](-GT:8'83T.4/,%SXQ],0"M6=5CP&.W`5`)OP@!7$FW4"R
M/8?Y&V50PUQ=0J"0KR9,22:YEZ!W;,/O6(RD=S1'ZWB&^X:RM9;`(?@)XY:6
M[#K/0`[(&=5E.BT)YR3^G).Z'<3H-):@9#0EQXNUHGZ,1.L*%*^I8$P)KV6-
M79(KY)]#\WEPX',3.BHWX6S"I;(4I)<;.-462PQ1HQ7P&(5[`+3P4(0AK,XC
MW`6HG'.JAO2*;`2(.''A)..233.=+:1-SD"PI0'#D#D0BKPP0*%I@8<SL&T&
MK"!XE"PS.K`(6"P/ON(<C`J.,B@@VYDP*9PL=3CJZO)*1E=?(`EF99`+6P(\
MQ-QIA?A'6@FSAW#R3@SQ"J0?(DIH.9;P1TCI++6XO".9[$F<1M]940SYEI@=
M6].XX&-U#-/NF+;VIE,0K;KAD>).@$!C/#9B0WF?\1.J-L0=(K@+6$ZS)ECR
MZUZSX)I-UPB4#;B.>7F5^$7B`.5*0<--:B)2*X!Y-EI;W[HN]D[Z7F7/H,=@
MY"AM6\(68K>D4`B$(:QH,.\5F"R8(<,V2G8@,4ZZJRY;1X'+DID<Q'&18`BP
MO0OKX5X4R)SG,P;T.+Q.0$,D,DIDLV6FNHNN_;QIKRQ,NEQ3GI!,$[&0`9%)
M!'<E79:!57,0=%`>PJ3>,&!I0)3U2?D9*ZC#`@?F<*_I?HXH2E4DXY([.^3A
M?$SPO).`RD(!5Y&Q&*]^PJ+009+!&2=49EFVY9[]Q*$D[;^@#FQ*U`6PX#GH
M&P`4=D<%D6:V<;2?9GDAR7`%J3@A?$XZNG.&G](RO'(9K4H^O%]SPG*4YB2$
M].9@`MH3(V%,Q:>SY6G4H!OQC#H4^R9+-/[%3,U+4K+K2JQG'DU4G*ZT>K$(
M$:;N+42X9UEYH04UT7`A4U,R/\+XT^`6&<>4U'&"4#E_59VM'B5#5C*$-\""
MT[WJ;U[G/M@2AYFP+@5C@`R#!KD[Q=WF1HP[QJ/X#6F6L_DE(?&V!*^T.<!/
MP8M1B)'VQ5&]MC?Y:!$-Y`O!-"FN1`F9B$];7@HN.52&Y9*?3;H#OR5\\V+K
M#"Q%KOD\5";!G4AM+Z!7\%9F<:!HD(C;T](0<Q=6[VL<?JM0@6J:%GG<&6,I
M8,,K[O))&^@)LR3EJ]N`46H[M_G-*>W$99G(8EMTT!@,$`I!J""**WX878YX
M*U`'56J18XLITBBT\EKC"Z"3?"SYG#(V*^L[@$%)$_J![/3DQ61&1F`UZ^X(
M7?U"(FY=K.P-73D@-#<P&U4:\)!3;CO$H!(@=M+92>GB%<1@,6`QA<;>1G3B
M).HG&8:EQV5M;R:N-6J01"SKZ+=*X;/E?(Y.%XXQ]T]1\5`STUV!0A@FN^IJ
M*Z0G<<G.?I(CF!FPB?'!G-B4+&%AJ;*B)I\T-V=EN1`G"W[9;I?$U"(!328G
MKAXMGES!Q8(<-.,XO*M*L92S0O)9V%!8E'*C0!A&IIG2[BA&&0/=ZHD"BUE4
MV*2:V#)LYO_'VAUU%/?_WU'($$`>D65>LED<F7C(FM7BHOX%X[#[Q/-!0"J"
M#\(M?]:2#E8%>J,@RV1LR0#$P_'2(,ZX5,Y/*N6"=QI&\ZMEFI$/3>`7J3RK
M#7`;(I>V"4"J!B\-PJN]=O/T!EVM!P^K@Z$]5*W!P%5[O8&I]DS7Z@\M71L:
M_JF;YU-'2=F["9)"Y#EU\GQX7;S/O3^4=TGPX-BL%PRC+FOR5%5"S::0,3+Z
M7J%9X7,9KJ'VPCR,`&^7(!2I?X28L@MJ"D@]ROSJOZJE[^`45EO><2$P`@V-
MR0'_,_V'T@OB/SO*",CXGRAY58>!!VK#L"@8KG,7.9^%;1Z-96$JJH>TN9>D
M=(:(_$RRWPP-*8!#LF4'F&!K:(!)X55%.8W2(2N;EO1S8S5W\_7/^KE9^.'?
MB+PB$(FBA3S654+Z&`8G81`(:KDBE%W7SFWS+^?*%REGM>Q[U]*1C`S^9:W!
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M#YJZ@>?:T4ROXWHVO^_UQ7$+'G,XU,.+*LBB>QW'\W!(T^B`&,GRT6DG!.`:
MG?>E\^$V$2[;X]V;`<?DN2`<%C`"0F/S6/\6J;<J&E]R&O-Q>GD#@GH/30H7
M#&V[WX)T<IG#*Q]9,NO?@]F2!/MN!KHC^^XSBCN[EZ@=6_=-VW15VS8MU>H.
M'-6W>IKJ#GM:K^OT76MDMTG41R!-["]O<1I$*:]S1;$:I(>QUM6$3F7.MEQ;
MIS<+QG^J@`L)1AW/DTDX8[=A6MB9F9XR";-Q&ET5_0J^A6BU"B=J@"46KD,*
M9.*H@6WP)CSZBWMJN!0@UG=6%A,355D?DE;##<&_'H9<:3Q_]YDU#7E^;'73
M=4J%<4SBS8;*)W_?@??O52>ODCQ/YL6<=OLKN_K^V::NZKYYVA2@?C]>O5J[
MF6IZ[R;;K[VQU;N(T8!(\(51QY2"R@)EDI0'(DU2G3VD40]8Y5[>N'\WE]'W
M)]C+"\`3OF).`04G*>F_HB_0?CV+)J^V/(7FQ-5G0Z%CW.@&^+4)@P-F<`U;
M2(`;_$>_/QR.1BTH)Q)LZG+&U@R5BP+OAB,4'<)YC?>I\)64`CT-(PI9085X
MU62^1ZKX`,K#/Y)7D]YWSK6-7HR3;VFP^-LK]E]Z]2_[7NTA[V]7N'TXF#R(
MT.\)HOU=!%KUT2&R]L(1>5_[^Q&(]%`4LKI-4-_%!)*CPV_7/'=?-(*[UKE^
MT!A^./C\#V[?481])XVR/]4IVF8*^_-12B/ZN6N^:"2'#1XVDA\%&4=OU-'A
M-CXWQ8J:'%(U2V=QS/:Y64ZEEG_:YU[Y@4HLTCIP2#'\0[#JZ4#RPP/QGIB4
M55_1;MU`S,4T":-?!\F80B(_WRW"G3F'S)&KZ6Y74UU_I*F6T?75[M!TU)'9
M\P8#7^N:O0%S#N&H?_VEOI!R>4,J4?XIO(XR]%+F'S!@<F=18?K0&>JP.%B@
MKUK=K@/+U`S5&VF6XYGPE.O`,O57OU^\'7YZ>ZE<_%?WTWO`KR]4S..RH[S]
MT#]GRV]::+F-SRD%QE[>S:^2V5.O7\/U?[IDZZRLI.II!)R*LH_3"]:#@B%0
M/+DL.Z)TBW*'%\DLPL"^W?L51[K1'_2&ONJ;NJE:`]=5>W9WJ';UGCWPNO#8
ML'N*U'OJ2#UC-Y%ZA&'H]I1QC!589J'.9Y3(*Z&<4N*<(I!NW5).L7[MCN?"
M4XQ!XW)P.86"2#"7RIHN.,S/>%7C+*=0<E8$-2P"+A88!)%6<G5Q$(KC8<EV
M8\ICS'B):S1.DX^[+$Y09-X=:4.(_?8N+FY.OX#>(ZKI'0;(]H;I,NHIRSA8
M3B)>6WTM"L+;)1(2E6+E92Y`X)H'XW!)M;XRY6T\/F<)2ABR<9-@$9SD&^NX
M4D1K1J*5`[L:[*JLE!*6+AJ+V6+%#*[#F)JNW5%\W2(O+]J7F+9"522R:N3G
ME_/+<^6/;O>B$O]YQDI=DRT@FDOW+8JI:2/+)N[.9A4*0(^/BS@\7EJ%MWS!
M_`&6AIRQFB5781@K(6;`%P7;<]YN34+6<Z5?%%XKIN:56I,\3G!#[/2QDW/9
MTA&#S%:IQ%JX%J"@]>$&<(4)3ZU9U"H,7H;C95H4+`;5<GR#55<52FB@%`L8
M@97[XW4Q>%)S=D[L2:Y"?Z=,$LJ!XQM0J'6>*!=7WSC;M%P+K%PYA>7`"<Q"
MJL(3+WF_MQ=)//?52Y(2SA=1S/E260:<19J6M$'<CX)&;`)K"?L+;)3R"NGB
M(-GFZ?";TB%IAK.R4#UJJ"*FLC6TVN*]$;`*WP0SBVB4#J&>J%G&P(I5C9<I
M2_>5GI1[2Y9=UJB<#JX%8]<6LNS62B4[1":K8>0%N,]^D@&^,9`%42B;8E/5
MHUK-H_L#U,[J6:/"TTV94'A[Q=8C(D4L5[;L?%E66Z*(T'F`?>C*%AE;G9BM
M%/W11;F#(^X)NU\AZ`O+U!81DG5%X,B`M3?QIT$8WX[DK.6HG%ME<D\%['2`
M60[%R2#%^==R<EU4KJZ$G;(D3E;5C,?A)U31411<9,UDLDPT2Y>233IM;Y0E
MXEF:(UY'N6EA(VVAW@5%!':F2&5@)!&2V#3R>JJ`):@.E1]8YEAX)N,5W"81
MEB,X^ZFHX8;E$3&1LX15E2*6`*N"BVU?`.Q$"U9IP65(T%(^B29=)V*P`JQU
MG)ES3*J3C-8`%&$Q(>2:-TGA58S.?BJZ]/'F;'<K#3_@[EU%25FEF+ILLB8I
MHA[6VE:16)"MX.#4I8D7YT.:DBJO^Q\'[]_0!QQ*_%IM%5BF1N%N4"D+:\(Y
M`P9"Y1YP8.D7G$N:"=.08D%UF#T#6_&=[N7JO7Q?M*&Y*/HN`40_B=K2IVO:
MU/63*H+)_7ZH`6&9ML>+2I+XFU6ZT8ADPL[ZVQ[>DD\(C1*\1A.O=UBV#8JR
M:D?ZF,I]83@!U1"0R]WP.T?:S=E/DI#!4O[SHAHN^Z&8`P5WF(8OAK5,87LB
M&J&P%HV"J!2-ZH-J'_=:?S4L44!E)C*J6'O&TL&4,&(OZ[676=/;*@6"NT^*
M.8H[U`OTAM=3#F4(46WRU\;*>#?XGMQPK\CN$16,J+\I%?4(YZ^S-W*996KG
MJ10M>+E`P7\4]3C/>,O*K98N+1S>?WVU%HBLK4XFNFU1JF665T9G8LGK\7V'
M@9TVDYA<,:S<*"N=53&$5%J^4EM@GHC)>U_"V8E4OK(%SOE]-+Q$\EHG8Z:2
MCR/6,W3<(=U1-)OJ,/1)238DH8X0!Q&?BZIS4(^I!>LM&<5"WC53`G79ZT=&
M%_QEAHR2;O04()ES*$;Q;<A4;KD_ZKU#LE1$=BTX3L@-U#8^B/M/8!7Z5#\K
M^)-EB$49%]#9;3U.1K@7H]-:*EQ4A<_DW@N\>P:K#XQ2UW5"YN/7D7355EN1
MP:"O(_D122:3R18[7GA4?E9"^?+!\Z*2;^U][$Q^M\"=D$F:]Y2C9&[JA$9%
M@KEQE[<%Q*VD$6E!"G4,GE++/7B@QMJDAEY\`ZQVT9G470.K&N4AJJ52<CJG
MF51Y'YL"GRN#5@!4-L";M[$V;P$964&)G/#O,RH</>4=U!<W`3,Z%"WCBX-(
M4NI%&'(J0T\2BR"X7+.*MA5*4[2U`TCWFPZ@!=)G/_&U2I4$%Q4$0P!1.3^Q
MAUQ4I\UX<4'IP+%=!Q6JYR<FSH9(%:G2F`9.33W*.DJ\:T!8]@GDX!,SL^1O
MON1,N9XE5WRN3)BXJ/H!_T;B>H4:?R(CE79ZA4&#3`BM_197.YUV6!.("GM@
MN#7!2S=9D?.JC$0,@V=&]M`X#:=P09!7B./G9A?\76J/Q[HO\FZ=Y`T3+4*Y
M064693>RI"33GO?E4IF!B!H3L]J^A4VZLO*TZ,#)K:Z`E:*[A;P)NMMETW/$
M6@S2P4@RE>H/,C/]:C=T)`"E!`32:T)EZNZ1M6\J'=+/J+US_2"D?2#5E0^Z
MB31+@G[SMLO>/22W\V-))ZS>:MD>E6@3OZ2-!]%AAB>BP2BQ,5FHL;UJ2=]3
M+),,!)AI>7?5M5::=-(0?+<5_9WUT2`[7GT00/M8O-Q8#E[PDNPW7GJE)*&B
MX#,[4219_&(`FH*X&`LZEV"_BW5[EW=>X6U\[T=)NO9K"ABAM^COI`N]!U$4
M%$(R@)X,`"L&@,L^D!9`6<4SM&K4:%0%)#Q<!V6MNS)CYIE<9B(HJXICPW8B
MKM]$469`ZS"ZY15TJ7L74\-SE!"N0E8=A?0=\OM/L8..U'N%];RGF#-4&\O0
M`'@W_X9.NSDV6,C/6&>%",O2$&%@,MR\W`PO`+J.LI[]Q...V*4N`YJDS0)E
M2Y%-@EK':`%L.D'O_O\6)3&B>+',>?$+]%RP-<B#E!*Y$(J0JEY16SD>V<#%
M]/\MJ^-RE:E80-FR&E:):1B%*D@+$-Y#]`_?!M&,]2TC;V49A\%MK^724*XM
M87:<5&<O`M,[`JXN#A?)\K^7"85[(-9GS*G%U&G"2-[E#HOK(XJ5#B>L]RT7
M-Q-%?PKK+[?#\*Y><&C\+G"K`$H\K?A].K#J@1G*$I/P\'+RXV*G(YV:."XA
M%/)"PNPP.]C!YT^J1HWEI&?P%X[#'`^DC8$L$:8QLW[@H'B`6;),QV1T)"%"
M,I24.A`GEDC1,+(C'M^=#J]V>*9\VY9Q<H7%LGGM6/I>1$(4#*5@',S+S*4U
MZNL8H>R.U=91>\%XB(Y`!=Y0_FYEN#.Y"]CIQMUW:/T@NU'0V@B<A!7!%BH"
M:/EK-1H>^LM,_5C8F'JOPDC8)2$.[\1)H998:B#\*,B-4.%@I(&5\4>D?5%,
M#W8F94.D5)@PR[AY()/H.^?`33P?F[12'T.*Q,-!Z`%12JO"$*30*J8=K&]3
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M@\B;(0OJ=UYBK[BN_,U'7<GCO%3[M0$`^R"'6?#]Y/IO@-,@!(4ZY<V#FP/>
MZC:THI8K18LBGL.KE9ZS04[-*E@V'+I5*"J-_2:T\DI$W)F4^-#(P<+O$6LB
MU+9$UEC@)HQ2V6^)*R.EF44EEQ$^LR03Q(U63XV[2:M.6;0Q9K1FYQN#1T@:
M:.#,F(864"@N:]"'KA<<@07X%'&ZZ`M=+)BW&WY&<!$M)XSE9/-?2Y"*)M&X
M;*=*F<*R\$J]5,(Y*(<L@4T&-RY.GH\97!(6#8!-4JB_$"=A19]7<L_>OW/R
MH?!<!5ZGE^TPRDI++3.[UG;%S:'5J!(680!PX_ZSD_1<N:H]V5I=F')NX&(D
M*;G@2O26(T2!V6"S(!X'5\2F,W03QU*]TZNUQRO>!*DS[ASKG,^B/RED`Q"!
MM\KEJE`3#F%%<NY5(5P,4/>>K.:QU'K,"E>"4D3N,+=&\DT$GL`\RW'SG-R(
M1;UN>&7F(*OC>%VL*;:,'_G5$#2%UW*'(?XW3!/$YO'1&L/VRWX_A0B92A)M
MFL3P-PM8.K'DQJRA]\&=5'1_U+WLB:YAW<LORH?DO)3]\#%5\SN*G(GWJ7"7
MD4.OS\5?WK2^OP22,0_3K",GZBFO<6P^W)O"=DT-J"@E$)1MNFO3I-$GQ5@(
ME8`'WEGOL)1R\S]+,61>,6J+P*/<6:>"@F44$Y"/GUBSL/Y31[4Y-L]2KA-4
MFHF+I;=DK<-&46)WW#7`+SQ.1TQIBNV.,Q$O*`4LP;N%.:A8%N.=&6.=\#Y9
M7F<\CD3DZ3'JB6QX944,*C&@DH`?<OA,HB?D/V61":6!5Q@$KL+K**;6&-2H
M[*RQ0P/KN^9TI!0KD=PDQBGT,`Z$ZCSGRC!(14[UN`C?0AJ]0!J(28N\042M
M0KU((2K0]#;A^9=%)T+6)9)U:T3G/HHO+/PK*'*_2VA,2`6+6:\%FIL?!6_S
M<9O,X#0I+PH9P"19,%:#$!:XQY0HEGJ71M?4L;$Z0[V/.49P,AT0H4!194+#
M7"28<$[J-S6%9?:_22("98D?1EDY.2$RI8PQ5AVEIS3)>PD>[TVAE!TE[R-Z
MMJKIG097I4P&N>YW*8".@"Y^-G]3AM^!J)#4$?"L@B_Q,L.;B'&RF4P=FSR=
M@F#B4GAK")`PXHF4Q20]4>8G,Z)<)C1Q4H3!UPRAPLJZ:"WGRN7R*B<7K6'8
M*C:GKN].4<]^6K.EMSA,1XKV9,T3A2\I8RE;(=TK;LRYZXA<RXZ<J!36%HBD
MNL@:DI.SST69#93I<*I;"OA(*V[:**-)EG.AH%#`C%+9`]M!888OLB!K_K!E
M/&.!?R%5#QVC"3<DRL9[JV:B*3J9JCBE"YB`)V\)#P_`Q:/%"\ZW0K>G`!!8
M&&EDHF4H$5X6MU,EO0BXZ@M;4'?>9&7<1+!$-'O1JX%3*@)3E%5HXXGLR&1G
M%%ZEV],=XSZZ4RF1H;RFR`J8T-.U-[\JW8)$"+VD^G@7V-5=%K50'Z0YS-Z/
M"UFA.E6:8_"VP#GS*^34V!RC-\EH@R&K(9EO&;^LU$JHBGNS\!IY*-ZR*"R"
MVLG[-:>,<@RMB$'FNHD6@-?BV](W!@(@FB>X4Y11BHQ7/>`1#&@@'>>4!/F:
M"A_E6(&"S`=D0N5MF&@$"B>M/$+-<.1'>`?M-+\.KD/U*AC_B=88-N5=C4Z]
MV>JBG_U4O[AKA3*)*M1H`HKGTKBMHW84/II;)P((AQ8R<"("&\L>V(][&P*@
M4S^92NL\3#TD&TR?M:DMC'5OV85CNFZ3MH7#O3GG;J"6BZQKR.L8*^7V-J;J
M4"?DNV+9*)^7BO8E/^T,%C4IV=UK?+I*K<I?JYW[Z)JQMKO+N"`CLI8`V"4N
M#<4Z4!(V2#GD_XBDO9>T3EJ*'%!1L5*2^(SU'N10I,(Z63JRY.HU>)?'+*P<
M*%J^^CYV?8ZI.!Y=:^KZB]%7^%]!VJAKMV@_W*%FPV=%>IET.G6Z2OM>V1\0
M5FQ/3&$YU/2-+B#A1?$3MP!?W17R(=/?BF)76/RJ0\HSJN*4#1Z&."WO@SV6
M"1X#>:&[5`MER$I\%*\L=T,B"*.LRCM;23LHX*TGFYM).]S9O"-"]WU_A&[Q
M?3LZ]_U)^ST=`>W?2PNL>T/HI:A_$8D]KI(==BTE<R;O.<[+Q!26<!8*PA-"
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MK2B:<Q^&:'WJ+GNX)=(]ZY'=98U3=]D#F?K4L'1-'\\/RZI=)YF23I,JO_`5
M9,A$LP?LZ'A@(!ICJ;6M=UF?K-JWP^^8<I])0=\7F"5R@E#Q;;\,XJ_]\BZ:
M[@10/T+?JH_+G*RCI"3G:Y()5B7G`^]I971LW>_8VH-;4^YH\5N_^_,#]WM^
M?%M]NI9;SJ&WW#J.WH_F>F+"ZRE?8\.I\/CZ]!IV1SN^2_1@>N%MU$G]D+;Z
MV`-NN>\'?\6?5X+8[-*'7&)]VFM_S]D\8(15K"DM&"@([6NI3W:13B`[@>S'
MDD?&Z(&8S9CK*OR^P(#G$Y4Z7;D3R(X/9"]#I-K**/,>BV.L6&3LXU.O.K9E
M_5@6&?W8MOKR+3(_D-QSK'88U^@8YM$9)QYNA_&/;:M/1R7,EVNW/1EU?FA!
M=O\@VXP@G2#U`I'KY<HT)UO.R[AR)^+TPR+7RQ"@MC+A--?O/#K%S.@XNM-Q
M?R#=3#./;:LGW>Q%R3U_#[.<E2RGP@1'2SI<W^]HCG=LM^D'(1PGN>-HY([U
MY&(H)6UB2U=>6D'0CJ,D'7K'U;R.H[G'=*-.Q.-$/)Y;LEBOHO`4$];GZ\6H
M*"<YXY"W^@.2BE\HQ;7I<I]J#N'7[!_Z:B47__%9]K6L_<91NF53^=Y=^<@%
MZ_?:Q9H>?(X_T*&>O8TOJ`Z%R%?C^6GTXR#(0VR/^7?J7O/@%/]).(X`V!DE
M"]?R_0=>US8MK:=Z?=]7K=ZHJ_8\VU$'AF&,O)YCV5T8#$=9QA&;.\H2R]#=
MKU\N!U\78?J5I5N^^EUW'<_W)'@_+7S8X4S"Z-<A56P=1;,P[;-.EG<[JX_@
MZ4-GJ'=]U>@BO+I=1^T.-4/U1IKE>"8\Y3I?]:_6J]\O`>38L>]344F65P7X
MZR\MBZRBUU"4H"AJ2'R"YS!1,8J7,-S'!2\NGNT",]Y^&*WL5>]Y[FC0MU3?
M<DW5,GL]M=OUNJIIFP/0548C;3B@6A`E;BR6:?CJ=^U<TTH\V'PC-0#,%[/D
M+@PO6;GS9G3ZD,2W9-0@S,D^)WDPDW_O)UG^(<G_&<+Z1"D8AE"C)/U45IC7
M=X8A74_3'?B7.G"'/=4:.GVUV^_YJMD?F5W#TH?6``M`Z:]^OS#^Z;R7X/2D
M^ZW"^D.88P.]"U:2?]*[^P+SOHT_BA(SG!Y&8;8O!%P%I#7PM+[E#%77MSW5
MTNV!ZOFZKW8'`\/LZE[7[5D(2+N9-KWZ774<%PB848+X<=NL@NP3*]IQ$:3`
M)J2"KP-6R!HNPAZ*BSE#WS8`F337[*O6`.B0;PP=U>^[MMZS1L8(7FNISK)%
M<8R5&D6MI3$V+DZA:]I?-BQ'(:LQXG6IM,4LG):VY2O\@_<FN[K7(DPCM@[#
M#U2E$X67Y4-=-\&#);2=%5"3MI"%&-]+567>`1&)LU#IB@[RK$,'JR>;@3"D
M?(F!*J=9E'-I:FC]AC6OWO./H_YO\1A[9+PN1>#^;Y^_O"\_#GY[4P/-$]>.
M^X@U=F=WI3AHH:JIF=6B4E06@&J`8;DSK)=5@.D,"TTCH,BY5@/5E_>BT39V
M"<R65ZR^')8*3<,X_!92P56LH)K4UV$XM!"W@_7A`<A45I45^UG,@K$H=U;,
M"&,`70?<B;(;JGSUKR3"MH%BJ>%T"F*$,N,-3=-D>JYTTSA4+O\,0:3J*/T;
MUNHPF2J]*)DEUZQF\$TXQ[JT5)J(]@,0P!I$<^R$TF7MH2-1F[<[1)CFB"$T
M`FLWB,W$>=$TT%VHF&6'6F_<W,VH,BXOX!]<Q\!]J!RY5,>7-W+,RJVD(0AP
MU$V2-^.X#K"IQS*>8!7<G$KQ17`@(.]1C;E9M$AHE4HV#@`,LPE5_T<(#%*I
M@#*#!!U5H,RI]`"#!Z_&V?VC1%PJR(0'<PLL`Z!SE5!_C1M>%9#:N6.9/(8X
MM"#L(4_%R<61G<OM-44[FPE0P#07&Z+^[0!!@/S93_7#S+"2&-9[PK:36,*7
M50(NAG^R^R27G>MF[(+P8ITK2\92BE@.K6'!'=XBH"CEAB<%HWU+TMD$"#E6
M`1S/EAF659MQXL2&P<X)_!M$GI5;2&608474WV<1Y$4Y5/9W!=TZ=%BB60UU
M7ZA/BD0@%G6XJ5<&&X=?]K.?Q+C4;X7%!2$B&IKA*J^!#&"%/1I%6219%E&)
MR3"=*\'D7\M,E`YD]07?G)?H![PG2P18[EL8C"`MK5HJW.M8!FCDMB[($W\H
MJA9V9"LG>.#:_2K"7E$-1]8@)&,E+J<1W+)KNMQ8SIY5*B,:.0^H)#55W\/&
M.^(,,JR"S>*G^"8F93EN-@\=\=E/!X+<U;Y,4M-MM@\9N?B&X,-5<AO6L3O*
MI'XG"7:Y+6[^!*LU)@M"X3EH>%F>Q*RJ.N"RJ,<NQB&<@,&HP4`YUBSYIB)/
MFH7J)+J.@!,D=\$LYP6[902G]DY8?GR^G$M/(4O*@ADKD4F$"TYULASS]C%%
MUP0L<$Z;QKDERG^NO*T4LV,)`,4]Q5&P=N?RJ@`3G3L6`A5`I"^B="+(:94I
M\]*05V%]ZX&HL`ALHNS'@A2)%;MDW;LX-*O=EJH$?L&,"G+O!EY(%FM'$B/-
MU[R-S:52?`OI';7YQ8*RO)V78-!1C(UGL(XQC'/1,"$K*TD5)&-V(WG-=-::
M:\9>F/*5S((L%[=9E$AERVSC.V.@&.4<?!3I2/`9G`LH67%#Q0$M%X@D0#!X
M<^7)+>\B%B=4\+Z`,9#@.9Q,99Z":A'GRVBSQ3Y*&I[$,];<GIJ7PUA\#%[B
MO[(S99*$5(R:I!!YKK20!E9(3Y7</`]A^5RK8`KW:\E*C6*552KA2!5Y1>=K
M7O&1`Q@&>$W,8%)T:\9&`:Q2:9B]V;+XH[PGJG=9J\EXCPUUG;*X6G5N#[JB
M;SRRD*&W?2%#\_FJ"9ZFWLO4#ZJA6,/F%@?K@SV,C_)V%?7NG*9Z=UL2A@TN
M<IUJ-$SZ^08(=[F-.?#(FZS\3"U,-J9=^EZ6N.*)?JP3^MF/^3+ZO@'(I1*&
MS2!XY*Z/_GHUEY[\#XW^]_"ZDT6<P_-BU?YV9[WHW9W.;A<W_WY1>L]QCVV<
M8I-0IL^\&31J)Z4)@+56R'E7`*:./):5/%5@CVYV/-/9Z-T#">UYS&;=CF[]
M,#DE;L?SCRIHZQ&;-:V.X>X9C3<@;EK5\=8"GB<`8YTD<H9!TG#)+;YS;M%`
MUK<E77N=\&G%[!/\3O`[P>\IX;<;L?'IA,3UJ3&D8N/?%(%5&G8+PZ]P7=+6
MF\,C#I3-GJ3%E[K9D[1XDA;7$G\3B/\D65[-PJ=B-P^?\3#Y]0F")PB>(+@O
MJ?')@FO7^?:#\3C%P+&?3<T`%F.2;?!GT]4ZON]CH&,R776YP#AH7:9GT1#;
MD5H$8PM4*2"`(B)XV^')4HJT._NI$KE:Q%^4X1.OLS!4/B1YJ/@$G@BW`&N?
M1WG10OR,=;N*XNLPQD;9!%=Z\,WSQ4Y@@-!J-`B+K\*8"#EN"&,!@S]#$=TC
MVMP6H,'FY$L*@;NZH\@57M@+@T=&X56ZQ$:=<`8FD]%C;&\^7:;4/UT.W,$P
M6Q&Y]X20:>K5#0<FPI]$I[*BB75#(*P4%\Q/O(R`;5='GB!:^RW&(6KZVN!L
M::^UR'7:*8S2MM>.LEBFV3*(*3:3!4:NAPX,QL-V,PQ^PI"G-+P.J#$Q:WF?
M401:##LCZW\49QT6A)3FT7@Y"S"PL2&*NGB:!3_#`U?)A"+@1,0A+'619+RM
M<.5:2]&#(M*K`2)$B6(@#K,(;C=KU(PAJ%?+G$+"KL(R@JH((2M",A?45QK&
M4BH.9(I\.RO"OPCJO"'W-$WFO#OVA#7=IC=IQ2(@?<W9L"D3^(Q5?*J!=BVS
MG?U4G0]?/%>^%'''36"I8-;93Z4ZSH*%(R*P[:'CXW+(:4B1DS#&S[K>T6V7
MD7E0CEU=+TXQB[YS""KD>6])?.>W<)7PGRLCT:%;.HVU8\$X@HE4SG1UJZW[
MA"%6=ZK\;'=LTV+;=#J>[=66NLK+5U)LM\B):NN`O5$67'<&0]!?'Z?U/#?,
M@,MVGWKE=3VW;VE=U33[(]6R>EW5LX>^.NKK5M^P>X[KFZ?&V+4L;68<H\;7
MZA7ULQ]+IRBL9A7I!^-4*:.8O8#83IF.4L(!9V87LR!F4>X4JGZ+M'0**),"
ME9T`PQ_G24K!TB%'*4:,.>93+'-:X$YQH]D]Q`?+NXUCK+F1'4HYP9VE6-U8
MR#%%V.>I=_<C(DY_C-[=KO/(D%=G^Y!777N^Z,_]S_T"6FAO%]Y#FM2&X9@'
M&O'8MJ_-(AZ?):+QL#!F?^VT5V-(BP\''36WE[TKN]KRRR@BN#Z<KI*3/BAU
MVP<9(Y_!C^1Z'=L^NM9+#W6'&G[']O?<4^OE5;_[(XS#%#0=,O9,,!<31,$`
M=9(GQ_(M>>\J!GA^Q_*.KN3=8[=MVG;'W7</ZY?B+JXPU2>*3]K%G$\KU_ZH
M4'P90LU6X5_,PI4L9*L6@>*H`K\,Q^MHYM'UCWO@;BW/[ICNPRG^CT#=GRZ2
M8">3'BQ]?V%PO"<H8UWIU1V[=^HE^:@TB%3F\+VHOO(^S&^22?%QAQ7Y[$&W
MK_55W^PYJM4=]E3/&3AJ3QMJGJ;[FB;<0L)K`3N>!V.JHA7,LH[R-AZ?*\'U
M-3J><^!(4L$8\H@SA\28U0C%FE3*Z^A-Z3$N'^_`#_!+2_$95$W@=WA@G,SG
M6*P;^);TP+GLQ=L4C`T%<:_N+_AZ52_X.BRJHK`SWMGIZ%BNM>\YZJ"KC51K
M!/_J>?V^"E_W1B.C:SN6P6MQZMH_:Z5K=[&3'54,+HK<=K-L.6?E<45SAD&$
M\0OQY).H4O/(0ISF:D73GNY;`\=53=_IJ9;O6*IG&D/5Z5E=S[:<?D_K?P4X
M-M:!U790$'C3[;?YE+LL8NM=%%Q%,RKO6:WKO#-\,^!Q6Q_IJN]B=6#-`WP#
M$J"Z76\P]$9]0^]:1^PD=O;B(ZZ%UZ%/-IVLE,X147=%ID7`PS/:(RZ403BF
M*H#2SZS=?2T*X^2@/3EH]^R@=1_@H+6>SS^[]ZE/SK:MG&VS2D&7%^]Q:R3<
MJT!XQG(6AV:N6N^?Z-:8YY-;I)[MN8->\S$ZPM;;106B-87Y'8L9U#3-#LCO
M/X@9U#2-CN<;^]WMRZ"QFZ%^L)Q$.:ML'GQ_1HK[6#^PY75L;<^1`(>W;4LS
M.Y9]"H#8$OD_4O9474<_/J2WS8[F[9D8'MZVW8YM[+DLP`MTCKTHI_T)BJ?0
MA\U(/8MXJ)/ZCD+99\\0UOE8XN>8=L=VCB[`\]$TWS([GG,*>/NAZ=4)BH=$
M]9^2QF]G+T2?C/IL!/ZYGCOH-?\(H@:FCJ2W(>7FHM^>5>8HJNH=DY3!:\7\
M:%*&:;@=WW2?7<HX./J[F2U1ZA>4Y0D++#HZU`?QVMTS!AS>IAWLSG<<:'_(
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M`C?8[*E5X`O=[*E5X.8FT9?7F/8$OQ/\3O`[7OB=&DN?I,4#W.Q)6GRAFSU)
MB]L3_Y?4DO8$P1,$3Q`\=@@^HH;Q9B$*.ZJ-^Y&5._U[F,&4'Y98%>WCE![-
M=E'M]>V'T4I,Q,#KVJ:E]52OCU5,>Z.NVO-L1QT8AC'R>HYE=V&XKX94[Y4Z
M-F:O?C==V]3]'1327;/M/=;4_11E?X[2,'Q++8FS?%<U=:V'UM0UFVKJZJZ^
MIZ*Z3?NO@OM+AD6\LQPVEC\&`^LH9_NN[0^&ZJB'A9HM;Z1V_6%/-73+-'Q+
M[_;@_:<.PVGJQ/V%-80.!036:&%/T$^;6J>GX2)@J6&B\RAV0$>MD34[19V;
M8H*F41S$5/<[R^$+T3P]BC'>.DDG\"/OPOSE_/)<^:/;O>`MV+$L>1`'#*&*
M!NP%$+#)ZK^6D^NBQ[P2E#@%*PIR)6!]G7%UL-XDQ?6()O=4QA?>"/G+LS)F
MK-/V!GQ'1<I%2WM)3V:A40U[9=VUBU;$XEF<?#QF,588)A4GL*5SI3O.E_`Z
M/+><\7>390[/$=HO9S@4;`H;@",04IAK=L?:9)>PXAR(-[HN`58%%]N^`-@F
MC9:KU[!Z1?\1HJH23KJW80K+J!#/C\L<X!%C8!00A&C<C2>#:+;,PT?47"_)
MW.J][OJ]@:=U-<!LVU4MHV>H/7MHJ%;?\OM.5W=-V_YJ?M7M!EYB^*:CVXY3
M[OIA.V/0F831KX-DO$2@L]KL0WCB4?2]ME=SY`)IAKVZ_DB#O79]M3LT'75D
M]KS!P->Z9@_&`+;Y.PZB:HYJ:G_]I75=U4,5>_VX"/&NQ]>7(<>?/0D!0\T<
MV7X?Z/"@/U`M>P!_&5U3M31K`"QJ:'@]1I'+@^-+>O6[Q)Y:UWU?YX91DG9G
M<*UB:J/&?[](D^LTF&<70-/&=SL[N5'?''C]T1!XCHVAGXZF]OH]3QU87L\?
M&L""G(?U]MXU]RG[5W!.SNC2I^0NF"&Y?%YNU&7T/0(VLA#L*`RP\^,UR!2,
M=2`O@`=FRXG<Z@)>7O`-=92UC3)"#&(ET>/;34A%YW`&I,$%:.#=;'F%Q(`\
MZL2.<@6&_!,Y%R@@-S!9BN!2$L8L0/J,D!.6[!,Q%=<+V`><0OQ0S'$.G!>F
MX8O!K8H](2F/B9EE&>T87A4K?1V\*342/E$634+.O*.,M>:(@3G!#F$DXL5A
MQ%[6:R_#X%%^5V4P<,FF&'Z.C!Q[J8]O(K@XG,D5J^\H"8QGK(QW@^^)1>-7
M+&"8?8`!)N$,`(HVZ`@XZNOL#=;@#SB'Q,<"!6OJ1]-H+%@E_Q'9*G)&&&3[
MI4L+A_=?7ZT%(HM_SM#3$`([AI$609971F<,]_7XOL-(PR!+8HI7IE$1F7B#
M^CI(\"$>RL'06`'*-<_H`+E`$I02^3E'<7C_/B2?!M3%'A`:KU%&(V7C"`$(
M4$9XI.'U$A:7I'<=N;,+B2N$.(CX7`B;+P$45W"BL&0ZG3PAX:<$==D50487
M_&6&;67H1D\!DCF'8A3?PD.T8RXI3NJGUS0D+8]?"XX3<[DUSZ8'<?\)K$(?
MOP+Q%5$2#B?CHB>[K:NBUU/$^#^J,Q"\+_4&>AU)6-W:(ZA\1&H6)%,(J5U0
M^:R$75+;H**_;^U]H)KYW0)W`M>0X\-$62[HCN)G@/\X3/,`C@.P>PPG@%M)
M(Q*E$=<G(0CQ2&SB.A>1DASX!JA#2(P\*";HP3L45(6ZS35,D3'6Q,D3Y3^D
MUR'<Q$$K`"H;H"6'A+,P(I6W!DUDPK]'*LA7BYSL)F!*XAB6@>^7S9J`[BX(
MV]B%IB>)&A-<<*&PD<JE5H(%;`3H`4"ZWW0`+9!&[D%KC?D(L/A%!<$00)/E
M."_V0``"96F98<$=/(QROBR`RP?K%"<FSH:H`NEC<9C34YER=<>)(X]Q@QT*
M\L7!)V:>1BD<#%]RIES/DBL^%PR9$BN-E^4W$H,I=,'GN;$@G)8***E\J=SE
MNK$%ER3A1-,ZT6/'.$'\GJQ(+U7R*(9!\,`[<1*GX11P$2F@@#17D_'WM.B?
M1FPW1:Z(V`:O\VLW7<ZX`CR+LAN9_\O7_'VY5*;0IWC$H"L7]+J^<I@<AX65
MH.T!(`8(P%&BL@FZ1L4B$T00[)Z,JIX*-XB+9\2T:%4+UB.,K`827P>9#,@!
MT(5[),@;(BW('?A]189>.PAI'TC@Y(-NHH*2^-J\[50(Z$P:Y<="78ZHXQ%-
M`*,0&>#WH?$@.LQ00.0.Y1#&X8OWTU)_DD@I3#='6L?4A+OJ6B701S$-P7=+
M)EDA(><1S8EVE_H@@/:Q>+EN1R+6*\AV]AO<_PC0LZ1642:?*%('?C$`34$(
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M1]RQ*!O7,O(A5B`X@,Z$:\6("(7^FV1&F=7<>X!6(`%[SA'?!W?8J<I40$+C
M\DL<@.;]/DBC/P,VU,>XH5.A[K).A>4ZNG\HKP/ECQ#%G6)&QE&_!2BSXQ2D
M+AF:IJ,8#KQJ>@X##-+S<N`NL&OE\L\0-.(./0$B($HI3$/Z'(YOF-+R)4:]
M.HN`UY.H]7X)W]]T^`+N.B3*]&<!T.'+\4TP`R;^1KD*Q[B[`-:5((-/OC$9
M"P6J:!(%*0ZV%K`=9;%,LV7`_$Q,D>B._[V,,B;6O)Z$&;#W*]CI%0C9W]Z<
MDQ<,-*8HRTD(3:93D#++>5K-+$*V+LY,N0F#R;^700H#95PP+93;*9"&&8.&
M="(H8%"S8@;Y41K"0N-K]1]A!-(,K`B4KACM-!QLY\6[2Q1R9R"C7,"8[_()
M[+P*MBK09#SH\`-/YTQ"&X57*:SZ3L(>BV$/PA"]@4S/*_925U)@Y<5ZMM2H
M#N/^LW($NR8`:R_F>C6C(YT6!SBKV`!GAM%\P,R1>"">5?")LNH(E]#"Q63J
M$OD+69J,!CB@?#6ZXE=`LO(.<8FZ\<$.8L^Z+;+[U[Y<E$?@,I(#L32,1JF"
MQL`<"2(+).!^YO)%V-UZ\HIMPX"LQ->L_"]S"C(;_=H743^#3=&2.YP\,B.T
M(,GE(H!:)4R?6'/Q[J,BKQ&ZI2V[_YL$Z?+KP6]`J+XL$N%Q1LF.:U2UT[E'
M?1V'I)?1N5XAI96GSFY`:!&\09Z<LY]@`3K^F%E2E]RF@M-?#OOGW*PQ3U)T
MX11R@]```WF%BQFN`N"*V8QPE!\2\E>8U8"K"*^1#`TD+%$U,*MTN33$*1#J
ME=Y[6FY[3U_A@YF4?OU^'1+H:>@RH](G"BH@\@E[!8*C_@]A&HL>0*%>N0-Z
MB;$%Q%?;)SY1S%U03$'ZB%(@\5.R$+1^"@-!F6!,9M55"GA9/G7!GT*1H7R.
M+!'"<(F5!<-)Q(C!+555SN@*X\E)-^FM^+%RA=%R>1N1R"=0)<J0T#*W$C.3
MTM4D.UPQ"-DNX]*6CY^=CNOZ'=#:.&W#[Y)ER@F8H+H4G0/31K?XVF(6%!XZ
MN'I,]"3N3A6!TF1Y?4.`(V<`"0V<T'`;"KW22O-UCW9AF.*\T,Z'QBT!?5C'
MF,PU;,VXY)^-<TVCU\C65>SP.DVR#.$U#L,))]QDB?Y.,2M`:W_6S7/;0=O6
MC`2[.AV]8)M&PBNV7:.G'^`"W\QP[A())-GN?X(\F-UE:-B7?W_WKJ]077DR
MOHT3E2HD96BS+.$;7!/-:<",8C&`8_A,%4$$6O#%ETL_Y^[QRI%,FY]5OC&\
M8BX.>J0V:2E2`*\%B1@TP1#W]HT<77SAS<N&5__!GZHLO<,<=^3$4Y8+_&1;
M1L=T[D%0Q!%DUF@4+5"D0(P"5\Z5(3IQ"L]IN2.Q&E2I^##$H6C@.S0]AD([
M2192F!L,PF028&YY-..$^S94D6RCZX#T%\[$(QA_PF^>N+(GNKV9JHN8%K%(
MHY))%S(2N1U7K\D*Z\7;04JS<(O!:N"6*5=14G5,,<\3:;?`=Z.Q</7A^6+T
M'CH"[E94F`(G"@\@'FBV;$S9TQ$R?Q]^^ORVWWVG=M^]_>/#KXK(]1,T<<@L
M)3!$5609SX*,+@.L'&W0P8(6+KQF"Q";B'80WX$%HZA$CFAN_98JNH$&RUQ?
M.`Y%KMQ$UZB@+>-YF"MSVOY,@;L].2'K=SGJM8I>/>LW1$\`X=Y//T<#23)+
MKAD*`L?(459&C9RB$0@CF0Q:L93(QXXN*`Q!BH$^W40+.3HA$V$_\^!?*(UC
M\(P:DR2.+MNJ!Y==$[R`DN%"J#DX(<;Q=I3A,H4ET2K^.UB@'!+S-%*TFC0,
M7-S`IJ&!)DSJ5H*S-24A=VT#WU'X/_T+TPN`$[.X2WUGUG4=/2%]SU$'78QF
M'\&_>EZ_K\+7O='(Z-J.93#K^H7YSQV$\C?LI08E(-:@D</SPUL$Z^X="E;/
M&S@#HZ=J3M=6K9YAJ[T!1O%K1M?RM4&O[S@GA\*3.Q1VY%$H\4=A"'3R)FQ?
MSU@`\V)Y-8O&RD>NP3TT9O<%@^ICK/SW<B:9LQU22.T*$T6^@"H<:*<$ST(C
M)ET;%219V_8[FJ]U?,V7E)F\38XH+8B@>.!(=0V8J3>N+:LWW=E,&EL>!%EZ
M2-KRE'@H"Y`24Y^O;M>PI/V2Y>X;!32@<"`4+:'\H32L!K-9PJ(PN8:$<:]B
MR7K'T/6.9[BX$R`_7)98!P=N*:M!@L5J$+1)G^?PKH)$V%S)%,+/*%G9H(=&
M<=SB2:PML/Z/BL5$20,ZY2JRB'A6`?P.-WJR:-90P@]QL(WXT6$(^;/AG9N%
M`0:EPCA$?"_6@#8>S*P:<Q4,#<Y5&XYAGWMB!/+$E597,O[',`J\N,Q8,#!&
M"1:C4SR5O!M\$D/9*`RI.9Y.WO`B#8L02WQ,?%CS>F$*2)?7RAC3A28L'^M;
MDE)(\#A81#D-@6]>AR"BDZ`M/(1PJQ:`TPU)6L>`M]Y>&=O[>HSBB;7=S]J\
M!M86Q'&RC,=$XS%?)@=A;X9AQ.,0K901:8GY391.5N-""PMD%J)I&&\;QJLA
MX2#$EPTHI<)*;Y+@?,7;##(%<1!$0,PCY3*(_[Q+F":;82!<7LVY$9/CT.@'
M+*,=2(,M5E&9XISK\BQ<%:^F&`;=VQA:RI,U`1"392AL0+"M:33!8%:ZIWD:
M!GEI`D(34^D'I019:=`\C:ZO)29\]E,]W!)N=X3A?@VN+`#A;72;-+FQ8']H
M'46^3]E/:&L,.(AI[V&620FZ991ZE1!)-GSL</?'NPO<()#;,3I3LWPY(0Z`
MO]TL,0P$>"]E@)Y7&@4PDITQ3X3`&@+-ZHEQAL*PB>OYN,SC9<[[)7+])%F(
MW)3"R70B=&V$KJ-@$(J,FY4`!Z41G,WVY":X5ZS+1<AQ/72IC_8ZEK57^U'\
MQ!U[K-,JDQS0102";5:&4(@M((5E0FZ=,C.W2?XM:8C7%PYVGA-5FX01S)*#
MZIW*E""LPS0PE##LE9L(2*@J:>C/EM=Q?$]Y70"GV__-,L\=1Y.2>?#:?TO(
MUYJ!O#-C2U3^(1+6HA2&G@1WF=1DI$8IWTOA[[7E(IN0ELA6/U]B0CWFJ.#Q
M%5F1!%Z6<KF4PL;E\[Y(DW\!03M7_BNXI87@`*16\/=8U@R]6X+0:`'A.@`R
M/^7/NJEU3$VOPE#7'="B5H%8!>'&=M%6FUP9]SRD/,D^_`I,]2U@R/?_"7>7
M];QAN+;QZG<84;?A&\MCL<^-ZZI:'$O#[<>I;,WDM7/Z299G*\;,/=@EN[[G
M=0VGJ_:&`U.UK)ZM=KNFK_I]W?']ON=IO=[)+OG4=DEW1V9)-$RH+%%E+"'9
MR3JY-;M^6\:$E*%_2B\)T@E%747`XBB2A32`QGC`]CC;2;+(><LJ"M0:SA>S
MY`X3`\6X7%1&_Q#H"QBX.&0!A#!`R/+)+F9!4Y`(=US#C]5H!N0'Q*-Y2')(
M!6@8DT;&T1I_QZ2$<DLX;91Q8P8S@X3Q.%EB!1**%V0^O)K-K]0O&BUK(8>`
MJ$DC0U>$*HE82L8>.5PRV0!2CB('9>(3"EU;BNC(@4B/\S.1:"<2;F^419@L
M,&4P1PXV68[)0C/'CV@,*?3(JS`.IU'.)*DZDT<[(Y.<9--B5!P:'V3.'YRS
M.,%6@R//2)2/@!T`"DPI.LK-CJ'!W=$TC#_9RI*+2RDB/P"O)&LH0W9YOD(<
MI*"FN()R(`*E*(!4$([I>;<1:7G?T)O/#7<Q%4#!16ZXW"*PAN]Y4EFYI%G+
MZV7"S17IL\L\P=!-GF$7C]-09/+]=Q#7PL2+$AWP7Q[MR&I0('=`/.*1D+!'
M1Y@B0;[*V(XJV>8ZGDKE9.K)YM9?Q.8W!PI?4'&*25GF!W=$B,R2/ALRUNG7
MA!<9X!)RF?HIFU8%YZ#)HCP/"_NI(($P0D$$SY4N+7FE_Q%IS1UN9,UJ5GC+
MU3J&:6^-N!1H)VV[P``I;@=Q`.]Q3B%4XR5=/I8(D=9HS+EBT3J*"PV+XPLB
MH_`U!F.1Q27E5F5A2JI;!]#E@0(SB?%-0XA:7$`L03*OOFZMW,%FJ.F6T[&U
M(@:M!@P*E6FZ$#`(6U>5TDJ$]%PQ;$37+>#`\M5K8.@HIL'1GAWH0^')>2#<
M(\^G+;<NHP6>@)0!LWWS>BR$_S0`W$40X#N&8V^(=33.G")F;X-H1I(PTJ'I
MD@KB"'*4-8/_.`U'>_'J7#*RQ7%;G&8STLX##`D3%7\*+EIP!#'*:YD=O;W\
M6`_DA',":`%^S%BIA,K;PNK:(-L5M!$K-215TP9_6Z2$W+)H$YZZ#4MBPA9>
M3^XTP>H[6*"$^`K6"N)!4,)!11P3;1_G"B_VJ=P$6#<`P/`]FB_G5,&%T#6,
MV2!,+J@/0)B^#91Y%1QR[6(B0X[9*L#DN'UY&D0IK"'],\PK%9!JC$CD&(BH
M4IIT57*A'!-9_(SJDC:C/FDXQ?@U%@C([-]LI@;]1E0[+!,=&*1)-H^^*ZQW
M'\];:&12IYP%*9R0&BW<!^N.7'4F$+Y^]@*R,0S!:J&&I#*L<.5.R9(1!5KY
ME%RA0<CD3<=]]M.Z`[=9SB#N+"6_,L?IPKJW92O@?2&$<6H\?K`6(==Y9/MD
M9_OVR;KV?)V$]S_W@WJ=KF#6!FT@GJR4_#VM(DGVV+"U[X%VSVW;UV;=<Y^E
M.^YA84QS%]*2%SR\$>EJ/^(RXNR0.[#N9>_*KK;\L/Y:JSBWW\:L#?QVB]:L
MG^1X,:DFX(H$<*`]B5RO8]OZ1N\>?P,FW?`[MJ_M=[>[POK#P?$_>#`CE:";
M@)H?8<4/BG5Z:BS?DO>N8H#G=RS/.S9\?^RV3=ONN-Z>F\J]E-9C%:;Z1+TN
M=S'GT\JU/RH47X90LU4K46;AX@DBW*I%H&@.7#Q0YF\X7D<S_6,C_0_<K>79
M'=,]4?QMZ<;3=:K;R:0'2_-?&!R//_AK?Q45R.U5^+LXFV#.8W(=B.95$V69
ME>EFO5D`3.5R?)-@.;%Y,@EGS`=6A@TSH[DHVYCQ%[_Q7DYJP)HY55J&+3/N
M[!@'LS%6PA>N;[$^&*#N[%OG&VGSC)RQ),23[^/D^SA`WX?]?*Z/O4_]`NS8
MQ^OYV,EN3OZ.%VSS?]`;Q[C1EV$'6&_X'27I-(PH;@]SV)]<TW^LV=,Y?["M
M_R_[7NTA[^_EN3`&$4;E@VA_%X6SR=$ALO;"$7E?^_L1B/10E%FY35#?Q4X#
M1X??KGGNOF@$=ZWS!SO9?S!2+7IU*\*^@WU(U2G:9D13@..41O1SUWS12`X;
M/&PD/PHRCLD+1X?;^-PTP;9[#%(U2V=QS/:YU.I!+?^TS[WR`Z5LT#IP2#'\
M,SKM3D#<UA=X\I"(>]U5LN5\SHO)M^<O2VE(2H#Y/E1@A!*O*7GD[*=*;Y6(
MNIHP5TEV\D*<O!#W>"$\ZY%>"./DA3B0J4^&[37VW@_+:G.:9(I37J7*+WP%
M+,'Z262`YX*!4*#4VM:[3)^J?3OD2;'E<B\P-_8$H>+;/K:J`YZ\#&:U7]Y%
MTYT`ZD?0;SY*A2B"?$U3M*/3?8R.K5/=A6?64IXLD/+\^+;Z=*J9<^BJV7'8
M"-<'*'^LAG`='\F@`C+'=HD>3"_VG7ER>`?<<M\/_HH?<E:"N/1%(XLGO?;W
MG,T#1EC%FM*"@8+0OI;Z=(%M)Y"=0/9#R2-C+&TVFV&5G!0SI:+T1*5.5^X$
MLF,$V<L0J;8RRKS'2A8K%AG[^-2KCFU9/Y9%YNA*>+Q\B\P/)/<<JQW&-;"@
M\;%=G8?;88XN^_WIJ,3!A]0<JP1R,NJ\>-E_,X)T@M0+1*Z7*].<;#DOX\J=
MB-,/BUPO0X#:RH2S)N'YF!0SH^/H3L?]@70S[<&Y02?=[(AUL\.1>_X>9I1U
MQVB(<K2DP_7]CN8<78G7'X1PG.2.HY$[UI.+,E\QH9Y.2C#%GF*"=APEZ=`[
MKN9U'.W!N>@GXG$B'H="/`Y'1>$I)I2`]W)4E).<<<A;_0%)Q18YU]_WEP6\
M^+Y=RO7W)\T"/H(T]+TD1F-AW97"N>2U9VTHI1J^U+B:-27D;GUX7VHBNVW'
M2!N+`,,0/^OPA64[].K/NNMT/-_#YHC9@C6XG-U1`6#L8HG_BA-1J1=>+MR#
MCUK)&>MESIK>8CMPQS7I&].U.Z;N5]KOWC)]F+<B+N:",3:<K;:W8\3%_16-
M7L92=TJI(V9SN]*R@^99V?"R5C2!H6RK?-'!F@D_&QW#-CN6ZV$%9]9YEIK5
M7H5RM\P$+H@2K%X8;*N.?6-9[UI63=HXMWF/V54)9A+=XL>__K+,U.L@6/PZ
MB++Q+,F6:?AQ*G</_\3VUT^R/+M$8/00%A?!';:2RCX#-'LSV.OO,+#R5S'8
M,$ACN`K919B*=Z)Q-YX,HMDR)TC&>`Z?PNG?7H7)[.O%T-=-S_955;=U3?V_
MFJ:97R\_#[[JGOX50:0YIO95>Z5,PG$$!YQ1]FPT^=NK:/+5<VS+\MRO7;\W
M\+2N!J*A[:J6T3/4GCTT5*MO^7VGJ[NF;7\UO^KF*SCBB$T>98EEZ.[7+Y>#
MKP"ZK^R6O?I=U<X-NP3./?NI;AZ0MSL>8V-V>.4B36+X<QP2N"Z2632^8_\N
M0/=P:-0`X+JVU>_IKCKP!T/5&CI#M>OT^JJN.W;/Z1NN;O6_ZO#B[X@"'`..
MZ,9[>ZG+,>,-13Z%F(:ME$>G5,^.KLU58;X],G+I[`-V;V/E?7#'.CX3*QIU
M+WO41QWN>/?RB_(A.2_)'3ZF:GY'DDS[`/7;,%YB\?QIFLR+A'9@=%%^H_27
M0$CGV%BX?&?PF_(:Q^;#O>&T<I$F6$<3.?+U,IJ@AYSDA91-(&@HDC16S)]<
M4T"8RY%]ZA>?\B;<\3A:S+`K/.P,2'=`Y#^([XH6XHPD%Q-\NPEC)<+^V["#
M.)O"JG%1<Q(-KA-L*`[+X70Z0]O46.P..7D`_\P1\VBZ,VQ5/YV%"`G6ICO.
M8'<IXSWP+MLT[^!-RPK)ZD4#7^$6L,]Z/F-B0OA]?!/$UR%O*)``WUI9$8-*
M#*@DX`>#P.[++M\D?L4QMA5/PT625IJE7X7741R3JP^M;?#N:AX]LCJ`L]/!
M/O"S)3D&J7!>-"_&P7,GP88#H3K/N0*D>':G!(L%T-"BX%"<Y/C`/,J!&I\K
M'V-XM0MG.)/FYA)?@::W"9>AIL$M;"R9XFDM$NH#$2AP'XEWHH`)'+`HD51"
M@X13:@"?\+GY443L=&^3&9QF`(NX0^%N`L(`C8`0%KB'E9+XP`DH;U$,H*W.
M0*=R]I,HS82;'2_3%`X7H9!E828:5R@+V!"<.0P1P;-C-AO-BU`BB0!`FY63
M$R)3?WK6^!WD["DL`1"?.BO![$3X3N*A3/#^.X`+D-YQP6T3HF>KFMZI*GZ1
MI$@3&7P;`^Z$RJ4`>D5_-W]3AM^!J"0IW!B<&['N2[S,\"9&\$(F4T<ZK:BJ
MJ0N"B4MYPRYZ`--,Z'SQFL>*](02SJ(YS(3*%Q+E+^>7Y\H?W>Z%($7C$,Z"
M$"JLK(O6<JY<+J_R9!&-%<.P50.$W/KN%)5,;VU;>HO#H(KR[R5&-G'Z&S.*
M=@<$:Q%@E4VZ5^,97()H>M>!VQMF\$2'AIHP:3:L+1!)=9YQ78G(-!8T`]IZ
M#LR>7I_==6@J?!"IH_00WCV<9#EGK@6BLO!L90]L!T69-'ZY2S+&][",9W!S
M$8!4_!EXU7@6$F7+E@M\%G@"_#_?G:!T049KD[>$AP?@PC.%Y16<;X5N3P$@
ML#!2!QB(..%%9E<GO0BXZ@M;4'>;X=>XB6"%J,<7G6]P[8Q2$9B0CDNT\41V
M9+(S"J_2[>F.<1_=`7F+RA0Q_'K]&:\M3.CIVIM?E6Y!(A#=68%`^?$NL*N[
M+&JA/DASSG[B-,58H3I5FF,HH%412I+5`J8#S`")#G$$>.AU2/[_-&3\<EQ9
M1D7<FX77R$/QEB$?SI;8_Q@O&I(T'`1H1QZ#S'43+0"OQ;>S*+BB^M0H`,+]
MHY'914&K2@@H#`/^+YL0SFDYQM8#F?*:BNWEV(.6U/-)>`78?#6+KOD(2**J
MC\P2I!G2(W0;YW#GKT&15Z^"\9]H=V!3WM7HU)NM+CJ\7+NX:X4RB2K4:`**
MY]*XK:-V%#Z:6R<""(<6,G`B`AO+'NC!WH8`Z-0.3+[PG\/Q31SA2?83.`Z&
M573R;]F%8[IND[:%P[TYYT:REHNL:\CK&"M5F,[!5)T9",+3NV+9*)^7BO8E
M/^T,%C4IV=UK?+I*K<I?Y26^8=>,]H.V'4%&9"T!L$M<F@XR]GGP9ZB`E).D
MC`T5>R]IG;04)H*0Z3?GFA8C4R0^!V1Y!740GX>-LQN)4C7'>1`(BLTN4+]%
M4QVV@@.*EJ^^7^UD#3O+<IQKCO\5I.T<$0*K:>+Z.DH&`A:,PN4-Z73J=)7V
MO;(_(*P1W&,R8B[AT90N(.%%\1.!\TZYNBOD0Z:_D6Z:P0QC6%:'E&=4Q?''
M.`QQ6G;Z?"XA?A#("]V%H4Q0JBHEA8M7EKLA$8115N6=K:0=%/#6D\W-I!U2
MO79&Z$XNLL.E_7MQD5W`!01\N;@)8)QQN,R1@&>D5YT#!<H*\Q`Z"`#1T.HU
MKI(==BTE<R;="=3E9LN)T+'@U3LB&&%$HR"QXS04`R2(.B`>7V&W3-!?B)"*
M-P75X^88F4A>`:5%"0CM"L4@RSA83B+N#9B@+V4B"7;8_++!%D$J$-F%LN6,
M;M)T24V@A)VC>H_8/\T.CVW-]%4C_V5XC8]^$HK=?BW[9E\;#`<C7=6[/4^U
M-'>H^D//4`>Z.=![1F]H&:,'6?;7Q];4L'[5'+]B1.=@40JX/-1J_HB%.>6Z
MUEZ<9('VU)#AE()F-*S"S3<`=P*9#7F8N4"`-@5TOS%%?Q+>AK-D00\#&EY%
M28ZB53)+KDF\DF2/C#MW6TNLCV^B<,K7@QP1O5P9<D)DUJGRNO]Q\/X-?<C(
M'LE^!3&<W)))+(_,=O,->]>>DXR%AH)K-&LP8"!4[@$'JB,XES03ZEVQ9,<@
M,2'*-W$L;G13:I>K\#/*GLANFJ(\B8/U[E9<D5UTLHZ"*/T[A@ITR\:[(AKT
M[T4/HD\H<^W`!6FNNB![NF\-'%<U?:>G6KYCJ9YI#%6G9W4]VW+Z/:W_U?AJ
M2![(!5"O5[]KYZZE2S#;/P`8Q"=A].L@&2]Q@!')0!<D'HW@NVQWY&OD@DK8
MU537'VFJ971]M3LT'75D]KS!P->Z9@_&^&J]^OW_&G_]9>V:JHA2;/?C="2X
MQ=L8]7.)CN]L&];0=[6!YZI=2W?@=`U=]2VKKSINS[%\JV_VS.%!4&$$BT)P
M4=Z#^`X8AN!X7E+<O>PK9%Y2/$-3"F/4FJ72[W#=IBAKR&%`9,]A6@/J422`
M?$N6LPF/E0A!#2"Y(PMG,W*L95E(UESX?1%$/%A#N.F`7);F'^:)H_8#(,'+
MUM^K,/\6ADB3TS]#--"C)2D:1POJ)LYEH'FY!^Z^6<>"D"\@FV`-Q*7VXM)F
M@36D6/L("+AP=$8)&:.*MN-1O%CFO,$X:GAL#?(@H/LD/$YHAGR+$7ED'V(,
MY'77,"XW<17*D;0`9;G@K`96B6'U-!0R/UH`G4E`\E]P&T0S%E-+$5"E9LM9
M:;DT>$N"V9;FGL?<&Z-$S7>T#UW`$07@?R_).T@(QMRS3+EDAY^1DHF&>SI-
M/$;$,'*G"E1BA\K18L7^CT([*>H<[0@A05H'H;H5E9X1-H:R1,Z!*,<APP`A
M`4A`1K:4T)X0;J!2HVJ3(H`F83"#OW`<80]`O_(,](.8V3MP4(15EBS3,8D\
M%`R`UM\D)K3B2$P^6R(!>$_A/H;Q>-MHMIW"R91Q:!DG5^A<IQ7S[YG_/2PI
M4D%YF!>N<.NG9-6`'_(90"^:PDT""L"A7KB7ZL.1G5O@U$'A43_(;A1TZ,&M
M)T4.`RA2U#RO[M:+Z=R\Q(Q;-]'U#=#E600CH=$\!H65`V6ZC">,KB'P^:XI
M:;!";="-AI,O4PK6!!H8L=`'M`*Q(=*P<+R%Y*(O"02GEDWT&1C$.``:7&K1
M]`"Z!'&B"D7!(?C1"7/4VC!5W%5C6P+F8+&X$2I(TSLRRE,@"=V/GUVO8VDL
ME/1GQ>IXFM:Q,;0T8V:V;2?DP3YR^&@'SY6H8)6T"V/DN';TSX.`G]N4+V8P
M*8T-42D_\C"5D-PZ=$&+G\C?3+($#P1%,D8C%29?8@D=88/)2&*X0V)`WZ6(
M&N)=@G?U=9F/<*0NW=T5O#1D;MV$F0P[\!<803Z:+*SL]EN`*A\V^0.)2^!M
MH?DN8[+5P&$B]H((`'<LOTDFI18Z+KN1L$/'I[)"]14[2\GDC?!DU(Y\9D3A
MLV@.<D-*?091^^`B'7-QE+M@>R!BRI`N8R=4V0P(5FGR/9H';-7\9O`W'X7]
MFRB]&RDF-:470X;?TE8'%$C.M![2\S+Z\:/0YT3`^0YTV+<?1BMZSL#KVJ:E
M]52O[_NJU1MUU9YG.^K`,(R1![J.W87AONJ2%BOB9C5)A]UZ/U5XL*"1S\'W
M,+N`>_8AS'>QWP:M;N!I?<L9@G)J>ZJEVP/5\W704`<#P^SJ7M?M6:#5&7YS
MV/"KWW5#<\IMKRZ[=LQ`!#,>]?@'QN#M:&--!SFR7:MO#VRUW^N!WNUHANJ;
M>A^(IV%W!_VN9ND&*:PM.Y-/LV'9U8U]1/*%%#8-;X"H`6M@H'B79/CPQRG`
MY`*EX"3NYGD:72TI*>AS<A$06=C+X6I]8^0.3$_M>G"DEH<&&=OIJGZO;VA:
MSS+LOO?5_-H2$O[J=]76--MW2S@\<I=5D'T"#L+BZ#].!TC`GA7!]58$UUWX
M1T*&^KJ;+BX"9)0F<XSHC>(EW/^/"QZ_FO5"(-VA=%,JL6`4_O4AB8F=@$H,
MK[X5W97W`J`-$P=:"8#J&J;EFF:=".P%!+5+)VS&Y8S/"B-['8QLUY%@U+#T
MZMX:;IFX8<]*+*SV/0(43%.Z*&NVT$`\X<"3*E"&/,GH.8_4:]NN;=AFC3"V
M[F`S5C&"*Q%=QWT2%,=WGTOK6S>>T*<9W9X_@BA&?.F"U@@SR>+%06"(\6AV
MLD-(U%D.L?#GI1*M`H?IN@!3F=&PU5;W4"2?)=TQA0A?I(AU^=W%+(AS`-`0
MOF6>N>=DJ+K;MDW7,CQ)9-Q\/_5$L_Q`R+[>*CNL\L;*JNN2`^-Q*#@_KRS4
M2O0LP[!D/E\N>$4(0GME"&HD_?=M?,'L!7LEZ9MB9NL%=`P/#JPBR*S=QGV;
M9O2-*?Y=9B-_UHVWXJGK>+YFK]OXZE:JF^_.9@E%##0[;_=Z[GW?T_LC;:#V
M^KJM6O;`5+N]D:^:6E^W3,WHV5ZWYG>N8K5GFZZT^\WVTGQY#T%F::6\<'W-
MU>O;N)]/81:B^0S3?,M8CT/87>LQFH:M&88A\\\U>[CO[DK*R;X,%)M>VW:1
MVS"=M;=6VD1-NP@R!`O^9UC:IIGH5!_F>7E1^^8]RW)\V?BTS:;N._XNLU&_
M*^W0,#(1P4)SDWY[7K+>:K\Q-<O3U^''=KM<H1!Y&F%H#9DS#X&S.ZV`\#77
MK$C636NO[F^`D?SCB$4$/.>N6H]7MRW;ENZ_O.(561EOQ07+$I_T[KX`3WL;
M<^-\?-UE+E4XXR9KS?,2@'9U<L4R][AM;@2RMS&6GSELD.FM\COH(Q7=ZW&;
MK!NLLAS)QU!X]9Y32&CE&JZCFX[ARD:JZK*KFT(MC6W]&BT1@V`>7`.1Q&##
M<,("M_:S3;TW,OL#2[6=WE"U!OVAVC,&KNH[7=MWL.1HUVKQ70R_?`*"9VOX
MOW*;]V_DB#9NM-M0+,.T8?,/W_B0XO@_3H>\:`1&BWZ,FT6+@[OYQAI7CF'Y
MOB<5]7GD/JM0^R.,,<437NU6LK<.06%HA8EE.J8EJ[WW[&*3,.UG/?Y6_P-I
MN)+\T[SV#61BBN6X8($<G]-@\LR6G%;9P/-=779%;+89!H!%E&8/CT'_6`T[
M_YQ@^7:I%\0_>.VR+BM=)MS_%Q3)MY?*8([5'WJ>H:M:SP)@#H8]U>];?75D
MC$S/-;V>WQ]^]32MW4!4*0Z&!4?_^LOS`6D7AS1*TFD88>K4LV=#R)Q,9$-H
MCO98"%=W*,$,B[=E6.1.*B*PK\0MHX_BUFB@FKIFJ5:W[ZF^V?=5&*OO>DYO
MY';M@T@9(*!@6%@%+,^;,D!YYF.>6HO16YNG#&)"=9DT"-MJ#C%E$::4'8SQ
M;S?);':G)-]B2OO*EE=9-(F"-!)U-RGD+V55HP)*K:+T8XI=JV1X\^)A5(R,
M<52LUC3&NCEEW<XO,6V%JN)DRFLYT;VHN%/)<N=1HR*160Y9G&*&*4N-[LYF
ME9![>IP#$4:X"F:X:!Z6)Y668*GL5YCB4-3_F90AKY6:&^=*/TSS`'Z4IJ81
MITF2QPENB"6]SNY$$.6$13@W9'6NA6M9?`C7AQO`%2:LU)<"]");2HD%E[Q2
M!]^?$.TP\G,>99C+ALFCRQG_/0VOE\R1FM62Y2B(=Y)0*JN(`H7=\,!)VDIU
MXVS31<VBJSMIY7AJ>`*SD$J&Q2Q:]MYDU^<)E'W+L#-9@/C'ZB;`XP&CM9U:
MYJY`Q>(Z;K(M"=&*@^>))5E`50PH*%L1*1+;9PE+X=68T8^QU7@OUP4T4X@M
M9@M-_K7,<A;B2Z<LZM0Q=)8BQ^4GY03L.,0L#BS50_7R1+1XK<+!VICW:H!R
M`6Y:3P'PC8$L[I\H)<=RIXDJ)J72)@#67KEX3;PL+XPAMA[1K:<$6LSG*(I@
MT;PB3V@>8,A\F2>^U8G9+-D!\UUY`CBO#[@F-G=3YK]#&9@U+CH6V;?%I+`O
MV7<KX$B'TL<8^(_3?P0X$UFN/N%[V>ZE-\L>6=ZPJZM>'V17R],]U;-,$F7-
MKN>ZJ#RW26\4]BG(=>_CI\'PD]K_^.Y=]^)R^*OXXS<%6X*ITV`.5^;7%1)-
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M%(0J@5*=`10C0ZP#P`K;5[;)TC$:=L025<)J8Q4$1`Z`%DEI15%2EF*:S`"O
M%12?9RR+)2)1CU@!R$OP*26.RD%`I5?Q[PR%OW'(2]<N:7'P?0$P$D<D<-$+
MN*0BE;4`';P6!N.;U1V=415<QNUY*A][\Y:7?AAS49A-`50`$T,GP,KI"U0D
M%K.("0EXP)S?ELMDO)9GOE1J4GY9D+PJULBDK^#Z&L16A$##L6,O!7$0'/'8
M>?#4(Y1+2XA3XB9FZJR1-*7;Q>J:[>9Z2>E8"GI:6)Y.<P)9$Y)E9T6Q*ZE7
M!*LU\[/C6!W-L;B(7]3.I]&7*.2Q0LM4UX[K9TP`K-;=$B7^ZY()B4(/RP_:
MC(')S`X0`:0FN'XL<:8LT[][=N?TW5%?'PU43S=U%!4LU=/@XW#8[??ZPZ&O
M]5OKQU?8W=8=F^K\D=5,7&3A%A6<I(),.ZN_M,)6ZVQ79K,2>U[#<2ML5F*_
MK1S7NX_C;L:X2T12&";M@O4>;AVNO=2[_XCU[M/Q37GG'='!0Z[`$U)8V815
M70A0`9N$"Z0;Q$S&Y4$$0,D986LH=5@\U15/58Q!))+PG-M!.,.%*=)+?Z3)
M<M$I[5O=6?A=N>"U3SO*NW=]FO/LIZ99@UH)R#>=BJ&EK#U?E7%@,*`M'2`W
MJ.OQ\))UTLMK4/XYJ?]9.]=T%%207^(;;^2:LWQ-:\'$L5I>]GF-T1"\J49&
M&A++KH^/I=Q9)``<&D8`D)9)+5Z$9U-,5ZR.#4VZONB^@IL,*=Y"(0;>C#1-
MNZ'W&$H,@*%53YRJ,9*F1.<>I3G5(V$J.JM3R)=4'45Y365PV>*$>%HM"IK.
MJX!C'1+8R7$Y(FH4B$G074559B^=X`=1`0ZDE3E<8:HH#@(,9[-85CMF,([(
MZ$>2V26;I029]3IX\]IX(UB^9.;KCG-1%*Y2K>6.;AXN/>5&O-MD1O4F\;@6
MRRO0^6&X:8BB[:G,;*4#$LN_YK!N/%XR-'7*`B?B&MP4M7FH%QW=$LHG)^D,
MBUZ6-$]6"Z3668B,I7#7-'N'(4E99K1RA4-$ITEPE\E6-.5;B@;C&%&!R\H-
MQ0!8H5318J-8.*XF52*X59.(ZLZS^?E0=74@4*Y2TB1XF4\T4Q5[QN*IK+;B
MN%CSN?)V6@'B!.X":CQB!E:MJ`V,K"O''2^/(FH!8+6VFV4\03Y$9I4[#A7E
MM>YI;\J;518=*FLX%NTM5BC4IS!?I@C@%>I$="5F.E1Y'JS'!+9!66!%U)1>
M%U6U*99^PFK+UFAI?H?DBFI8OK:TOTCKY7A1*'M5`G19(5E81CSGG=LPW5)Q
M&'<JJA\P"H<G!#]FRZM_80%++%?,5;IIX4-DV,:*X7$0`QP)HF1MEH$HU%-8
M/39%B*N,K(+*)\+SO4$C[$BU)WJ@_/VI7HZQH&'&2TYT&E3&LVII"\5G1PW`
M4,?(6&:L(-4JKHA.#C\;GM6QX)5*5454MKA/CW57XX84+*UBGNL.\AY>VH58
M/;[S\7/___:`KC%C!/\&A0`JD$22&0EFO'PJ?Z'#IT2=M-!H.RVRP_D]"G0=
M&ASQ-X"$\K/N&_@P\\-L"@E#JT"";X1!@@^PZK<LRV(U[E78^KD8Q^YP3=2N
M[#Q/<AAUQ8#02"+X9BW7H4-O,!5P#&+-%F&,>U&)SC.+OLO$RZD1+XXB#21+
M;@&%,.7HV$&X2D8*)%;KS10;]H`4PG$:SH'44=6Y5;I+6^+(T[1FOAUIV1Q[
M.DW-"S?<"6_^A77XIM,LS&G*,7"RB(@SNEBQM4K,ZJ;#R\C?U%D$+(]Y#JE)
MHB#/*^Q5F,U$Z3MNBZR)*BV"CU1J1TS0*7QJK!XZ+WK$$$68.3?@:4UHVJF<
M+A\T!`*XC'D34-$7E$&;EH*R0WAJG5#1VUL\ES)>I"$OV-5HA3S[J80Y"W0@
MT8`H`9RF(+3L.,Z5+LG/*[.>_53.6]*N59,GOW+RC,RI7<PISAWNU,^Z8^/C
MLJ13W9BX@61,YG>L69]KN.541<SO.(ZSJ<6T]"8WTTL8A(^]TC)W$\*EC-CH
M9QOWNVT!!S`N(/*N:;+0E`TV)G>N*P2&:;&<^Z4-UF%8<SJF:39!29@_LOL+
MF6]J'VX(VKVZWVM[M4UI8=39](?:H;_JAN/;AOE=-US;M[Q5N_1(<UQMX*I>
MSS95"_L^]GJ#@=JW/1?&@+&-_E<+[=(7]C_]][HWJ,7Y[F6[.P(K=X:WN\$_
M"?XL>F,N@QDNP-@;O`?>P.YJ@Y%JVJZ'L>2FZAM]6_5[0\\Q/<T?.?Y70'SC
MJ[U3D#\<%#L,V?B#?#)O8Y8TN>$"#N`H+/DHG@\2QT1L`.3.PXB-R8F->2(V
MCX7WIABN<V*S*Y#_V,3FD4=AR4=Q*,3F4]GA&<O23<,45$9>0>@1,',-S36^
MZZ9N6RXFW+B^KWD(0].U'#GV3K57.[+W>IX^<$:JUAT-5:MGN6K7US1*!`""
MTM/\[NBKCE.W%B:IE-UKWZ"$E*+H0Q]]Z%>\EV&AP5X(%]6>X%$/H1L!"@UZ
MMNJ:UDBU3-M1N_JHJ[JN9MJ#@66[/8(`A15<&/_DZ+3)'AH+6TDP>A_-T(,7
MA^_):#@"O$G2!V<GECNW==NVO'MW#I?,=7W#4WV]VX?;9';5WG!DJJ9A]7W`
M`K<_,HJ=2XL3<<2@D(ABO$)%8I8*GHR`Z0EH8D?UA+[X=A.29^%U].8_2?NY
M#.)D&O$ZNLE5X?%$\PC%LI.]6XK0#2IFCF29"UN)<)OQ!71@CMHDJ(?R)E%B
M*J;0DK^/F?\B:DX]B\9,1V2/A9--)A.SD;;$V^$5X4\5T,`ZY.P'YKN]#86/
M@9D(EPM8%B8>,$)$*JYU[BOS:#9#;9@4LV])N5:F\2_3<E'XS>OHEJ]+6KH4
MWL;:^TV*-GUHG"R,G^@DCEC\.,W'`4F>ID6"AE=`Y3B91V,%Z&DP(V\G^D;I
MN?.5(FGW8OZ6]Z7ZP/\^O-SP_3=G?9$8T_8<O>M9JM/3ND!"^I;JNSX04=VQ
M=-O7_>Y`PXNT)B=:VP):*_M^2B[S,`@--=/7O7Y?-?P>R*S#05_M859P#[YT
M3-MR!J:_#83N8S//BD.N9L&BMX10WQZ.',]QU-X`&;$.`GW7!B'?Z(WLKN4.
MG;YK"6*\?QS"FKEE-7`N#7WF1<\?"1]'UWUW59'TM('G^4-'-4W3!;4&]MX%
MQJSZPV%/'U@]H^NRTE*_?V$N6:!BZ)_A!#(H?>\U=[\45!,4]#0;WX23)7`#
M.6R(QPU%W"E,C4BS<!ZI+"-*O)SQ.&#L27PNEW9I@UFM>L%W-(8MH^P&'V#U
MB465S*(8U.[`O"Z'VS:=D>'UNVI_9`/2]>V>VNV#`&3ZON/KCJ-;HQX,KC4G
MZ%,5"UWW'$^N6;#)[HX;("0.MU8OT4T#EO4H@.RW4!]"!-G2=]2V=-/<0>$^
MHMRM"H)I@[;VR-I]3P@2H-^[J&6XEIGIAF_[VN-`<I$FTY`R1JD<AM`\+\/T
M%CNX[`(DL-_OL"5+\^SU(''[MF&!KJ@:0P<;,O@(',M2^^;(LH;``$VSS^Y-
M.TATX)Q2R=F-=B<IE87N]9G[2.'5#Q2>]'B%L@J(NCVN9_E.WS!45[=ZJC4R
M>ZJG`0GI#?!WSQPY/;]4('7@<UR%O&_%TN8^4##1Q^D7[F[COIH]G&V3;`)X
M/=)MD-[TO@?2&P@VJN^/#+7K@MP+6G.O9^NK-(!52G!8C:,UNY"V*34E*9Z1
M^G"0[?%Q(MKF*+WYIELKG.B.76Y^L[U)P)"P0K8KH'L^N(91&/18O-M^@-*$
M"YMC^RHN:.>6@,9VFZL;-+-+%@GW.2EK:!P>`&2\$-FI\G5HW8JTW:%PP4OH
M4_>H/J(_RW978F3J9E_71RH,AE<"@-!S?>!^H+UI`Q,`8CCL2K16>;1<QRH`
ML.'F)'#<4_VI5&?>QO6!#HUJM`J05`A3I#`_8L,2V.2;57],#(&VL6ZVIR)A
MVUZRS3'-;Z`R16F>G>U['[#\6(2.]2ER[',R9'%C!P=CO:D`DK5S(+<!I.(Y
M0)MMP"P_@HW">*,R[HA-S!>U#UBN5C#8_-*O!>2VFWL^-H&?D8Y_UWW'@3]V
MP#9(7VJMBFYXUI&SC>U`MA%&&2S`91.0[8:-/"^6Z3O`,A-!UEIZ5_<-[45A
MV3T@VPC+S+7RG`[KV+&P(L)*+H*<M0*(F'/UGYC<_@@X@5#E`IQTQ_?T5>SQ
MAGIOA)8<Q[552QOUU.ZPYZJV-G2L7L]S?72!,[7F=T,S?($E:Q:[OO;R)_3[
MX8OIXUB^;YDZ&3<=[QZB8L,U@)5W5:<[H+J]GNIKCJ,.8/-P9^QAW_7O\?4;
MKN>;[869Y3W5:A4S/R6]<&B[;35)U78K[T$6"'>,I]4M/@1/#6YL`CQUA9!V
M+WX^K:MLUR$J:TYQ!VZQQP40B<*V;V-A`&,TK[N$*5.<91!FXS1:/*8X,0#5
MTWP'.(%C.)9OK8!1[P^[7=WW5<<:ZJKEZSVUU[<UU>TY&/32-T<F%OH$\O8Z
M>J/HE"*#$?X93_/`@`K%*M((&FK9*++G[?_4,NF3,HP-8P0HWYOE5+$X!1R=
MOF1-IGF^CMSMF1>&J55RGE.=Q2)`I)<`P/'#($I#"BH0F0X4>*^(>/M.$8^!
M&?7+='R#753TCN5J'<.TI4TU[DD4-\+L,FECR\(S*8KGS8*8)7EF&`TR7O)@
MEBF0DI0%;2B3<J46F[R6_<F"9RCE#L`@)21D&'\Q4?Z]!'K+SH*G'V"%30;'
MIA%$(^YDF>8W\MM4&^:QX7);8;MTO7BQF6%9EFE;NSUI$<#@#5-OJ!WCCS!`
M%DBE[KM8*FT(--1R/%4;]KK]WG`P-&PJSTZ!@QP(;6MJY&W`!X5W8NMH"[C!
ML'1-\S<)MJ"K;EH&?09YYA[ZZ;FNYO5\N/,];`EI#?L8.0PLP_1ZYF#H#.V!
M?T]D@>776Q6T;7GWD"$BIVLV'NI]P7U;0\8;&GW=47T3(ZDM:Z#V@`JJ7=0C
M3+]GV^;H'LCH>&K/"1H-ME\%37/\R5K0K,8&ZE;/'UJ>K]I.%UCM"(LR@D:)
ME98\;V"-!I;AW0L:[6&@V4T`D^G8A#F,'%!HL>L".&S'`$UIFX"F!LRQ[(';
M!SA@@RL$3Q?NU,!%$477/)BS[_9'3'-J;[%9`\[F04UE+'Y1X+6LU;4U@`IZ
MN593'/0&CN$/4&XP5$L'G.@.08SP0:`8N8;M^H:_KD\[6CSDMJEKMW!$J015
M&.XF688[4@\I;^G(S^+AN01"XX>S<-\[AW`4>PB@-QT2G(PZI00EV3?U)DJ)
MMA3X';1-W[X_P'X36DF*N`.`MK3WCXBPWPWC:`:'95B.;F[%.%:UL(V`01%W
M[2UP6>.H9\ZZ6('2$R")A9/;C\O"J-VVBHXB74JLPCW&IJ31;)EO8^KP/")"
M.^N-!*S`;H@CT'7/\'RY7]##-E:+Q`Q2I#SH8!+*W8ZAL.H\VQ0*+2VB*K6_
M5>U<;GY]SW9JO`TU^K=4EDEN4L^#-*1('5'U>Q?@:/++#KRN;5I:3_7Z/L;2
MC;IJS[,==6`8QLCK.9;=U;]6;;1B_Q)1V'X[57"P9M+`V]+P!MA;=!N6/=$_
MA""M?0Z^7V!M'+AO>9Y&5TMR4'Y.+H)T*\?K%A=&ZQLC=V!Z:M=#3=;#=CV@
MGP#+[@/)[%F&W8?!VIN).3!.":%'[G"E$Q=_=90F\WY#,[8>E;V0NOT.OP-[
MIWX>07KW-@_GV8<D1K"E0,S@5='[^3EIC]\&2M7P/-TQW4K[KGU!H(:9HNUM
M.>-S@JC5`:L:KN/[AA3XW+#RNH]H!1L%)C[GA5K3W-IS+=^K>(1:=]!`7^"X
MDRI,MHXSVOV!MKJ'#4WNU+Q^`YL1TQ'<A^@Z[E.=P?'=Y[(\*'`I^L3J,XE\
M@6Y*&7PR03\$_&@-@-V,X.X0"HTNK6<E#^TF$=\SY":W8K$K+8X/@\RU]1UL
M8@651=?Y)"/I!W#/6RUSNFZZLM^WMN:5%NND@:!8"2<X2Q9SYFA][NVU1Z6#
M[N`;%?UQS19VU4!Z]QML#Z"U'$^WC4W[1^\LY'7W6VR59`W3\@U3VN)6;7%W
M8R>I;/>)RE!8[:$IUH/MZ?N,?&@!TG[SS/<;#/$D6/0@K\RF6>;K0GX>C$6[
M3L=;`<SNL_'622>>[3TL&6^W\6XK4-A]`-B:S%7=U2W[Z<+=GF2S[?[:ZF97
MH]V>A5[NFHE8[8+1*@=Y'(&\-X0FN[?W-J\#W%)UZH'-&7V-Q8V9]_M]-^K-
M2`6W-C'/:C7_V9/!9LMSV:H2V!_I5II9*_`;$V]-?S08=&W5[O81CP<]M3?2
M7-74!OJH9_?ZGN_R>F>(NDT)AX9=P>D]['VWP"VS(#FEY0&KQW`'6C22!]^!
M?8+JB4_M^2_(/>Z2?0-@QZQA;37"7=^)!_;LM>I)T.TM>^7R($\(FZ?S`.X)
MJ\W].`&/H71H#:(/B>ZA.`OC194E?HI`JPKD=Q/S1JF,YBGF;6='\?"0-X/1
ME0,*>3L\N1T54]/T`-(`5L]V5Y-OUA/XC7)Q5M)[GUJDK]3L^9#$_;()Q+99
MJRO0VT>A@FK\L8"6WU"`J&DS#7L^_`TW\?^FBDOK=MN4Z-P$(/II#Q!X>)T9
M?4VBZGT%`UIW>%^^^S&`I;TXX;T9[FM@<O!VK6KO\$?K]"Z"LL5+_/+M6K5Y
MZ4?LJ5D@RUX.9J/@Q]9$D\JIZ*9FV<Z^^.2]X-G1V:QKO#&(L!%T//F$#>$>
M?QKFJINZI_O6P`'-TW=Z(*=@_(]I#%6G9W4]VW+Z/:W_M;G2VVY$E$UW?TB"
M8AMX'ZSINX6!UVE@]ZYAF-M83W9BX'V$&O!W*FM4S0W>$W0W)":-9G,`MFON
M3OEIVO4>*<2G*/MSE(:A"%W:$858S6?9D$*8311"7P'P/K?_M&D@6["\C6*!
M].8T$,.W#%#YI4"@7:2!'(L/9Q_R7DOT[\F'LY4/9S\\T#OY<!X,^0?Z<`CN
M+=6_ZCX<_P!\.#O+8-L"D)L2\`TSV'2)FF^7P;8/*?OO"0;?SZ+\[KFU#*-!
MAG#EL/,GV/\3.@SW(.B^E)3!+1C_1ADLK=%+6,3$T&7UZN4E#>Y>4FU/&C1M
MPX?_'5O2X.Y!U)XT:,)%MDSI5CY-TN#NKU1[TJ!I&:XG5X-Y\J3!W1]H:](@
M#%)/@3O&I,'=XT=[?M*&)/>`T@9WCT_M4=J.9EC62I#R;M(&]V"U:$\;7&$&
M:](&=]W^:8N-;M8`JQV=#<<##?=QK9X>G#6Y^P-MS9JTGSAC<O=;:Z=(KF';
MOB%?NB?(F-S]!MLS)AW?<MP*1WZ2C,G=;[%=D/<=7_.VS9A\7#Q@:5!Z;MVY
MJ>^$5K1)V=$&=^0G6J>-8U28_D!`WANIZ(PTQ\6^HUX/RX%JNJ7V>H.!BG5C
M80P8VNA31O\NPQ3OW>T10;4QZ'`CJ.H<JN;S0'4WJ:QUN#Q%0O2:Y,6#RX5N
M@<]^<Z&?IE_R7A%HORVW-P70IAAT.,$7992N`>3>,?<2I:O7NR,+PZJE/4-<
MQH'!?;_1T69C=+1I/&W"XUY5T_WT:EX3-ZM[<%6\QVFK3P>1G;5J7D,$`8-M
M_7$`V75IB%6`[+PTQ!J`V+8I:8I;]VE^DBY9:R&TGR99:W1/%^?958^LW=;7
M6`'4[DM.K*,VP"6<=JO#KNMK/,EFVRVWU<VVU]=X7DYN5(NH/PDGMQHYN:YY
MOOTDO)Q#AY:_0^C0X#`\+$.T,:7/&+:<1],(^_.,;V#E?WMUD^>+7W_YY=NW
M;^=9.#Z_3FY_Z;_]'Q#!`:5LP!L+>'+Y6CE4%E[/A5^9?_7]*IU-HE_#[XM9
M-([R]R$U:II$<W2>)/'?7A6D>Q;$'X)YV/T>`;19FS!J6X0_L-?^^DOC:`^:
M[G.4S\*/T[?Q!`.WET`#RWF'\\4LN0LI\(J3/3RJS1;QUU^J4/CK+Q6`_W51
M!F\QF.5`4#!6_W<\2Q4.6`,&7WY;/!C&$^DQ0S5U''HB/01$78H,^X7CT;9(
MM98L'3@2R31:<L%EO3OY%^FH/R_G3W"LMJI9&QPK/.:HZ&U_BF-=*X,<YS%+
MYUI**T7]_=W3D,L<5H%#]V=!EGV<4E22O(AZ^MH)U>P?&+5>WKG*FN^!GROS
MY1<W]AVJS<6Y;N1)_=$/&0T^+^&0[]%Y?]!C/JD.1ZXZ'"Y2M?@[3DBU,5*)
M7KT?>:M>RKG@?7I_4-1:ZXP\<-3J8S?I,%V@C%E#L<L@3J;1'M#K;@'8(QFG
MJCQ1ZEAV&TI/_=#(U1(J<;S(-0BB:'P3`8[]>9>`K'1"LV=%LVJDTH&CU2<\
MJ^IIO@?A>?ZCVL^JP7M'>'C!]Q_T\/9^6$<'G;5%P`X=M0_77J=O=J[FWCPY
M6Q6)//!S/B1U[#EU_$-#JI,0\Q(.[R3$'-GA'9P0\]S06=^JY\!1^W#59HO$
M4^O^@)3]B:?K^U`=^,D>:$#*(1[K2>MXF>=ZLM2?>,&>D>MDJ3^AV=[0[+!$
M[0.`CNDX"!ZCC#NODWC7-4&M-#VXCO8+NI7[(OD7:3)9CO./*<]3DJ9LCD@3
M^4P_$EDP-M,QC3V&QJ\@ON.[+B"V95B.;IYDG>VQK12=$?&D&>NU'4^8?A"8
M;IJV;^HGDO^B2'[K)1Q^S]G#6*3D=`.?^`;:U>2^DZ-E"Q%YD]/;9Q)=^^F=
M/"W'=GH'I_\="'CTNG!@.X:E>2<Q>'M&N(8#PW]"GC&^QTS&PV7%^F;XKN\3
MWS%Z3`,4KID[7,W2W3IZ4UR-:1GTV=*/&=V[LUF87@?Q7NR/M:I=$E*55T`\
M^V4Q2N&P1`V%;?'O15P$S5<U[_Z+P![;YT70=<VN7H1FZ_L+N@C[M\:?;L/V
M;,'>B"W`8_NZ#12/`S=N$T?G"[H-^Y*"3G=@RSN@J4CM[[T#]-B>7$&&<\"*
M$IIQG.=4E'2OEC3RHT5</U'(Y=X\G2L'>%2:[.%2KL,\VE-8X8L\5]<TW>_`
MHQS?._C"5J,HCO+P'5S(R=LXAQL97<VP:GR(+2K?!_]*4BHU)9-D@%^<?XR?
MJ&[)X1WOJ8[92ZUC=E2X=JPLX]!P[4,2G]#M%!'_P@_V5#CO1SKE4^6\%WW.
MS.X+BJ/O'GQHQQJ[[N>KZQ_[!)L=ND=\HGMUX)ZL2P]!L5-(S`F[]H9=IS2X
M$Y[M%<].,<@OXO1.,<C'=GJ'Y5H_'/"<ZKT\5_3]DQ[MR3/[(L_U9-]^H0=[
M4G9/[&#?V'52=D]XMC\\.RR!^Q#`P[01U[#8)=1-EUTZT^:?/0IN-VSSX'7+
MR^55%OY[B1[*V[`IO+SVP!ZB(&"":!(%Z=UE@'6&I2B(PB-W\?%I-%U7->XM
M)U0\MD?,TILQR_<<S\+D4M_6_:^Z;7BZHP'YMW"P0\4TYGX18F`MJ;.?)`"V
M8$\IG33%^V@69GD2AX2_<KQ@\<O&(8//?[,>C^'Z9ABN/R^&:[YMGC!\9QC^
M^5MRPO"GQ7#-.4D'+TTZN#^'JGCLB3'KQ\2D%W&BEFX8)CM1Q])T/%'-,HR#
M/U$1(#?\]Q+6UT_F"V`T!?\I->GY/(GIVCZ)\JP;JF%NE.F(CSW!F0IZ[[KZ
MP4HP6U#;BS2Z!8A=S(+QTUE$#NI0#\T><C#`T?53$.C#SD_?K(B5OI_<;*U:
MG^V4F;W^^*(XPR97E8QY\=W^3L7Q-9.D/</4#OY41D&4_CV8+</>7?'G?\'H
MF!=Q]PZS(JI,I7CH;;Q8YAD]H;^8TWMVAO&4>S8/;\_FOO=\JFKQ@-M7A$3M
M_U1.W1Z/L-OCLZ**X5N>8YY0Y>&H\CT<+]%Y_G$ZC<9ABB@SB-)PG"?IRT(8
MP_,=CB#Z*4+O8:MHRIB5HBZ`UN0I+.US<A&FTR2=CY+T8WX#6-6[JS=+6.;O
M`-_B+!R%>\K"/``\.WR\.IWHIB=JVZ[OF2?*\=QXQI%LSP&KSX-JE7274Y;O
M`Y'MD6DX6XE6AQ2>^%PX>S)X'>GI'9+QYPGV+%K(G^JOO9CZ:U4$,O=L/=P$
M@8Y5(CPT!'JZHFK/A$,G[^M!'HMFL3`0V_*<'_&8MIEO$%[E;^%(TB4N^5,X
M">?4]>>"CJ4J2:U_=N.XUR/`H@.3JO:[9^MD)CF92?)*)M>>4>V0KM?>][QA
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M=<MX2;:8TS5LNX;=R23":`5).>1&F=,%?,8+^-*,H:<+>#*+'M<5?'%FT=,5
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M^HNT]L:MU[:Z;J+&]Q?PZ\K;^.4&[^(5`Z*R.CL3)_BO&PQTR1"Y>1S^8\LP
M9S^Q>P)__G]02P,$%`````@`;X(-1\!9,?:9#```=J@``!4`'`!P:7)S+3(P
M,34P-C,P7V-A;"YX;6Q55`D``]+[S%72^\Q5=7@+``$$)0X```0Y`0``[5U;
M;^,V%GXOT/^@=8%%%UC'N<Q,FV#2(G&2@;'9L>%X.L6^%+1$VT1ETB5E)^ZO
MWT-*MB1;U"663"F8ETXC\_)]AX?D.3R\?/SU9>Y:*\P%8?2Z=79RVK(PM9E#
MZ/2Z]>6I??/4[?5:O_[R_7<?_]%N6\.A=<<HQ:Z+U];O-G8Q1QZV1NB%439?
M6UWDVDL7>5":]4CHGV,D\+\M^5_'@D^_WPX?K?.3,\N:>=[BJM-Y?GX^X=S9
M%'EBLWG':K<WU?WF`[NR/IR<GY^\B_PR9$OJ7%GGD4]=COV*'8`$/YV>O6^?
M_MP^.Q^=G5^=7EZ]N_Q?-#5;K#F9SCSK1_M?D/CT?1MR7%C#D^%)A.,_K2=&
M!:2>+Q!=6S>N:PUE+F$-L<!\A9V3H%`WH&N!1*FX;D48OHRY>\+XM`/57'0V
M"5O??V?YB:]>!(EE>+[8)#_K_/[?QR=[AN>H3:CP$+5C&65A25G/+B\O.^I7
M/[4@5T*5\LAL):4<`"UM"OE7>Y.L+3^!F-L79R<OPFG](BO\R)F+AWAB*0Q7
MWGJ!KUN"S!<N;@7?9AQ/KEL+PH64_/O3#Q>G,O\/=\Q>SC$%JLX]]8BW[M$)
MXW.%NF7)<K\,>S'X"X(Y$4IYO$`3.S)=)[6HSJ%`AY#SCR</M$W6T9\\$`K-
M0Y`[8(+(*KHN$H),"'8*XLY9Z#$9#!#'1<5?H&1OACUB([=\3CT8SN;X]<B#
M_*7CZ@-E+L<5CF>8"K+"AR+5EE@Z]BX2LP>7/8L>=0C'MO=ZT/M%'8SVC@C;
M96+)<9?Q!9,S5*3?WSB.4D#D'C"NO**&$FG=(D%$?S+@,`7!X*;JI,[3<CY'
M?-V?/)$IA9YE(^K=V#9,E![,Y@/F$IM@42[]\I&4**8A7F&Z+)MR>JFEP@=#
M2@V/WGK$$17(+E]_"U52/3D1_7[_LH!A#(NRR2574B*Y.SSVRFTF?8DEPH8N
MRI?8V4A$6IW.TL7]R<X/KV:1NX(223UYS%9FJB-G1BB^@DF@2!V54PNE.F(>
M<E6BV]U$@:2#CC!B3S.D!G/LW#PC[H@OU,%\-,,#17[@HK*%4Q7*(XKW*Y:.
M(&`!]QE-\8T0R_E"C2]?(,\#XUMGF$Y_0^X2LO3]WS_!6.05=@J.B>R(8HQT
MCB&>0K,"*)7'AW0#0_8*/+?*A)6W_E+-4BJ6KI2^TNB2#91\I9=(YROB4FU*
MII%>:JFM,9\33WHC`FQ7D)X4':;E&\N%*RJS%R['`O^UA+KO5[CTMLI7>CEN
MZ&?F83%BVP6%K2\I^GR**/E;528[`?@9SL8EB7HHD=6(,'-(9H1?O%L7!H""
MXC@BL*HEJ7'KTKRY\J5V$(@Z2VCSH1:2VH*I6F)=YKIH+-=*R`K?R+%]JGZH
MLN,5J;-J_CIGM$K^1>JL$?\1&KLE=H_B-5<M"^G.5]GNNO*KYA6,,V*`UE*0
M,`@%GOTC06/B@DV`*]7WU]9?4[F4W`\.0U%YG]C6W)]$/;6@]W:9\$2X```<
M5*X*^LZ!.&HNIY)UJAPTU=L><9>X6ILCNZ[*^<K@:G^R=:&IXV]:J(!M9DW5
MMZW6JZZVF0M56[44=CWP\@GK:PBXV>'>'[GU)\81TF+JR"5/_ZNLJX0M''[%
MG9V:JX23<V>&@@`@0#ZQBEVY^X;Q>&,']:HM-A,DQFJ?S5*TIP@M.J`$[SK8
M]<3FBU2+=^W3LV"[S0_!YS]V9G<P=!W<77*YMV)3'?A"V+UNY<G1,<-@QQK)
MQ*]);PC]<KY4LYYN(\8C$^(S!M49H1<]IT*E&&&Z7=T;(.+T:!<MB(=<'2--
M:B/(A<">T`'U?S2'*T/;8VE,H)1;=>1<!__<_[4D*^2JV<_KPN2_WH22-.CS
MY37""B9R1E7$)Y7`;C(36._P!$/[.]#S?76`<>`SHW:JXF1D,LPC]VB?GL<$
M"W\X!CQ8#+&-0:G'KDY]DM.:0!T1G@9K-(5AA'(96W:Y&7,=S(4<.F0H.`MV
M<C;#7-+5NR8Z_<@0W1J$[!;1/S-@:].;0*],ICR3:4)"8WASJX@N=1V09\Y"
M*1E,X!]PO`!S--AAE"[WY+1F4+,%YMY:;G7R8)"3`]M">J,PI6O!IV0QP6&(
M/40H=NX1IV#XB8C'`U,\L8F.28Z,)OCDGI_29J3(8L4-CT-'W-X4"/^[MU(1
M/Y@3I.@(N0-;EM8F'IYO\D\XF^_Y.YO*F,[5L!@'R.IPV/O3TY;UK':7J;_A
MKP4GC`.7Z]9YRUH*`,<6OKM75W;IG2@D^^$MD,WR&$*Z/S6-[LZ@'66=TU,-
MR9^](?))1E#(]/P-,=5,XB'9BS=$5N-MAF3?-8=L@@\:I9ID$6]YGC6H43-X
MIAG1(=]FMFNJYZYI["CK!ID:KV&=E&I+'A`TD7S*X)4:G`J'L)_?(&]=2"MD
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M;-2,TTW3<2,NM3D:&2+(PSO3+&ADO.`()D)L22=I%&UD8/C(@MN;SC4!YO8W
MJ>VN(*9,@8T,6R?:2_LAOHJ$W,A5]IPB2[#S-<OK->]F*<9J?"K?V"2-W,*0
MD^7^Y*X)=N=M5%/+-]J+6<T<=]B%D7$D*2W'-[<SU8G+6#,>,*[ZG>=Q,EYZ
M?NC(7W9,\_(.*-6PL9ZI>M'NO]/.C1SI"E(^6&D.<V5,C8_[=T#7YG3;`-`S
M!UJ!8R3P'?;_U8V418HP<^X*-,LFP65OB1QB24Q@O)],0`/ZD_L7>R;O:QJ"
MFO1ILFB33&0-KX.+-;2*'5.:'DW:2*-?U,Z3N5Z\\ARDR\Y:&TX[FW]`U=00
MOS6`LP_C'5QL/601<5ES$XWFJ0<+?W[V=[>DGB7/E;4>G.*;J'/SV<E6#RY#
M+,`JLN7%0S"BY^:RD\V04R/K'G"V(F!.W:[E3<T]&FQ/H-/@&F*YN2K_G'=@
MH3620X^NH(U*ED/>0FLDA^T(7Z8<\A;ZS=G7GLM4N^+^0ZB3L<TB(:&A<Z0V
MQHY:9A["..[?RM:?R'LC=<C3LIB)R^;"71.LFPE&[;?+#($G)39RMG5[<U_T
M;C\-;DUBL^LOKW#J=]:@#AJ&&WEJJ2*AY9[#&WD(J"*AY38`&[G[^%"A';Y6
M=-BN97-1T1*<A9TS\2D&02-/-I0OI#3!_-2@(',YOL5;"]64+Y7X:GLC]]>5
M+Y0D5ZF1&_#*%XW.VF[D$?_RQ:-SHAJY"[%\\62OAC9SY^$Q))44?=)L,?PF
MK;V(@69GX3=))<:+FKDQ\9B],![;;N2=`4<25Z'P<B.O(3B&(&.QZ<.N+#CJ
M#JK7O$)O$F7YC\6;9)/^#KQ99`7>=*\AT.3WV4T"U3^_;A)5[N?4S;WE<4]7
MA#.J'G!QY>)0[*&<S$N#BY;R[=62TM##R)RW>;(R%^.U__21_+*I2]YCNH2.
M"#4\XBER'_#>AK+,Y$9VM<X7+EOCS9"76UNR\YFYU=XC4S6PR4/%?(4S524M
MA[F;X@MVW8Q,->*1[SKVU'QF;T/-:IE8%#"[;S4R(I%+"-F#8R,##X44(*LS
M-S*^4&QF+GSI9(-"":^71([1L9$GR7./^O&+=E,F[48&45XEAL*>R6$O`ACR
M#56(;+P;2ZR?#YN,,W1E1\R3CY!"HKW`:.#>!K/^B(7ATYMGQ!WQ!;#QT0P/
M%`KYVD.MF7Y5>@7@5YBC*;X1T`.4*@FYY/G`>'<#,'B_H#_I^[]_DD_O;AX=
MK2F[B+X-P321%U9,51Z?0[",NS;*8??EYOKUENTSR[5#EO(<<OW`[CYE7!>$
M^L>7^WR**/E;52C5E+G$V2R@1]?3(Q>:)KW1'K[97"=RFKA`6CC@[1'9?*@5
MH2YS731F_GUI-W+LF:H?ZJY1NL#"&\(]DB'R>FF+C)+47<([>PSDI8![_L,;
MY5!'C=FB[$^B=F/0#]0%4*%9/PAV7]>S50[D4L/6V;6'Z]XOU-7MX$AMC&3J
M#*5+55-]2;&8ZR[H7?LY!\J/'5F[=!#AC_\#4$L#!!0````(`&^"#4=">GW[
MQ!X``*[[`0`5`!P`<&ER<RTR,#$U,#8S,%]D968N>&UL550)``/2^\Q5TOO,
M575X"P`!!"4.```$.0$``.T]:V_C.)+?%]C_X,L"BSO@\NSNV>W&]"Z<5U^`
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M.,T^9JVQ_PFS.>\CE]%4`9V>L`7]W_&JV3']B2S*\;OSDQ?L'?V#3OAC'`5H
MB"8]!O&G9+E`GX^P/U\$Z"C_;1:CR>>CA1]CNDX?SGYX=T;[_^4Z<M,Y"@EA
MO)LP\9/E73B)XCF#^JA'Q_TVO*N`O_!1[&.VU9)\VY[2=J?2H4YW!71(>O[Z
ME)"]2><83&[]D"RF[P2/$68'YBIP,/8G/O(TX58<=)\8/#HQTB6_QLC)#"6^
MZP3F<;HCO&^.FD.>]S<.UX"@'%,N%*,9"K'_C':%5#BB<=BO'#R[#:+O^"[T
M_!BY27.@MX?:&=IK'[M!A-,8747Q(J+76>G<]SV/;4`GV(&O-)C!(%J7#O;Q
M8/(8DPN+,#<V9^@]I?.Y$R\'DR=_&I*3Y3IATG==<JTFY.I_C`+?]1$VB[YY
M2`R2:8B>49B:1ED^JE'P`[*O*'M,EJ/8";'CFM^_6I.TCQPN_W[SLB!L#&'3
MR/$G,8C<-1HG9I=)/*)!L,D1C5/DK2A"950O#=!@LO&A,1;*$QA$ZBF)7":F
M>O1F),.W<`GHS-$Z:@551U'B!*S1Y6:CG-+Y01A%3S.',7/D];\[L8>_A1Z*
M1S/TR)!_#!S3Q&D+RCV2]V=$U48""]&UG2GJ8YS.%XR_?"-];J/XR@G<E(!.
M[KR?G"`E70;9]R^$%R7:2L$^(=LC&4N'8XBF9%D)4*Q/!E*?L.QGHKFU1BS5
M^8V*I2%.`TI]MJ,-"RAJHQM$YV<GIMO&,!KR48VNQGSN)U0;P41V)=2CI$.A
M>6%9>R*3IS`=8_1[2N:^>4;&UTIM=#-JZ$.4(#R*U@:%M2Z)!_'4"?T_V&3T
M$!`]PUNI)&4-I62-*#H7R(S02W(9$`:@28X]`M8V)05JG4R;,T^UG8"PF4*K
M'ZR@U!J8MBEV%06!,Z:V$O\9]2EOG[(/;1X\G3G;QE^DC+:)O\Z<%N$_<L:!
MP>.A/W/;M*#J?)OK+AJ_;;QR/H,?G24E)&%"N69_[SMC/R`R`6IUOS>=WU*Z
M&#X'NT'1^IE8SSR8E#6U_/1>13C!A0&`X,!ZM7!V=H3#<CH9WE-FH&E?]JBJ
MQ.W*'/5SM8XO=:X.)FL5.O2R$(<6L*V=J?VU%6K5[2ZSUK1M4V%3`S>/L'B&
M'#<G=E71$P26K$)6:$3)!X:U$P1'O7S@,@[K7GZ8G'K^_#1O<TH[M`@/F8IZ
MUJ/PV$,3AQQS/>BVN^\'UFCN^&%C4+/>;4+*9CB>H_D8Q9I@5KJV"..,#!&[
MZ1@=KRFC!REO@!Q>;QUB1R/L*C"30X9"C_H*LE_I4`9BG[)Y3ZL3MPB,8D"3
MG6!5`Y0`8<S#>0`A$(88`<*T'4&T;V":A`,Q<`A`Y`:M0!'0^,PHYG(IQELF
M#AXS!I/BXZGC+`B[.G]_BH($KWZA@L/[X[/S/"#S+_G/OUZFV`\1)GK@[ZF?
M;?(;\B_*&1)$)-4$WV%,U,%!3/^FDOE#2MGJ8)))LMG7%62!,T;!YR/#@Y\"
MT*4JPPYB)L'>O!!N[6/T&/LN*@3<_"L^%Y"AV5@@6!,!-@J9I_-K?O'R,=IJ
M!P%MMI<HYXE":L#-)1HNQ/RVG83ZUPM-N+<5!_K+KV4/%%%7KA%V8W^1^9Q6
M)Y<P1'1'F"K>`+#!`'N#F=D/FL*;=8;8%X01/)-+XC%P7':)20^@H#$,W)&+
MD(=OXVC.V'A(^%G\Y-`XBFS_"G&H[0B!3P8`XVT/SIP&(Q7N`>EA5>AX8/AH
M<R+C&+';\Q'%3%ZHQZ/:'`3VE8RZP=IQ_\7?9+)J?6"P(,3,I+/K-*8N9"(%
M1UXFM3V@[^R3&!VESB!XI6/L>[X3+TN;1K8RPO9&;KM<*,Q%17HS9:3B76["
MMFM("C6G'U=A<F)W-61NF=`ULN2])X25U\E<JYDCF3C9BV(/Q2Q3\>]G9T>]
M!4$E)H-]/KHXZJ68P!<M,OVI+?R8E;&,57.9B:*J*[VL\#\[.SD[HQ3(;$^?
MJ$Z)O,]'29RBXL>(Z%,OR4W`N,3G(XRF]!\09)-LB]T(J,MZB@UT#K.!VJ>$
M\!HL<+\X4-Q5A,Z""N\.E`JFC#<%I=X?**4:FG,*PGPX,,+4R!<%XC_`(,YU
MK31"OV(.J-XD4E&\(,'9X9)`+._FZ%^`H:\@8*JKMM6[@V]H*1;\;T`8;SN2
MN5BKJ)!EA`5R./@&WW9&MX?NKQ=V(2Q=X#HM5"`%"L^`38C+5MHLWDV6',1!
M:#YA'L)UY.`9#7HB?]$#^$R6AYS16\>/639A@:W(I:3<'\1I,YD@FO27N[9'
MSLN0<*4LPBLERS%8T`I)-(!<Y,E1'P`"OS6=+Y?K?_X?V;GD`,^6]^@9!1(K
MF&)G4+SNPD6:8`;,N=2S(NL!BL%7Y-#M/Z\<BS69I99\O3%>!99`KHN5_IT?
M]W#ZE)GJ1$=+W!X"^KS,R1"YT32[#[_Z`<()D;.^HF06>>O_"M#1&,"(`5WM
M#MU2D,MV==TA]@BWT-&MTQU6U-6[=\KRGR;'Z(@(O"=ZV*$-U2OXC:X%+E5X
M]S^X=8_O8VK(M-96/2WF<:A^IAV(J'!76^]<,H"^SF5OO</)`#TT%%SK/4\&
MR*&C$8/[E]1,Z0VD+NY=4W-W=\(F):]H:$+&+49>,Y(\%92KGZOU,2)]]X,`
M4:\*V=D24+8:06ADI?H5-.7P@9"F^*5<UT!J\]`=Y=5@"F0E$)4HJ8G)EW8R
M<C)HH!;U%9?.'Y_>=:UAJ!HF,5E>3$0:1.YOPL:O`L>?TXWP+711G)`[LS]G
MY1"$--88`@;'E(9^+&A9$^H6D5AMN4V-[))KQ_?=F?_DA+\M(RD3%;2$H-PU
MFJ`X1EY^\0F(MMG*`DA+1_UR.2*3\\Q">GWMPDIDGM/I:1=&E-*2DZG0T3Y\
MI*9YI:X'B).I5*UKJCU$"W:=;PB^DOM7H9<1Z&Y>R%_(RVNC3F,D%E;JVQN"
M*,FTO!&*YS)`MIM![,)[WZ4UC:G3'\7/Y#]8?@N)VQNA7CY\MCYBZO&:&9R?
MJ-QU<Q=-(%;MJ_/BSU/^]N*W,9,"F55E7@6O>F(B"5JV`D460TM-@ZK0;/0`
M2EWT4C<9Q/DQDMS)W*:`,./2X9=>4^+VG88>2#,?TCM>LDV*[V#02?E1N87U
M$$*M<>'Q&$S4U$)I%Q@<%FGLSAPB)*SDJTU]7WKNU/O#8(<1M:JS>/>UC%N2
MP%=VFE'TB&)JMKZ-8E:F!F=JKNP$&QF[8U2I57;,C&U$\N"#HF*/5.S9(I2K
M.TP7QHU^1B$LV8U+VI@XT5BIGY71:;=D?T:Q^.`K=K<2MVJ#/X0EF1H,!%7B
M8:74?HDB#S^@1(`1MZF9*#PGC":^^*Q6OD-02;62AQV%2!I#"R0'EN"HD1EX
M+4$@)A,,)J5;608SMRT$U-\6MS&1'G++I*J[LZX77-!B0T]UM2"&W`&\#B$Y
MMSJ:5>:-K(::*6LKX%&KM:%$C=QTU<7G4>T5("Y@7^"9R.UCKN(JS,GP[H#)
M4+*NY=B^/V!L^=;G'/$/!XRX(?--3JD?#IA27!$TQ_MO8'AOI2TTB.%0XWX5
M\AQ@JL*.A.-KR38G)^R(L,11;G,*PHY8ZP4NVIQ\L",AFEC!P',/S)-#PWP+
MGN+6YF:0N>G`"U@!GH*UG1N^HE%K1)`L.%#!4,6,9_6H4'4%T1KCB)I9J#T2
M="6O62?LM$R#6E-I81B$DOW43H$L\HJC(_/BA>#766FS[XQI5_9T;6C76G39
MBN\L=JV],IHN>AOALP6*4->32135HAO6.%]`J61JS&@KJ&_+)KE=,<)JGJ.*
M4%=8"R=JL(S11B!V<=3LM01HQ^>MCQXG.;E8PH\'B'`U"J-87'M5FN:XBC(G
M"TYJ-]\Q&9=IR&-@EWZDLGD,1G'67-C;09/%\;+7>-@.A512[`KJV&M4:H<Z
MLL3_@CG9ZV]HARKU)4P*VMBKV4B+IHO3*8O#8*]I604U6>YJ@:.]DE4]CJ*,
MP6)SVLOL];';S$0LL(3:IVI:J"3<5!`28(]8HR0=-D70#BU5<1%E$;AE++6#
M1&VB@&R16R)`9XKY#U'@).Q]^&190J.].FI$<L%D/_KA5*'T@KBQJ4H0R&78
M$T(F[&YEB/Z+"%\\<*3M0>J0TZV![OUGY-V%"=F._CA`?8Q10C34K\Y_HIB]
M)"4KAJ\Q@F48%M#5YH?JCO)J,#55\645Z51_I`4M0>J81!AG%4"G*'27?=>-
M4R?H)U>$M2_)CZPDIH#.:GV-T%:5.QG@2E((I.4R-IL`56N8((S9M45+W^8Z
M\LK/0[DWV7F"!57L#)--6=S1-6G/6PVAX2W+%+(L=G$/BS!0)KX=&8P"B.YK
M"M35=K,(%R*DE+_H;S'>`!VKAO!6(Z(S-2(,99N[,^2E]#TYM4TMJ[#9;"PC
M4L5(4(QLXR/PBR_Z&E:ER+JN4-\1N\E^R6*'24WA_9=F*MS:-KPE9W<A+%PL
MG:[Q&G&B7<`B_!5#`VI%V*K#7RHO=F'O*HF\)0>KT(H''MDNS/=3E8<K.6O-
M[MH#3O[3H:+$?M&%M#]M5.4&Y2[D_#4Y(XIVM"YD^C5!7]7L!)_:M\O5)]&T
M13>A/=??6SA@IP.71-X%\(1!Y9(*.ZGL"I(F]W2";Q@(\IBLU=&!&CYM;ZRN
M%?,Q1@\M"X=N^1^;0CUP^?=<6,%ZH1ZF'H/"++9F!4,9+H'U4MH%\&D,!I?(
M<UQN`NU*Z;`[\<V-9:$;Z\TU8;?1%4CS?C/)66>UJ-Y4AV:-4Y,IX`URK]4B
M8XU^8T1Q!A'GK]$X,1"F;>BYX^S=<?SH+.D"W-'L88232Z*,^^%T]5_ZY+K@
MLM<8`$*NN<JJUMU'9./TW=]3FH1U%[)]-$'Q0[1Z>!UYMU'<QW1MGI";DEWC
M(SQ($TPT2(\@<ND$3NB*B&!Z%A!*[?5)7U//:HZ3NQ`3"8!;R&OK)4U^:WC(
M\VQ.FO:H!GRE`SS\0^2A.6.M64%`Z:.SM1WMPZ?F@5:%K@>($]!S&7+01+'N
MNKWMPVST/=H!LZ(W/&;RA\.W6T)`?/-"O>*ICV<4#EKX<YQ\85<\QG<A$>_0
MR'D1X*#6%R9Q)IS2.X-"]-5)<@%DB!9Y`8K!Y)%(;:Z_<((AHF><B-.#R2T1
M79V`D[UB;%@CMI^'E.[OP82*743YV+R`^&W>'DWL+':F4N!&8\D#T,5'V'#F
M0WSB!NAQ'RN"DB5O&TA5FFJE6LZM>L#64@W2&%?[NV!GU:"/CMD'WMAJ%'69
MY@WN;S&+JJ(0"Q_?:`1K@1`(G[A@=$UW%^'A<U-4*]BKFIC$QUMD]`"__U4K
MV+=%`BN$(.V3(;=AJ=.`FZEE;\'L=HA0,BB!5_;5>.),:$DZK+<ME=!4X0_@
M(;&M5C(N*>^Z0>4@SE^68X/680V%EWSCPQ$<B$])Y/XV)FOA745S"DWVY),M
M'FM:(C8*&9!7SL)/G.!IYL14!,(H?F8*W6U*Y")TAW$J\]EJCV.F=-E\$41+
MA'"6<423,9U2Z=]M"Y2\`XAM/(<H3Y1B9+O<W"\/4?A,5$CD];\[L8='$2%P
M^3L-\"%Z^+]04KRBEK$M0OC2FU/G(B/[?H$X*#JS39_7,]TW>2MS&RH&B-R4
M/F`^F$P(J#$]*-=^C-CC9))SI=#-3!$NQG(?`R<4`[/5!J0,%YF^)O*CT@02
M1JD+8:-11^`$\J?SCW;E<=RBR>I%,'K>V1\_D?/OA].,:8IXM=$IP&BT+1)M
M(3#>1*#()%^]E"DFD)'QC7"LQNMU%[HQ(C_>A2L[7"93]=-D1H1QPOZO$79C
MG[%_'A_<T\R=.F<;"#T[?D#U02*A?"%]$]-GKFZZ3M$N%S08Y/@N/R1?X@B+
M+K@V9NH^Q7Y&_G1&Y;QG%#M3Q#Y>.PFZ=?Q85FQUWU!TD=(E;V-V]%JBY?8\
MG;I)<RQ^8OI&E4>9OE1E4YFY7ZD.M+646VZ?RL58TZ5%N'CA>K7-0?86A8=:
M:\AEG\9KD3%;N;+>N7[#0[1S]`>"P'?D)]1R>$?.]+/OT<H]8L6-W]8*J'_V
MDQE+Y:$4G?F+4703)GY-BK/N**\&T[(6"?/D,L>*4*FZM*$9@SME%-]7UD*K
M*^Y5OIFBJ`"W9;H"?T)Y*W!.YT8M'ON4W70'&$*G2Z0=G"TV1\HUVRM[LH;8
M'&?7=/^TH!S9'*,'12:N?</FL+Z]$ZK6B&9SF.#>J<4U[</'#;9$(3.&??":
MAC9MH*961)NC\1H3L8%9`CP@SZ:S)C7]%0J)?5I64TKM*?"C(%WW)76HV*2"
MAD!">VU(J:IEEV?,Z$K8;!,<!=93^'!9Q1>`9<9?*9YU5DCPY59\`;@E`G3%
M=-?0NEQZ\D`A;*Y@;_8IV\8((8_(+4B@IAA:%+-=1)>S*X[/(/.(\[R8VB@J
MKLSL=OQ&,\A&,U38@D'JE`5L<.3Q;W3Y$Z&*G:V-\<WA)_^BU?2J$@DKE"AR
M';<U"P2EOJ"0J(WTH8Z^-R=G"2=4_WY&^>I):^.H]87`*DO#?4K([F2IG_D*
M2#RYLAX682#U:<K['`060-&\_'<45,Z(2D_8RM1FN)A:Y6J3<^V[A$A+=PJ_
ME+/113E`S^L>%T551H+WH*FIN`IW8QG]&A8.K],IJ;4FD>Z**JMT^=:_%K1Q
MR]D<B-`8<T4I&#R6H$&=\!:N=X63TJ'"X75*_H9_K8]QFI4#P-\P"]6Y<@(W
MI7:1_&G'P:3LIR/``8AW7YT7?RYXM8/?!D((_4K6M1;*2AL0X9]ZTF1OT*R_
M@T$G5T%*+6!5C5K'-Q9YOM74BUW'[U2BR]J_7^)(JP=WKZG-EG!&R0L#[<_;
MJ408&5:T,)@T";>="0]F-_X4T=LQ(#?_OO?CQLR=I^C0Q[_=QFA=67)?].3.
M"YL4302O"?)ID#2'"$:'[M2NJ?-9&!C8W+KO$+94"F'>$-!7\5Z/,5%WF$:W
M*K%4R/RX/\;LW5OAOK$`--A'MC:%WHJAH"QS=L$4PA&2R_ALZ"%=,''48535
M_[IHN#"D+&SM6TNBKX1^!G.LG^]:V)FN!^Q.,$M[JVZ3[66S:@7LHA5O#4T(
MJ?`^HNZMP!X-)?;G=KVRY=FT'-B?3O9*%HAOB+`_E\WRY6G)<MF)&LYU?KA2
M@>0AFA+$R2*4,F_Z;D)X>;)\\[:]>=O>O&UOWK9#MZO:468OO_;H>K9:9F][
MGHY32R8^M$]#Z>RP?IW!A@03T03ENFJ.>YG2;KIH;"A`0+IX:@LC#LUE*TI4
MK"LPM'1>Z^<]2&H"<,;=8.KB*G2I='-+G%1:125[Y(]PLZLH9"I[Z@14F6Z#
MDS8#I(N[[A4693:#!0!/M/Y&;\6,)SIN%Z;#_W:`I(M[.:LRE%VN&G+]WJ>W
MXF;*H`64[?4`L'(_"FU/&U7!6A4[S0+123I+A9N]$%D#@E=;7O\MPO`MPO`M
MPO`MPO`MPK!;$88M*N8VAZK93<S.E0UOF9P[%>JU+\[+[LVGX*RP.4K+;N*J
M6S%LKKC==K![FUY?FRMXV[UW.9$:-A?YMIN8RK8YFXN!`Y/8I.4(O%YX=\FL
M:0CM0NEB.WG&CH$/X$_$=5.BT/2E%%1^+;(Q9%1:06W['O>QFYDH1Y(6)'Y3
M1-H/#BJH_2K5DWV'9*S)?6%Q?<'\\0.:K<1,7D5F6"FC22]K21!WT)_&B-&:
MDL</V<`/44+X`#=.5:V/D8B(*_J(:<#>!LR(P$VAD3:%\,U>!0[&@PDS4DIK
MEG,:=@Q>H,+J5\5+N(]./(A9(5&/I3.2_<<V@`@%A9[`&&7[-S-]UV-1:6WF
MU*TYS_J42\Z=L+$16&YPXL_I"JW350>3K:.>/U>X#9Q&[_:@W>#C#XA;/4JU
M:VMP/D3A;H05#V`$YM),W_('X\I>();%O'5>='H:@;*F(G11)/DNW%Q='NB[
M#&<$']ZBBIF!I+49:/+G)K<FX0(C;&P4%A[.,G"X[8U"M-[DM;!LM#0"!;E%
M77()$`E\FX&M]BO%O(]K-C</<'.#VX7K8#+!**&=KV)$Y/Q1=/-[2JL2M$D#
MX:0P3^6P%\^(3)8L1T3[PT1CHYJ@)*-?TL,B#*0"M;S/06`!]O02%Z8M8X0:
M*O=FJY@.T3.11_*'$U9,F!S3W-9?7`SY6>>Q`>TQ8*M*7$7TPHLR!E3V,Q&0
MR97H"CZ7UD#QK2AC$X'%S=>&M9O.M\=/Z?@_R"470.%L$N:'<!O#1,#GCX>4
MK1*2^T+<W@@E2X:PM29<OJI7%S2A5\C74S1'@#,%B^U%:T.Z3&_H@K5;`<5Z
M_!3-RU`O>BF(7-5GGJ22`7C<NF+ZB$&DN_*BEY),5^QKL?D/W"LHS$U0%??X
MF0?FA),#3D%H0F*A5;L3F4R[(2QV3(`G/1E&7M&+V(74$&VT=<6^+B1T:!-!
MHD5T(25#&U^Y[;<+B1+:*&NZC'1+Q]I.`YZ"WH5DC<9;6[JO[=7;C.SKVDUM
M<>*#&0+P?-9=R$G0QMZ@MZH+R01P]!%[N+J0&J!--WT+?Q<"]1O?)ILNZ0+9
M`Y(*52-4NI`LH(W\3H$OX`']#:J`F'9H*5@=+2D08AFQ)'Z@G%07-MBD99;X
M6E=6Q<3$<4V`[PDUX_N.>#:QMX/$[O_LQ"P11!*S#Y13,)_[R>K@T<0(PH11
MZ/I&T@M,!4*OTS4&X\"?9H#P7;K\MA#.Z/L(XPH]MV[*#=`E':R`7Q9L(6@,
M#_?RVID3506S#*'<[*Z$`[>C/?@\1>ETENBC4^YG),AAD";WODL%NEO$?\]&
MV`PZ".P:+2+L$[B<,7T9SM^*C%7L!(Z':B2>)4&$FO#:%2Z(+Y?E+_K1J+P!
M8/##B,AJ,W+M7Z-G%$0+EDE9B-JKJW04/:*8"@"W43Q(9B@F&(P(=%+438S=
M,:I0N&NVMHFQWZC"&5N;1XA"]@2OVFU\W'<L2[TL65:31)+;`4>BZ!%(H%!T
M(0)%#]$Z::<+82>[['VNM-R%H!,32%=5'O`H$V4;H5SQ5#"*<D4T<'M8*_@;
M$>'@;:)ZW@=!E.J(5T,<RI^R4[RU1,<0<O=NF7U-(VY'W+7JHAM4O`RQ@[*4
M;A,=I5O(9C+:L2%5^*I!S6[-BKE&0=VX3YBWX],Q1K^G!/&;9R3WUQBKL<2W
MI0@:&5%S*\-RM7-A,^#Y32GZ5U%$Q+%JD+:LI(VPM9D:(;2T_V,<N0AY^)8<
M4)H404,.[^A6=X+'E*BI[F`R0;3L/0]"S1$@C$AWCP/I>_?%=R,T_>H'""=1
MB/*#+#AAO&9MS"_>Y?R&%L!@ZJRM!Q^$$@\1IY79V4??(X79BU809Z0I#]#O
M;X\9F5_<1:T/2):YPYXFHD$H#\Z<_%.U*(9"1V!\6!I#3;D\87/KWKQ[0-_9
M)W'ZOU)GZ_#:UUM^^\2W*G9O63LWL1(UMP!VJ8S#;VL!U-)**KRF-L`L=T*+
M6EL"N?RJ$+;O-/1`H1P4'M_SG7A9NKQJ=@Z_/8SE4&XOX.1;=\>:UQPUVRUL
M=8:.4G4-L2D"/K]086=*-.TUD@)-%'X!ZW=G8_0ZL4.E)H)M_$HJO,W)OTU0
M*]D'NI#8JJZ&EIT;)2,<>+*Z^%GA&FV@DNO#E6,/.-1)BSB*ZG$7(I^T\!::
M-+H0\61LA6O?Q+4W`$J%!HU<)^!Q4(8W0"/4[4VQUD&]QIP,'@2DGA4KL<7(
M[KK-"*X.!+?IH"I0V<'#U8PA*U)^<PS?'0B&7`4JQ_&]#9J?-!%;;G.L.9X=
MT7--(FN[UJMLU)1@NZU"0=4T4UY6J?U3(#L+]4J+4^X?H@3A473KAT02(D+0
MNL``'L13)_3_8(8V6G`D"GPOL[J%WB.1EDF;O#H/IW,1(38BL%T&A#I[S]H7
MHW;I8!\/)F4L"%)/_C3T)[[KA$G?=:.4A90_$K194/F!H;'ZP2)T1"5.[-Y+
MHM#L@X&:"2DV[9-K-+9\3^3G#C\Z2U;:+?3(+W&*O%(VV4%B8-]>6<-(2R@5
M[^/F^_\JP@G>>G372F:_(R;6K<QF#3.[ST->2FE=EBCTAO2M9"MWBJ1&D=U$
MWDPFJ(?QQU,Z.7W:FOSG_P%02P,$%`````@`;X(-1R]$LDM[5P``,O,$`!4`
M'`!P:7)S+3(P,34P-C,P7VQA8BYX;6Q55`D``]+[S%72^\Q5=7@+``$$)0X`
M``0Y`0``Y7UK<^0XLMUW1_@_P&.'[TQ$J:?(>D_<O0ZUNGLMWYZ6+&EV[WK"
M,4%5H4K<J2)K29:ZM;_>`/A^``18()(UCMB=[I;(1)YDGL0KD?C7__'ML$>O
M.`A=W_O3=]:[\7<(>VM_XWJ[/WWWR^/5]>/-[>UW_^/?_O-_^M?_<G6%'A[0
M!]_S\'Z/W]!_K/$>!TZ$T9/SS??\PQOZ[#SC?8@^N][OSTZ(1XC^=X-\#_W'
M^X?/R'YG(?021<>??OSQZ]>O[X)@DTI[M_8//Z*KJ[2EO\0Z_83F[VS[W;3P
MFP?_Y&U^0G;A1S<!=B+R--H0;<BOQM;L:KR\LNPGR_YIO/IINOH_Q:?]XUO@
M[EXB]/WZ!_+P>'9%WIB@AW</[PKP_CMZ]+V0/'TX.MX;NM[OT0-]*T0/.,3!
M*]Z\2X3N$[B(&-,+__1=`>&WYV#_S@]V/Y)F)C^F#W[WG_\3BA_^Z5OHEE[X
M.DD?MW[\CY\_/ZY?\,&Y<KTP<KQUZ44JK.E5:[5:_<A^&S\=NC^%3,IG?\VL
M)*$@XCY!_W65/G9%?T3,?#6QWGT+-]_]&VWP7P-_CQ_P%C$=?HK>COA/WX7N
MX;C'WR4_>PGPMEF+?1#\2-__T<,[\BTWM(45;<&:TQ;^:_)CYF??(?KD+P^W
M7$"KDJSXI1^-*?GD1\Z^DZ:%-Q-U]_0?E%8EA?&W"'L;O$E5IC($7Y<UP1R#
M":5B_75)X)ZZB!\TFH#)VCKA,Q-X"J]VCG,D@JWICW@?A>E/*)>F5V,K\8G_
MFOSXM^OUFA`W(H'EYL7Q=CB\]C8?@\`/;OP@P&OJF.'U<Q@%SCI*VV>H__1=
M)Q$_9ABID!+*`(?^*5AC);/%W_%LO7[;/U,QAST10F,L]JY^>?P.N9L_?>=N
M?EO.9]/I<O&;92_&]G3RF_6;]=V_Y>)1(A\YW@:Q%E"A"?1KVLC__==87[TF
MB$A(QI]![&!KM,-U4/9Y)UBG>,A?6PR1//'CVB?1^!A=E=QB&_B'CMZ::N2?
M8<T?05E][^_=M8OE.5Q[`82Q52VD_7*^7,YJ_$RE#8B*YP&L$D\2H'F.\=RO
MF5&-1@'D3WCOO#G/>TPH3GX2G,A@Q76>W;T;$24_N.%Z[X>G`#^1#O\]T>9W
M\5=7EF:>>:HJRGKM?#F?E[O-$"5-L<XB:0P56D-Y<^A7VB!B+<(2MU_[I*QF
MIL#?CM@+<3@`'G>E00/).QEPJ!'@"['@B73Z7B37NZH*&QC_ZQJJN/=4C?XC
ME#<WE&Z[5^LTDA]YOG>5B!UZ(."S034.<$PY@#!PZQ%?P6'T'CL!&:^D_WQP
M(BSG.B(!<'07:"4]+IW,K54SQ4<H%7CU'#>0_P31-@9!:FTV8$2^)S+6[M'9
M(^=`6QDA-T4<<!`#<5G"I07\;;/:`#C[%#@;?!/'$SE7*+T!Q\JB&K(NN)PN
M;)M'0R9PA&[X_8EQUG7'R&C&7D=.BO08"QT0NYJ<3T"GFCF`^$,[Y(_>JQOX
MWH&HXNP_^V%XX[-).O;6I3Z:_Z&5I)CEF8IJTGXYLZUQQCTVCBLU@6@;J-1(
M<90+QL?^;-$\IJ4=A!^P/2]@IG9Q\PI[E8T'R.C"$+NU/^0\;YZE=26D?7`R
M'5ME/I8FF-#]H`YTTDM&YR,J;)OVB6C.^G7:&.W72[A&:!A383&7&@($QR:#
M"@7M2U@M[PTA-"COIBQGTU5[B!C"`I1.P$-<:);S2BER#6'5B*.9MY$=.+>]
M/`BZ%362#O/V6,"Y@?5=9R`4=&3#I%J3;\KQK68D-=(=W2"D5)J-YY,Q(Q+]
M2=K>D_/M^K1Q:2N?\<[9?\(XK'S&UL<UDV7CKT]LM$_G,(JZ2#K1;+*<3NW?
M)D6:$'&(R4-$(&(2$179"V>:`H)>;!88-FY_JQ=@J9MU&#BZVQ41J)"10)9<
ME/M2!@'J8D^'TYZF9=Y%+SB@^<`!?B%&=5_QK;?V#YC.Q+_@Z&Y+%.?'?24I
M9CM=%=7D^Z;5?)%1+VT!L290J0T4-X*^I\W\,$*D)>1O*5'!QL#]&<2N&L1G
M!EF7#+(GXH&[[BX^7^G#E8VHIS/?D,A!>DMG_[.[IPN`'KYWWF@G^C,^/..@
M,1"WO6.\6V]12+9[6%E3>YST[9E(E,E$B5#T:RRVGTDGOX/7BM*"1=G2U6N%
M:E>@?G"=G>>'D;O.48="N&:Z?DDJYOV_C)5`!@&98O>.N[GU;IRC2^9;O`Z$
M\[3)3KU9!?D5TN5L5F,4%85<#R7"@'IG'<BJ!#H245<$V9J/S%C?*W:U4A\K
M,`4,2_Y^"B-*U_#)?\`4+*$QZ>+S_O[)OW'"E_O`?W4W>//^[9<0$\7OCO0<
MH>OMKM>1^\IF_&VKQ'TT992?^O576)K-DB1S-5#DHTP1-@8O#<OIKZD^*%4(
M/;^A[ZE.)"+\@#*U4*X7_&(VN)'M!B,'F9$]8F0ZU*<_I7]?4_L>"_;U,ZLZ
MF2(_P0:G_AA>CFP]?3D]4XQ=@#%5[@D'!]=CH_@O/AE]X7L<N/ZF<0#8]H[Q
M*4:+0I*./K'MU=A*IABI2!3E,I''A*(CD_K.\`Q#*TBK#+(@$\5"42P58GZA
M%:@M^37A9A:2#,QG%C+VT1P<R*O7W]SF+83:0W#T3S20G8':2VL^KO*="B'=
M/1%C>@GA/!A51O<,0Y;#G;#82E@,T[3"A09>%C'K)^('_^"X[41('@,E8ZR#
M[+<?SQ>K23,=8T&0A.P"I9&2?4)1(&47/(VT%.`Q3\PR-YJI64"NAYS[/0YV
MCD?&\X)E^=I#QHE9U4#VVR_&4VN1T#*10>?34`OMY\&PS,)H(>1Y6&PE+&;(
MR.-"3L5&S"!+?'LF'&\>7YP`OZ?5O>C.'O9"QJ&/<;8!;SU&[F63RW!2&BF<
M1<C.1*6"$9-\%==!*\I&B7"@I;$>@-MY'EH8^>O?K_PC`XKY0(VM6RFY;6DE
M2MY0W?D8XO6[G?_ZXP:[,17)7ZH,)#_Z[9IT5AO:87W:.[O*EZW_W@"/:HW*
M5Y<A`X*$*NG[B`HP2X<S];?E]._;R[FN01VY&2)(WQ$$M(X56]6-,SF=_"=/
MY&^A$U>U:AP1=I5BLC=14TW:UV83:YEPI=`"2_$C;5P5&D'%5H"F34:L8>NU
MAK%^J!L%2AU2![."L#T,<51=_*S\TB0W68O2`YI%OA3!7@0Z+=!!Z>)I`*[J
MQOR]Y`0E-\ZAP7EG6Y)!^2'CWJJ\YSR9SY=%KX7?@3\#1QSB'Q\_/CW"N[!P
ML[H.$LZE6\Y;EYXQ[M"JYW272\LN^G//1ZGEPG$G$(6HG-8:&TIT%ITJK@$&
M=VRID`UY8KA)`?E9Y<JV&AU^()'\+%PLH-^4O!\VF4GD5UP:Z$\G>N^$;GBW
MO2%C=G_O;MBZ$BM0^\:K]RK]FNG]$@F=)'UF.K%G=I)75"C0ZF_3(DPT*^[(
M1*.M']"+)MR0_GI=;#MYPG#6D78KL(C`I**[+2K)C2LROP%6KNT'LIU#]BN0
MP39J%(B:;=W(&@:B8TUTNR?ND)+ZVML\NCO/W;IKA\2Z6L'LM@K49XDTV$V?
MHZ?\U063=#LH<^1B@VS)JM`D:JRS#EZ1VIRI[!93G0X')WBCOVNQ&N2H0@>I
MBH./L\T/$EE.H>OA,+Q>_^/DANR0RD?RM^@MK=L9WH;A"6_N`OHG+4CXY417
M*^^V;)LM^2W/(?4(-QEMM&BLL$(^2U(;TX91H>41BMO.2^/&XA$91:7-CU"L
M`.,:4P$H]@`8+DG8V@7L+B84,D'(C6UT.M)@E&L#&FFTDJP4<_297<L,Z8;>
M?;;?TX;B!O@Y8[Q'3<^$.'I(NN)J/I]/D]E/05+"1:`L,BV0+`A(XKF+%EQV
M!UQ&)BTMW,DF*B(K0`PAZ.DN,M"A?]#8\^KLV8YG=.,$P1L9[/S%V9]XB69R
M[QH<`$@II)!M-;=3(H4O;&S,_E(0/4).A%+IB(GOA5GQ.:"/WJ:)73VBGY;0
MLX.3.!=-P6/R<S)ZX1]4TH3],7*"R##Z62OZ9[QS/8]^^WYMT#J"ZP&]+40/
M.2)3BEG%`9>\E883BC\Y;L#TRI=GE7R@Z7WPD-R@E'SZQ7(R;PW+M($X'A?N
M'1L2-<^V@"UM@>%15>#3[73E66XXE(W/NMYZZP`[(?Z`XS^5W(,C`IRXS7I)
M>^[<7HU;N1NW@=)&T/=I,S_`Y"/T9PF6KD!K@&R2UQ$KCG,Q7:[8T=NI++`A
M")MQ$#FN]]EWO'A-)J"U+EBRYQ8'7_QT#1AO/OG!=?@!/T>/>'T*6/V+NU-$
M+X_?D&'$>V?/;I'GN)/F5DS&!+VJR^?V9"NMB0:(J8!2'2AM4BUHC0B4Z<$V
MK9T04550KLL(%;1!B3I`PP-(FR8G*ZA\.H,)\#&IX1?YZ.G]GY&?RP>-/OT0
MLQ2@>O@,(#%L[X3AW?:1G@QK/(TO>-!D)*FU+KU[L!BG9V69$+9W0L4`G\,X
M%Y&MB,@8][@.5:)/,WI`!OR5G=>([H('=_<2??R&@[4;XOO`7>/LEV'RV]`2
M?U1%6>9YI*:@_$;=-+T`+7/,1!C=Q6321BAM#;'F"L^$V4-`VYH&C,-8FUG@
MF%K@:R)U`,3MQH,&;G<PHYY=R5+S]#!6W(0P:[/])>,[E6T:23K>W)ZL5LE%
M$C$K[PJ,HY<MQ'+[3VGB[V#JA6K!0VW9V=2+E\64OP)&$#7:Y5N;4F8`&1+X
M=,>5W5'YB@LG._,5Q+:$2Q4))KM_>;7D;Z]?K-+U]:)T5!!?6%,?0.9D;T9@
M1'S`K]@[P28[=O#?4@>N:*`A4518I*#EI0$04?'0_60Q;>4>3`I/'T#M[D"A
MF<<O'"!A(#W#8O]PH$/PPB4.HGP]_M/&!\)<562/KBQ6RV52]2T7A@Z9-,/G
MD'0!LBJ`).\8Z7MPJPF=W0V=F;%N*Y?R0:[8'-JH[;*R[/G%XV]T.(W914_W
M3A"]%4N0<`[KGB<+(BQT452VY/9B,5Y.\J`1-S5"A<;B&67<'&+M52K;]'LV
M6!A?^K>,-5S+M`>H_LUC]V8>8Q'NG)!2BG^=K0TSL4@5IBL2N=(N#O/Y3TNY
M`S491J<="HI)#\[ML;VJQH.X\E>IA=(J`'#=A!X-86LTA+EI2P>G+\]B5.TY
M6&ZW+^TI"1D:NSNL;2W',U5Z#V"1KS];M#-\\%QN6?]3MAT4FWV/I1`D5^S%
M)Z0><(B#5Y9X\^D4$579:4A!@IVR',.<5E)._B:T^:(PBO>].(=DE%XCF9Z4
M2QMBF7%Q4RAM"X[:/9K$+IB$%<Q&0=$$K@"[28IW\OPJR]7-"$STEN7]ZG,P
M1%5<VQY/TWHD12*"K]N?!<=6@@/`&]&"?!-R8+\G\^2[X#&B4V9VEN4>!XRM
M[5^/^R8,-WCJJ,3H65.W1033_+%8='*4BPB/NS%P#NF!7>^:C@3U*\/J;]-B
M&&%_E4%><?#L&P9MU5"/<M@#B29M].3$%Z&!@"-./!BX/D4O?N#^DUOU1_0&
M3(2IJJ'2<34.B).!<"X1/)J<![&!3TDU'4<($8!7/"?D\*G1+H/@D;!R%N]I
M2/ZHE6BBZR)+/G=&22VK@1"G"S8^:5PN-##"\$M(B6PQ"*(4CD;)?L[B*Y"4
M*>BAXELK$6_NQ`?J`,C3&64#@X9R7%#""84DJMH$F$G"&DS5QV`8HU9?QL[J
MKY=9PJ0,IG/I@*F!$_]M_&X\M@H3NR.9Q+*N9H0FX_%H'/^_/F1CNQ#V:C0E
M_Y_9=OI/>Q'_,YD<TI\6:$>+$OVODX>)Z!&BF47L@0]XS58^T,1B/YT.A)W\
M0CU-7P&(A<<`OV`O=%_QK;?V#_@+CNZV3\XWO@-QWS#+39X:TBX]F4SSSBR7
MAF)QZ/O/?AC^,$*T@(6_143R"%U'4>`^GR)6FR_RZ2H.V#TBVDPPKYM@3Z`#
MDZC-+RM\$II"4]JB%Y[V=&\QN]-:E)#,>]A\XB%'$^E*^M/Q<I9F%J:R4'X7
M.5`943VP+!A8;2E_6K#9G;`9RM=KX5(A(4]D"\W$CH?'[;DUTJ_!D9VKDT)!
MVLFX1OMD<=%D[HQ$"-`$MAH,`,#*!@9-B*LA@E^EW7!8:&5B0X`0VP1F>.VQ
M#,+P@<Q0W%<Z:KS9.^Z!YBG]0DS!:O+$]8EX=YPJB3`Z`)?72[YJW'*:LS`6
MCW+Y(Q2WP.9\61LH:01J/MV7&:JG!^F-`6D/.,I/@Z&DI!7P<%W=S\OC=T4K
M0I+YY.SOGO?NKJD3%C\+0,^2`BK3PFF9AT0.R@7!<NT,3(Q4=Z?HZK.[)K-%
MC#YAC!SF6$/@3Z-K-1&E;@)-(V'_B.-@(S7'Y3YM?MS+4T7V&-1TLIRMTN%N
M)FP`TUP]P"P@8&WC63WH[&[H#(UIVSA5&,H*S0'3Z84LJ_[CMR.-E_Q1:N4Q
MHUU=N6V%.N-Y:EZ8'(M(A>@EPRI&X;&[H#9/[2N[9R%:E2%A`21S'5RS&Y7[
MM@;40_#YUM.3G,<!.:!\%'`VG2UX7!C`Z4<=Z.*Q7QQ@O1U:#YH@XL.+`G,,
M@3#%P]*2G[3T"B!QBGJHA-TYCSRC\LGY81"H.TI&(M:!#9(V39XGHD[-$##T
MH86W@R-5XHMSP-??7/XXJ^%1HW2IMZ]PW'R1'1S*Q2`JAW0Q1!)8]W(N*%L5
ME#E^\%VKS`N.";KS(<3K=SO_]<<-=F,JD+]4&4!^]-O-*:`Y%)_<<.WL_X:=
MX*.W^4!(6?E8PD<-,$#4OK2SS&=9VG$L"L6R$!6&/M)4)B+.+`OT`;.[`.N;
M"3(N1IG0:@8M"VP?'-==O[B/CO?[FW_KK?F+:YPG32^L-:LANSICS::+Y/[9
M1!"*)=$<*\-E['0@L9J10"ZAZ8!E=X!E9.U,3)=LW4Q@`XCQ'+T\1;KV$N=A
M@V.Z9@WD#STN[*1/8Y<0#:AHD@Y@MCHP4V,[L9L51W<"0\#SHZU^$>]I,(9T
MJ<(SGW(H`EYX2`NVC"7#X8.P8I`(-!0C;CU"2S88^^QZ^#;"!]XB`.]IPXQH
M4$'A8&]:S(<Q(A>%?J7"$),&R(BSL=E=L)EDBL#=JDSA&0.>*?=Q[M,3#B3)
M4GH!C"]%+53<:MY(&5I+)+[5D`D<`FFZ`TSNI$CO:<PRWM`&A^O`/?*RCV"H
MT^1_?/;4K`)/H`>\P0=FU/BN6L'2L\2+8(1JTD;![Y8VAUBYW.S:9LB%:MV@
MFSHI1=`PO!.Y+9]_7(,-CX?"JTVE7AT,%Q4O"YTL+5XWU^28H'>BZ@<NS\@!
M7)VJXL+RK`2^7E6LW)V'A24=9=\>##LSE51ZCN:I6Z.?$OG`E2%[P2_-TS;\
MP^!JS:WEZ5HVX/`8^_35/X.Q^=N#86RFDD+VVU*A2R7R!\W8COBE&=N&?QB,
MK;FU/&/+!H1G[!,][B7E"O&38$QDS2N,Y^SD+./C^@5O3GM6\_2S[^VN"`,.
MJ.*+])9?*G\0G.N`U-:#%(9=)1?D,RDW"PQKMC@(\":YL97[(<M/&65+J6GI
MQ-+I?)JF5B024"("B@MGX&BX]-/);\D<(>*;H;M)3OG`,J#1G<K>7S?$`#R_
M<.OH^[<GTKBX!Y%Y%XXES0I)^]QXDIZ8KW*G>-?L"#V_(2H<NI/1#MW6`AV(
M<V)'%C!18+EA\;-]*[O]S4%P4WD;F+HGIU<KWP(]@/UNS:!;.3F@C7!IQY5C
MXQ`VR'FZT3@AW-]K?7$03$RU4?%)6X*(<1\!NKNG%W([#5L@P[.PZK)R)"R9
M:W@<;-G;DWAU,#Q4W.*:S:PIAXG0&WFZ43:3;QB[=O+.*<\W\%V[DG(*V?=M
M[\%Q[8S4]<ER,N,0;5#Y^5KQ-E-N@&G[DJXJ(-^@DOECS9Z<;]=AB*/P"XZ^
M$"O$1^E:OCSG)0#.-6LB7[%O,EE5"$<DHEAD5D*<UGI/ZA/M]_Y7>DDE^5W6
M&BP+=5B@3,&(6,"A(H=`-[%_-G%-8!!@HGUVG6=W[T8N#F]D>=;P#@S-ZHK(
MWT$QG2P;6%:0R*@V0C<#(=2Y6.M\VN<2!\(JOC-R2,4Q"@RGC@%>NZ)*GJ5'
MC#(F;U<^"*_&&4'RUZ%HT!6`+0/`G*?77:3LV!68>NH$D''>WC^R`H!II=_D
M^$`HJ!G0_I;Q^@&M*DGZQFQN359)/?J"T(9"R*;K"FA&:%419E+3<SXA:+T!
MS7!M+EPQ3#/U!Z1IF-<BD+,/2&^7S1KOMO3&'.R%C+=)$2Q6&XO5T']V0EH3
M*U:Z;07E/*$F>]2S-)5?BUBE5R06EA[(Y*_89%83CC6:7)]XQ=HMD!QZ><:@
MO>S>[65LO*"%9*41QOG?8=#1YGU1[=9J$&=*'6*\:595OD[)<F+K"3CPQ2A,
MFBS.6*5W,":&6!=:O(@0(F9.IQ@B,*R>B4U!D;S!HDJ%C:7P_5M-J>NO3K#A
MC$GZ:,'XA$FK^K(7QHUG=.(]J021NVT<*!"37PXH12W0^[?2@VD]`J9*W^,8
M_L0,T)+5<'P1EFR9^`&:LSH\-&%.,Q/,7L)A/AG5_\WT]`))%*25F+W(C=YN
MO:T?'&*-1+%=YCWC$5M"*>F+.\=D/I3$X40LNJ;5Q)E@5)`,%U:UP[4&`+<E
M]FG';)^/V4R`4F!J'G9DS=5_=>E4E;BF;WP`\A/Y634+5ORLH?K27`6D)S:K
M^6)1X5-2B#DYW<K$F2\PK0F9W069B0K3K6Z6EI@6&\(T'VB-:SDVY$^"<"%K
M7J$BN35N9@(K23X('G1$U<@",2KS'*BY5C,#RB8PY_\Q\_A7#30_9]CW2XU+
M^\ATN:R.J9(0"7?!@`9$MBHBDS[?Z$Y5CZ^#-^?O-$=;\%W8KPU[-VU3NLSP
M:CFO#FSH^W">K*Z]+:6]2:\M.D7563-\$'M''YW`<[U=2!B3+DFX:S*;^.#N
M3Q'><'8/VMXRN/?3HHK"1L4\&<6D$FGDB]>T1HA)9;>-)7)A=FVT@F4LH?G2
M>S\,T9&`#=,%O`3KAH_5U`Z-I'\6=V!DC`1"M>T6KVF9BEMO[1_PD_/M@?1.
M])YIUSL1A>_2&VEYYT85!)@DH+16\C=]V78RKLJ$HU@ZRT*F\M$#IM[C[N-\
M0%93:@V6B-R7#>RR#6A:<@`T!NONQ25NJAD*CJ9WVX_?UB]TP9XJ>.?=..$+
MB2'TCX__.+FOSIZNXRN3]PRQQBG=75?I).3E=&(5B4Z3*=)&8YK['J(-LNZ(
M_:70]`CEC:.\=<@08,IF=MEF.+49C0XH^3LQW3HU'?L+SC6`CR#G$ZP>5\ZT
M/DBT.1SW_AO&27J(]'FC]O=,QHLV910*>XV3`IJIS*L@R:<JG3T"/7:D&2[C
M\O5Z'9PJF5'IO;^@9)7USQ(;I0RD97\[;8I>-4R('9[VD2,\N2%^P?2.ME`;
MV7W.Y6(Y6\1;V9F\..KG$@T?U="(RRKCHANX!8F0!S0T@F0QX"YZ(9/P\B>4
MA6IDBUJ*;-G>=+MY(#O<1QR\NFO,R=79,PW(W^ZV=**Y\]Q_XDV\JLPR.#^W
M5%O3W0I`9ZY)=?EJ[_-T&[&8,LU+.*.U!AM2J^-\LU'Y-:K0`*J_@1K6!C.L
MZ9&*9F(WC6MT?L'!QL`OOO>*0S)\8U\^?/(C9U_\/<7RQ8_^AJ,JRD]^D/R(
M/F>=0P=]2@PM@FI#IK"B.+/*HRF4:(AX@8'53(G5C`-`V!0!B)KH#4<H5S0K
M\;_U`U10=L"!%^A[)+?PI1+15^SN7JBYG5<<.#N,PN03'5E;@P^PVJ.&<OS5
M^R'_4.&9'<&Z.PJ7J8VT_4<(QD5`T@L^L\EBK#L&-X5?IAQ*M/N#1=WNAF?!
M]A<OR,-M6##Z4)?>C(0!(V&V]N7ZS\J*L^)OR`PF</:WW@9_^W?\UI!LU/R<
MH3RMQL;EDSDL*RE!F1QL2`0A)@D14>9SMS0@LE41F<CG$KI3FMC%!V_,W_W#
MP?<8W1A[P[M3%$:.MW&]'?]KB5XRRP2!)BH)W),R+9C4N&M,SN6'J"`9C"7:
MT-IGHC7((`D'K="IS4JFN/7)W>/@QHGPS@_X/4GY*:/L*34M[4#6S+)*=&%B
M4"H'BAQG@+&5P)CS_48'*CM[';4I[W[`.Y<>&_2B+\ZA*8^]\3&C_EUN6R$S
M?%$>)N5R$!4$Y>'GP+'5X)CS\68W*CMY`W"0U99_G(@R+;77*@^97+\HM2SO
M'F,K*544"P"O<78.#EL:A[&Y>:/3E";1=;QPWDTGYKY')B3"&U&:GS7NZQ4%
M5-;3ER67SP0!WWFB`9:M#,LL$S@.5B=$DQ7T)((Q\3_CZ,7?W+*EJ;@XG\<V
M7>L_%]0^Z2K*>/)8-STE/6^RG$]M*TDKBSTO%HD*,I-TK#!J^AU4W10C=K$&
M:Y>6I#43QK'[,HZ9-+?S0DF>`'>&J?7$Q#!R#S0#]Y/C!O1*%%J3D-Z%0N],
MWL<+^R'[>:.GR+]M//))JR;IMZOY?&XG9?DRX6A+I*-7*H8>LECG#<3[1N$H
M_J7IW-J>P%ME\%0ZNT>'%8$K-)`L)H[B7T*$L)X,8*M^?:X!S(0I97;GD4G-
M@OT%HS@MV/5V<9-?</.`3/+5082ANEXJ7KAJB4&9],P)OS3?^F0X_IR+6AQ\
M<M2//:/N$'G.A2X..]4//JQPP^>O.-9P;-9;H/GB>^<-?/@"AA!TN-JI>.)"
M''H\=IYTN$,@3380!J(O[#CRL$="FNP@C$K$%ZXN8T#42GQAG!+;4D^T^H;7
M)UH1X6Z[==?D:[-*)0%>$P&B8XP2KQF/3.TZR:YZKJ;+^22)1ZE4XGBQV*0V
M32+8=.C1#=(J@TS%LD623##H,4?=B.VS$9L))_+,S(.(I*TTA8XC$4PKB$>$
MEN1?;ES-@%9Z;/Z0@N?-!PN^,O(]U6PZ2Z-$+`X=F3R:OYL(1&]$HO$@H0N<
M50(7RT.Y0%:,%"0FZ`)H2WP]P!#0SK`"]UMLHHOT))YLXBSJZUV`V:E-T4!!
M\#P`Z;G*2%]F:$_3"U02<<AG\I"3"C3/=DVHK"*J6![*!,*.`71!M#M#-,7X
M5GH5&2^VBB;&DW@2DA:><'`0$;W^F'E^UW20W3B<S%:3=+<YE8*(4QZ,D_E,
M"%89`A4#R]PS\=B*>`S1E,N)`CN;D8.D87VCBYTG-WRA_+G;?L#/T9\=U_OL
MAV%6"I&7/B3UKLDT+1F%Y"\BGXZG&6D*<NDZ$Y4\0E0V^IY*_V%4J`,*E,RE
M'SQCV(US="-GCW84+"WT^=6-7E[P'O;(MXK;EI*]I*T$P<9LA>]Z\_=3G'UQ
MM_VK0XN@1+R#T>)W#+)/J(B*XR6;;H45[EPB)5\J$X9G&F$R?B6OI@=[47X(
M&))@4IY8)%:[64`)]?XM^^O_='%`+/'R]IG>TW[]S6UEEOAE"(H)-5+(89\L
MJUP;H4P@^I5*`\I-[@.JW06J<<9)N6HC]=I-!<K!6^]XBD*FD-4X791Y`X)M
M=37DD^0GZ2"RZ'>QP!%B(I$%-`W3CK/&+Q6<QGG&=\=&<G&,`\JHG[%#;W9E
M6;IUZ@O/U*C)@&"=C&(*M0975FU860C_H.=P>H1L=X)LG(LJCMS(3FG+@?+U
M;OO)]1QO[=+R&V$4L$7+\-[?N^OJB7VU=R'X*5)(>AXTGDWL&B_)'"\3C0JR
M1RB6CGY-_GS"WR+TGGRYWZ&9J\\85<86/'L05)7QX4:*MII(RZ9$H;E?DD)0
MQ>I.UV%(VJU>'Z;RINFM"SFUI/>Z)O8BR5\J9Q"FLLL5VE`BWNQ61Q^0JS$&
M!K)X2Z0/W,)TR5-J`9JXMO6#+7:C`>5-JG$YVU]1,"/(:,#UW`A_=E_QYI;P
MWMNYQ.)$*1R%[]]^=O[N!S=[)PQ%"U,*$DR.#.35DA[$+B:3)/4YEG[%Q*-<
M/HH;H-7!61.(M0&[=-67'6R==C`V<%!W]]+P0=&8`V-TKB&M)2.>D2M*&0:S
MFU136#5:K&38/2KY-&T(>L;>IT$D:*YHD`%P740$2;YS+0O!^3]C#P?._MK;
M7&\.1&=Z1)[F5W^,M_$X?M/VED%.MZBB<.W?,NFA$XEL,%F6B3[RJQ9W![F*
M07IXQR[S,H9U6@7KE(1"$E#2*XN$D['-``DFW$"2>W<X9%/;;)FOK,E$EG+`
M>TL]`+=;@`]ADTG)>178J#N%MZ6YO$+ZK5<]&MVT@'&..-/K:F?HJG!@-4T=
MYG<7#8D_R/7JY^L-IQL;,T\ICEWSXUCA+II;KUYY`6"YSIB):A&OFP>!K>-I
MB#+9XMZY1M<3-@,_#.\#?XWQ)OQ$@-Z&X8F>Q[ZE5_0X^_O3\]Y=WVVW.*@7
MMN\BP7AP5%)/-F_?FLQG:3RD#:"T!42;0&D;*&D$Q:V@M!G#`;!'$UB#,D%+
ME.O1#G9NAV-J!QHWD)O:P4WL<(SMX`OL8":4=6)^'KW4C0DQ]XHSX6E./-6Q
MZ5[Z]WCK!SC+F,?AQV\D$/O!QO6<X(W=(OF%F)*\2<Q*]-O=>L3-<,BK8]UG
MBP;G>3W"D%ZDL!>K)*4B.9(2GU")B96KA'*=T#-3JG"$A>[]E12+[U%E5WX5
M=$.I<OW$)7IUDVAR.1AKSZFUJ1ZI)=W8DA%M$G(>:H#(Q=EKWQ\$+A8^DK$2
MR\%IJ<?/>]IX#*JI(+\',5W,2_$C$P5>JU\+-+L#-+-\Y3I;G6O-MA@`3SXG
M=TT+TAA$;\#QI:B&M&--K=F*PYE4'FA*@C:,S>21P`C$H"8W%+"H9I@!,4F8
M/"!^!YY-JKGK2WO:RB?0#`"-.-LX-8"-?2F7E.`5\*9]8=QY[[B;>E5GP8/&
M.51L77HZ8BVG5HDX3`JB8GJH32R_`W\VI&E<BR!\H:O<F&7%D)G$P"9:39Y5
M9T7-"L!4>&`&I7F_[1^O\"P,(7(%Y+,V9I;=P(E<T@C=G(*`<\#"5%=R%KIB
M%T)K=`29G(&0HNYC'%Y4+`!*C61/Z3WV\-9M[2HJ3T/0HZR"0C&*9:W3R/9=
MOT^D_0#>=9R%;EIAR',L91#T:/:S1H(TV`"4(O'Q+7H.CQW#:_N$U<<A2%+1
M066LOJBR9'@G$O7`K/0G`QE;<9RMD2A-\(&8$F`GQ!]P_.>M=[U>^R=Z\M%Y
MH]W<4^!L!`,OF9?-LDA"(^G8O!I/)QFGF$#T?2KZ!YK$DDI'B?@18@V`<4L[
M>,8T]AYR4JS'6!HPYQ3<ML)`62,-BX\RTZ#V5P?!Q0[3B.E,EHD/PKF%H1&A
M;N#3!AH.9A(E[;!R/!S&%*NN7'`BG]UUGMV]&[F8WE!P%[W@(-D\]G:%WZDX
MAHI8:/8JZ*HP_UE,VYA-VT4%X2S+E#6-LK:+OQ]0_]N;R5C/G-J&VL-G]MB+
MK0`:%CHPJ#5DJ-IW&.&DL*(D[4S%=T`#04$1:9>=K58K(<N+:Y]#H6]GH$.;
MG[9[GYAG54,,@T09QY,:T.VY3[("0.G%TTIZB60U7HV%7,O[S+1Z]@`RIWJQ
M0EPB_(4\208-!+F?(7?B>A2TXRQTF3\-BZAM'BYFK="$`Z$P[:N3W:WX%+V\
M@]1?A:5M31_Y.=YJ*1X"QT/=1'A28V$XL]NSD;/9;8S1X6(#9"'725OXUVR7
M83#O/L!'Q]V(ZT&TO@;*N+(N"CZW$`]%$[G052$T`V8D2Z$E1S('1K1FGQ23
MK,$FPR#8`R:]K4LOMJ-I0=+?N/(:*,'*NBAD1-DS(<%RN8@*'@[!S@+,"%:`
MMN9`@^-7LTN*^=5@$AA^Q>=LVOJK\E-&V5-J6GZ]8#K/CK/$$N#[G7.03$M0
M,!^*.1HT>D[9Z^N((9V<)E^V?!SV"(![TW85]J[L2<6WZ?M02PQ=$=A9;B\;
M.\5YO?R#I:8=N^@M35Z=`09QZ?L[82FL_/<FG3EM5/YDWBR]BHB\"URSJJ/V
MMHSVQGRWZA8EQRT!A/#:]JU<H%W9+KN%TYF5#,=[WR%M.Q'?67UV@OV)BA_*
M!F?+7N40MAW+VZ*LQOB+O]^0^/+Q'R<WXEWIT?H:C+\WZB+M19/Y9%PC`5O]
MCP6!\T$#O&:2,)!A0?2_(,R%#,`>H6MR*,4WUA!YUK(O*?WZ@'BGO!LW6RXL
M$?_`=R#[0<P&79]OK]_??KY]NOWXB*Z_?$"/3W<W__X_[SY_^/CP^"_HX__^
MY?;I;T,FHVC74<ELP.1,MF+:'2!]$(9P2>OR)7[L99U:/9\95.C8.L$I=&7K
M9-=S>..^BC]Q:%'$/PP"R/='U1=`":%>3F<VKT]\,F(,J<<Y"V&\/%5G"6@N
M2[O7B>ER1K_!*8KZV5W3Q=WK78!9S8?&92G1DZ:+G#:K(7N]UFRQ6B8WJ26"
M4":IWP6L)E9K`V0!`!(7(-6!RE9'9:2<J)@S6=E0@0E@>KQ8'3(>Q<$K^4?X
M@%^Q=^+M&O*?-]K?<910*/4XF9;Y0:=7J324B(/JZ[2@B[LZ?T^D^W'%1N2D
M3C<B?=\ZJ3/.16JN^VMQP7+O)S(.((-N_)";D%EZQ#Q/6+L*1UF7LS(UV/N@
M7.B`(#V,ZX5;'-`+,A./CQ=2CH$?X36KN!^XNQ?8+,HF#VKP^=P(.L=X\4V:
MK0.\TF-`H[NB#I+.,)VMK.6\/+3SF1C#=W"<#:'$R%C,`$9RW?$P?J;W]$8^
MNE[_X^0&9$2WV;CTA\X>?4X9.Y2Q71-7J@.[FD4TDM7U=FU$S1^!(6G6ONSM
M`?9X-2O-O8@$$&YVU-PJ:0Y/R8XPBK.JP1"NYN\5LI6QP@S^(G?'*/&`0S(@
MQ;3B><O2.?\-HT-#KAHJTXQDGSB_E#R7FYTQ?XNO&H`LRZ<-K9WD+5,9++EM
MG^-]^N5GV%%DJRN6!Y5BDX"PR2?#];2TC/_>\7YOV8;B/F^223PEY%/B%]FF
M%)65UD>BHR(J#KBDI29\C#GT;;0G`D&)TN9E)9H(T<.0Q-L]X>#P`3]'/SO1
M*6!;`0_XZ+S1\5EXM[T/7&_M'IW]`Z8EFC<XN-M^<L.UL_\;=GC)I6>+-4JY
M\W25SZ<;9R,\TN05X<H!T4;IG=UILR.4-TS7&;*FZ2^2QNG/X^81;1^*R":M
MEO24B7#D'&B](FJ'#6D>EOYZ^%..$AI,"Q-,PC"^VV>'B7XX_.QZF%W=PW4B
M[@M&`P!/"VDG'2]6RY3:88A*TM"O5%Y\3Q;4AK<FA'9'A.;8V.:`99X)K3((
M!CT)R@YR'H9DSI-*A;W%REHM^*QALH9"F`[`N&3A`P/CR1.O6*#`$/#\>&-5
MR)S]=73C!,$;^>%?G#U_LUGJ73#V<!122$0?6XUD>D.)Y"%020O*9#,ZD1G1
MPIQ49I:"]<864P@:,AA:OR25AM(UU6S;>C@$;/%C/A]%UAP`/3\X!V>'P^NO
M3K#!&P5N-KT(1\P&;>0OX1AS!H9O(Y3(18G@$6*B!\'2LR''%-T[[B'>(F<%
M9G&P3G["YF\#(J#`4P7LXUEI.-1[]$^[ETB=><7WP(E74$:^)$)V`)[/NUCN
M`&G7&7#2,>942U=*MNX>-Y[^A^5;@WNVTZUJ'0BV_>Q\<P^G@_"`??D9@RPJ
M-2Q_:FHU37JJY'W@P_9GH+!E49CR_D9W*7IZ':R61(^?">W#R/?PQU>Z<-AP
MY2[W,=,)'PTZR'[TU7*^G,9)'YD4%(OI\VY=;@;(V5`LTU#$J2!GX[$5\1A)
M"A%P(TL,X2'O@YR-M_@*'@0FJ-)]MI.Y-;/F/(KV>5VO+$F[P.'0%.3V85V8
M.%0%O&FXG2L\NG:^4[B-L'<>YF=.-CP%1M5,!=E#4?/5S%I5>4JD`)U;.Q>(
M91B()#T[HK'5T)@E9HT3=5:68>NEY--77X*2^5-@E,Q4D/[V>4IS_NV)%&A*
M=@1B&08B2<F.:&PU-&8I6>-$G9)EV"`K*:[7OI)2>L;D2DJQ8>DUB,5LE0T.
MO2&LI'1'8<NB,+:2TN0NI964&E@(K_Z"(UJV]#[P7]T-WKQ_^R7$FUOOD^LY
MWMKU=M?TM&!<=8&M;Y[(SY)+0WR/ERUUIE"#O#E/4^DU[X5E)5O>I$%6T!RE
M3:+G-_0];16YW@\H:QCE+8]0WC;*&X>IVF/28//48+1,.OK^E!CIQV/!=-O,
M8$[6,B3M]?"I&"<T6/SR`DM+_2%-PB\FT*A6_9FO)K.9[H`#7@T)PH9Y8>_M
MWO\:(LKVQJ`#6DI)+]GT11_PTGX<]6^]5S*MT#R\D14*'W4D-97OK6<KN6B3
M-0PUO.D88GHQF%T:WB2C&_*_U$2#'M`H,D@BI*C8^/)"2;<!C:KPBPDMRF4,
M"6-6ND/,4`<TO=JP<4#3%'2&.*#I2#9]T6>H`YKL'E>=`QI9H?!11U)3^:*I
M67)+2[3)KTF^K/6:7@PV;QS0^$(+``<41=Y(!!(5RUY>`.DVC%$5?C$!I<N:
MPEQW8!GJ,*97&S8.8PI7MP]Z&-.1;/JBSQ"&,;?>VC]@FCG/=ZO",V9C0MZP
M?/F'Z6*14SL6@+ZG(GY`UU$4N,^G**UO<^_`%;8Y`UVV8K$GKX*-9[IJ/V_3
MWF!4J#M_A=P5D#`<_7J]9L?A2.P@@<8C?UVS`ZGAO;]WUV_Q?Y_PM^@]4>-W
M[A=3%&.4Z6JZR9^KMV?9!.(KRMM`Y49&*&X`_9K\25M"K"FPOKQ/BR35<=;T
M+#37*+#4[.;S9?9V,*&6),,OOG?CD+9H\?,]?GPAO4S(3S84/&TZZ9"OBJ1_
MK>;S^70<)Q\28:@@#<7B@+(0=2&SH)")TQ)UP;,[PC.2I]A.JRQ?L<4>(-TX
M"4#IK"`>521WF+?-Y5O?,]E1MRDCW0]-)W,K8U,^84S'ZXG8'^`GU7H1QW7'
MHQ=,+R:/H>($*FA_*^N<I0Y6RC1Z>M03Y>[=MD;JQF#(?=AX?\K31"$JV\DQ
MN%@6NMLVQ&;#?:D>5!8(JI9^5`\TNUR5>NNX`7JE]0?0NH`R9))'`K1FNM4V
M;N6]JM`Z6HG>U(&+/ECC\U!T;U)&Q8%F5<8WC\@,WU.@#YTE@PZ0_><CY`<`
M?XL\W[L:<!P04:\6"KBF`AEB)TIEJ^^/>,?F^[RQ'?=YDT-JGA+2`\OY>&R7
M.$5\+-^W2L4!#9_UH+-YZ,)8'.C8N<WK2F-FH3VT=J'T]K'UB[C;S)Z!ZBI3
M!61O;YHLIO-5M7M,A<#TA]T@6`8AR/5ZW7!4F!D)<!CMQ:K>7^NY2G"U$N\7
MEL.&-^VCULJ34"0LJR%[H-FVILMEE8JI*-")Z3EX+/-XY.AY#J@*24\I*%IH
M<^L'6^Q&A9%H4@R7CE>9ZX!SN9E0-48W6`AB%'I77A,39%8T/6EPY-G0O'Q9
M9<M.EF_O:FNW+-<")BWA;$CSK`)H,9,).&E2X%'%L24/O);.+;DK\^,W'*S=
M$&_X^YF<)TUW;LUJR`YN[.G<2HJHI+>$XE22X747'4"L(I!,$N2.I0Y4MCHJ
M(_V6F"M9OR4P02^4O0_<M;@46<L;T!0NJR-;IX[\C03V9BJC(Q6)?`\#D_H<
M:!QR,Y'0)<QTXBS2?50#.CC6-].-R_X&R^B)`L'.\=Q_,I)=>YL/.%P'+FO[
M;OO^%+H>#KG7;G408#Q&J&@G.VN:S5?39-NU*!^1!E"A!3I!3-OH_](N?BSI
MSP36L$S0$FOZLX.MU0YFPE$7WN?12=F6QH)5TPUGBB\/,4BI7!@V79#A[T0U
M0/5X/]I9L:D#<L6X!'$S7)_P%<,1W/UQW4BM%(5@[Y<K:GA#AG/^WMVDZM[3
M"\62J$"O6V6E>IS](_E)G(;>DOFI1[;)!44="BML#-OC>B!@AS/SEMD2=['M
M^"[DI'64-P^>:`I@O%H8Z<EXQM9)=9*QM+*J[=M<7(SZX(;KO1^>`MQVP$Q[
M,Y<2N1ITEZ\%,Y_9&H-8K@KI]:'/L,$:-;G:+#CZ`9&);KVM'QS`]C/[YJ*V
M:,6S.TC@HN<DV(VE>/,YN:J5GJ0_!?38-L_KQ"^9#"I"3>3W)6=IK8KXW$@B
M$15$DG@1"P4BND:@A0,R3@(T.2`#NP4KY8HE%K8;94"<^D),T(56A??@F94K
M(U^1()]$\,F5RP7*:M`+E^4X/-%&:Q0;Q<GI?+#`?*N[J03E*G:"8UT8XDBJ
M]RH]:)Q7Q=;E+W&>6XL2D9B4071,W?$4.J/$@Y##I,%3H\F7ZERH00=S_AO_
M<`SP"XDR[BN.$Y0^^0%V=UZLWOJ-)N2&M&`4&ZBR?^W9./7/CNO19*;KP`U=
M;_?A%-""#CAP_<T7'-UMGYQOHN_?<\NFZ=DO'(6>Q"J-2DMJE5,!1RA1$*4:
MHH**;');4!)1+;."3;&F*%85Q;J2#AE'=`I,]`6,*T/Z$"Q0I59>IU:."E9U
M-G\_A1%X81>#L:`6#0U\L"&%5ZIOJMR]'S!0A?IG3WY<_4S1Q66E#B`L2JHJ
MS33;MN5#7AZB:'&I(-ZD&U#Y.:-&L_,9AQ^/IDJFHX7@1LC9$J51U!S3H>.3
M(IED8H^*I2\PKK1M;FJ2?CEQ1GF/;F4O%SW$&_B=3@@[%J=RM>!SP1%'N&VI
MT=!@$4AMX7\`*_YGK(!;"VM:9/S`EOC/1=:PG++/18*34&%=?V@+^LHK^<-8
MPC]O,7LRFRRY;.E[S5Z5,%WQ%3BS][W=%6GX,%362*S.#W!9GEO&3O1E^2^9
MYA!7$X45I+%5Y)&P(",@FS0AK95@'"$/PV]VM;IAC4MB>^C)QS]%G]TUE?D)
MB\X--CQF/,>^KH.D7\SM^725GA`\12@1@X@<H&K%9V.QC&-IR8,_%Y"M"LA,
M9CN?'GD..P<Z1']W[[B;6^_?78_\EWPP'/+&B`T/&NS7ZJW+;]M:LV3-A`JY
M<KTK*@:E<F!ZKW/QI%6YK]B%7FXB(TW:@.RY^`Y5[*TX^+7T4/=.1'H%TO&Y
M<:&.OV&GL8MJ?,YT']6DA'0<G*RF2>6S6`S]_HD<]$8$&3[!?CX6JX`EEX.H
M((`NZGP\-O_;@/50(GID7107ND:&"NM.5!^!X:5J68*I-5\MK1(E>Z^VT$+'
MCA`LDQ!D:-@11Y&!7_QW:#F:VN/1>&;!#Q4Y+*AP\)SZ#[J&B&]T#R"\]C8L
MD]+9MQU3%+UA=-#(54/^2L/I=):2(9;&LI-2>>`[9]HPVETQFAM8MKIA>80I
M-@P0DUBZU9-_O?['R0WP?4"7:Z*W>_*%(J+I1_+3XX&_4*\@P"S/)+52N!9P
M,LUH%Q]DBWR4B$>I_!%B+8R8NV:-Z"7B*L;OX1VMV]Y"Q7[,,&5V(!J_."$K
M%W],!#/<6(3;(#D5/;O"517+Z1F#XH!>=N?L\-V6'HD[[5GM;58H]`&O_9WG
M_I,&D.OPS]C#@;.G@61S<#V7!I'(?>7L"6@6;GS<JTMSA=L1TKHE>=O4R==9
MZVD1VJ#0/G)"M(LU8"QP2CJD"R&F)\`PQK,JQJ-7Y^3&2^YJ*[:/KD.4:,#*
MA)1U0!_YJTA]#_5A#&CWXWUP,PO=L2V?DVC]0,,*Y'?;;8@C^O)-@#=N].33
M;B=ZZ]51N8U>;.#G(5*AY+2O#H'(2;5#:Z8>'5=BIN"E=A9Z#-Y3)X)R[5"L
M'GKR4:S@)7<P>HS>4\<C\O++[Y3:XK3^SDKXL?5T8BX.W)!.=P1+XM5GC'<1
M%054]NO3B,Y$L&D[U*KX62`LHR!:8ME92&P5)&8"!(<#.9^;`(.LXQ$5OC@'
M?/W-Y5WD47K$Y%I<H5WI9:;Q:IZZ-O4$^C[ZE4J`6M3N#,*6!6%L8:S!54I+
M7U6HD/[\P3\X;C7T<QX"\.FX9?E#/I/)N.;5L0Q@O^X"I.K9`B"F?;OL-DW>
M70`,XM\!/CKN)AG-B<\,-3]KTMN;%)".@BMKF3I]+">=B`&?%M*`RBZB&D(%
M,*%;E6C`!0_#!O?5B3#AYIH5^&N<<;0\;)0/31K(5WY<6&E>62P(99*`!N\Z
M@=GJP,RQ0^1F97IP#0'##W^-\2;\1.#<AN&)7F9]Z[F1Z^SO3\][=WVWW6):
M[8/[767?-\HB2:44RF%E:6*)[/B"O%0Z2L2C6#Y*&X`B6R_XXSQL'-$M^8(-
MW-0&;F*#8VP#7V`#<[Q4=.\R557,.!3VW@6/SA[?;1OW<Q1>!.9K61MI1UW,
MYPLA4?T`4<%T]1EB8;XOR'8=<IC`#"-__?O02-CLI6WL:[`0-.T>R&@W3NBY
MVW[`S_R9EN`5(*I5]9"?H=CC21/)OL\E$L?[`5&A\/0Z#V:96(1.>]^!O0Y7
MQOMX1&JT!1"%-J=U1`B-@U=W+5Q=;GK4+&5J[2M,7"8Y5:B8.-TX$17"KCR?
M#<SN`LP@3[@N5N%'LQD`>4$SN5-3BA>JN<^;9TA="?GZ../Q5$@3V*5L/?A$
M;!G""G>;ZS60AF,2(.9L<1BZOL=R&VY\CYU_2+43%S61?-DLIR0T4CA(O<H)
ME@EF3IB*SKT1)">V3^#)93A9LI&S"W"\>+C%!"];9*<%`DG3[]"'X!UZ_!T'
M@0/,1@5WKE!3UH!`/&T^[O`%"R9/_%?,<I*KA[1#SN9I&=W*R9[RP1Y6TA*,
M@9I@VD68Y0,\X%6'9/RP0BNQ52#(]$`^@FCNE/_>($VR1N4/9<[L9);$W@6=
M%774WI;1WI1OU]RBZ,AE@&!>*]R)+3YAVG,5MR97T[%=\EW0J4IG!+8<`J,>
MS-]%K<($\>(XJSJ^2O`#WI(1(]X\X%?LG7C3#.$K)OU<H(=\?4[B-XGCY^+H
M"FDJ$"42@9B@#6,R>]B3!ORDJ$TV@1BA(!:9G5S`&U#>2#AEB4AM5M*2\?^`
M=Z<]??HMOI*)4U)#_*SI$P`\122=9[)<K1;C^"1`+BJY&*SO4AI-Y-<(R@(!
M)3XAH`>9W069D1,#;1S*3@X(#0'34>YI.8E[A\R>/N"C'[I1H0XR-WP+7S+:
M68HTD>]*IFEF0B(0,8DH$5DLWPW58>K#F=`HQ,$K`9K6ZP8YCZ?FA>6^L=4@
MX'02[0TU/`A%&\4S`-/9K(DJP%.K,P'9:H!`>,'=[^&`A_;_XHUU@E4PP1M`
MC*BH(>U)4_*W)FH4;Y0$73W3A;&!+7(8(7C#<4,>@9H,,R`F27<J]7?@V:2\
M,3]K')65?&TPW<Z9.-LX-;#>B.N2$KP:9A_UV?7P;80/BAU5_AH\OS)=5,)Y
MXVBNY'I4+&)RAT6SCG#;F-8"%YAM-3>5(%S94`/B7%O]WM;7X#FG7.5V,;?'
MRQ;.P9?SU8M63#GH)3Q5)Y5@W+`6]HJ*O7\K_D9]8M8D8``LK&NEL``PL1I7
M-(8W53L;9M,ZQU!G:P)7E6$@QU1#XN('-USO_?`4X"?\+7I/-/A=T1^:)`R`
MC0UJ2?NIO5RU=X]Y`^A7V@1B;0R,K&=;H<C6J[H5ALA9@4O+D)9G,AC62IT>
MA#PQV/GXG#U;K5*2%8X%]G`J4+YL_9E@IB4T%,R&`\8<1]H/``[FT!]1)"GL
M?YWFS]SX)WHGVI&2M+4JE_S[9ODAIY3"=,9*,@J+@H90TZLGK+8Z5H/\4G/9
M"O$4S`7#R!`3:[Q<>YL/^!7O?9;1?AT$-+\RUC<^/?+DW^-@ZP>'3W[`;M\E
M8]\GHIUP<J=#ME$F:U!89?0U3[O'N%UV0*+0,BHT/<J/:=&#2G'SB/P'Q0J,
M$%4`>#YIW'RV,?.9BS<:"5F.1;J^SH7%*:I[RZA"A^S+B%.YP@H[A_.I_C@%
M/(PQ;D#MD6H08R.-I-04JRK?9SBQ2GS^7/P.>&Q1/70]F[?&#-`SYAI1UHF]
M*:`47(YD9KE#W]><BH`.+PP)#LBW6V5P84-\6%+BS:&$$+6CB?/5+#]M(@XD
MP/5MM8,6#QB&4/-6P6&EV=?Y2"?WX%E38S^[>QQ&OH=#_@4TDF^:/Y0FHY:D
MJ\U6]G1JI4?4.%W8(9-M^,ZP/J"60\EUA56Y;,BK;OK`78XFDC@-'6M386CA
MD)NTD7H,)&E-'=4P4GEO&$&DK)3TL<G%:C5K"2%A(GD0`>0<F.+PD5=S&UKP
M.`=S.71(800,',V,;`D;#>;1&C1*M0.RK:!['+C^1O01A>]!!0V14K*>-5DM
M%M6@42ZPD`E&L628R*$/JP6-52YLZ`-<#AMK7O4,TEV[!Y:!=>1B-QI.9+A:
M"R>M9@-:4(@"=TUL^T@KP+<N0#8];';9H$$#Z46J^7QE9RQ+!"$FB9;\_\5S
MX9<<SX877\#A>U=K)WQ!!9SQY;G`BP$"9ZO,_WF&@&%)Y+@>WGQT`L_U=N'U
MFO2#)Y8Y^`%OW;7+S\EK?=$H>]JTD2_@,+:SB7(L%*52T?<%N2@1_`,4H?0B
M9N0JPMO$4F!9)>N<989)64;3$/?5V9^<N'[4+]XK(3?>D-'U)S_88C>B-T['
M=U`G]U,W#SX499@?^JHI*'LO^F*UM);I,#AK@J:5IHVPJ72AF?1N^J0ATZ/B
M/LU@#<P,;0/F/FUAY[8@X$]%*VP+5HB[_1$=.O/,8&CLW"T(%,;1':P),UI@
ME?$*5?.(BM=[XBL>T?X5)[^_#_Q=X!S">W_OKGEW<'63971,T4%!A<S?:78\
M(*Z@6"PC21->"DVEI211VM@(Q<VA7Y,_!W!"IW=KL;"0K7&C^_10!8T+#_Z;
ML^<5#S,W7CF#'N4A3%=C#B,J9!_I9QR]^)M/SIHTS4^4EGP=E/O-.DD[L&7;
M<R[=1_F6%(K%CU#2P%#(K`,^X^\''*X#]Y@.<;:Q(.1Z9,)!]#JX=,Q>V'5%
MX>DYC!R/NOVPN"UV<C&=!>8<)(.S?W9UF%S`D%B<_5,^[WXUMY1XG/UDH$SN
M:()R7TSZX&(*+_%3O/,#TAL34F=T'S1[:PZNQ-^R$0?)X/(#_\35G;<S!`V)
MT37MY(^X6M9,B=F5QSB5SP=`\3-M(J[_GO74*#UE.VB><VF@Q/=FBP+ROF5L
M#3%VEB^9/)TL)B7FP8YZ%16W"XH/P/5%`U"X`69\;S7;\:+'?N^VLO4V)5XT
MZ-KMVBC4"DIO)$SO8X]W:V&/AND&:*L!-,45>7<LLDC2.,#\N@_<-;['`5LQ
M;O_,Y<=AN%320>%@87J"O.1@(\3$T<V1>)\$G$EGP,OXPTK'K/W#@8R^PACF
MD<$\$I@A#R8`GQK=C\.BNF&@N!,F/>2??7\3\F_B;'S4,&>J[2L,YL<%OH3I
M_&6$F"3`"S?/1U4<@X6(^B9A![NA&854.#0W>.Y5Y46C%;0D*CPZGK]U^8GZ
MI=^;3C`H-BY[L,.:S:9)\D#\NN'L^NXZ6[G.D*GRW0'8D@",;+XW.7:VL5[#
M"-*_K%_PYD0[O>OU.CCA3>$6G2>ZM]]6F5)!@,F^2%HKA=KARV0A(!5.1SV)
M^.(-4>A7U@+\KG=?1K!Y1DCR16%[-&6'+O5S:B:#96QAV?,5%RIPA-?>Y@NQ
M%.?7Q7J;#%.K^VAK""0"Z-)>FB2+Y71>CQ0E-8I59>(<$98ZSGND4BV=J0,>
M5&#L6@L^1NQJ/GKI)G=SE-/Z#6&CX<?#<>^_89P<&&33]O=.B#<W_H%V2_'Y
MGSW3A>4RYALD\6&@&S^,)`.BSK9`8J)&``II<LM9/2RFFJ2G5^-EL:MGJ@PJ
M:C-"N3[TQ5RCY&@>8CH-)3J"6;@6($U:V'R<[('VS:%2]P?]0T1+Z<FA[O8N
M.6JJ7P:PFJR,1<XAS5M!#5X+I$]^Y.SC?9RK]S4K9\6NTFLK(C_Y(O&SUU^=
M8!.BD[?!`8I>,+IWB8HANB>Z_*%"J=S\NH]/"QM2Y2ZBD1M@JL@""84*"BJP
M;CFNASG^+3`C]/Q6^?5`!G^]6:<6DW19QWRTZ4"7YDBB:NQA1@G%Q79),8.*
M#5W7G.?3AGFCZ#;!P8UC^K!(PU5NPUI_5_-T-6X/;BV>,WXIK*B]?\N?24X'
MLB&AW(#@7/D@@>!,I14.<"T:%MQYTZ'R&C'I)(L/)DK$H_6A#">,VK$VQ.C7
MCN;CDB:J-@<L'9]JB)&,S7KOV%&I\)K$X%<W&5+)#UDZ"QY0[&K75H5L2_F@
M-4H2E).V1RAM?8"C'3.FJ\6I6X_>-A&'I@>\(Y2BAW6+9LN,-N1`),\TE0@D
M:?VAA)YB8"RJ_I>T%,EU&)X.QRXS)RV-`(>D[IK+%[J?SVQQ>"IU\;7XE*F"
M"KH,.EB9,FHM</T5N[L7>L7O]2L.G!TN6>P7:FI:<>7&V:]IH3`:U*A*[-5$
M1?1G,KZ(FL]X0L:U\VG<%N/._&@@\0[OJ,H/^.@']&O&!5+B_[:&,:EW348G
M&87DCV7-9DD!@T0NR@0/KZA0#]#M1NB@K%9QUA)9I:T#PL'&01+O0S<_;))E
MC1I('T-9+F9IZC)G>@'$(`VP8LJP/=D8UKJX1"&XX\L8@X2N5J(,WQS#X4AA
M*8.WDL'^\Q=:/9S0GNW56DH.T+$)<#YVTUL^_74U;6%Q*;55M"`W2M;E$DU`
M:MO#V]*NVC(I$H*<V$;L#_2:V`BN!GZ?A&R//V=\";"H]=P.XKD*XN.WHQM7
MD&F\_$._?-/Q2H?2T@2;C.VEMF"5:P$?J<Q;,:YFYGQS#Z<#HE4(Z<0_C&]/
MB">VX$%))]]J$4F;Q2]J$/7)<0.VS%-8P*#[^_1RA@_NJ[O!WN;!B;@[Q[VW
M>PG#+5DP*H1<:0MK5+MD*:^@'PMW3$.4JHBHCA<V.NO']'&5UM0L;R[>7^:(
M3)7=6H9I2I_DHL9N(F1/I,<4SC_[:?`21G>M*!3(.1F;BXM4MPL;`FHV-8N#
MF3TBCCT&/P:4YJV60:'<-_C#C!+_XM/=PKT;O9D>)U9:OO218AF.PHX._=-4
M3,R5_*.-%L\Q?SE.OF:2P*.E&;+W/FQL^#87'S\?W/#W3P'&MQ[Q=QQ&IJ)G
M8[N7&CN;P,B?;UB,^Y]E4PT151&E.OY1`N?YMF=A,TU+0DZ2EA00N5=;:C$W
MM5C`L=A%QE(1\7N+I-R/I:>R8F=5X]O=3@%N"']:11NOYZA';TE"32<6F;$E
MI2"I6/1>',S>)\$L>:Y\CB)7H;]8U=1%P!G.NAS#M52TA+`>B^,%[%#ANH]8
ME-?1U&A9V*![ZZT#3'YXZWTYT:J@2:)K>'V*7OR`ECXH7%"FU<G46KZ8D*T$
M2Y):<VL\6UBZ(GJJ(?D+BG5$=]OT"MU<3?1!?%75`*-^C[;7U"D,Q?8]=1P]
M?H!:YE0IZ1+X6C6`&'Q^7Z3^L2YJG>6SZ^';"!]X5T%I$'P)*R69M@HGAE:V
MIJ40]"MM'K'VH8Y,&#9<+4[U8[C!KW;4Z*=E.:/\42XJ'E6"[*OC[NGA,#(C
M8"?I=+MO6W.7$+M:,,A?'60M]"WN)L,V/Q^VI7JQ,Y-,LPL+=5KMG%R/F=_,
MA)R2@78\`PT^I$DR6$N@D_DD%Q7^[M)=/!RLW9!BB2'J]F5N.Y<0\'C*JV3J
M3+5%NKM\QS_3)XU_%Q;A]!B6A;8\_H>,FR7S7&1<:Z.FEH`F_`(7'LG2;<ND
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ME6'PN\F-I_^_#?:F]T'.__*7V$FPW*`,XI\#/]2>_2QHZ8(">H/Z"E?A+7O8
M5XXU*D9DIM5EQMVSS=LR5F8YA)<=,054U1D'>5_B\J-;)8"S7WYP(IR=>#?B
MV^U:7&Q4;(4F?WG61&-E7D'$K(UAV2.(*EVHR?%'"*F:OTUS\0T69=&&6F]+
MK??*L]YEQESI`-)?/);[C(/8/Q4J_H`/CNNYWN[&]Z+`64<G9T_+V_6Q-])-
MD4O;/^V$4G8':#*?V]KW3Y-P?)N&XWHTSM1&!;W[JZS9V_:I@6^C>?MT<-^F
MW^U3`Q^H>;FG:+O/[A8/8L8"'_ZU[9]V_["7.-]I2X;MKYT+FK-TS0>DIQ67
M^BXWRF8E!7UZ/2L5WPWTT=OT.>DXT[A3SBI.(7?'B1".__;L[.FB>(_&>HR<
M(!JPN692YGK&.]?S^K98[_/9,VW5LD#HY](O><(JS-_M]TM<>(<)L!L.E,IK
MJ'/5LE-*1L\]['"7NER(?6S3?;&^;S&5V[4N]$!_R-Y:GT%GR@:5[=(OL,\R
MO>G?7T*M:%'UN5WAY_,4OO8VUYN-2U]Q]A_<<+WW0Y;9\!RRB2YW#64`JH$L
MO,+CEBYN.)E.IH6E6"U=HE*/.&)983D85$"#?DWQ]%.]3;Q$>VE?4?/`YF*^
MHL1B[J5]2CU5_(Q_2G-+R?`?M'EQ&5ZOR[O*L!4_;V7=%HW,#6MR"9<?=H>G
MDHO<]Z+V8/<.+^;[2&\>#F@5$R:P:+F$\<S/>HDKH?1X*8'',M\5RNL8;_Z"
MUD)E,:F4B]9W66,6JF,UTY,^V>%M^F-SFY.][Q[U\S$XFTIQ8^`1V&`XT+DH
MI_2I+G'<'`,L%^SM:632V-0%C7R;]%<X&*+M7H):O*R7];[,H>OY!F8Q,%VV
M>!U&Y.N)G#H'EUS##R)Y.]8.L.B5F@*7EJRMA$Z2CK.)O9IJN\4Q)70R.H2N
MGM1;:G:/7T)S2O9`OD2_B=@]?@ZY\_9P0W>XN*TMVUK]ZPURJ224*YF,>ZVD
MHE>)(2V;:$4F/U]?C"WYR4"H6-T=_P%*HP!^%[5:*#CY.?P\PW@445IGT?]!
M+S)<"\\`&8G5"AI<4J"6AZ50]TZEHI5TE)8X^?^'"-%]?1&U^'P)Q5;T!PVM
MH5GQ0X+%Y=:P"1/55.^;F97NZX:.`!VTS]//T)&GO5'NB:G11U9U^'AZ_CM>
M1T]^7LJ-NT31^##(*F*3)I+??C6?S^WD`I:G%XR\RD8D_=NZ>*]F&#=%MW>W
M66,C=#P%X8E6;B$_CX@<XJ4']C+]A[,+,`M9[P`6]LXW3D[K$"7":$GX7!S4
M(MGYT.P"M,8O"[N*)>)C><6):PJ0;HWPE?G[S=X)P[OM(V7.]3>7NT/+?=YD
MI\=30C[-;#I.!MY,!-O69#'C5RH&ZBIV/;!L)5C&NLDV1ROUFD)+@/+DXS].
M;O1&Q[F^1T>V,EQI?`>"+TV*J#A7,FZ,Q:!<SC!H<SXZ6Q6=<?:(W*^105RC
M@++H;GOCA"^?]OY7WB$]J5<@.-2@AWQI!MM*CT&EXFB,I@(1DPAV%$D_3+L[
M3..L$KAC(ZEXQ@'FU"?7<[RUZ^SO_9`=P)'G%O]5&(YQ]5$X;IZ=]"@Z8288
MI9*'Q#E-L.O<4X8-P,%6]^5P46PT8$[>>FO_0`_%T2XXP"_8"]U7G/Q4FIY2
M4F"8*J.:BO<V=I!%T2B6/23:ZK=!0^^I;@,`#JNX.X?.TL;4LYA*IY:UO8O/
MKH=OB4+5J9W4*\875L7ZR!;N7*WF]B))J&2+!@UI?+]2J8B)-5WQ0"=("Q9D
MRWJI3J3V64C-+)_*,3!?1)6P3X^AX<EYWC?OM`@>'T9(8+K(^H\UF<VF;>&`
M21Q$).B`K24*](BM2P#H`+"%_'R`@+POT:N%\[E)8`;Y1*<7?[\A'S->9>,.
M%&L/&AVJ5UN77L>93"=6@26)D']!R0KI=10%[O,IHE^!;L7=.P&)2?T0QH^<
MO7@P?A[*.=M5IJW$F\<95LR$P8ZN>7Y6'D`W&F`8Q&B=Z')?`"6*\M1M/K4F
MRH09P$16#W"[#GR([!%/0X6F`&/3;1B>\.;#*7"]79PD%Z<2?,%?V:_X6Y!2
M+YMF6:M&\F=R%Y-5<2`72T:QZ"S]]3&I5$#DQT]`'5_N`7QAD.<RR>!LDW;6
M&O/D3#,X%K)?5DX9;+JX0+.@H;"S43N%34%;>PG(Q@-)`Z2V!LNU%/0?QB&A
MSB21C@1\2X)%A0=\)-[TXM`,=7\7.(=RE8/K4_3B!^X_:6&7]SA_6!@@.LLT
M'2NZ*JK0Q\V*<U"4RT!)B_7:)"AOE@ZSGW'A+<CP8,98E4A12HD66L%HF#B7
M-;6(<99Q08+'Z3DD\R.:H_5*_L/;<FI]W"3E.3HH''^=I1/D3!1BL@!W7?2B
MLSNA,\:]%J<KT4IDCP$PYF<L*M'8^"P<5V(%Y(\Y369C'E%B4<,@21=8'(8(
M8`&QH^Q@`FH4K#``7K2FU/(>AV.'<HXI/:<[;R;(`))HM8!KI,E@4F=;7$Y`
ME@&DS%84>L+?HO>DO=\EOV?^/"!C,B6DO6HY'G/Z%.)55!QB\@9"FH[XFEDS
M)*K4O$W$E;(5!D"6IO07X:-P%%')F&!#$YLWXH)(!=$'BC/>@DO_D'$M`2F`
MTSXJRI#V1&<`.4\#LB)102$?>;'D$(/*@CW[IP-;,S]:L$%QI.)N(IH4C3$0
MIGSPZ4T2\A\S>1Z6+;$2*B=)%T*^Q/*&PY@N^$2<$>`#9$W9]5IX4S`)%'/<
MC>L$;X_.'DM49>`^;Y@YC4HH1.-E.@0C$@92E$$/*EL%E4F6"-VLRA*^(?0D
MW)\.!R*?R'9WGKMUUXX77:_7_LF+Z#:POW?7+@YY&R6=1!A/S%?33[;F\VQ.
M+)DDZ\<MH#OB9WD;*&\$I:U`GN;ITPS6T,S0DN[?IRULS;8P<S*@6QS(3PMT
ML*C!`,8_0:3P^C`#E](AE=746D[5@Q;(F:.^T"O'*KA327V90#E$09];4B>Y
M8F2"7N`Z'O<L"=/9IV5.;KVM'QP<F9HBDF\;G9A(J:0RH)^EQ,TEY^5M4$'X
M`/8B>P!OU\"O*?@M!;_)KWS^"79RH^3&Y:F.O,VTC!N>GG>-R2R57YKN\[.6
MI2^'MU:+95*A]7G7;Z8*MZ_NJ+5E1&MQ']M1=5M&=2-]8\V1LYZO#$T/:W!P
M<+V8DFG9WGM,/@AQZ1U.$S\?<'0*O%JZ=1<)QOFGI)Y*.5TK+Z.,XTB'`GPD
MPE@R`"V$?,S:*518#I*FR!-.A+YB5G\;O[K^*=R_)<>/2O65H<HI]VFY.%#D
M#:"L!90WP0:RL='25B#B28]FL*MFR+ZUV'?@8E.G<)$','5;0HS>G]R(KL[>
M>AOWU=V<G+U@VZ#Y68,C\T8%%)(;ELEB'Y-#?2V7!+IIH`&7K8[+U,A:Z&+%
M<33?#(-@QE_=Z.4![QFEPQ?W^.1_)-/PZ$VX2:TJ!9)-8M44-GPG"<^*PFCW
M'HL#WM'N%;;=$388%^6<6LA2"?MUYV^(U^]V_NN/&^S&U"5_J3*6_.BWI\"A
M5VH^OAV>_>J7K__>`,MJC<H?"UHND[S;Y'T4"S!+ES/UM^7T[]OON:Y!/;H9
M(DA?$SA>Z*PI@\2]2>TYD_U%M7'Y\PFKM(YY009T-W`>&EL%C;'HSG.C4OQN
M!`[L]2UIL4U/PGB^:LKH?+7(%@L+W@*>"7LVI!H!!I(`*W`J#@O.2'SEK32>
M#H+U^>R7QM<'TY;EEXOGI"N/E_Y^^1EJ?;Z;UI81K5O6T[JI;LNH;F8-K.K(
M^?)6"1I([T$:N-L6:@")^H_&9TWV($T**(PXQFD?0H.LORV5/G*\#?KB>U=.
MX6>%\`9[VY(&X'8/P(WU1B(G+?5'7#M!<.N7XZ?`]Z+TZMU<*V$-A;:W#/*M
M117YM=6IE1P;_^5XM:4B\])B!:^#K;&@%:P=@^V&U12M)/VS2#`9(X%0+22\
M_QA&[L&)N'4Y*P^9)%*I9?G*4LMQ4F>3"*!Q.Q,QBC/SWM"OR9_@)\G/@6@7
M(.)4!"@S&MVI1(0Z7"V3GK^R;CA*JNS1E,2X$%_3P)C[K.DI$4\1V934V8QZ
M`9LA):)005:?%2:Y\R4]D"P`2.+)E!Y<=A$7+N`Z<G$9F6FUL2>;>`G-`-&!
M_16[NY<(;ZY?<>#L<*F,WMTI"B,R3'>]W7LG=-?7WN:#NS]%W&J6'849[!"[
M::C0J]C)YFG:$$I:JI>M+#0W0JQ!-B5*FH3I3$V8QRZ9QTG,X]5*6,96\O-6
M"T;:\(UDJJL^CSC%+OT,H\?,2<SPF0@F_R;_(G^AA93)/_X?4$L#!!0````(
M`&^"#4>YM]OUCRP``$Y``P`5`!P`<&ER<RTR,#$U,#8S,%]P<F4N>&UL550)
M``/2^\Q5TOO,575X"P`!!"4.```$.0$``.U=69/CMK5^3U7^@^ZDZE92E=EZ
MQKZQRTY*O<WM2D^K2ZVQD_OB8I.0&C%%R@39T_*OOP!(B8NPDJ!`07KQT@+`
M@P_;V<\/_WA9AJ-GD"`81S^^>O_FW:L1B/PX@-'BQU=?'EZ/'RYN;E[]X^]_
M_,,/__7Z]6@Z'5W&403"$*Q'__)!"!(O!:.9]Q)'\7(]ND\``E'JI7BXT2V,
M?GWT$/CKB/PS&.$__>M\>CLZ>_-^-'I*T]7W;]]^_?KU39($FS'?^/'R[>CU
MZ\WW?LHI^W[T[9NSLS<?*[],XRP*OA^=5?YTD8#\PP&F"?_T[OTWK]_][?7[
ML]G[L^_????]Q^_^K]HZ7JT3N'A*1W_V_X(;O_OF->[Q831],WU3F>1_CQ[B
M".'6RY47K4?C,!Q-22\TFN*I)L\@>%,,&A;3'6%((_3CJ\H,7QZ3\$V<+-[B
MSWQXNVGXZH]_&.6-OW]!L-;AZX=-\_=O__7Y]L%_`DOO-8Q0ZD5^K2,9C-7U
M_7????>6_IJW1O![1$>YC7V*D@*!(VX+\G^O-\U>DS]AF%]_>/_F!06O_DX^
M^$,2AV`*YB-*P_?I>@5^?(7@<A6"5\7?GA(P__'5"B:((/_-NV\_O"/]_W09
M^]F2[*(HN(I2F*YOHGF<+"G5KT9DW"_3FQKY*P@2B.CF28NM^):T>RL<ZFU7
M0J>XYR\/>+<#\HW)_!I&>'F@%]['"))/7(0>0G`.0:!)M^*@^YS!O9<`7?@U
M1DZ?0`I]+S0_IQM\GRU!>\J+_L;IFN`I)^1>2<`3B!!\!ETIY8YHG/8+#SU=
MA_%7=!,%,`%^VI[HW:$Z4WL)D1_&*$O`19RL8O)$5<[].`CH!O3"#O=*BR\8
MG-:YAR":S*NO[3@*'K+ETDO6D_D#7$3X9/E>E(Y]'S^4*7[.[^,0^A`@L],W
M3XE!F*;@&429Z2F+1S5*?HCW%;D>T_4L\2+D^>;WK]9'^I\<JO[]ZF6%KS&`
M3$^._1&#D[L$CZG99>*/:)!L?$23#`0;1`C7&60AF,P;/[2>A?('#$[J(8U]
MRJ8&Y&7$P_?P".A\H_>IE:C.XM0+::/S9J,"Z>(@S.*')X]>YB`8?_62`'V)
M`I#,GL`]G?Q]Z)D&IR\J]PCOSX`(@I@6+#]["S!&*%NNZ/WR!?>YCI,++_0S
M3#I^\W[RP@QWF>2_?\)W4:HM%.R3LCW"6#D<4[#`RXJ)HGURDL;XRG[&DEMO
M8*E^WRA;&J$L).C3'6V805$;W>!T?O82LFT,3T,\JM'56"YA2J01A'E7C!Z!
M#D3FF67M#YD\A=DC`K]E^-M7S\#X6JF-;D8,O8M3@&;Q5J&PE271)%EX$?R=
M?HP<`BQG!!N1I"JA5+019>=R,C/PDIZ'^`+0A&./A/6-)$>L$TESYE'K1,20
M$=K\81!(;8GI&[&+.`R]1Z(K@<]@3.[V!?VASX.G\\V^Y\\31ON<O\XW!S3_
MF?<8&CP>^E_N&PLBSO>Y[KSQ^YY7<<^@>V]-@,274"'9WT+O$8:8)P"][O>V
MWQ\H+H;/03<J>C\3VR]/YE5)K3B]%S%*4:D`P'.@O7HX.QWI&#A.AO>4&6KZ
MYSWJ(G&_/(?\6[W/EQA7)_.M"!T%N=-"#[.5?JG_M>5*U?TNL]9G^T:A*8&;
MGS#_"\7<5A7Q@_C^U":)&X,H(#K/_*_D8P9\..B7\;<Q';7/A<3+)4[JH!9?
MHZXL"/AO%O'SVP#`MQCGC^0_".`?7[][7SBR_`G_Z9<Q_G1`/G\=>HO-<%BF
M`.&/KW9_?]L[/1=90KPEKO$6\\)_`R^YBH)+O$0,TKA-]:C<W8KD+[]LEF7,
M6);Q(TH3CW@%U(A2[]<_CALR<G3N\=Z+@VO\-\0`DM]VWW22552CLFRY/QIS
M9/@;DMUN?_3-\+`"LNC/_5.3[_H+_,&$J$<#\/)/L&:0Q6ZW-_KP\Q9'U`Z2
MLS&3+"7>A\0ZPB=6U&E?E%_#$"07>&<MXH2/:[W5OFB;@@4D5UR4WGE+UEYD
M-NN?NEGB4;/7>OD8APRRZK]OZ:F^^..D3IN7^)N!\'_N//=U?]*BQ=L5=05\
M[3_!<,LIS)-XJ?-V;*B(&:=[%"<!2*BC\_MW[UZ-\`3F`+^2P6T^5RZ!E+H4
M)`C0EJ0GC!-,P8^OSEZ-,H0G%Z]RB\=AP=/@;TI\SD[X"-ZV$J</)YR$?$J)
MU,<34A+.L\3JFQ-6C'>IQ.?;$SY\KJ*$Z7].,`E8[A*GOYUP$BL72JB^.T'%
ME36V*&'F\H22HBQ9@M8W2_[#VZ:*LE?%I6ID6/$UF)*!WQ,VZ=WH]6C;N_;?
M\7RT'6NT&>ROH\IPK67%N8<>*;H9>KWPO%4N,((P19N_-"7'XL^_-.R*Y-$&
MQ572D"55>K27=CO-H&$'E=+/:6^)^FR947L;+P3L-D;H#N"=./->^'/2&L7*
M3+=^A?<>#&ZB"V\%4Z^IL9"UMD(Y0B!MJFT;/]JCBZ.PYS2R1Z?D5-;:6*=2
M"=1F6QM4DQ!,8L/$_[KZ+8//7DBMFNF%ER3K38@`9Q9J?:W,JN0ZA!-H-K-!
MZV7!\^![-=\6^):]BR-?N-TEG2S/0_DM%?>Q,8O\L</T`#0%/L";^C'D;1]V
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MJH`HZN)*HYE;GB+:>+&DCQ(<M]Q$M,'A,-PE/F[YAVCCPU'TE?BXY1>BC0_W
M7+5Q`AG^):VKTZM")=)!N>K69P(WD4[#57<_P_NMJ\.?VP=3U-I5!T##&XQC
MK.GF$WA0NT[EK10Y06VA.G/+,;`U5#QOJQ(H-W4J>D!Q314E3&ZJ5O1@$MC/
M2J#<U+#H`25QSRC!<BM4I^6N$B+4AI,?_I.G8U?9%109C-69FYQ[6YS4&;(2
M03=U-'K,Z*XOGZNA%NWPX?I%[R^XXB!@TG64+^%SD\_2@T_%BZ!$S$V&JZOR
MH8I0WZ:N0<8[U:L]V?4+Q[1,$DIV0)^5>Y#0`#6YJSBWIV5/]R+C>Y8^X:WQ
M>[F*_)GL]!C$#&X0RM2I+UH/@G)^GARE+DY[4QT0IZYT2W3R`'H&R6,\_.>N
M,WR[5Y+KCD'&0-O<@J[["1D#C!U8WGOF&7N,UJ9D9#%P$4-^)HLAS[N-_HS_
M'68$K=&G!`L^H\]>LH#17^RP98AF4BV+C'$>ST8S.X]^G0C)(\EM;H/VC?"V
M><5([0@?$W<)PRSELERR7C9F\@E$(/%"DL8\6,*(IL`A=1X*F#DSD?6R%W!(
M5`_7^%[,<PEG&.[)BM37)J4*SL$\3D#%7^GJ!=,=DV)57K*^P2>;>D[@GOB&
MP/0M;B)\@P'$VY)]?M$>@ML[3G(@>:VM!IL6&_`<[\\Y-QZ#U]H.Y?F"B\];
MLY4-2N]`6FYX#IWU-E:HQ$]\?OS(82*D%)A)=K.\GY5@M3I)`N19+:V%UW'!
MY!$O[F0GV`L!S'L3-_)+\`S"F(9DB*<A[F-G%GF992[!Q<\V:&O4U[S+EH\@
MF<PI9U010=18JY:#V9379/QOW6@@W(WM5"C?Y8)0!!9$*S-LX58'+"E+VTYU
MXBI<NS)C.TU)'9_9\/TT).QN_?QM[E'7W:DU0.%O,E=SI[8`B<G!=7.9=NID
M*?#KKJ9-;8%6KSJ.;MY`3NU*KCZAG2O0(;$..F>WKA'HYN?CU/Z1ZH==]_#1
MP*JM'-C-!6CX$"IKLNH75T.=V,Y^=T@75BN<9&JJ_46;VC-[\KPWFX;0CW_[
M*#:$UL8HS**6G-*:<Y&D:Q;U..G8A3I>!G37F/.$BR@/]/"K5<+QO4W_+Z3;
M^9,'(T+\&&]1?/0NLP3_,Z_A(EFO?7QY2(A6':GOXX1.*$T3^)BE>9Q6[@BJ
MB9;JJ`>(A,3*8VITRPZ&.=&T8N[.5-1]#95&L?FR&]X+.^]_WU>8Z[G-6NY(
M%1'2?:?&MH@9.Q1'Y`]I"6MWZ_89Q%C(M'<3PPXCS(=DJ;L.XZ_H)@I@`BHH
M%?+7-R0_@5#^PB.,Z!!6"A<%_\E02JO;S^(I\./(AR&H7>RSF)!XG\3/$*-U
MOOZ"0'`3;4TC8_S`/N?QO))J'WU\ZE0LY&!F]<O9@.:5<WMXYR7`0^`2Y/_6
MFAYG"#M%1_!-YT-ZSW'F4&MBQ>MZ/L?7XV1^]>(_>=$"3/$=.(G8T+)L8SRW
M[*[#6BZO0J+5^6G4&0TMT5O;Y#<1*]<3?PXJG8<U+Y6J-_*N@YE3(]D4/AJ4
M.]Z^K/+*.9V''086E0.E/-%JGV',8@MPD>5"[NRO.L!`YD=%MR)!D:ALH%+7
M8<RIGHE8>3Z-;L.8RQ3@[0+]%-`75GDNC6XV(S;(:RH)UZ!-+-F16&)0$1=:
M%8,T^*2.@QX>#K*0$3.##PB7F^@9[UK#^T-UT,/#H=W^T!U\0+@PU"C=]X?J
MH(>'0[O]H3OXR4^!6W2,IG'[)XP"22`OHZ$=>M>%;G/L_Y;!!'!+`W'GH3R`
MI2)P/@`!]5V>8IXT)W8ROP2/@B)P_"YV(NJ4Z!X(K1MFF6;WD`8OLAI;\70H
M7&8!M25A,D1:24YCRQX:6Z..NCO&;A<K<\A6JY!2Y(4;BFZB>9PL/95,5HJ]
MK19NZ=%>5<\37=6HN^X+LB]466^ZZUXC^\*6=^^Z[BFR+WQY[['K7B+ZVN=&
M+)9$=]C.2^208AQ,(\BR4;6+;#YF%)OZ^'9AS\>,(,M*TRXX^IA19%O2CR!L
MVC2*6C9NUXLGF,:W9C=WO:2"6<-3HURX0(GF>JV%_G`58=D^#<ZQHMG5`+V_
M^@Z#0KZEX;&N(%$W(K0K@.[`#C>`<U<3NNOUU<V:3I72CKB9;*H_(/O1>[E>
M^+V_]=#AN+N5D3]FE+OZMG0K0SQ\UD3%BFD.3U:Q1C=%0D.X:K,NKI<Y-H2K
MMM#C>E5D75R[1V>Y7CI9%U&]N,,C*JO<`;V=:-1.5997="TP94EZA.#]<M:Q
MQ'(.WU4T<"6"+GC*/E0E>&Z*2IK.9*Q$AGF430F4F]).)Z!V`X&W<'W0$5':
MZ?7VG#CC$B(_C%&6@(LX6<68=P!5H+8EO"M_M)$4XSQ#,`((41UL7H,O+UV\
MV==%6<))0OY-K+:UO*?BTJV&!K>22H&4,)[,?\;/B(?OTV1*<K]>O8#$APC<
M)]`'VQ]1\2MZSX&AW5B6Z]M^!F0E>#/::6<ES0+=2\0%,([P";Z,EQ[D>5^S
MV^I1O8()(K1\\^[;#^\H)>0OOTR2A1?!W[TB^=HE0'X"Z=TSF6].`+Y8`,UI
MWB"OQ0![HWG&2`F@V=E*8L8*=5A\0W$(@PVI]Y6[OE)]=,LWR;S@S8QM)Z0%
M\\8IN`\]GU(C/-Z<QK9#<>@C$>';,GG`;#X6X.F95@C(X72T$K9`":`WYYVW
MQ/]9R=PHO,`4.EJ>#WW)RG+9LEG4FUL-@VD\#FC\`GG!@N(^=F:!P<PYI6IV
MSYR#N@-?Z4_\Z2AUMA/@\XA@`+UD7=DTHI7AMC?R8A8,6L&VD=<MAXKU0'+;
MVA3=A-P2I\[VYI7H5@=HN&)M>_ZMID91/(&NAE890I'[DK@:-F4&-Q4.R=7`
M*#,(FM*!N!H>90;EEAJ5_14X.210)2R)J\4?V^DNZF^UD.??`/?NS3NW@B4,
M(,?GQS>HO3^A5CN@FL=[N_F<VWV]Z.:T8)XU8T?=!%A=O51G(=G*0=?+XRHI
M@&JN0VP9VOE=)5/%<.0X[A;<'V#6K+ZD#"1F=ZNW&KZ;'K+E$L.(\8&+",ZA
M3T)=\JA8HC?`]Z%/?-2'8AUF>]=<>S"A?C7E;'EV0N7^]M*T;ZMYS+P7X@JH
MG9!=:0`;\]OB?+[>_N?_XIV+#_[3^A8\@U"@3E7L;'5>-]$J2Q$EYKW0H"7J
M874&GX%'MO^R=BRV,`L-0GIC6$F^6&A)MA[V#V!!J>3,B-_>B`9_"A992%JO
M\PP.'%NON*V=]'C/(,H`"7S"CP:Y3S[#$*`4\R"?0?H4!]O_Y0"K,8`1I-5>
M.:%/A.X0>Z2;ZQ>AT]TF.Z?W+E1Y.\U[RW6^N-4USL23]9(YK?F47<9;X5[K
M3+JZX;K<JK60(OZ+[+1QT@!T.H^PTP9+`UAJB)5.6RX-0*DCPSIMGVS!NS%?
M8@E/Y+:!J"6([3;S/LT=UM2`Q;-A0J7'$5K*D;<O4)%:AZD24>MC1)P:AR$@
MIAE\-0E(V6ED0\0>$TOZHK`S1<$=AJ;\2T6!C81J)MU1[(1XA)AJ$H^$'XT*
MP9)X#V$G([N%N!T21X;*GF2C+6MM!]6(BB^51+47H0>79!M\B7R0I%@"'"]I
M]DLNQAI#V)EC1ORA\!.2KHEE1Z`\9C8ULDLN/0CQZ_7@1;^N8^'%PFEIIV9M
M_JX5CP$'M&:K`5!:.>KGZQG^.$OWI==W6+/BZ2!U>@YK1@1IP<E4Z#B\^0CM
M($I=!S"GDB>4!)G)^YFY28E0$],$BTTF4/#N*O0R0MW5"_X7"":4C1\O$L!G
M4N3M#5&$I0&$1Y^!9"DB9+>9C=UW"WV2[)WX'(#D&?\/$K\^_/9&T"N&S]>'
MCQZKF<'O8T%4]NVRB8U5^^R]P&7&WE[L-F;"@2G>:..-'?!!XK3LA8K<*9SH
M5U6I:?2P%+`:9'XZ28IC)'B+F4TMTHPJAU_XY/+;6S&/D_=>`'/YNS7JA.>Y
MVL*.>\'6I$$RBJN(*L(NEJH=9HG_Y.$';//V-V50X8Y6[V^I/B(@BFCJW+SE
MORJ<[D9W,(OO04+4B]=Q0BM"H%ST$IT.(V,?&"I2H<+,V(;<EEBDJ.C(%'OV
M2.7F=="EL='/*(45769%4N`'<ROU&Z1;V#7>GW'"/_B*W0<YMWJ#W[DIJ%H,
M9"N-QD;@^A3'`:+IT9@S8C8UX_[F1?$<\L]J[7<;**GF2AE&:I0*%9(WF-72
M"L7X`Y-YY943T<QL:X/J+ZOK!+_&A19*U:0EZV6USF<[:V0]B8?8S.=Z43"1
ML:I134E5<'#5N;"5[:>^UUA8.^LITQDOSC7K;!1U9\!4K%T;],Y.Z#6ON%(_
MM@'IPPFD!DALM>T&KX\GO';>32,JJ0W`WYP`;CX2+.EA`]>W)[B4GXC;8TJP
MH>'ITHS9WU4_N!H2TA$L@67=U<"/CHCI>4>Z&O+1$<0V*E%7(SY:0JEA!W`U
M^++S)A39BEU-.]?WR=T::EQ/N-020,%&<RL?L;Y[K[J:Y*3&W+7Z5]&3FA%*
ME?E1L,-\?V6U/5<3V%S?="*O/X::B>5I=R00\9T,MQS:CJ]N>?+<9&-UH6FX
M4;M>R%P='C4O)-<+#>\XQ.Y8`W93S+AYYS"<;ZM8-+SMRW/DZ+[0=9+=GBM&
M)'>Y==RL=-D>K+H;5;FIW!3IVN/$"^4MKV='+R63WMR&;'+')"`:]1N7L!Z[
M;MKE?>"F=KL?=%6"54MDW=0^]H.L*.U&>1.[J?'H!U%Y0IX25S?E66'1`7XP
M=7F`W;2YJ,`BBGHO\7&3Y9;CPXM3+@^4FX^J/C+-V.D2(>?/EHA%MEJ+PA(R
MHJ".*C;:40='4,5C"D(OQ:>)B+(5"/K+YD?8,9AN>`^(T8_\-5X-#B'")/:M
MQS*4SRU"64@^JY"^A=_85#89X-,IXRV1TE>6+MF_,?O'(D?8WDK!"!C!%-S"
M9Q#<X/T>+>!C"/+,V>?KS]Y_XH265Q35\]`886`S+*F3QO'KCF(RMXW"-N>T
MM)(?*$:H>BWX?I)YX3B]P)?^&O^19L#EH*S6UPBVJB?6P$D54B!,0]-L8BF'
MRQP@1!\EDEN[D%PWMB]RH^&=QUE0Q<YV(L'+QTJ2LF&GH6UZJQR#*`,'O\>`
M9J`,_C"BKSD4W4H2/DJ[#6@N^.&N_J*_Q5@#'%@FEU-^FX/);V,H4X;_!(*,
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M*%T\]Y=J$]OVX`/VB3C9X@=HBS_95T_V53?XJ+;FK9/:D_T6GDP0NPB).9XC
MM4*<U,$G!9I3J!Z;Q'P)'E,#(4YF&-*Q[]/$P/?>FBS;#4DM`E!Z#KP$LTV;
M_YWB=>-PH1H#6!&:\_3'MS'>;F/_MXP$`-]$=/?AC747IP7](+B.DS$B:_,`
M_`SO'`C0)$M1ZD4!GLBY%WJ1SP/!]%?LJ!?X-7UVU`J,IG:*P#^F-Q'FW3-F
MEM,&V;S6]BDO,AB0<'TUXFL=[-,_!0%8TNLUS_`LV#L*'8<W'Z$:2*GK\.;$
MB[G2[3V\F<V^QAUF5O:V/S.1^H?5TDPX+WZ_TG6>._LF>L:O]R9HG<ACNW\7
MZ-?;#F4#^:L7HBC*('HBM)#\ZX_I)_JH(W03888.S+P7SEJH];43B!HMR"M!
M*/KLI07+,06K(KW39'Z/^30?KKQP"LA-A1GPR?P:,ZM>R(@&-3:LD9UZEY%S
M.ID31@L+*<TGA]WF5$!=KMY]7`C4N]L?3Q4H#TJ.ES#+-<6;::G)=>VF!K8Z
M$K?K*DX-V$0"D^O6!0V8%+D8UUVI%1#C<!"N!V)I[*7NO*/K,7[J6A#^5<;3
M-1P7.R+6N*BCQPPP=3/VK1\`*\H3UY/0"W0MIP+LJNBH7('.N[RWPLJ2W=."
M.U9'C2(?PJ/QM6I;!:*BR=E?])0URSH-N@5;=Z'2<:'QPP`,[7CO%T3=0N\1
MAI2UOHLC/TO(;N`HU3L.9D/UN8$^>H9)')&MZX7U6.D:K?P):XUB<::5);A0
MF1.C_:"HEV]%2;]AS8:F7E;:;++.1E3MQ;=FWLLX"R#YPBU8>.$U8%LS1,VM
M&,V6JS!>@TT4D/+>E_>S$YV2P@5]GDBL9_(,I%M%U,/&#&BXJ>Y%).DTH'E(
MUT/>STKVV/R91IMWV@MY5G.5'C8YT6Y<3-W[77#67%?"FH-1F[UR725K#EJ%
M.ZB;3!63M3H2,%49LFY*VX-`5(W-KAGUY%R6ZP9V+=SDG+7KAO56VTS&/+IN
M9F\%FA)>;8SLP[_+%-A:M2=@V\EUBY,^8JV>W[*4G;-!5`]I[/_ZZ"$07,1+
MHM7-EW$H854D`#V.*)$7W@KBH_SPA'<'*F0=XC9WG:5X'C<(9:+`(NUQS+B`
M%PQ';J*AV66]2BW87;V4N(--S52119+"=M[<+_CP$*L3",9?O21`,W+G5G\G
MYJF[./TW2*?`CQ<1_!T$N6$3`U_\B;1[+U%S[8D(IW"FF[XHO+AO>&O?-E0C
M#?A9"I_!9#['I";DH%S"!/AX`-&Y4NAFI@X3O7+O0R\2%&)JMK&B2\.?EX0G
MUIK8I%'HT]]H9"4;#?/`5#(:GJ_+)H7++3U%]!\_X5,%HT5^%?%N0*.?L(;1
M+J.Q,X''Y@3*I-DY^2*`C(QOY!YHO5XWD9\`_,>;:.-3FW,JXRQ]PCPDOE0O
M`?(32"]5UNVRIR\?U#EK3.C9@R$1!/"[_PGWY1D/>OO<06%7/-^4<G13'))/
M28QXST8?7SI\Q'X&</%$N*=GD'@+0'^\]%)P[<%$5,5RWU0<(M*52*G\Z/6$
MY>YWS+T5;9ZN7;(:Z[LIM$[KK!.UQU:N+S4`PL#CH9!V4!Q+,?>?J+14?PM,
M,R^B3YG9FT2"VSDRMYP,(4I=>J2+%><O;6YE;Q%ZB*X),U59LF7-\Y6K2LV;
M8\)E>_4'LC'?&4R)_^@-O@F>84`*NO#%3G;;05#],TR?J/&0(/H$5[/X*DJA
M)+VM[BA6%>L,K4"MQ$Q#(G?=8YRM@2BK8.UH>TJ3@5L!H8/B!IK+('P,7-VB
M.L]S/0Q+VZ3BJE.$+H1[U>RXZEK1=M_V("2ZZHAA"V*FCLC5%`E[!UFJQ'35
MVW?O2#/-,JXZ_'9"UXQ!Q]6"=,.XAQ4TSZZF>&B]`"W4,Z[ZW.W]?A"J3_?G
MDG<8*._);:B$_;@E0%M><27^1R,,<K-_U'64SN:/:0,-1\WN;-X8'8S4CKJ[
M&6243#'"S22S?KBJ:>UH#MIN/B7?U?*F=TLG90Q$L4M]"5_?.I"!A6R427HH
MG\&^Z(K$/47\XRPN^9:<1?E"4D_.GD!IU[*2XB>D@X.`S585D^!86Q4[#];%
MOZ`?_Q>I$U5G"VD=-Y[O15]?L8'4)Q"!!+],Q!"XA!$D=C]R<1:K)ZQ*H=;7
MQJSRO,$/^&J@\N]ML0("5PA1CP'-0.C^(.YCIXH``OC!>B+/+W@&8;PBA*GL
M+96>=LOAFCG]:N5R37[KY$BY9T=*"ZQ?3^]?+=)7D75PU?*K\=1489/<ZZX+
M=DK/6KT:BL(+XJK73&O4%+DZ5QU?]O)8*YQJQ_6F>X?9^+/FK@YR4*P0RV;9
MSY[9W_LY6*548Z7&"&5Y?GOT!5&?TPLO]#.B!8P6U"EA,J\Z,V#B3`@();V%
M15GD9(&X[D$"/M_P%VP(DY^]%[C,ED)!N-[&"I68@9!266MC1=5`EEJ@X"E_
MMT:=6.%1:6%7L='^,*DI,[J.?U!QLUO7K\H]3+AP'U^TE\0N@]\#0:WZ_K][
M4/&>HEF1NE_"G![]?-"9W?A33'B"$/,\^]Z/C2\?/*)3B'Z]3@"H5\;L'T_F
M=^WF6,'LYAQ`$N/$`,'HT`>U:V2610,#G]3\[JKY>Y2PV#)Z9Y;0=;WVCO11
MTV%7F?^C0*(NZ52Q:`B3KFON96C4%0#'HX\W)&/NG+*CT[CW`*0)KL9=Q;IY
MWJ\>[SX`EL;AU1L6SJSU-R%EN>IS,=35VZ.6T.T8_R-;VJ;*S>VT`D>RN&SM
MG]LY#0:^M#V9&HZ@/K7,V:!2M&0*%A@VO(25>.:QG^+7*UW;B&TY&==/QO63
M<=UIX_K@S"C#2-)=/)ID/7M-TKW[G0-'2\1\](^A\.MVS;B3!O\3DY0QLESP
M>_GDL''1V%`6"3G$4UNJO$AX>IGH;)N+JZ?S*O^NDVA:N!F[T72(JW!(A5]Z
MNDF%^?2F@,0[X=N,E(HG`G_FA404[^,F;4?((>ZZ0RGI<N1H_7)VZ'A9>$-<
MYH`.`EGM77MR1#RFPDW\N?.>V#/3'OX=*#G$6R//]9HSU!JR_-X_/PAN-*?6
MHCRO1\`@]R-7W]S(Z]RKJ&F6B(/$62C0[`5D#0J.ME#<R77=-A(GU_63Z_K)
M=?U`@3RYKN_?=;U'S5HG/^95_NJF7I*>EL.0,<)5[^.>EZ)3C1NW7(&'O>D5
MK,JN.O(.>V%8YI!N_K?Y\W`5!:?EZ%.+Z&J]L[[#`/OTTG*U?MJPSPS#*]/5
M$FO#7@AE?7ZG4FPG\6-_^FI7:[8-?(DT33>NUUL:YFW7T;6S7+23Q#^X)ZHF
M!+4IPW640I`-UX!RE4Y:`]MBD.I*N54A?=@7GG(05KD\)WW"G@Y22Y_\<J5.
M6@;-@[1OC\KM4IVYI8<8E'\N:[$/,<&FM5P410U:DF&"6LY*N"M9*(P4KQ@O
M$D!1)^<#1G3@NSC%J\R,+53K8\2C]<*+?!"&9,US$)AI#X1-;?C6780>0GB7
M$UNGL(0EHZ$5>N/E,HXH%?=>,DEH9:>`IH/!JTGAY$U`H:?E&>6[(;='RV=1
M:VUF#V_/\?;,"'8QM[&5NL*_9?AJY$2#<!H9P>P*I7!)=M(V+=%DOG/`Z=]9
M(&KT[H_:QNU]!YC1-*I=>Z/S+HZZ`<L?P`C-E2]]B9ZI%J+J0D*S5>V<:YV>
M1JB4%"`L2WC=1,W599'>93@C\V$M*O_2$K0V0PVU'S+.,),8;F.CM+#F+"*'
MV=XH1=M-+J6ET=((%?BU]PD[O&!<8)O]2F8^1I+-S2+<W.##FNMD/D<@)9TO
ML.P"TUF</Z:]8L#]J)V*Z2%Y3S#OF*YG6/I#F(4@DJ`@]YJ@QX!F(&3[Q7T&
M-(L=W8W:1&[-EF69@F?\CE,1L[R\\/8N;'WEA5J<$=;QT1[#;MZ\BY@\%'%^
M<*MZ$4PR?DI\SL^5-4!J"?2,?<A:E*`TB,]T1C'TD#W^!_CXXBR-S:PMQV]L
M)]ZOJ-9<U3D([EE^>R-(5M1&6TFW^L1M'C:,5\3F[S5'L*D[Y^N#ME8+$<?M
MNFE!`1XY-H[I\L4J&+96W=RCX7SHJYSMK`4LBGF\(T6+=U3Y^D[7K=FJ7'1U
M;W$UU<X'7'<#BV^H<#TV6P<X1?N>JQ5T6D.FRYZZ'BFJ#:!`4G(]UE,;*[%.
MV?4(3&VX-,U8^RM;,GS\6(H3UT,66Q]'X5ET4Q(W<A:E!]'1\#\SX+'\!CI%
MYKF(G$%KH^O!=/:PY5LW70^-T\9<W\+E>J!:ZU>[Z0;1*6#,1:!4/:I<C^'2
M!JZ3DY?S<5:]F:X5%/%'ETNP3XP%AN(-PLY:.JSNXLK-<P1)&67N"#6U/\-`
M?`010#]["8U%-!#Y8S2NI:!KDDQ)?%@M+&S[(RI^1>]Y,1>MQG(S"L(,G64)
MY^`_&4K)X2HAY)`M[F,M+_D4K++$?_+(3H@7B;?<</=%*%R6/N$S^SN)=C\'
M96-ABO+68QKQ=RHPK01^\V/KN&T'[HC2;>5<MW?+`6QYO;IN[^8#)SE9KENU
MY3M*\B3LSVIM,8IZN83IAG,GN0"P4`XB'QH)J#87K,JAL9R(A/_0&\-.2.XV
M#\/D,82+'&[>;%AM;5!]&R-40W-'/]0@7=!A$/2+P@(XC>W3O;[TEMX"'UF2
M`J)P^%*:`[/C<.;S$&?X$=>?3K6?$?9TDJ6WF+^($+@&@!_IR6IF.USI$JQB
M!#%=WB,,\86^$_NHV,GZ/%0CQH87)H;.U]5?]*/W6`/8F1\"F/]ZPD_H)7@&
M8;RBB6=*_=[F89K%F,DD3,-UG$S2)\P*G:]GF#KAU$V,?6"H$+HE&]O$V&9"
MDLKR3KLW7_FCU4B9-IQB52#@L0.NAS#(V;BZFSF3575=0Z$'DNP-=ETMH8>6
M`O_GNKK"!&!U`<!UKWNQ\*9@4F0R9L[;R75@,\+O.6\75T=4=,C=MVKSY;DR
MLHA51/2H/*P$TB*7OSB:2%N#\J>ABZXJPIWPUY!TMT>>J5S;7Q2<-=O+0_:(
MP&\9_L;5,S#CQR+-8,O6P7`:&5$;U(9EZCJXS0SE%XU7(*F'JHH2C');F\F$
M2"JGWB>Q#T"`KO'A(N'L)"#H)L)K[X7W&1:H_<D<;W;,(K`HU!S!AD+LYG["
M1'CW=R.8?H8A0&D<@>(8<?8WJUD?W^?O<79#LS1,(H%]@M'*[-=G7V.%KY>M
M;.S.MJ=/O_]PE-'LY)%J?:QXN7DT#3[QF+KSEO@_55,'*G2T/!_JJ"1)&\YM
M;LWCD%>O^@Y\I3_QTZ0I=1[<O#AUN/7GR![(RGSK[.:.=K$Y*U[S`=`NY"[8
M;0=`]4[Q#S'AR*H[4H,88;9,5M,AT"PV./-:#X1R\3/';6^+>AA`+UE7'BX)
M\NSVULH"<25D1I:H(U#XR"3W2C8[OG3M:D(+F="Y!8<C&#J]:83"\"XR%7'5
MU>0Q;6"IR-&N)S=1%_6J"ON*BLGU!$TROGTGQDA!5G/=54<+,ZYL[KJ+CK&=
MQ9&67??84<&OE=;?=<<=G8W7"C8W<]GHP";1`[ON6R%3O=2N-J:JPU4N747!
M(T)GQZO+66\E'80XZ@_G/=]D&/&4*QM@SHX:&*8280/-AV.%1O[<N>\I*5%E
M2RYHUS5-RFIS`4Z[Z@-',\_)E/,<69BKC'$VL]1=G`(TBZ]AA&4,+%YL<W"A
M2;+P(O@[_2#)71B',,C7,`KN*\1,YHS.I</?#--V'F)L;611&/M^G%''\WM,
M/DWP(#9'"CK8,#(97P/VK(U_QN;9EZ]Y]?";1WA_:L;!7!7G'H)H,J_BA>%[
M@(L(SJ'O1>GNFIRNA0[T=\*;/<-.0Q[.<>^&W.EH:P&V^<-Q'7&.NW`!9.V-
MH5]:\XZF<C>KB24K#^--A`'+Z+;)2>1`K=;7BA-_A,\&F'DOXI61-K=!^QWX
M6MG#"3[=6>2#"J)J<](>QH[#-Y9FLTUZ=7(FKN-D'.(K-J+9EXO?BW23XMW8
M;BPK+F=@0=9A"E9QLKVH%)=5K:^-67TA54$V96]XWG.-1L-G.-3O?-?=$O08
MM.9N<-T=00\=Q1O`=1\$/=!:/A:N^R/H@:C([[GNC:`'&I^==-T500\G?=9U
M?P:,P4CBO.HC`U&UZY#'YO%T1C@X9;Q$^V!F;)LGWB@Z]<1[&AOK"#5TO(PZ
M`[D7>.1)#H2TVY!2W:K?<3HC##%-DYC/UD#G=%!%^%#W("MZ<Y>.:UFYC4<>
MQ5FJ.M,=YM`.KCY.1WAZ+\'C4%CM.BF2D\EI;.,\\B!4(7P8ITN,?/5,<>=Z
MA$>GD.W1O;>F1<*C`/\ER?"<R]S0`SE:;4D5VI2U1[.2(2JG$6V(]$+9FR_J
M8?.0*LRD>E);+_GI)*MB98^=[6E76V%B=Z'69%^E`QS0J=6!Y0@/:GD(B?EY
M20(@Z<<+!O\B1BFB8<SGI-`FQI[VLLO5JI+\6"59QOUV&]0*E]QQZ3H"P1G5
M*M=M9&?4N/.N&)^N%%W,[/$`IXNE^61>+5=AO`;@`23/T`?EJE5G,@XI+=1D
M4_A._(YG0C-@T.FI,QZFOV<7/3;YU70@8S^%S_A0:_)GK0<>"A[%-J<%>:ID
M$\>1?(T1RI:K-JI7(Q]QZQ'K\3R[[I/8YV*8.0ZN^SWN9P5T+^C].4X.AJTC
MOAI92!RO\K16G16QW)(4\N_4'P'E;C:>OZO?,KR\$B:QT<CF>6/36TEIJK`Z
M1RCT7(0>0I/YSQ[Q.Z(%5J=P\6194U+Z2EX\$6\H0M95DL3)18R70\E>KS6$
MF9(T4B19IU_::1A.KNKK4)XX.1['>-Y4BAE;]G-M46YYQ]-59PP;SYOF.G28
MYC".<N<BVKJ`'>'9;J8GM'J,'2I3(5?$<=O;SM'4,EOE@![)']X28HF0BO_G
M_P%02P,$%`````@`;X(-1T@0/J#R#@``@)P``!$`'`!P:7)S+3(P,34P-C,P
M+GAS9%54"0`#TOO,5=+[S%5U>`L``00E#@``!#D!``#M75MOX[82?B_0_\#C
MAX,M4,=QLKOM!IL6N6R*`-E-X'BW/>>EH"7:YJE$NB25C?OK#TE=3(L4+=E.
MH@7T$LCBS'"&W_`R0XIY_^MC'($'Q#BFY+0W/#CL`40"&F(R.^U]ON^?W5]<
M7_=^_>7[[][_J]\'HQ&XI(2@*$)+\$>`(L2@0&`,'RFA\1+<!W,4PQ_!!'(4
M`DK`'^>C&W!T,`1@+L3B9##X^O7K`6-A+N0@H/$`]/MY!5]254[`VX.CHX/7
M1LF()B0\`4?&JPN&H)#4()1*R*+#X9O^X<_]X=%X>'1R^.[D];O_FM1TL61X
M-A?@5?"#)#Y\TY<<QV!T,#HPK/HWN*>$2^IX`<D2G$41&"DN#D:((_:`PH-,
M*-?&`MF"A)_V#/N^'A]0-AO(*H:#/S[>I(W2^_X[D-*>/$Y8A-<XU)N<YWB`
M"1>0!,A@B3#YR\.ABE6;FY58+)E:PW?OW@UTJ4&=\/X,PD5!/X5\HJFS`EG-
M\'7_<-@_'JYSB>4"<2>;+G'S+3!;;[$%1@QS[0P*Q<.WQX<&.9'@)+';_%"P
M@:II((GZDDK*"4S6S7P6CZ()1<%FMO2;05IH4`?2+P5;KI-S%!S,Z,,@*U1&
M'5NM$"2,R<Y6Q9J5NELP1-C-)@O<'.@QF+M95(F;!Y,'Q(6;*RUS6T8@#KB;
M31<IKJ'%Q7'@YI$%%1QBP2I89$F91T`V0^(3C!%?P`#5<D`YPL6(B"O*XDLT
MA4DD6^/O!$9XBE'8`U`(AB>)0&L$"5F1_**DO(>$4*''*OU;O5DL,)G2[*=\
MH3KD":,1&DNO!.KA\^BZ2D>1#;@#13>XI$&BM(0D_$`$%LMK*9G%NKX>P.%I
MSTM1Z)!K$:(I)EAK.SP<@C[(V<U'*0JDLH`A[/V@+*$L/)$SPRWY13\',`J2
M2#/>R-\9<T;A8UPP.183L07G2K-JONQM#L9>,+J7RFI7NIU>82)'=PRC.\JU
M)A<1Y#SS*(762#+\69/!#]ZQ1*P0!-0<2$)$U-PLGSB-L)HY0W`.(S7?@/LY
M0H)W&.Z$X1V4X[:8(X%ETS0&5'-O0/7U-JB"5VN*_="AO!GE:[D4CI$;PZS,
MC]2;>D@5)!S0*;A=J%6U%-#UQ!H8W4J/9FJUSM!<-BU^0#[4*JG].+ZU<:Q"
M;TTX2*6#5S>4\Z[+U8#S`O+Y542_\FL28H8"X<;1)O,#^-,V'5%5`G0M'7(5
MR'VB`O$Q+2:T50/>LADD^!]MRZJ-Y8\S$MX9=AJSX8KY$O,@HCQA:(P>Q7E$
M@[\,/WC&2OU>];-:$!=<VJW8@NJ42+<FWL5YSB''_'9J0B81O,<S(A=)`23B
M+-"A-2:S.XEQ@*6<1HZR4P5^IWA7=@I=EQI/S-IT_'2?Q#%D2U5F5`U6=8.\
M\LZ'&OO0!8TB.%&]44[$9XQ!,M,%VXXM3>1Y/61X6/:0$7I`).E0W@+E$8K4
MS"UC&[$<2TPX#/32>5N4F\CSHSRT4=:B^UHV,(5WN#?&_1)-MN[)5;Q^/(_*
M>"HQ'7*-D<MF-WX'EW`2(3GMRC<L0>$-AA,<25W1UKUW6]E^Y(_+R&="`7I<
MJ""BZ[];]-^B/64P)T-FV8[:KFR0O*!<\/LY9.A<;25*/#57PWZ^8QU^KWA=
M]HI[(9GZZ=9G8%37><<6:S?"DTBM@#4^6X\'=>3X47YCAWBY2)#*[.!M#J]*
M=]].?X=J%2U';1*F6^P-P=THQ0_MVS*TN:0.T2TZ;!QCD<[!1(ZL.GI%)-AA
M+F\HTH_U3W8W+J3K4'Q-?N<`C1W@/IEP]'<B'S\\-)^IJ[G]L%H)N)4@D$KJ
MH'S6Y%O^XLF3<$5%?@=YDF0<>)4_=5LZ3YJQ&:L@KIXO-9?J=9PC1XZN*GL#
M7J42.V=XMF1``\?8K0:_DU@IOG)BH'.-%\L0-'"1_=3D=Q4K>UB5+>A<9N-Q
MQZ(9B^U68[?U+`RU3C"R3T%NP>A'U<H,.C>`U<!0"%\K>'6)!,3=8:P:6%<L
M%M-%V^W4NVJLY1/[K\#O.U;^<"]+T\[5=G>U?#NVEMOXB?TN8"47<V$=C'N!
MT1D2U$2U`:\?9"O-F,D&5B31H?YTJ*\%B!^RY7E-U-V\?M2MA*,G?BR[Q(<B
M>NA@KPN[VHROU;.K"?V`6JE&):CKL7N`+@N:<Z]7GTN&221CL5)!&<G:?'Y@
MK11A'L07W;`/<MEJ!685=U#7AEH'O3KF->/L6OVV":L7\&,KM6>&XJ;PKG<_
M&>2KSCJF0N5B)-%YF2CK8=GD.*:K',S95\A"_IF$B(WGZ$YK<1?!FD[S5)7[
MW<Y*%GK<SAQOM(X9\;E-G.E9+"$$3<\E9+2ILB!1V@(Q1R#5%RB%.S?>GQO_
MCM39`^D<#XC!&3KC/(D7>GGW6?)<47:1MQJ9?8%1(EENT_+?U)F#_-//YZS0
M[Z[>A*7'77.]^IEBP-`,*-6`'$:!H1S0VJ4?OJ54F8*=>^[//8W):X1F<DA0
M1Z(43]KF9S(2><!BV=0)ZXKUNYJ51:WI:N:,7%2?,F>^!'(-.E]JDE5?/S17
M,Z->A\GO!U9&U#IKUZW(]H!O<6"N#JY^8C^>5GHS%];!N)=N6GD^KF:/;<CO
M!]M*<WI/V'4>L(])OW1JKEX<78O)C[65W+2.W77XRM?JCUK$C-`4Z`NW3M2-
M4Z<]CN-%A'K9.\@"Q>^_JFNP8'2!F#JL,LC%Y@(L[O6[P;33E-HOTRJ7,&=H
M>MI3MW+U\]N/_I0<!X]QE),(+%0M%RLY0`GB/P(81;U!>RU?A[&&X9+!8?AE
M(>8;L3N"$Q35-%G2.DR^41*^$6O+W;R&T9+%8?3:WKO#]O<#\^8N^6O]9J_W
MTG3*!"#.6\8JKOD#Z4V"-S30@CPLZE<_Y^NK5_WA4?]X>/#(PTS%)AJL6KJ9
M!CE?4PV\UP-6Z:#K=]Y'.$"1X(6L_DI6\^9P7B-8JU5,SD\IHVJ6=ZI9AF]W
MT60[+;93P7G)85VOR!E4I6\:.T+Y>LD=_$"]:>H&F^YK]*KCXLM_]%="ME#$
M<?MC/4U,QN+73HU2NE*REAHYCWK8J?+RY92U:B^8]--.]=O77-;2P&#+GG=R
M!^O6S%I*K+C2Q_Y*0',52I=PUE(@YU$/NU5>NLZS7NTYDWZJJ#^[X%,K<-K+
M]G;'\/$LD=&+C(MOT`Q&5RC??59+B#^]5.D22%_Q>Q)3(H,=MKP6*%;Q00_`
M"1<,!N*T-X617N)H0KGTP30<:]9T>A=YT22]Q>^T%S`D*^L!@M4])&JM(J06
MLBED["47+XEJB-\8319Y[5C66F%F$9I]Q)'T3:EF=JKY(XHGB)FV;B1-#4[O
MZ#T):0PQ<=F;*FN;&R8LBU/W8=B,(?U[C%B,B1;\B0H<H#M=I6G81E(3R5S+
M1D@^D6E2]MDCYDY;BC)3>:DH)K,G!244)R&.U:5W:1O5L.%2NTJ5%7EIJ[PK
MBI"Z8.R:!'8_L<O:I'IVN'GM3C1]9GA9^E!3&U.+>LT\D;]_N0YRH8;)5$JZ
M66!A5$G1)J1J?AN?&K29MG4HT5@&*.K[FV(^<0#E(6H55D6*>Y7<7BH4*LZ1
MGF7JE4S=3L0SC_#^=LCWZ8HQW(%I)4V[(*UY\TC)*`]U^[H@S6\8]L%53=0F
MO"XAQL$<WT/RUY*Z)N8J@E89@1Y01!>ZC4NK;'MPK$/<*N.,KRM7A^C6#G&N
M+E/DYTOK2TM]A,TQ=.Y;<(L&U/R_+)PY_E^#JR5JD;?(O@_Q(J)+&2^G.\]J
M#(4N7]]`UR8W__!W(AO^(Q)S&E[KC,]J:YT+^[V-XM82V@2L9(C5PN4*8I8=
M.[26W?J]:7@#IIW3*RMS2_F5$$WVE%YQVE-:*7Q"8E,+N#B>SOP]II=<UGRB
M9"L_\/!]$Z[PB()$71A\.YWB`#'5FR_UA?64.8:[.M2M&O0>%U(Y-:$*=:#D
M45JAA?\'P76[?&0FCC/UZN66QEHU%&:G5RL7QWZR=@$DTJ2<RG(Z['"4MDE]
M8R#XK&<^%!K'B[D^6H[,K&Y=AF]A[/@-$1F!1>K&FC#&!"N=U.!0?)D2T!G!
M_R"Y*"C/%4:+["3EFYAN)!GG=XP&"(7\BM'X6J*L:KE6!W9@=)=,(AS((16I
MI9'9-`T9OP6GN9'SAH2U>NRJ(FA3M\]T3#MME07KI>U37[I,A>I&29O4+K()
MV<'0]3TF9VDK=YE*FEK[3!7EK83BEB#+B5R%K51^_)56*V\4MDEY5[QA&>$C
M:I4QB=+)$4R;ME33K/5N_>[E5N:YFJZF=UCC)FNC06IS)Y@[C5@5F8IC(M`,
MO6"0E*M7++"K0"@3M,J*+"*0(3<+,$>AU<FK"-K4P<LZWC&YP'#-&9L(6V64
M\4_<5`($\8!AK?_M]#R1JR?$^8W\JQ0TW:XA7XNRIG4TU[="-K0VXWG^5=I<
M<K(@F:#J5=IM(K*%_!5R^*NKM$U.NB'CU?I,5ZJ@:ZBP2EK5[-*MU.<9,T>"
M/$]EZ&M^^8:\AVGP_F1F327;:9$*?4&`]V75[73*D5#,%SIG,Z;I1M53M&!U
M76UJV>+&%[OO6$5MZCPC-%/?[E&V/..RF5U[D-4D+9HN1XC+L3.8ZVG//@QA
MQVMU&=H%EDOG>\0>Y+Q8U\0R>1L--/ZOIK&98IW7KD=N>NG+G]D>H0<8)3!=
ME.71D$3HBK(IPF(5FF8#Z)JY35E;-$+>0T*GV/+1]==M\L6-QX>J3@]E<*B[
M0^6RR;1U7Q+;!.NV-EV3@"'Y\IKDJ8'LDIA$S"E3FT]&^+*/1FQ88;VYK>6-
M7(3XZ5[[F'Z18X:,H]371.IBI+0E]M&Z=6O:,=U6?`C5YE8M7<.6)UAT?N4Y
MVMI?_]K@H2OX=AU;WPK'KTDZU9?L'B$U?ZBX@1)M50(C=:AACQ!L67^[5B3:
M0OL65:L1)A6-4-/S='R7?SBX.J?KBCA:HU&+`IQ=7?6+7BT^_RC5L-[6C4[J
M_Q#^3XZS8[I:A96;QTW3IITE]WVVKHSY1LHV]0FGKN6LN)>JE7GP>O]@QHE>
M4\XVH5E+=PO=)ERM1'L\L0\%&>_:%!,;W\6;:98BT9NG=^4`2-;.8#9E;%&$
M.T[L0[+&NS;!DWWTFTVI2IB5,JLF>=%%Z?M!>GN'?/P_4$L!`AX#%`````@`
M;X(-1^8(DZ</K0``#Z8%`!$`&````````0```*2!`````'!I<G,M,C`Q-3`V
M,S`N>&UL550%``/2^\Q5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`;X(-
M1\!9,?:9#```=J@``!4`&````````0```*2!6JT``'!I<G,M,C`Q-3`V,S!?
M8V%L+GAM;%54!0`#TOO,575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&^"
M#4=">GW[Q!X``*[[`0`5`!@```````$```"D@4*Z``!P:7)S+3(P,34P-C,P
M7V1E9BYX;6Q55`4``]+[S%5U>`L``00E#@``!#D!``!02P$"'@,4````"`!O
M@@U'+T2R2WM7```R\P0`%0`8```````!````I(%5V0``<&ER<RTR,#$U,#8S
M,%]L86(N>&UL550%``/2^\Q5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M;X(-1[FWV_6/+```3D`#`!4`&````````0```*2!'S$!`'!I<G,M,C`Q-3`V
M,S!?<')E+GAM;%54!0`#TOO,575X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`&^"#4=($#Z@\@X``("<```1`!@```````$```"D@?U=`0!P:7)S+3(P,34P
M-C,P+GAS9%54!0`#TOO,575X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"
(```Z;0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902506445776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Revenues</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left"><b>Revenues</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>General</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. has not generated revenues from
 product sales. Pieris Pharmaceuticals, Inc. has generated revenues
 pursuant to (i)&#xA0;license and collaboration agreements, which
 include upfront payments for licenses or options to obtain
 licenses, payments for research and development services and
 milestone payments, and (ii)&#xA0;government grants.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Collaborations and Other Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Allergan, Inc.</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In August 2009, pursuant to an agreement with Allergan, Inc.
 (&#x201C;Allergan&#x201D;), the Company granted Allergan a worldwide
 exclusive license to develop and commercialize certain drug
 candidates for the treatment and prevention of ocular diseases.
 Allergan is responsible for the research, development,
 manufacturing and commercialization of any products resulting from
 the license. The Company received a non-refundable upfront payment
 of $10 million upon execution of the contract in 2009 and is
 entitled to receive up to an aggregate of $13 million in milestone
 payments upon the achievement of certain commercial milestones or
 patents granted to the Company by the United States Patent and
 Trademark Office that cover a product licensed to Allergan.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 At the inception of the agreement, the Company recognized revenues
 from the upfront license payment because, based on the stage of
 development of the licensed product delivered and the development
 capabilities of Allergan, the Company determined that the license
 had standalone value. Through June&#xA0;30, 2015, none of the
 milestones had been achieved and, as such, the Company has not
 recognized milestone-related revenues.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Daiichi Sankyo Co., Ltd.</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In May 2011, the Company entered into an agreement with Daiichi
 Sankyo Co., Ltd. (&#x201C;Daiichi Sankyo&#x201D;), under which Pieris
 AG will use its proprietary Anticalin<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;scaffold technology to
 identify drug candidates against certain targets selected by
 Daiichi Sankyo, with further development and commercialization
 performed by Daiichi Sankyo. For any targets selected by Daiichi
 Sankyo, the Company granted an exclusive, worldwide license for the
 research, development and commercialization of drug candidates
 identified by the Company. The Company has handed over further
 development responsibility for the two collaboration projects to
 Daiichi Sankyo, which handovers occurred in March 2013 and June
 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Upon execution of the agreement, Daiichi Sankyo paid the Company a
 non-refundable upfront payment in the amount of $10.1&#xA0;million
 in consideration for the licenses, and for each licensed product,
 the Company is entitled to receive potential milestone payments of
 $91.1 million, plus royalties on the commercial sales of any
 commercial products. The total milestones are categorized as
 follows: research milestones - $2.6 million; development milestones
 - $37.4 million; commercial milestones - $50.2 million; additional
 diagnostic milestones of $0.9 million. At the inception of the
 agreement, these milestones were determined to be substantive as
 there was substantial uncertainty the milestones would be achieved,
 they would require substantial performance from the entity, and the
 consideration was reasonable relative to other deliverables. The
 agreement includes provisions for the Company to provide research
 services funded by Daiichi Sankyo at agreed upon full-time employee
 rates during the initial identification and research period.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In accordance with the guidance in ASC 605-25, the Company
 identified the licenses and research funding as deliverables at the
 inception of the arrangement. The Company has determined that the
 licenses and research services provided by the Company represent
 one unit of accounting because, based on the stage of development
 of the licensed product, the research services provided by the
 Company to identify drug candidates using the Company&#x2019;s
 proprietary Anticalin<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;technology against Daiichi
 Sankyo&#x2019;s selected targets were necessary before the licenses
 would have any standalone value. Therefore, the total arrangement
 consideration was recognized over the estimated period of
 substantial involvement, which was determined to be the period
 Company was required to provide research services to discover drug
 candidates against targets identified. The Company estimated this
 period would be approximately two years. The Company reassesses the
 estimated term at the end of each reporting period.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company has not recognized any milestone payments as revenue
 for the six months ended June&#xA0;30, 2015. The Company recognized
 a milestone payment of $0.4 million as revenue for the six months
 ended June&#xA0;30, 2014. The milestone payment was based on
 successful&#xA0;<i>in
 vitro</i>&#xA0;and&#xA0;<i>in vivo</i>&#xA0;studies. In general,
 milestones could not be achieved solely upon the passage of time.
 For revenue recognition purposes, management determined these
 milestones to be substantive in accordance with applicable
 accounting guidance related to milestone revenue. Substantive
 uncertainty existed at the inception of the arrangement as to
 whether the milestones would be achieved because of the numerous
 variables, such as the high rate of failure inherent in research
 and development activities and the uncertainty involved with
 obtaining regulatory approval. For the three and six months ended
 June&#xA0;30, 2015, the Company did not recognize any revenues
 related to the Daiichi Sankyo Collaboration and for the three and
 six months ended June&#xA0;30, 2014, the Company recognized $0.4
 and $1.1 million in revenues, respectively. $0.4 million of these
 revenues were related to the achievement of milestones during the
 three and six months ended June&#xA0;30, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Sanofi-Aventis and Sanofi-Pasteur</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In September 2010, the Company entered into an agreement with
 Sanofi-Aventis and Sanofi Pasteur (&#x201C;Sanofi&#x201D;), under
 which the Company agreed to apply its proprietary
 Anticalin<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;technology to identify drug
 candidates against certain targets selected by Sanofi, with further
 development and commercialization performed by Sanofi. The
 agreement included the initial identification of two targets by
 Sanofi, with options to select up to four additional targets. For
 any targets selected by Sanofi, the Company granted an exclusive,
 worldwide license for the research, development and
 commercialization of drug candidates identified by the Company. In
 addition to the two initial targets selected by Sanofi, Sanofi
 exercised one of the four options and received a license. The
 remaining three options expired unexercised.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Upon execution of the agreement, Sanofi paid the Company an upfront
 payment of $4.9 million in consideration for licenses on the first
 two targets and options to select an additional four licenses on
 other targets (with each option requiring an additional upfront
 payment upon exercise). Additionally, for each licensed product,
 the Company is entitled to receive milestone payments up to $51.6
 million, plus royalties on the sales of any commercial products.
 The total milestones are categorized as follows: research
 milestones - $1.9 million; development milestones - $29.6 million;
 commercial milestones - $20.1 million. At the inception of the
 agreement, these milestones were determined to be substantive
 because (i)&#xA0;there was substantial uncertainty the milestones
 would be achieved, (ii)&#xA0;they would require substantial
 performance from the entity, and (iii)&#xA0;the consideration was
 reasonable relative to other deliverables. The agreement included
 provisions for the Company to provide research services funded by
 Sanofi at agreed upon full-time employee equivalent rates during
 the initial identification and research period.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In accordance with the guidance in ASC 605-25, the Company
 identified the licenses, options to obtain additional licenses and
 research funding as deliverables at the inception of the
 arrangement. The options were considered to be substantive at the
 inception of the agreement. Factors considered in determining the
 options were substantive were whether (i)&#xA0;Sanofi could obtain
 the overall objective of the agreement without exercising any
 options, (ii)&#xA0;Sanofi was able to obtain value from the initial
 licenses obtained without exercising any options, (iii)&#xA0;the
 cost to exercise the options was significant relative to the total
 upfront payment of $4.9 million for two licenses and four options,
 and (iv)&#xA0;exercising the option created additional financial
 commitments for Sanofi or imposed economic penalties on Sanofi.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company has determined that, for each program selected by
 Sanofi, the license and research services provided by the Company
 represent one unit of accounting because, based on the stage of
 development of the licensed product, the research services provided
 by the Company to identify drug candidates using the
 Company&#x2019;s proprietary Anticalin technology against
 Sanofi&#x2019;s selected targets were necessary before the licenses
 would have any standalone value.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The estimated selling prices for the licenses in the agreement are
 the Company&#x2019;s best estimate of selling price and were
 determined based on market conditions and entity-specific factors
 such as considerations of preclinical and clinical testing results
 and the Company&#x2019;s pricing practices and pricing objectives.
 The estimated selling price of research services are the
 Company&#x2019;s best estimate of selling price and are determined
 based on market conditions and entity-specific factors such as
 internal cost considerations and the Company&#x2019;s pricing
 practices and pricing objectives.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 At inception, the total arrangement consideration of $8.1 million
 (which comprises the $4.9 million upfront payment and the expected
 fees for the research services to be provided under the remainder
 of the arrangement) was allocated to the deliverables based on the
 residual method as follows: $3.5 million to the licenses,
 $1.4&#xA0;million to the four options to acquire additional
 licenses and $3.2 million to the estimated research services to be
 provided. As the license and research services were determined to
 be one unit of accounting, the consideration allocated to each
 license is recognized over the period of substantial involvement,
 which was determined to be the period the Company was required to
 provide research services to discover drug candidates against
 targets identified, approximately two years. The Company reassesses
 the estimated term at the end of each reporting period. At the end
 of 2012, the Company determined that the required research term for
 one of the initial terms would extend to a period of 40 months, and
 management updated the estimated required service period to
 amortize the remaining deferred upfront payment over the new term.
 Two of the four options expired un-exercised in 2011, and as a
 result the Company recognized $0.7 million of revenue upon
 expiration. The option term for the remaining two options was
 extended to February 2013, and Sanofi exercised one option to
 obtain an additional license. For the exercised option, the
 allocated consideration of $0.28 million for the option and the
 $1.1 million payment of the exercise price of the option were
 deferred and amortized over the expected required service period of
 approximately two years. The program covered by the exercised
 option was terminated in December 2013, and accordingly, the
 Company recognized the remaining deferred revenue upon termination.
 The remaining option expired in February 2013 and the allocated
 consideration of $0.35 million was recognized into revenue at the
 time of expiration.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company has not recognized any milestone payments as revenue
 for the three and six months ended June&#xA0;30, 2015. The Company
 recognized a milestone payment of $0.3 million as revenue for the
 six months ended June&#xA0;30, 2014. The Company did not recognize
 a milestone payment for the three months ended June&#xA0;30, 2014.
 The milestone payment was based on successful&#xA0;<i>in vivo</i>&#xA0;studies. The milestone could
 not be achieved solely upon the passage of time. For revenue
 recognition purposes, management determined this milestone to be
 substantive in accordance with applicable accounting guidance
 related to milestone revenue. Substantive uncertainty existed at
 the inception of the arrangement as to whether the milestone would
 be achieved because of the numerous variables, such as the high
 rate of failure inherent in research and development activities and
 the uncertainty involved with obtaining regulatory approval.
 Therefore, the payment was recognized in its entirety as revenue in
 the six months ended June&#xA0;30, 2014 when the research milestone
 was reached.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 For the three and six months ended June&#xA0;30, 2015, the Company
 did not recognize any revenues related to the Sanofi collaboration
 and for the three and six months ended June&#xA0;30, 2014, the
 Company recognized $0.2 million and $0.7 million in revenues
 respectively.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902481045312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_StockBasedCompensationLineItems', window );"><strong>Stock Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Options outstanding</a></td>
<td class="nump">2,616,735<span></span>
</td>
<td class="nump">2,544,500<span></span>
</td>
<td class="nump">2,519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,616,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted</a></td>
<td class="nump">72,235<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum term of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 130,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="nump">200,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense</a></td>
<td class="nump">$ 2,253,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,253,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pirs_PierisPlanMember', window );">Pieris Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_StockBasedCompensationLineItems', window );"><strong>Stock Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription', window );">Share-based compensation description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 1,000,000 shares, (ii) 4% of the number of shares of  the Company's common stock outstanding on such date, and (iii) such other amount  determined by the Compensation committee of the Board of Directors. As of  June 30, 2015, options to purchase 1,470,235 shares of the Company's common  stock are outstanding under the Pieris Plan to its executive officers and  directors. 40,235 of these shares were granted during the second quarter of  2015. All other shares were granted in the fourth quarter of 2014.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant</a></td>
<td class="nump">583,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pirs_PierisPlanMember', window );">Pieris Plan [Member] | Executive Officers And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_StockBasedCompensationLineItems', window );"><strong>Stock Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Options outstanding</a></td>
<td class="nump">1,470,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted</a></td>
<td class="nump">40,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pirs_PierisPlanMember', window );">Pieris Plan [Member] | Other Employees and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_StockBasedCompensationLineItems', window );"><strong>Stock Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Options outstanding</a></td>
<td class="nump">1,146,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">1,089,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Authorized Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_StockBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Based Compensation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_StockBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pirs_PierisPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pirs_PierisPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=pirs_EmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=pirs_EmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902486063488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">$ 333,979<span></span>
</td>
<td class="nump">$ 332,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_AccruedTaxAuditAndLegalFees', window );">Accrued audit and tax expenses</a></td>
<td class="nump">148,500<span></span>
</td>
<td class="nump">403,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">153,082<span></span>
</td>
<td class="nump">7,523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses, current</a></td>
<td class="nump">635,561<span></span>
</td>
<td class="nump">743,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract', window );"><strong>Accrued expenses non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Reserve for litigation TUM</a></td>
<td class="nump">302,273<span></span>
</td>
<td class="nump">327,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent', window );">Accrued expenses restoration</a></td>
<td class="nump">5,577<span></span>
</td>
<td class="nump">6,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Total accrued expenses, non-current</a></td>
<td class="nump">307,850<span></span>
</td>
<td class="nump">333,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 943,411<span></span>
</td>
<td class="nump">$ 1,077,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedTaxAuditAndLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Tax Audit And Legal Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedTaxAuditAndLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable after twelve months or beyond the next operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 410<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 410<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph 5<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902488024320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail) - Jun. 30, 2015 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-option expense</a></td>
<td class="nump">$ 268,039<span></span>
</td>
<td class="nump">$ 485,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-option expense</a></td>
<td class="nump">78,551<span></span>
</td>
<td class="nump">129,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-option expense</a></td>
<td class="nump">$ 189,488<span></span>
</td>
<td class="nump">$ 355,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902500244144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail) - Jun. 30, 2015<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">74.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902708789440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left"><b>Basis of Presentation and Summary
 of Significant Accounting Policies</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The following is a summary of the significant accounting policies
 consistently applied in the preparation of the accompanying
 condensed consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Basis of Consolidation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The accompanying unaudited condensed consolidated financial
 statements of Pieris Pharmaceuticals Inc. and its wholly owned
 subsidiaries were prepared in accordance with accounting principles
 generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;)
 for interim financial information. All significant intercompany
 balances and transactions have been eliminated in the
 consolidation. Certain information and footnotes normally included
 in financial statement prepared in accordance with U.S. GAAP have
 been omitted pursuant to the Securities and Exchange Commission
 rules and regulations. Accordingly, they do not include all of the
 information and notes required by U.S. GAAP for complete annual
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In the opinion of management, the unaudited interim condensed
 consolidated financial statements have been prepared on the same
 basis as the audited condensed consolidated financial statements
 for the year ending December&#xA0;31, 2014, and all adjustments,
 including normal recurring adjustments, considered necessary for a
 fair presentation of Pieris Pharmaceuticals, Inc.&#x2019;s unaudited
 interim consolidated financial statements have been included. The
 results of operations for the three and six months ended
 June&#xA0;30, 2015 are not necessarily indicative of the results
 that may be expected for the year ending December&#xA0;31, 2015 or
 any future period.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Use of estimates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The preparation of the condensed consolidated financial statements
 in accordance with U.S. GAAP requires management to make estimates,
 judgments and assumptions that affect the reported amounts of
 assets and liabilities, the reported amounts of revenues and
 expenses in the financial statements and disclosures in the
 accompanying notes. Actual results and outcomes could differ
 materially from management&#x2019;s estimates, judgments and
 assumptions.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Segment Reporting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. operates as a single segment dedicated
 to the discovery and development of biotechnological applications
 and the Company&#x2019;s chief operating decision maker (CODM) makes
 decisions based on the Company as a whole. Accordingly, Pieris
 Pharmaceuticals, Inc. operates and makes decisions as one reporting
 unit.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Milestone Payments and Royalties</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 At the inception of each agreement that includes milestone
 payments, Pieris Pharmaceuticals, Inc. evaluates whether each
 milestone is substantive and at risk to both parties on the basis
 of the contingent nature of the milestone. This evaluation includes
 an assessment of whether (a)&#xA0;the consideration is commensurate
 with either (1)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (2)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (b)&#xA0;the consideration relates solely to past performance and
 (c)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. Pieris
 Pharmaceuticals, Inc. evaluates factors such as the scientific,
 regulatory, commercial and other risks that must be overcome to
 achieve the respective milestone, the level of effort and
 investment required to achieve the respective milestone and whether
 the milestone consideration is reasonable relative to all
 deliverables and payment terms in the arrangement in making this
 assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. aggregates milestones into three
 categories (i)&#xA0;research milestones, (ii)&#xA0;development
 milestones and (iii)&#xA0;commercial milestones. Research
 milestones are typically achieved upon reaching certain success
 criteria as defined in each agreement related to developing an
 Anticalin protein against the specified target. Development
 milestones are typically reached when a compound reaches a defined
 phase of clinical research or passes such phase, or upon gaining
 regulatory approvals. Commercial milestones are typically achieved
 when an approved pharmaceutical product reaches the status for
 commercial sale or certain defined levels of net sales by the
 licensee, such as when a product first achieves global sales or
 annual sales of a specified amount.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 For revenues from research and development milestone payments, if
 the milestones are deemed substantive and the milestone payments
 are nonrefundable, such amounts are recognized entirely upon
 successful accomplishment of the milestones. Milestones that are
 not considered substantive are accounted for as license payments
 and recognized on a straight-line basis over the period of
 performance. To date, Pieris Pharmaceuticals, Inc. has determined
 all milestones are substantive. Revenues from commercial milestone
 payments are accounted for as royalties and are recorded as revenue
 upon achievement of the milestone, assuming all other revenue
 recognition criteria are met. Royalty payments are recognized in
 revenues based on the timing of royalty payments earned in
 accordance with the agreements; which typically is the period when
 the relevant sales occur, assuming all other revenue recognition
 criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Fair Value Measurement</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 ASC Topic 820&#xA0;<i>Fair Value
 Measurement</i>&#xA0;defines fair value as the
 price that would be received to sell an asset or be paid to
 transfer a liability in an orderly transaction between market
 participants at the measurement date. Pieris Pharmaceuticals, Inc.
 applies the following fair value hierarchy, which prioritizes the
 inputs used to measure fair value into three levels and bases the
 categorization within the hierarchy upon the lowest level of input
 that is available and significant to the fair value
 measurement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Level 1 inputs are quoted prices in active markets for identical
 assets or liabilities that the reporting entity has the ability to
 access at the measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Level 2 utilizes quoted market prices in markets that are not
 active, broker or dealer quotations, or alternative pricing sources
 with reasonable levels of price transparency.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Level 3 inputs are unobservable inputs for the asset or liability
 in which there is little, if any, market activity for the asset or
 liability at the measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist
 of highly liquid money market funds and are measured at fair value
 on a recurring basis. These funds are classified as Level 1 in the
 fair value hierarchy because they are valued using quoted prices
 for the periods ended June&#xA0;30, 2015 and December&#xA0;31,
 2014. The carrying amounts of $78,403 and $ 4,800,573 as of
 June&#xA0;30, 2015 and December&#xA0;31, 2014, respectively, equal
 the fair value of the cash equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company&#x2019;s other financial instruments include debt
 instruments, prepaid expenses, other current assets, accounts
 payable, accrued expenses and other current liabilities and are
 classified as Level 2 within the fair value hierarchy. The fair
 value of these instruments was determined using the discounted cash
 flow method based on contractual cash flows and the current rate at
 which debt with similar terms could be issued. The fair values for
 these debt instruments approximated carrying values as of
 June&#xA0;30, 2015 and December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Income taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Deferred tax assets and liabilities are recognized for the future
 tax consequences attributable to differences between the financial
 statement carrying amounts of existing assets and liabilities and
 their respective tax bases, and operating losses and tax credit
 carry forwards. Deferred tax assets and liabilities are measured
 using enacted statutory tax rates expected to apply to taxable
 income in the jurisdictions and years in which those temporary
 differences are expected to be recovered or settled. The effect on
 deferred tax assets and liabilities of a change in tax rates is
 recognized in income in the period that includes the enactment
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Based on the level of historical operating results and projections
 for the taxable income for the future, the Company has determined
 that it is more likely than not that the deferred tax assets will
 not be realized. Accordingly, the Company has recorded a valuation
 allowance to reduce deferred tax assets to the same amount as
 deferred tax liabilities and determines an effective tax rate of
 zero percent.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Recent Accounting Pronouncements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, &#x201C;Revenue
 from Contracts with Customers,&#x201D; (ASU 2014-09) which provides
 guidance for revenue recognition. The standard&#x2019;s core
 principle is that a company will recognize revenue when it
 transfers promised goods or services to customers in an amount that
 reflects the consideration to which the company expects to be
 entitled in exchange for those goods or services. The new guidance
 is effective for annual reporting periods beginning after
 December&#xA0;15, 2016, including interim periods within that
 reporting period. Early application is not permitted. On
 April&#xA0;1, 2015 the FASB voted in favor of proposing a one year
 delay of the effective date and to permit companies to voluntarily
 adopt the new standard as of the original effective date. The
 Company is currently assessing the potential impact the adoption of
 this standard will have on their financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In January 2015, the FASB issued ASU No.&#xA0;2015-01,&#xA0;<i>&#x201C;Income Statement
 &#x2013; Extraordinary and Unusual items&#x201D;</i>&#xA0;(ASU 2015-01). The amendments
 in ASU 2015-01 eliminate from U.S. GAAP the concept of
 extraordinary items. Subtopic 225-20, Income Statement -
 Extraordinary and Unusual Items, required that an entity separately
 classify, present, and disclose extraordinary events and
 transactions. Presently, an event or transaction is presumed to be
 an ordinary and usual activity of the reporting entity unless
 evidence clearly supports its classification as an extraordinary
 item. This guidance is effective for fiscal years, and interim
 periods within those fiscal years, beginning after
 December&#xA0;15, 2015. The company is currently evaluating the
 impact of this new standard.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In February 2015, the FASB issued ASU No.&#xA0;2015-02,&#xA0;<i>&#x201C;Consolidation (Topic
 810): Amendments to the Consolidation Analysis&#x201D;</i>(ASU
 2015-02). The amendments in ASU 2015-02 are intended to improve
 targeted areas of consolidation guidance for legal entities such as
 limited partnerships, limited liability corporations, and
 securitization structures (collateralized debt obligations,
 collateralized loan obligations, and mortgage-backed security
 transactions). This guidance is effective for fiscal years
 beginning after December&#xA0;15, 2016, and interim periods within
 fiscal years beginning after December, 15, 2017. The company is
 currently evaluating the impact of this new standard.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In June 2015, the FASB issued ASU No.&#xA0;2015-10,
 &#x201C;Technical Corrections and Improvements&#x201D; (ASU 2015-10).
 The amendments in ASU 2015-10 represent changes to clarify the FASB
 Accounting Standards Codification (the &#x201C;Codification&#x201D;),
 correct unintended application of guidance, or make minor
 improvements to the Codification that are not expected to have a
 significant effect on current accounting practice or create a
 significant administrative cost to most entities. In addition, some
 of the amendments are intended to make the Codification easier to
 understand and easier to apply by eliminating inconsistencies,
 providing needed clarifications, and improving the presentation of
 guidance in the Codification. This guidance is effective for fiscal
 years, and interim periods within those fiscal years, beginning
 after December&#xA0;15, 2015. The company is currently evaluating
 the impact of this new standard.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. has considered other recent accounting
 pronouncements and concluded that they are either not applicable to
 the business, or that the effect is not expected to be material to
 the unaudited condensed consolidated financial statements as a
 result of future adoption.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902499995696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning balance</a></td>
<td class="nump">2,544,500<span></span>
</td>
<td class="nump">2,519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted</a></td>
<td class="nump">72,235<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Options cancelled or expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at ending balance</a></td>
<td class="nump">2,616,735<span></span>
</td>
<td class="nump">2,544,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,616,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,519,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Vested</a></td>
<td class="nump">799,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber', window );">Number of shares, Expected to vest</a></td>
<td class="nump">1,708,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,708,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable</a></td>
<td class="nump">799,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding at beginning balance</a></td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options granted</a></td>
<td class="nump">2.89<span></span>
</td>
<td class="nump">2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options cancelled or expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding ending balance</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Contractual Life, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Contractual Life, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Out Standing Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902485914560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,027,305<span></span>
</td>
<td class="nump">$ 18,474,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,866,180<span></span>
</td>
<td class="nump">1,207,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">732,221<span></span>
</td>
<td class="nump">109,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">16,015<span></span>
</td>
<td class="nump">14,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,641,721<span></span>
</td>
<td class="nump">19,805,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,811,356<span></span>
</td>
<td class="nump">2,052,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">24,446<span></span>
</td>
<td class="nump">26,522<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,477,523<span></span>
</td>
<td class="nump">21,884,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">2,058,458<span></span>
</td>
<td class="nump">1,260,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">635,561<span></span>
</td>
<td class="nump">743,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">304,012<span></span>
</td>
<td class="nump">242,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,270,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesCurrent', window );">Deferred tax liabilities</a></td>
<td class="nump">24,446<span></span>
</td>
<td class="nump">26,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,022,477<span></span>
</td>
<td class="nump">3,543,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">307,850<span></span>
</td>
<td class="nump">333,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,330,327<span></span>
</td>
<td class="nump">3,877,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at June 30, 2015 and December 31, 2014</a></td>
<td class="nump">29,430<span></span>
</td>
<td class="nump">29,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">85,503,241<span></span>
</td>
<td class="nump">84,627,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,343,694)<span></span>
</td>
<td class="num">(843,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,041,781)<span></span>
</td>
<td class="num">(65,807,048)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">11,147,196<span></span>
</td>
<td class="nump">18,006,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 14,477,523<span></span>
</td>
<td class="nump">$ 21,884,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.5(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902486343632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,234,733)<span></span>
</td>
<td class="num">$ (3,661,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">154,555<span></span>
</td>
<td class="nump">189,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">485,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Non-cash Restricted shares</a></td>
<td class="nump">390,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(628,723)<span></span>
</td>
<td class="num">(72,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(768,905)<span></span>
</td>
<td class="num">(240,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="nump">897,130<span></span>
</td>
<td class="nump">487,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">30,481<span></span>
</td>
<td class="num">(422,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Income taxes</a></td>
<td class="num">(2,365)<span></span>
</td>
<td class="nump">49,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operations</a></td>
<td class="num">(6,676,452)<span></span>
</td>
<td class="num">(3,406,942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(74,286)<span></span>
</td>
<td class="num">(4,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(72,286)<span></span>
</td>
<td class="num">(4,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Proceeds of loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="num">(1,171,170)<span></span>
</td>
<td class="num">(136,900)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="num">(1,171,170)<span></span>
</td>
<td class="nump">1,224,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', window );">Effect of exchange rate change on cash and cash equivalents</a></td>
<td class="num">(524,998)<span></span>
</td>
<td class="num">(17,033)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(8,446,906)<span></span>
</td>
<td class="num">(2,204,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">18,474,211<span></span>
</td>
<td class="nump">3,689,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">10,027,305<span></span>
</td>
<td class="nump">1,485,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">41,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash received for income taxes</a></td>
<td class="num">$ (1,206)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902495339344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 23, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 23, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Counterclaim amount filed</a></td>
<td class="nump">$ 3,060,827<span></span>
</td>
<td class="nump">&#8364; 2,529,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Claims and counterclaims amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,235,350<span></span>
</td>
<td class="nump">&#8364; 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_OutLicenseFeeMember', window );">Out License Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Out-License Fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember', window );">TUM [Member] | Out License Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Out-License Fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyDepositLiabilities', window );">Reserved liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 271,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyDepositLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deposits held by the entity for a related party (entity, shareholder, employee).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyDepositLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_OutLicenseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_OutLicenseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902486371872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_WarrantExercisablePeriod', window );">Warrant exercisable period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="nump">6,779,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of common stock, price per share</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 13,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued upon acquisition</a></td>
<td class="nump">542,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Description Of Business [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_WarrantExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercisable Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_WarrantExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902501424592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 24, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 14, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 06, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,725,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,920<span></span>
</td>
<td class="nump">$ 3,250,222<span></span>
</td>
<td class="nump">$ 2,341,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_GrossProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cooperation Agreement [Member] | Milestone One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,698<span></span>
</td>
<td class="nump">&#8364; 43,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cooperation Agreement [Member] | Milestone Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,301<span></span>
</td>
<td class="nump">&#8364; 116,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of common stock, price per share | $ / shares</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised | shares</a></td>
<td class="nump">1,211,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_GrossProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issuance Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_GrossProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AgreementTypeAxis=pirs_CooperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AgreementTypeAxis=pirs_CooperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_MilestoneEventsAxis=pirs_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_MilestoneEventsAxis=pirs_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_MilestoneEventsAxis=pirs_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_MilestoneEventsAxis=pirs_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902481165584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May. 31, 2011</div></th>
<th class="th"><div>Sep. 30, 2010</div></th>
<th class="th"><div>Aug. 31, 2009</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Feb. 28, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues from product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_AllerganIncMember', window );">Allergan Inc [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_AllerganIncMember', window );">Allergan Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_AllerganIncMember', window );">Allergan Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration agreement, license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Collaboration agreement, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodFactors', window );">Description of factors in determining milestones substantive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Factors considered in determining the options were substantive were whether (i)&#160;Sanofi could obtain the overall objective of the agreement without exercising any options, (ii)&#160;Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii)&#160;the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv)&#160;exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Collaborative arrangement, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Expired Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Collaboration agreement, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Options Exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Collaboration agreement, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Collaborative arrangement, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Options, Exercised Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Collaborative arrangement, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Collaborative arrangement, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Options to Acquire Additional Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Collaborative arrangement, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ResearchCollaborationAgreementPeriod', window );">Research collaboration agreement, estimated period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Collaborative arrangement, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member] | Extension Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ResearchCollaborationAgreementPeriod', window );">Research collaboration agreement, estimated period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember', window );">Sanofi [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration agreement, license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ResearchCollaborationAgreementPeriod', window );">Research collaboration agreement, estimated period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Collaboration agreement, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="nump">$ 91,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="nump">37,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="nump">50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Collaboration agreement, milestone payments</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember', window );">Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration agreement, license revenue</a></td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ResearchCollaborationAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration Agreement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ResearchCollaborationAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of billed or unbilled claims or other similar items subject to uncertainty concerning their determination or ultimate realization under long-term contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(c)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph c(3)<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsReceivableClaimsAndUncertainAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodFactors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the factors that the entity considered in determining whether the milestone or milestones are substantive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 28<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodFactors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 28<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pirs_AllerganIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pirs_AllerganIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pirs_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pirs_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_ExpiredOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_ExpiredOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_OptionsExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_OptionsExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_OptionsExercisedPriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_OptionsExercisedPriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pirs_LicensingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pirs_LicensingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pirs_LicenseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pirs_LicenseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_ExtensionTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_ExtensionTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_AdditionalMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_AdditionalMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902708789440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Corporate Information</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>1.</b></td>
 <td valign="top" align="left"><b>Corporate Information</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. is a holding company incorporated in
 May 2013 under the name Marika Inc. On December&#xA0;17, 2014
 Pieris AG (a German company which was founded in 2001 by Prof.
 Dr.&#xA0;Arne Skerra, Professor at the Technical University of
 Munich, Germany, and Claus Schalper) became a wholly owned
 subsidiary of Pieris Pharmaceuticals, Inc., pursuant to the
 Acquisition (described below). The registered office of Pieris
 Pharmaceuticals, Inc. and the corporate headquarters and research
 facility of Pieris AG are located in Freising-Weihenstephan,
 Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of
 Pieris AG, was formed on February&#xA0;14, 2014 to conduct research
 and development in Australia.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On December&#xA0;17, 2014, Pieris Pharmaceuticals, Inc., Pieris AG,
 and the former stockholders of Pieris AG entered into an
 acquisition agreement, or the Acquisition Agreement. Pursuant to
 the Acquisition Agreement, on December&#xA0;17, 2014, the
 stockholders of Pieris AG contributed all of their equity interests
 in Pieris AG to Pieris Pharmaceuticals, Inc. in exchange for shares
 of Pieris Pharmaceuticals, Inc. common stock, which resulted in
 Pieris AG becoming a wholly owned subsidiary of Pieris
 Pharmaceuticals, Inc. (the &#x201C;Acquisition&#x201D;). Upon the
 closing of the Acquisition, Pieris Pharmaceuticals, Inc. ceased to
 be a &#x201C;shell company&#x201D; under applicable rules of the SEC.
 For more information on the acquisition, please refer to Note
 3&#xA0;<i>Acquisition</i>&#xA0;of the consolidated financial
 statements as of December&#xA0;31, 2014 included in the
 Company&#x2019;s Annual Report on Form 10-K for the fiscal year
 ended December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On December&#xA0;17, 2014, Pieris Pharmaceuticals, Inc. entered
 into a securities purchase agreement, or the Securities Purchase
 Agreement, with certain accredited investors (the
 &#x201C;Investors&#x201D;) providing for the issuance and sale to
 such Investors of an aggregate of 6,779,510 shares of our common
 stock in a private placement offering conducted through a series of
 closings occurring on December&#xA0;17, 18 and 23, 2014, at a
 purchase price per share of $2.00 and for aggregate gross proceeds
 of approximately $13.56 million (the &#x201C;Private
 Placement&#x201D;). Northland Securities, Inc. and Katalyst
 Securities, LLC served as co-exclusive placement agents (the
 &#x201C;Placement Agents&#x201D;) for the Private Placement. At the
 closings of the Private Placement we issued to the Placement Agents
 and their designees, warrants (the &#x201C;Placement
 Warrants&#x201D;), to acquire up to 542,360 shares of our common
 stock at an exercise price of $2.00 per share. Each of the
 Placement Warrants is exercisable at any time at the option of the
 holder until the five-year anniversary of its date of issuance.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. and its consolidated subsidiaries (the
 &#x201C;Company&#x201D;) is a clinical-stage biopharmaceutical
 company dedicated to the discovery and development of the
 Anticalin<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;class of biotherapeutics for
 patients with diseases in which the Company believes there is high
 unmet medical need.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company&#xB4;s core Anticalin<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;technology and platform was
 developed in Germany, and the Company has partnership arrangements
 with major multi-national pharmaceutical companies headquartered in
 the U.S., Europe and Japan and with regional pharmaceutical
 companies headquartered in India.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 235<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 272<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902506139136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">29,429,522<span></span>
</td>
<td class="nump">29,279,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">29,429,522<span></span>
</td>
<td class="nump">29,279,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902661088672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>11.</b></td>
 <td valign="top" align="left"><b>Subsequent Events</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Public Offering</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On July&#xA0;6, 2015 the Company closed a public offering of an
 aggregate of 9,090,909 shares of the Company&#xB4;s common stock at
 a purchase price of $2.75 per share. All shares of common stock
 were offered by the Company. On July&#xA0;24, 2015 the underwriters
 exercised their over-allotment option to purchase 1,211,827
 additional shares of the Company&#x2019;s common stock at the public
 offering price of $2.75, which sale closed on July&#xA0;28,
 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Gross proceeds raised by the Company in the offering, including the
 exercise of the over-allotment option, were $28.3 million and net
 proceeds are expected to be approximately $25.8 million. The
 Company intends to use the net proceeds from the offering to fund
 research and development, including preclinical and clinical
 research and development of its drug candidates, working capital
 and general corporate purposes.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Milestone payment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On July&#xA0;8, 2015 the Company announced that it will receive its
 third milestone payment for the second program in its discovery and
 development collaboration with Daiichi Sankyo, and seventh
 milestone payment overall under the multi program collaboration.
 The amount of payment was not disclosed due to the confidential
 treatment of this agreement. The payment was triggered by the
 achievement of positive&#xA0;<i>in vivo</i>&#xA0;proof of concept data and
 progression of the Anticalin drug candidate through a non-GLP
 toxicity study in non-human primates. The Company expects to
 receive this milestone payment in the third quarter of 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Cooperation Agreement</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On July, 14 the Company entered into a Cooperation Agreement (the
 &#x201C;Cooperation Agreement&#x201D;) with the University of
 Cologne. The University of Cologne provides research services to
 the Company for which it will receive up to two milestone payments.
 For the research services under Milestone 1, the Company shall pay
 the University a net amount of $48,698 (&#x20AC;43.660)&#xA0;in two
 installments. Within thirty days following achievement of Milestone
 1, the Company and University shall mutually agree whether to
 continue with the Cooperation Project. Having agreed on continuing
 with Milestone 2, the Company shall pay the University a net amount
 of $130,301 (&#x20AC;116,820)&#xA0;in two installments.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902487997104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Aug. 13, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PIRS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PIERIS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001583648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,732,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902505993152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_BasisOfConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Basis of Consolidation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The accompanying unaudited condensed consolidated financial
 statements of Pieris Pharmaceuticals Inc. and its wholly owned
 subsidiaries were prepared in accordance with accounting principles
 generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;)
 for interim financial information. All significant intercompany
 balances and transactions have been eliminated in the
 consolidation. Certain information and footnotes normally included
 in financial statement prepared in accordance with U.S. GAAP have
 been omitted pursuant to the Securities and Exchange Commission
 rules and regulations. Accordingly, they do not include all of the
 information and notes required by U.S. GAAP for complete annual
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In the opinion of management, the unaudited interim condensed
 consolidated financial statements have been prepared on the same
 basis as the audited condensed consolidated financial statements
 for the year ending December&#xA0;31, 2014, and all adjustments,
 including normal recurring adjustments, considered necessary for a
 fair presentation of Pieris Pharmaceuticals, Inc.&#x2019;s unaudited
 interim consolidated financial statements have been included. The
 results of operations for the three and six months ended
 June&#xA0;30, 2015 are not necessarily indicative of the results
 that may be expected for the year ending December&#xA0;31, 2015 or
 any future period.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Use of estimates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The preparation of the condensed consolidated financial statements
 in accordance with U.S. GAAP requires management to make estimates,
 judgments and assumptions that affect the reported amounts of
 assets and liabilities, the reported amounts of revenues and
 expenses in the financial statements and disclosures in the
 accompanying notes. Actual results and outcomes could differ
 materially from management&#x2019;s estimates, judgments and
 assumptions.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Segment Reporting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Pieris Pharmaceuticals, Inc. operates as a single segment dedicated
 to the discovery and development of biotechnological applications
 and the Company&#x2019;s chief operating decision maker (CODM) makes
 decisions based on the Company as a whole. Accordingly, Pieris
 Pharmaceuticals, Inc. operates and makes decisions as one reporting
 unit.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy', window );">Milestone Payments and Royalties</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Milestone Payments and Royalties</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At the inception of each agreement that includes milestone
 payments, Pieris Pharmaceuticals, Inc. evaluates whether each
 milestone is substantive and at risk to both parties on the basis
 of the contingent nature of the milestone. This evaluation includes
 an assessment of whether (a)&#xA0;the consideration is commensurate
 with either (1)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (2)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (b)&#xA0;the consideration relates solely to past performance and
 (c)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. Pieris
 Pharmaceuticals, Inc. evaluates factors such as the scientific,
 regulatory, commercial and other risks that must be overcome to
 achieve the respective milestone, the level of effort and
 investment required to achieve the respective milestone and whether
 the milestone consideration is reasonable relative to all
 deliverables and payment terms in the arrangement in making this
 assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pieris Pharmaceuticals, Inc. aggregates milestones into three
 categories (i)&#xA0;research milestones, (ii)&#xA0;development
 milestones and (iii)&#xA0;commercial milestones. Research
 milestones are typically achieved upon reaching certain success
 criteria as defined in each agreement related to developing an
 Anticalin protein against the specified target. Development
 milestones are typically reached when a compound reaches a defined
 phase of clinical research or passes such phase, or upon gaining
 regulatory approvals. Commercial milestones are typically achieved
 when an approved pharmaceutical product reaches the status for
 commercial sale or certain defined levels of net sales by the
 licensee, such as when a product first achieves global sales or
 annual sales of a specified amount.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For revenues from research and development milestone payments, if
 the milestones are deemed substantive and the milestone payments
 are nonrefundable, such amounts are recognized entirely upon
 successful accomplishment of the milestones. Milestones that are
 not considered substantive are accounted for as license payments
 and recognized on a straight-line basis over the period of
 performance. To date, Pieris Pharmaceuticals, Inc. has determined
 all milestones are substantive. Revenues from commercial milestone
 payments are accounted for as royalties and are recorded as revenue
 upon achievement of the milestone, assuming all other revenue
 recognition criteria are met. Royalty payments are recognized in
 revenues based on the timing of royalty payments earned in
 accordance with the agreements; which typically is the period when
 the relevant sales occur, assuming all other revenue recognition
 criteria are met.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Fair Value Measurement</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 ASC Topic 820 <i>Fair Value Measurement</i> defines fair value as
 the price that would be received to sell an asset or be paid to
 transfer a liability in an orderly transaction between market
 participants at the measurement date. Pieris Pharmaceuticals, Inc.
 applies the following fair value hierarchy, which prioritizes the
 inputs used to measure fair value into three levels and bases the
 categorization within the hierarchy upon the lowest level of input
 that is available and significant to the fair value
 measurement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Level 1 inputs are quoted prices in active markets for identical
 assets or liabilities that the reporting entity has the ability to
 access at the measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Level 2 utilizes quoted market prices in markets that are not
 active, broker or dealer quotations, or alternative pricing sources
 with reasonable levels of price transparency.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Level 3 inputs are unobservable inputs for the asset or liability
 in which there is little, if any, market activity for the asset or
 liability at the measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist
 of highly liquid money market funds and are measured at fair value
 on a recurring basis. These funds are classified as Level 1 in the
 fair value hierarchy because they are valued using quoted prices
 for the periods ended June&#xA0;30, 2015 and December&#xA0;31,
 2014. The carrying amounts of $78,403 and $ 4,800,573 as of
 June&#xA0;30, 2015 and December&#xA0;31, 2014, respectively, equal
 the fair value of the cash equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s other financial instruments include debt
 instruments, prepaid expenses, other current assets, accounts
 payable, accrued expenses and other current liabilities and are
 classified as Level 2 within the fair value hierarchy. The fair
 value of these instruments was determined using the discounted cash
 flow method based on contractual cash flows and the current rate at
 which debt with similar terms could be issued. The fair values for
 these debt instruments approximated carrying values as of
 June&#xA0;30, 2015 and December&#xA0;31, 2014.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred tax assets and liabilities are recognized for the future
 tax consequences attributable to differences between the financial
 statement carrying amounts of existing assets and liabilities and
 their respective tax bases, and operating losses and tax credit
 carry forwards. Deferred tax assets and liabilities are measured
 using enacted statutory tax rates expected to apply to taxable
 income in the jurisdictions and years in which those temporary
 differences are expected to be recovered or settled. The effect on
 deferred tax assets and liabilities of a change in tax rates is
 recognized in income in the period that includes the enactment
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Based on the level of historical operating results and projections
 for the taxable income for the future, the Company has determined
 that it is more likely than not that the deferred tax assets will
 not be realized. Accordingly, the Company has recorded a valuation
 allowance to reduce deferred tax assets to the same amount as
 deferred tax liabilities and determines an effective tax rate of
 zero percent.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Recent Accounting Pronouncements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, &#x201C;Revenue
 from Contracts with Customers,&#x201D; (ASU 2014-09) which provides
 guidance for revenue recognition. The standard&#x2019;s core
 principle is that a company will recognize revenue when it
 transfers promised goods or services to customers in an amount that
 reflects the consideration to which the company expects to be
 entitled in exchange for those goods or services. The new guidance
 is effective for annual reporting periods beginning after
 December&#xA0;15, 2016, including interim periods within that
 reporting period. Early application is not permitted. On
 April&#xA0;1, 2015 the FASB voted in favor of proposing a one year
 delay of the effective date and to permit companies to voluntarily
 adopt the new standard as of the original effective date. The
 Company is currently assessing the potential impact the adoption of
 this standard will have on their financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In January 2015, the FASB issued ASU No.&#xA0;2015-01,&#xA0;<i>&#x201C;Income Statement
 &#x2013; Extraordinary and Unusual items&#x201D;</i>&#xA0;(ASU 2015-01). The amendments
 in ASU 2015-01 eliminate from U.S. GAAP the concept of
 extraordinary items. Subtopic 225-20, Income Statement -
 Extraordinary and Unusual Items, required that an entity separately
 classify, present, and disclose extraordinary events and
 transactions. Presently, an event or transaction is presumed to be
 an ordinary and usual activity of the reporting entity unless
 evidence clearly supports its classification as an extraordinary
 item. This guidance is effective for fiscal years, and interim
 periods within those fiscal years, beginning after
 December&#xA0;15, 2015. The company is currently evaluating the
 impact of this new standard.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In February 2015, the FASB issued ASU No.&#xA0;2015-02,&#xA0;<i>&#x201C;Consolidation (Topic
 810): Amendments to the Consolidation Analysis&#x201D;</i>(ASU
 2015-02). The amendments in ASU 2015-02 are intended to improve
 targeted areas of consolidation guidance for legal entities such as
 limited partnerships, limited liability corporations, and
 securitization structures (collateralized debt obligations,
 collateralized loan obligations, and mortgage-backed security
 transactions). This guidance is effective for fiscal years
 beginning after December&#xA0;15, 2016, and interim periods within
 fiscal years beginning after December, 15, 2017. The company is
 currently evaluating the impact of this new standard.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In June 2015, the FASB issued ASU No.&#xA0;2015-10,
 &#x201C;Technical Corrections and Improvements&#x201D; (ASU 2015-10).
 The amendments in ASU 2015-10 represent changes to clarify the FASB
 Accounting Standards Codification (the &#x201C;Codification&#x201D;),
 correct unintended application of guidance, or make minor
 improvements to the Codification that are not expected to have a
 significant effect on current accounting practice or create a
 significant administrative cost to most entities. In addition, some
 of the amendments are intended to make the Codification easier to
 understand and easier to apply by eliminating inconsistencies,
 providing needed clarifications, and improving the presentation of
 guidance in the Codification. This guidance is effective for fiscal
 years, and interim periods within those fiscal years, beginning
 after December&#xA0;15, 2015. The company is currently evaluating
 the impact of this new standard.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Pieris Pharmaceuticals, Inc. has considered other recent accounting
 pronouncements and concluded that they are either not applicable to
 the business, or that the effect is not expected to be material to
 the unaudited condensed consolidated financial statements as a
 result of future adoption.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_BasisOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of consolidation policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_BasisOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition related to alternative revenue programs. The major alternative revenue programs can generally be segregated into two categories, programs that adjust billings for the effects of weather abnormalities or broad external factors or to compensate the utility for demand-side management initiatives (for example, no-growth plans and similar conservation efforts); and programs that provide for additional billings (incentive awards) if the utility achieves certain objectives, such as reducing costs, reaching specified milestones, or demonstratively improving customer service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 980<br><br><br><br> -SubTopic 605<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=45278178&amp;loc=d3e50180-110409<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 980<br><br><br><br> -SubTopic 605<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=45278178&amp;loc=d3e50159-110409<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 980<br><br><br><br> -SubTopic 605<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=45278178&amp;loc=d3e50187-110409<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 980<br><br><br><br> -SubTopic 605<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=45278178&amp;loc=d3e50174-110409<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902488113936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 160,244<span></span>
</td>
<td class="nump">$ 698,227<span></span>
</td>
<td class="nump">$ 377,864<span></span>
</td>
<td class="nump">$ 2,071,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(1,725,592)<span></span>
</td>
<td class="num">(1,118,920)<span></span>
</td>
<td class="num">(3,250,222)<span></span>
</td>
<td class="num">(2,341,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(1,969,082)<span></span>
</td>
<td class="num">(2,349,232)<span></span>
</td>
<td class="num">(4,363,405)<span></span>
</td>
<td class="num">(3,170,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="num">(3,694,674)<span></span>
</td>
<td class="num">(3,468,152)<span></span>
</td>
<td class="num">(7,613,627)<span></span>
</td>
<td class="num">(5,512,248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,534,430)<span></span>
</td>
<td class="num">(2,769,925)<span></span>
</td>
<td class="num">(7,235,763)<span></span>
</td>
<td class="num">(3,441,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(113,793)<span></span>
</td>
<td class="num">(4,223)<span></span>
</td>
<td class="num">(223,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,484<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">5,253<span></span>
</td>
<td class="nump">2,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(3,529,999)<span></span>
</td>
<td class="num">(2,881,637)<span></span>
</td>
<td class="num">(7,234,733)<span></span>
</td>
<td class="num">(3,661,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,529,999)<span></span>
</td>
<td class="num">$ (2,881,637)<span></span>
</td>
<td class="num">$ (7,234,733)<span></span>
</td>
<td class="num">$ (3,661,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share Basic and diluted</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding Basic and diluted</a></td>
<td class="nump">29,429,522<span></span>
</td>
<td class="nump">11,828,974<span></span>
</td>
<td class="nump">29,361,566<span></span>
</td>
<td class="nump">11,828,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35710027&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902488040128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>6.</b></td>
 <td valign="top" align="left"><b>Accrued expenses</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company has recorded the following accrued expenses as of
 June&#xA0;30, 2015 and December&#xA0;31, 2014, respectively:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,<br />
 2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued compensation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">333,979</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">332,892</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued audit and tax expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">403,450</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">153,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,523</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total accrued expenses, current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">635,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">743,865</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued expenses non-current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Reserve for litigation TUM</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">302,273</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">327,937</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued expenses restoration</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,577</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,051</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total accrued expenses, non-current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">307,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">333,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 <b>Total accrued expenses</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">943,411</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,077,853</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"></td>
 <td valign="top" align="left"></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20, 24<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902656673888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>5.</b></td>
 <td valign="top" align="left"><b>Debt</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>TBG Loan</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 As of April&#xA0;3, 2014, the Company and tbg
 Technologie-Beteiligungs-Gesellschaft mbH (&#x201C;TBG&#x201D;), the
 subsidiary of KfW Bank, Frankfurt (&#x201C;KfW&#x201D;), signed a
 repayment agreement concerning the Company&#x2019;s repayment of its
 liabilities to TBG outstanding at December&#xA0;31, 2013 in a total
 amount of &#x20AC;1.2&#xA0;million ($1.34 million). The principal
 amount bore interest at a rate of 10.53%. Under the repayment
 agreement, the Company has agreed to a payment schedule pursuant to
 which it will make semi-annual payments until 2016. On
 December&#xA0;11, 2014, the Company and TBG entered into an
 accelerated repayment agreement in respect of the claims of TBG
 against the Company. Pursuant to terms of the accelerated repayment
 agreement, conditioned upon closing of the Acquisition, the Company
 was obligated to pay &#x20AC;1,050,000 ($1.17 million), the
 outstanding amount under the repayment agreement, in two tranches
 as follows: &#x20AC;600,000 ($669,240) plus accrued interest on
 January&#xA0;31, 2015 and &#x20AC;450,000 ($501,930) on
 March&#xA0;31, 2015. The outstanding principal amount for the first
 and the second tranches, net of capital gain tax withheld, was
 repaid in full in the first quarter ending March&#xA0;31, 2015 in
 the amount of &#x20AC;931,312 ($1,038,785). The capital gain tax
 withheld in the amount of &#x20AC;118,688 ($132,385) was paid on
 April&#xA0;9, 2015 and with that the TBG loan was repaid in
 full.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902486373712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodMilestone', window );">Milestones arrangement, categories description</a></td>
<td class="text">Pieris Pharmaceuticals, Inc. aggregates milestones into three categories  (i) research milestones, (ii) development milestones and (iii) commercial  milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value</a></td>
<td class="nump">$ 78,403<span></span>
</td>
<td class="nump">$ 4,800,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Subparagraph 2<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of each milestone and related contingent consideration as well as a description of whether or not each milestone(s) is considered substantive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 28<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b,c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902498051888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Related Party Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company has incurred the following expenses related to TUM
 (excluding value added taxes):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">Three&#xA0;months&#xA0;ended</p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">June&#xA0;30,</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 Six&#xA0;months&#xA0;ended<br />
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Transfer of licenses and protective rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 <b>Total expenses incurred with TUM</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902645666352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ClassOfWarrantsAndRightsTextBlock', window );">Warrants</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>9.</b></td>
 <td align="left" valign="top"><b>Warrants</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In connection with the Private Placement in December 2014, the
 Company issued the Placement Warrants to acquire combined up to
 542,360 shares of its common stock at an exercise price of two
 dollars per share ($2.00) to the Placement Agents and their
 designees during December 2014. The Placement Warrants are
 exercisable at any time at the option of the holder until the five
 year anniversary of its date of issuance. The number of shares of
 common stock issuable upon the exercise of each Placement Warrant
 is adjustable in the event of certain stock dividends, stock
 splits, combinations of shares and similar transactions. Upon
 exercise, the aggregate exercise price of the warrants issued are
 payable by the holders in cash.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company estimated the fair value of the Placement Warrants as
 of the grant date to be $664,064 and recognized the full amount in
 general and administrative expense for the year ended
 December&#xA0;31, 2014.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ClassOfWarrantsAndRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants And Rights [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ClassOfWarrantsAndRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902709512048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left"><b>Stock-based compensation</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 In December 2014, the Board of Directors and stockholders of Pieris
 Pharmaceuticals, Inc. adopted the 2014 Employee, Director and
 Consultant Equity Incentive Plan (the &#x201C;Pieris Plan&#x201D;),
 which became effective upon closing of the Acquisition. The Pieris
 Plan is intended to encourage ownership of common stock by the
 Company&#x2019;s employees and directors and certain of their
 consultants, including employees of Pieris AG, in order to attract
 and retain such people, to induce them to work for the benefit of
 the Company and to provide additional incentive for them to promote
 the Company&#x2019;s success. The Pieris Plan reserves 3,200,000
 shares of the Company&#xB4;s common stock for issuance. In
 addition, the Pieris Plan provides for an &#x201C;evergreen&#x201D;
 provision whereby the number of shares of the Company&#xB4;s common
 stock reserved for issuance under the Pieris Plan shall be
 automatically increased on January&#xA0;1 of each of year
 commencing in fiscal 2016 by the lesser of (i)&#xA0;1,000,000
 shares, (ii)&#xA0;4% of the number of shares of the Company&#xB4;s
 common stock outstanding on such date, and (iii)&#xA0;such other
 amount determined by the Compensation committee of the Board of
 Directors. As of June&#xA0;30, 2015, options to purchase 1,470,235
 shares of the Company&#xB4;s common stock are outstanding under the
 Pieris Plan to its executive officers and directors. 40,235 of
 these shares were granted during the second quarter of 2015. All
 other shares were granted in the fourth quarter of 2014. In
 addition, options to purchase 1,146,500 shares are outstanding
 under the Pieris Plan to other employees and consultants. 25,000 of
 these shares were granted during the first quarter of 2015, 32,000
 of these shares were granted during the second quarter of 2015 and
 1,089,500 were granted during the fourth quarter of 2014. As a
 result of such grants, 583,265 of the Company&#xB4;s common stock
 remain available for future issuances under the Pieris Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Stock options granted under the Pieris Plan may be either incentive
 stock options (&#x201C;ISOs&#x201D;), or nonqualified stock options.
 The Board of Directors determines who will receive options, the
 vesting periods (which are generally three years) and the exercise
 prices. Options have a maximum term of ten years. The exercise
 price of stock options granted under the Pieris Plan must be at
 least equal to the fair market value of the common stock on the
 date of grant. The Pieris Plan become effective in December 2014,
 therefore there was no stock-based compensation expense in the
 three and six months ended June&#xA0;30, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Total stock-based compensation expense, related to all share-based
 awards under the Pieris Plan to executive officers, directors,
 employees and consultants recognized for the three and six months
 ended June&#xA0;30, 2015, was comprised of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Three&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Six&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,&#xA0;2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30, 2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and Development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">78,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">129,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">189,488</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 <b>Total stock-option expense</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">268,039</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">485,375</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The fair value of option grants was estimated using the
 Black-Scholes model. The following table describes the
 weighted-average assumptions used for calculating the value of
 options granted for the three and six months ended June&#xA0;30,
 2015:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Three&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Six&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30, 2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30, 2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forfeiture rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.1</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Weighted average risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.73</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.71</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 A summary of the Company&#x2019;s stock option activity and related
 information is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-<br />
 Average<br />
 Contractual<br />
 Life</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,519,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.6&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.8&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options cancelled or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at March&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,544,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.6&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72,235</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options cancelled or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,616,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Vested at June 30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">799,068</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Expected to vest after June 30,2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,708,607</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">799,068</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The weighted-average grant date fair value for awards granted
 during the three and six months ended June&#xA0;30, 2015 was
 $130,456 and $176,898, respectively. There were no options
 exercised during the three and six months ended June&#xA0;30, 2015
 and 2014. 200,673 and 375,319 shares were vested in the three and
 six months ended June&#xA0;30, 2015, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The unrecognized share-based compensation expense related to
 employee stock option awards at June&#xA0;30, 2015, is $2,253,478,
 which will be recognized over a weighted-average service period of
 2.5 years.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902648608848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consulting Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_ConsultingSharesDisclosureTextBlock', window );">Consulting Shares</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>8.</b></td>
 <td valign="top" align="left"><b>Consulting Shares</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On March&#xA0;6, 2015, the Company entered into an independent
 consulting agreement (the &#x201C;Consulting Agreement&#x201D;) with
 the Del Mar Consulting Group, Inc. and Alex Partners, LLC (the
 &#x201C;Consultants&#x201D;), pursuant to which the Company issued
 150,000 restricted shares of its common stock (par value $0.01 per
 share) to the Consultants (the &#x201C;Consulting Shares&#x201D;).
 The Company agreed to retain the Consultants to provide investor
 relations consulting to the Company for a period commencing on
 March&#xA0;6, 2015 (the &#x201C;Commencement Date&#x201D;) and ending
 thirteen months after the Commencement Date (such period, the
 &#x201C;Term&#x201D;). The shares issued in connection with the
 Consulting Agreement were deemed to be exempt from registration in
 reliance upon Section&#xA0;4(a)(2) of the Securities Act as a
 transaction by an issuer not involving any public offering.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The terms of the Consulting Agreement state, that the Company has
 the right to terminate this agreement at any time during the Term
 of the Consulting Agreement, upon providing Consultants ten
 days&#x2019; written notice of Company&#x2019; intention to terminate
 or immediately upon notice in the event of a breach of this
 agreement by either consultant. If the Company delivers notice to
 terminate this agreement for any reason within one hundred eighty
 days (180)&#xA0;following the effective date (the &#x201C;Return
 Date&#x201D;), then each Consultant will promptly return and
 surrender to the Company forty percent (40%)&#xA0;of the number of
 Consulting Shares issued to it. Therefore 60,000 of these shares
 are subject to certain forfeiture provisions within 180 days
 following the date of entry into the Consulting Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company, using the Black-Scholes method, estimated the fair
 value of the 90,000 non-cancellable Consulting Shares to be
 $284,400 based on the closing price per share of $3.16 as quoted on
 the OTCQB tier of the OTC Markets Group Inc., or the OTCQB, on the
 grant date, March&#xA0;6, 2015. The Company estimated the fair
 value of the 60,000 cancellable Consulting Shares to be $192,000
 based on the closing price per share of $3.20 as quoted on the
 OTCQB on the interim financial reporting date, March&#xA0;31, 2015.
 Therefore, the Company estimated the total fair value of the
 Consulting Shares to be $476,400 and recognized the 90,000 vested
 non-cancellable Consulting Shares, or sixty percent (60%)&#xA0;of
 the Consulting Shares in an amount of $284,400, as general and
 administrative expense for the six months ended June&#xA0;30, 2015.
 The remaining forty percent (40%), or 60,000 Consulting Shares in
 the amount of $192,000, will be recognized as general and
 administrative expenses with an offsetting credit to equity on a
 straight-line basis over 180 days. If the Company exercises the
 option to terminate the Consulting Agreement within the 180 days,
 resulting in the cancellation of forty percent (40%)&#xA0;of the
 Consulting Shares, expense for cancelled, unvested shares will be
 reversed.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On June&#xA0;30, 2015 the Company revalued the fair value of the
 unvested and forfeitable 40% of the shares. As of June&#xA0;30,
 2015 the estimated fair value of the 60,000 unvested and
 forfeitable shares was $165,000. Therefore the Company recognized
 expenses in connection with the Consulting Shares of $79,666 in
 general and administrative expenses for the cancellable Consulting
 Shares during the three months ended June&#xA0;30, 2015. For the
 six months ended June&#xA0;30, 2015 the Company recognized $390,733
 in general and administrative expenses, including $284,400 for the
 non-cancellable Consulting Shares and $106,333 for the cancellable
 shares.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ConsultingSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting Shares Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ConsultingSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902656689392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>10.</b></td>
 <td valign="top" align="left"><b>Commitments and
 Contingencies</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Arbitration</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On March&#xA0;20, 2014, the Company instituted arbitration
 proceedings, or the TUM Arbitration, against Technische
 Universit&#xE4;t M&#xFC;nchen, or Munich Technical University and
 hereafter TUM, to address issues regarding the calculation of
 payments due from the Company to TUM under the Company&#x2019;s
 Research and Licensing Agreement with TUM, as amended, or the TUM
 License Agreement. Pursuant to the terms of the TUM License
 Agreement, the arbitration is proceeding in Munich, Germany and
 governed by German law, in accordance with the arbitration rules of
 the Deutsche Institution f&#xFC;r Schiedsgerichtsbarkeit.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On July&#xA0;4, 2003, or the Effective Date, the Company and TUM
 entered into the TUM License Agreement, as superseded and replaced
 on July&#xA0;26, 2007, under which TUM has exclusively licensed, or
 in some cases assigned, to the Company certain intellectual
 property and know-how that has become part of the
 Anticalin<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> proprietary
 technologies. In return, the Company agreed to pay to TUM certain
 annual license fees, milestones and royalties for its own
 proprietary drug development and sales, as well as an variable fee
 as a function of out-licensing revenues, or the Out-License Fee,
 where such Out-License Fees are creditable against annual license
 payments to TUM.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As required by the TUM License Agreement, the Company provided to
 TUM its calculation of the Out-License Fee owed by the Company to
 TUM for the period beginning on the Effective Date and ending on
 December&#xA0;31, 2012, the Dispute Period, in the amount of $0.4
 million excluding value-added tax. TUM has asserted that, under the
 TUM License Agreement, the Out-License Fee due to TUM for the
 Dispute Period amounts to $3.4 million excluding value-added tax in
 the aggregate and has threatened to terminate the TUM License
 Agreement if the Out-License Fee is not paid. We believe that if
 TUM sought to terminate the license agreement for cause as a result
 of this dispute, it would potentially face wrongful termination
 claims for substantial damages if the arbitration tribunal in the
 TUM Arbitration sides with Pieris in its final decision regarding
 the proper amount of the Out-License Fee, but we can provide no
 assurance regarding the timing, nature or consequences of such
 decision. The Company instituted the TUM Arbitration to request the
 arbitration tribunal to hold that the Company&#x2019;s calculation
 of the payments owed to TUM is accurate and shall govern all
 current and future payments due in respect of the Out-License Fee
 under the TUM License Agreement. The Company has reserved a
 liability on its balance sheet&#x2019;s position other long-term
 liabilities in respect of such payment in the amount of
 &#x20AC;271,000 ($302,273). An adverse ruling in the TUM Arbitration
 could have a material adverse effect on the Company&#x2019;s results
 of operations and financial condition.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2014, TUM argued to the arbitrators that it is not the
 proper party to be sued under the action for a declaratory
 arbitration decision brought by the Company in relation to the
 Research and Licensing Agreement, and that instead, it is the Free
 State of Bavaria that is the proper respondent to the action. The
 Company has responded that TUM has capacity to be sued in relation
 to any disputes arising from and regarding contractual provisions
 of the Research and Licensing Agreement and is thus also the proper
 respondent in the action. In accordance with the arbitration rules
 of the Deutsche Institution f&#xFC;r Schiedsgerichtsbarkeit, each
 party to the arbitration proceeding has appointed one arbitrator
 and the party-named arbitrators collectively selected the third
 arbitrator as the chairman of the arbitration panel.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On December&#xA0;1, 2014, TUM filed its statement of defense,
 maintaining its earlier calculation of the Out-License Fee. On
 December&#xA0;23, 2014, TUM filed a counterclaim in the amount of
 &#x20AC;2,529,400 ($3,060,827) to suspend the statute of limitations
 on its claims. On January&#xA0;12, 2015, the Company filed a reply
 brief in response to TUM&#x2019;s defense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The arbitration panel held its first hearing in Munich, Germany on
 January&#xA0;20, 2015, however the arbitration panel did not come
 to a conclusion on whether TUM is the proper respondent in the
 action or on the merits of the case. The panel had previously
 indicated that it will first decide the issue of whether TUM is the
 proper respondent in this action. The panel resolved that the value
 in dispute for both parties&#x2019; claims and counterclaims would
 be fixed at &#x20AC;3,500,000 ($4,235,350), as the calculation of
 the outstanding Out-Licensing Fee also impacts future payments. On
 March&#xA0;3, 2015, the Company submitted a reply brief responding
 to TUM&#x2019;s statement of defense and counterclaim.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On March&#xA0;31, 2015, TUM submitted a rebuttal brief. The panel
 requested that both the Company and TUM indicate to the panel by
 April&#xA0;27, 2015 whether proceedings should be stayed as a
 result of settlement negotiations. On April&#xA0;27, 2015, the
 Company submitted a reply brief requesting proceedings to continue
 without disruption and moving for leave to comment on TUM&#x2019;s
 submission. Following an approved extension by the panel for
 TUM&#x2019;s submission, TUM submitted its proposal on May&#xA0;4,
 2015, requesting that the panel conduct a mediation hearing and
 assist the parties in negotiating a settlement. On May&#xA0;8,
 2015, the arbitration tribunal set June&#xA0;1, 2015 as the
 deadline for final briefs and offered to schedule another oral
 hearing in mid-June for the purpose of supporting further
 settlement negotiations if both parties are in favor of holding a
 hearing. The Company submitted its brief on June&#xA0;1, 2015. On
 June&#xA0;8, 2015, the arbitration tribunal issued a procedural
 order indicating they will proceed with the arbitration without
 another oral hearing. TUM did not file its brief by the June&#xA0;1
 deadline set by the panel, and instead filed another submission on
 June&#xA0;23, 2015. In its procedural order issued on the same day,
 the tribunal panel reserved the right to reject TUM&#x2019;s new
 submission based on the content of its brief. The tribunal&#x2019;s
 subsequent procedural order of June&#xA0;25, 2015 provided that the
 tribunal will close the proceedings on July&#xA0;10, 2015. The
 order clarified that any further pleadings or submissions will not
 be admissible after this date. The Company submitted its final
 brief on July&#xA0;10, 2015 to address TUM&#x2019;s arguments raised
 in its latest submission to provide the tribunal with an overview
 its costs incurred in this arbitration proceeding. On the same day,
 TUM submitted its summary of its costs incurred in this arbitration
 proceeding and subsequently, on July&#xA0;23, 2015, filed an
 additional brief to correct some of its earlier submissions on
 costs and comment on the Company&#x2019;s cost overview of
 July&#xA0;10, arguing that attorneys&#x2019; fees claimed by the
 Company are disproportionately high. The Company replied to the
 TUM&#x2019;s on [August, 7], pointing out that the higher
 attorneys&#x2019; fees are justified and resulted from the
 Company&#x2019;s submissions on TUM&#x2019;s standing to be sued and
 translation costs are also reimbursable in this case.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902495321600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of common stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,360<span></span>
</td>
<td class="nump">542,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_WarrantExercisablePeriod', window );">Warrant exercisable period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_WarrantExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercisable Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_WarrantExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902486352992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Total stock-based compensation expense, related to all share-based
 awards under the Pieris Plan to executive officers, directors,
 employees and consultants recognized for the three and six months
 ended June&#xA0;30, 2015, was comprised of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Three&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Six&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,&#xA0;2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30, 2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and Development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">78,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">129,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">189,488</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 <b>Total stock-option expense</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">268,039</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">485,375</td>
 <td valign="bottom" nowrap="nowrap"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The fair value of option grants was estimated using the
 Black-Scholes model. The following table describes the
 weighted-average assumptions used for calculating the value of
 options granted for the three and six months ended June&#xA0;30,
 2015:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Three&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 Six&#xA0;months&#xA0;ended</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30, 2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30, 2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forfeiture rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.1</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Weighted average risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.73</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.71</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Information Regarding Stock Option Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 A summary of the Company&#x2019;s stock option activity and related
 information is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-<br />
 Average<br />
 Contractual<br />
 Life</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,519,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.6&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.8&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options cancelled or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at March&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,544,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.6&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72,235</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Options cancelled or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,616,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.3&#xA0;-&#xA0;5.8&#xA0;years</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Vested at June 30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">799,068</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Expected to vest after June 30,2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,708,607</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">799,068</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902645380528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Related Party Expenses (Detail) - TUM [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Transfer of licenses and protective rights</a></td>
<td class="nump">$ 13,836<span></span>
</td>
<td class="nump">$ 17,145<span></span>
</td>
<td class="nump">$ 27,893<span></span>
</td>
<td class="nump">$ 34,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Total expenses</a></td>
<td class="nump">$ 13,836<span></span>
</td>
<td class="nump">$ 17,145<span></span>
</td>
<td class="nump">$ 27,893<span></span>
</td>
<td class="nump">$ 34,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902495341408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,529,999)<span></span>
</td>
<td class="num">$ (2,881,637)<span></span>
</td>
<td class="num">$ (7,234,733)<span></span>
</td>
<td class="num">$ (3,661,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">102,135<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="num">(500,597)<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss, after tax</a></td>
<td class="nump">102,135<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="num">(500,597)<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (3,427,864)<span></span>
</td>
<td class="num">$ (2,874,983)<span></span>
</td>
<td class="num">$ (7,735,330)<span></span>
</td>
<td class="num">$ (3,658,515)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (a-c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32157-110900<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (c)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902701557984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>4.</b></td>
 <td valign="top" align="left"><b>Related-Party
 Transactions</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Research and License Agreement with Technische Universit&#xE4;t
 M&#xFC;nchen (&#x201C;TUM&#x201D;)</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On July&#xA0;4, 2003, the Company entered into a research and
 licensing agreement with TUM, which was subsequently renewed and,
 on July&#xA0;26, 2007, superseded and replaced. The agreement
 established a joint research effort led by Prof. Arne Skerra, Chair
 of Biological Chemistry of TUM, to optimize Anticalin&#xAE;
 technologies for use in therapeutic, prophylactic and diagnostic
 applications and as research reagents, and to gain fundamental
 insights in lipocalin scaffolds. Prof. Dr.&#xA0;Skerra was a member
 of Pieris AG&#x2019;s supervisory board when the parties entered
 into such agreement. The Company provided certain funding for TUM
 research efforts performed under the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As a result of research efforts to date under the agreement, the
 Company holds a worldwide exclusive license under its license
 agreement with TUM to multiple patents and patent applications,
 including an exclusive license to an issued U.S. patent, which
 patent will expire in 2027 (subject to a possible term adjustment
 period). Pieris AG also holds an exclusive license to an issued
 U.S. patent No.&#xA0;8,420,051, which patent is expected to expire
 in 2029. The Company bears the costs of filing, prosecution and
 maintenance of patents assigned or licensed to the Company under
 the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As consideration for the assigned patents and licenses above, the
 Company is required to pay certain development milestones to TUM.
 The Company also is obliged to pay low-single-digit royalties,
 including annual minimum royalties, on sales of such products
 incorporating patented technologies. If the Company grants licenses
 or sublicenses to those patents to third parties, the Company will
 be obliged to pay a percentage of the resulting revenue to TUM. The
 Company&#x2019;s payment obligations are reduced by the
 Company&#x2019;s proportionate contribution to a joint invention.
 Payment obligations terminate on expiration or annulment of the
 last patent covered by the agreement. The Company can terminate the
 licenses to any or all licensed patents upon specified advance
 notice to TUM. TUM may terminate the license provisions of the
 agreement only for cause. Termination of the agreement does not
 terminate the rights in patents assigned to the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company has incurred the following expenses related to TUM
 (excluding value added taxes):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">Three&#xA0;months&#xA0;ended</p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">June&#xA0;30,</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 Six&#xA0;months&#xA0;ended<br />
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Transfer of licenses and protective rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 <b>Total expenses incurred with TUM</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company has accrued $302,273 and $370,999 as of June&#xA0;30,
 2015 and 2014, respectively, related to the amounts due under the
 research and license agreement (see Note 9 <i>Commitments and
 Contingencies</i>).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The part of the agreement requiring the Company to make payments
 for research conducted by TUM expired in February 2013 with no
 further obligations by Pieris AG.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Consulting Contract between Prof. Dr.&#xA0;Arne Skerra and
 Pieris AG</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In 2001, the Company entered into a Consulting Agreement with Prof.
 Dr.&#xA0;Arne Skerra, pursuant to which Prof. Dr.&#xA0;Arne Skerra
 provides advice regarding the use of new proteins, in particular
 Anticalin&#xAE; proteins and antibodies, for the purpose of
 research and development. The Consulting Agreement has an unlimited
 term but can be terminated by the Company upon three months&#x2019;
 notice with effect from the end of a month and by Prof.
 Dr.&#xA0;Arne Skerra upon one year&#x2019;s notice with effect from
 the end of a year. Under the Consulting Agreement, the Company
 incurred and paid to Prof. Dr.&#xA0;Skerra consulting fees of
 $11,157 and $13,711 for the six months ended June&#xA0;30, 2015 and
 2014, respectively. For the three months ended June&#xA0;30, 2015
 and 2014 the Company incurred and paid Prof. Dr.&#xA0;Skerra
 consulting fees of $5,534 and $6,858, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph b<br><br><br><br> -Article 3A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902481059632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Detail) - Tbg [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2014 </div>
<div>USD ($) </div>
<div>Tranches</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 11, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 03, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 03, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance', window );">Amount of repayment to TBG outstanding</a></td>
<td class="nump">$ 1,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,050,000<span></span>
</td>
<td class="nump">$ 1,340,000<span></span>
</td>
<td class="nump">&#8364; 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Principal amount, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.53%<span></span>
</td>
<td class="nump">10.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Repayment agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the  repayment agreement, the Company has agreed to a payment schedule pursuant to  which it will make semi-annual payments until 2016.<span></span>
</td>
<td class="text">Under the  repayment agreement, the Company has agreed to a payment schedule pursuant to  which it will make semi-annual payments until 2016.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax', window );">Capital gain tax withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,385<span></span>
</td>
<td class="nump">&#8364; 118,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pirs_NumberOfTranches', window );">Number of tranches</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Repayment amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,038,785<span></span>
</td>
<td class="nump">&#8364; 931,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_TbgMember', window );">Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance', window );">Amount of repayment to TBG outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669,240<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pirs_TbgMember', window );">Debt Instrument, Redemption, Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance', window );">Amount of repayment to TBG outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,930<span></span>
</td>
<td class="nump">&#8364; 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=29642582&amp;loc=d3e27881-108397<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=29642582&amp;loc=d3e27862-108397<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The undiscounted sum of all amounts, including amounts deemed principal, interest, fees, penalties, and other under the loan, owed to the investor at the reporting date, whether or not currently due and whether or not any such amounts have been written or charged off by the investor.  This relates to loans not accounted for as debt securities, with evidence of deterioration of credit quality since origination that were acquired by completion of a transfer for which it is probable, at acquisition, that the investor will be unable to collect all contractually required payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 15<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27045933&amp;loc=d3e13503-111538<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 470<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current period income tax expense or benefit pertaining to a gain (loss) on an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pirs_TbgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pirs_TbgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.2.0.727</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>110</ContextCount>
  <ElementCount>187</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Consulting Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock</Role>
      <ShortName>Consulting Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</ParentRole>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Corporate Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation</Role>
      <ShortName>Corporate Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Revenues - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation</Role>
      <ShortName>Revenues - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Related Party Transaction - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation</Role>
      <ShortName>Related Party Transaction - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Related-Party Transactions - Related Party Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses</Role>
      <ShortName>Related-Party Transactions - Related Party Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Stock-based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan</Role>
      <ShortName>Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted</Role>
      <ShortName>Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity</Role>
      <ShortName>Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Consulting Shares - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation</Role>
      <ShortName>Consulting Shares - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>pirs-20150630.xml</File>
    <File>pirs-20150630_cal.xml</File>
    <File>pirs-20150630_def.xml</File>
    <File>pirs-20150630_lab.xml</File>
    <File>pirs-20150630_pre.xml</File>
    <File>pirs-20150630.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139902506277552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company has recorded the following accrued expenses as of
 June&#xA0;30, 2015 and December&#xA0;31, 2014, respectively:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,<br />
 2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued compensation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">333,979</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">332,892</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued audit and tax expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">403,450</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">153,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,523</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total accrued expenses, current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">635,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">743,865</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued expenses non-current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Reserve for litigation TUM</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">302,273</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">327,937</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued expenses restoration</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,577</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,051</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total accrued expenses, non-current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">307,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">333,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 <b>Total accrued expenses</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">943,411</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,077,853</td>
 <td valign="bottom" nowrap="nowrap"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"></td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
